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Abstract
Inhibition of steroidogenic enzymes, which are involved in the biosynthesis of active 
estrogens, represents an attractive approach to treating hormone-dependent breast 
cancer. Synthetic routes to novel steroid-based inhibitors of two key enzymes, steroid 
sulfatase (STS) and 17 P-hydroxysteroid dehydrogenase type 1 (17P-HSD type 1), are 
described. Biological evaluation of the derivatives in vitro indicated that most of the 
compounds synthesised were active against the selected targets to varying degrees. 
Particular attention was given to assessing the estrogenicity of potential inhibitors, 
since agonist activity at the estrogen receptor is undesired in the treatment of 
estrogen-dependent pathologies.
Modifications to the D-ring of estrone-3-O-sulfamate EMATE, a potent STS 
inhibitor, successfully afforded a 3-sulfamoyloxy-16,17-sec<?-estra-l,3,5(10)-triene- 
16,17-imide template, from which a series of A-alkylated analogues were prepared. 
The TV-propyl and A-pyridin-3-ylmethyl derivatives were 18 times more potent than 
EMATE in vitro, with IC5 0S of 1 nM in placental microsomes. In vivo, these 
compounds inhibited 99% of rat liver sulfatase activity at an oral dose of 10 mg/kg. 
Importantly, they were also devoid of estrogenic activity. The SAR for the 
derivatives synthesised is discussed and a QSAR was established.
Substrate-based design of 17P-HSD type 1 inhibitors resulted in the identification of 
several lead compounds, mostly D-ring modified estrogens. The potential of 16- 
alkylidenes derivatives of estradiol as enzyme-generated irreversible inhibitors was 
examined. Small modifications to the estra-l,3,5(10)-triene nucleus were 
investigated. Both studies were assisted by molecular modelling, using the crystal 
structure of the enzyme. D-Ring fused heterocyclic derivatives of estrone were 
prepared and an SAR was built around N-alkylated 16,17-fused pyrazoles. The N- 
ethoxymethyl derivative emerged as a potent inhibitor of 17p-HSD type 1 in vitro 
without being estrogenic. A preliminary study focused on the design of dual 
inhibitors of STS and 17P-HSD type 1 is also reported here. The synthetic work was 
supported by single crystal X-ray analyses.
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Breast cancer is a disease of major importance which still remains a leading cause of 
death among women in most Western countries. It is estimated to affect 
approximately 1 million women per year across the globe. 1
Britain has one of the highest incidence of breast cancer in the world with over 
40,000 patients diagnosed each year, accounting for nearly 1 in 5 of all cancer cases. 
It is estimated that 1 in 10 women living to the age of 85 in Britain will develop 
breast cancer during the course of their lives. Although modem methods of 
treatment as well as an earlier detection of the disease have greatly improved survival 
rates, breast cancer remains the commonest cause of death for women aged between 
40-50.3
All women are randomly at risk of breast cancer, although a number of risk factors 
have been identified, most of them related to a woman’s hormonal and reproductive 
history as well as their family background of the disease. Hormones, in particular 
estrogens, play a major role in the promotion and development of breast cancer and 
currently between one and two-thirds of all breast carcinoma rely on estrogens for 
their sustained growth. This particular type of breast cancer, known as Hormone- 
Dependent Breast Cancer (HDBC), predominantly affects postmenopausal women 
who account for nearly 80% of all cases.
The past decade has witnessed the accelerated development of new drugs and 
strategies to fight HDBC, and several compounds have entered clinical trials or are 
already marketed. They are all designed to deprive the tumours of estrogens by either 
competing with the natural hormones for specific binding sites, or by blocking their 
biosynthetic pathways. However, there are still significant limitations to existing 
treatments and cancer therapy is often rigorous, debilitating and uncomfortable. 
Thus, when designing new drugs, not only the quantitative aspects, in terms of 
increased survival, but also the qualitative value, in terms of the well-being of the 
patient, must be considered.
As a result, drugs that are more selective, less invasive and ideally devoid of side- 
effects need to be designed to efficiently combat breast cancer. In order to achieve
2
this goal, it is necessary to understand the underlying mechanisms of hormone 
action, in particular that of estrogens, as well as their implication in carcinogenesis.
1.1 Hormones: the body’s chemical messengers
Intercellular communication is of paramount importance in the maintenance of life 
for all complex organisms. In vertebrates, including humans, there are two major 
networks of internal communication which are intimately connected: the endocrine 
system and the nervous system. Together, they provide for full coordination of 
physiological responses and regulation of the body’s chemistry.
In order to communicate, cells use chemical messengers, i.e. extracellular signalling 
molecules, which bind to specific receptors of a target cell. The biological response 
to a messenger is therefore mediated through receptors, which are membrane-bound, 
cytoplasmic or nuclear proteins. In the nervous system, neurotransmitters released 
under electric impulse provide a fast and direct communication with neighbouring 
nerve cells. In the endocrine system, hormones are delivered by the circulatory 
system to act at distant sites, offering a slower and more widespread mode of 
communication. The complementary function and synergistic action of the two 
systems is the key to a comprehensive control and adaptation between the body and 
its internal and external environment.4
1.1.1 Historical perspective
At the end of the 19th century, the concept that some organs were able to liberate into 
the bloodstream substances which assist in regulating body functions slowly 
emerged, challenging the existing view that coordination was the sole property of the 
nervous system.
In 1855, the French physiologist Claude Bernard first introduced the term ‘internal 
secretion’ when describing the glycogenic function of the liver and its ability to 
regulate blood sugar levels. 5 Forty years later, the first hormone was isolated by two
3
English physiologists, George Oliver and Edward Schaefer whose work on extracts 
of the adrenal gland led to the discovery of adrenaline.6 Meanwhile, the existence of 
a second hormone was being revealed as Bayliss and Starling discovered secretin, a 
hormone capable of stimulating the secretion of pancreatic substances.7 In 1905, 
during a lecture entitled ‘The Chemical Correlation of the Functions of the Body’, 
Starling introduced for the first time the term hormone. 8 The word derives from the 
Greek verb ‘hormao’ and means ‘to excite’.
Since then, a large number of hormones have been isolated, characterised and 
synthesised. Some discoveries have had a dramatic impact worldwide, as 
exemplified by the isolation of insulin by Frederick Banting and Charles Best in 
1921, which revolutionised the treatment of diabetes and the prevention of its 
complications. 9 A century after the discovery of the first hormone, thanks to the 
efforts of scientists in the field of endocrinology, we now benefit from a 
comprehensive understanding of the nature, mechanism of action and regulation of 
hormones and how the endocrine system functions in integrating the activity of 
diverse cells and organs.
1.1.2 General principles
Hormones play an essential role in a wide range of physiological and pathological 
processes. In general, they coordinate body functions to maintain a constant internal 
environment (homeostasis) but certain hormones also affect behaviour, and thus 
influence response to external environmental conditions. Five principal areas of 
hormonal function have been defined. They include the maintenance of physiological 
conditions, the general growth and development of the body, the control of 
reproduction, the different behaviour patterns and the control of energy metabolism 
(production, utilisation and storage) . 4
Hormones are produced by ductless internal glands or groups of secretory cells and 
are then discharged directly into the bloodstream in response to a stimulus. When 
hormones are released into the blood stream, they are carried via the circulation to 
other parts of the body where they act on remote target cells. The response to a
4
hormone is dependent on two factors: different hormones activate different cellular 
mechanisms, and not all cells have receptors for all hormones. As a result, some 
hormones limit their effects to specific body tissues, others act in a more general 
manner, stimulating a response throughout the body. In any case, the hormone 
interaction with the cell depends on the chemical type of hormone.
1.1.3 Chemistry of hormones and mechanism of action
The two major classes of hormones in the body, peptides and steroids, differ in their 
chemical structures and mode of action at their target cells.
The peptide hormones range in size from a tripeptide (e.g. thyrotropin releasing 
hormone or TRH, Figure 1.1) to a polypeptide containing nearly 200 amino acids 
(e.g. growth hormone). Many peptide hormones are synthesised from larger 
precursor proteins called prohormones. Theses are specifically cleaved by enzymes 
to give rise to functional hormones. Peptide hormones, because of their polarity, 
cannot pass through cell membranes and rely on an intracellular second messenger to 
elicit their response. They bind with high affinity to protein receptors located on the 
surface of target cells which in turn causes a conformational change in the receptor. 
This activates the production of a second messenger, which eventually leads to 
protein phosphorylation and results in the physiological response to the hormone. 10
Figure 1.1 Structures o f a peptide horm one (TRH) and a steroid hormone (Testosterone).
The steroid hormones are generally smaller than peptide hormones and can be 
grouped into five families: the glucocorticoids, the mineralocorticoids, the estrogens, 
the androgens (e.g. Testosterone, Figure 1.1) and the progestins. Steroid hormones 
do not bind to cell surface receptors; since they are lipohilic, they easily pass through
TRH Testosterone
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the plasma membrane of their target cells and complex with specific receptors in the 
cytoplasm or the nucleus. In the nucleus, the hormone-receptor complex binds 
specific regions of the DNA and affects gene expression. The action of the proteins 
resulting from the transcribed genes produces the response to the hormone. 10
The physiological response to a hormone is also related to its chemical type. The 
action of peptide hormones is quite rapid -  from seconds to minutes, as compared to 
the slower action of steroid hormones. In general, peptide hormones allow the 
organism to make swift, adaptive response to a changing environment while steroid 
hormones have a longer-lasting maintenance function.
1.1.4 The endocrine system: control and regulation of hormone 
release
The endocrine system is composed of specialised cells, organised into glands and cell 
clusters which secrete hormones into the circulation. In order to maintain the correct 
regulatory function of a hormone, the endocrine system receives constant feedback 
information about the state of the system being regulated.
The secretory activity of most endocrine glands is controlled by the anterior pituitary 
(or adenohypophysis), which is the dominant gland of the endocrine system (Figure 
1.2). It is located at the base of the hypothalamus, which functions as an important 
link between the nervous and the endocrine system. The hypothalamus receives 
messages from the brain via nerve terminals eliciting the release of hormones into the 
pituitary blood supply (hypothalamic releasing hormones), which in turn stimulates 
the release of pituitary hormones (trophic hormones) . 4,11 The trophic hormones act as 
messengers to other target glands, providing instructions for the release of specific 
hormones (peripheral hormones). The hypothalamus and pituitary gland therefore 

















Figure 1.2 Schematic representation of inter-relations between the hypothalamic-pituitary hormones 
and peripheral hormones: direct and indirect negative feedback (r.h., releasing hormone, t.h., trophic 
hormone, p.h., peripheral hormone; CNS, central nervous system; + and -  indicate stimulating and 
inhibiting effects respectively).
The major hormone-producing regions of the human body, besides the hypothalamic- 
pituitary axis, are the thyroid gland, the parathyroids, the pancreas, the adrenal 
glands and the gonads. The production and output of hormones of most of these 
endocrine organs is under the regulatory effect of the anterior pituitary and is 
regulated via a very sensitive feedback system (Figure 1.2). Regulation of hormone 
release occurs most commonly by negative feedback, where an increase in the level 
of a circulating hormone decreases the secretory activity of the cells producing it.
There are two types of negative feedback: the direct negative feedback is the most 
common ‘closed-loop’ control mechanism4 which occurs when the levels of the 
target gland hormone exerts an inhibitory effect on the release of pituitary hormones.
7
The target gland hormone can also inhibit the release of pituitary hormone via 
indirect feedback, i.e. by inhibiting the secretion of hypothalamic releasing hormone. 
Positive feedback is less common, but a hormone may stimulate pituitary or 
hypothalamic hormone release to facilitate its own secretion. There are many 
examples of endocrine feedback loops throughout the body and for instance, the 
secretion of thyroxine by the thyroid gland is directly controlled by the trophic 
hormone TSH (thyroid stimulating hormone). Similarly, the corticosteroid hormones, 
secreted by the adrenal glands, indirectly inhibit the release of ACTH 
(adrenocorticotrophic hormone) from the pituitary, by modulating the secretion of 
hypothalamic CRH (corticotrophin releasing hormone).
1.2 Estrogens, the female sex hormones
Estrogens belong to the steroid hormones, a class of chemical messengers which 
mediate a wide variety of vital physiological functions, ranging from the anti­
inflammatory response to the regulation of events during pregnancy.
Estrogens are responsible for all female secondary sex characteristics. They are 
concerned with the normal growth and development of the female reproductive 
system, breast development as well as the typical female body shape. In addition, 
they are involved in calcium and nitrogen metabolism , 12 and they are of critical 
importance in bone development, the maintenance of bone density and have 
cardioprotective effects. 13 There is also evidence to suggest that estrogens might 
have neuroprotective effects and are linked to cognitive functions. 14
The first estrogen was isolated in 1929 by Edward Doisy and coworkers15 who 
successfully crystallised estrone from urine extracts of pregnant women. This was 
followed by the discovery of estradiol in 1936. Although a number of important 
sterols including cholesterol, cholic acid and ergosterol had already been isolated in 
the 19th century, these two discoveries had a major impact on the field of 
endocrinology by opening it up to research in organic chemistry.
1.2.1 Biosynthesis of estrogens
All steroid hormones are biologically derived from cholesterol and have in common 
a cyclopentanoperhydrophenanthrene ring structure (Figure 1.3). Most of these 
hormones are synthesised and secreted into the bloodstream by the adrenal cortex 
and the gonads (ovaries and testes). The series of reactions involved in the 
biosynthesis of estrogens is summarised in Figure 1.4.
estrane androstane pregnane
Figure 1.3 N um bering o f the steroidal skeleton, designation o f the four rings and nam es o f steroid 
nuclei possessing 18, 19 and 21 carbons.
i) From cholesterol to steroids
Besides being ingested in food, cholesterol is synthesized in the body from 
acetylcoenzyme A, a biological source of acetate, via a multi-step pathway. 
Cholesterol is stored inside fat droplets in the cell cytoplasm and its breakdown into 
steroids is. regulated by hormonal signals. 12 Most of the enzymes involved in the 
steroidogenesis are cytochromes of the P45 0 family.
Pregnenolone is the first steroid to be formed from cholesterol and its biosynthesis 
corresponds to the rate-controlling step in the steroid cascade. 12 This 21-carbon 
steroid is obtained after excision of a six carbon unit from cholesterol by the 
cytochrome P45 0 side chain cleavage enzyme. To yield the steroids, a series of 
reactions occurs at specific sites: pregnenolone is converted into glucocorticoids and 
mineralocorticoid in the adrenal cortex, while conversion into androgens and 

























Figure 1.4 Summary o f  the pathw ays leading to estrogens. The abbreviation for the enzym es are: P45o 
SCC, P450 side-chain cleavage; 17a-H Ly, 17a-hydroxylyase; 3(3-HSD/A5-A4-IS, 3 (3-hydroxysteroid 
dehydrogenase/A4-A5-isom erases; AR, arom atase; 17J3-HSD, 17(3-hydroxysteroid dehydrogenase. The 
abbreviations for the steroids are: PG, pregnenolone; P, progesterone; 17a-H PG , 17a-hydroxy- 
pregnenolone; 17a-H P, 17a-hydroxyprogesterone; DHEA, dehydroepiandrosterone; A4-dione, 4- 
androstene-3,17-dione; A5-diol, 5-androstene-3(3,17P-diol; T, testosterone; E l ,  estrone; E2, estradiol.
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ii) Pathways to estrogens
The biosynthesis of estrogens mainly occurs in the ovaries during the reproductive 
years of a woman’s life. The pathway from pregnenolone to estrogens can be divided 
into two basic stages, each taking place in specialised cells of the ovarian follicle: the 
production of androgens in the theca cells and the conversion of androgens into 
estrogens in the granulosa cells. 17
There are two general metabolic pathways which can lead to androgens starting from 
the key intermediate, pregnenolone: the A5 (5-ene-3p-hydroxy) and the A4 (4-ene-3- 
oxo) pathways (Figure 1.4). Any steroid intermediate on the A5 pathway may be 
converted to its corresponding steroid on the A4 pathway by the sequential action of 
two enzymes: 3 p-hydroxy steroid dehydrogenase, which oxidises the 3-hydroxyl of a 
steroid to a ketone, and A5-A4-isomerases, which catalyse the migration of the double 
bond from C5-6 to C4-5. 16 Both pathways involve a series of enzymatic reactions, 
eventually yielding two androgen precursors which can be readily transformed into 
estrogens: the 19-carbon steroids androstenedione (A4-dione) and testosterone (T). 
To a minor extent, androgens are also synthesised in the brain via the A5 and A4 
pathways.
In the granulosa cells of the ovaries, the enzyme aromatase then converts the C-19 
androgens into C-18 estrogens, introducing two key structural modifications: the loss 
of the angular C-19 and the aromatisation of the A-ring. There is evidence that the 
adrenal cortex can also generate small amounts of E l from its androgen precursor, 
androstenedione. During pregnancy, aromatisation takes place predominantly in the 
placenta, and most of the E l produced is converted into estriol (E3), the active 
estrogen of the gestation.
In postmenopausal women, the production of estrogens by the ovaries ceases and the 
aromatisation of adrenal androgens represents the main source of El and E2. This 
takes place extraglandularly, in non ovarian tissues, such as fat and muscles. 18
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1.2.2 Regulation of production
Steroid-producing cells store a limited supply of hormone precursor but none of the 
mature, active hormone. When stimulated, the cells convert the precursor to the 
active hormone, which then diffuses across the plasma membrane into the blood. 
This is the case for estrogens, whose production is regulated by the gonadotropins, 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) (Figure 1.5). The 
gonadotropins, which are released by the anterior pituitary, do not have any direct 









Figure 1.5 Estrogens production in the female: in premenopausal women, ovaries are the main source 
of estrogens while in postmenopausal women, estrogens are produced extraglandularly from the 
adrenals. LH, luteinizing hormone; FSH, follicle stimulating hormone; ACTH, adrenocorticotropin 
hormone
In premenopausal women, estrogen production follows monthly cycles during which 
an ovum is released. Each cycle is divided into follicular and luteal phases which 
correspond to pre- and postovulatory phases.19 During the follicular phase, the 
secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus 
stimulates the release of LH and FSH, which in turn stimulates ovarian estrogen
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production and induces endometrial proliferation. As estrogen levels peak, FSH 
secretion is inhibited and a positive feedback loop is activated, where the release of 
LH from the anterior pituitary is stimulated by estrogens. This results in a surge of 
LH which induces ovulation and marks the passage into the luteal phase of the cycle. 
The empty follicle produced evolves into what is called the corpus luteum, which 
secretes both E2 and progesterone. As the level of both hormones rises, the secretion 
of LH and FSH is inhibited through negative feedback. Without continued 
stimulation by LH, the corpus luteum regresses and the secretion of progesterone and 
E2 declines. This consequently stimulates the secretion of LH and FSH and the 
beginning of a new cycle.
In postmenopausal women, the ovaries cease producing estrogens. This is partly 
compensated for by production of adrenal androgens under the influence of the 
adrenocorticotrophin hormone (ACTH) (Figure 1.5). Without estrogen feedback, the 
circulating levels of FSH and LH rise substantially, which translates into a number of 
symptoms characteristic of the menopause. In the long term, low circulating estrogen 
levels are linked to a higher risk of cardiovascular diseases and osteoporosis. 
Estrogen replacement therapy is generally prescribed in order to prevent and relieve 
these symptoms.
1.2.3 Estrogen receptors and model of action
i) Early experiments and the ‘two-step’ mechanism
In the 1960s, thanks to the pioneering work of Jensen’s and Gorski’s groups, the first 
theory with regards to the mechanism of action of steroid hormones at the target cell 
emerged. Their findings converged towards the hypothesis that steroid hormones act 
at the level of nuclear DNA to regulate gene expression. 20,21
Initial progress was made when in vivo experiments on rodents led to the distinction 
between target and non target tissues. After injection of 3H-E2 into immature rats, it 
was noted that uterus and vagina would continue to incorporate and retain the 
radioactive hormone longer than muscle, blood, kidney and liver, where the levels
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dropped relatively quickly. Further work showed that within a short time after 
administration, E2 was found to be concentrated in the nuclei of the target tissue cells 
but no nuclear uptake of the steroid was observed in the absence of cytosol. 22 
Additionally, sedimentation experiments showed that H-E2-protein complexes 
extracted from the cytosol and the nuclei had different sucrose density gradients, 
suggesting a transformation in the cytoplasmic receptor complex before entry into 
the nucleus. 23 Finally, the binding of these receptors to E2 was found to be specific. 
From these results, a two step model of action which should be applicable to all 
steroid hormone-cell interaction was postulated: (a) hormones enter the cytoplasm of 
the target cell and bind to a receptor for which they are specific - this may lead to 
alteration in the structure of the receptor; (b) the hormone-receptor complex diffuses 
into the nucleus, where it exerts its effects.
ii) Refining the model
With the identification of an estrogen receptor (ER), capable of binding E2 with high 
affinity and specificity in target cells, refined models were proposed to explain 
estrogen mechanism of action. 21 The ER, initially assumed to be a cytoplasmic 
protein was later found to be a nuclear receptor, as observations suggested that much 
of the ER may already be present in the nucleus before exposure to the hormones. 24 
The cloning of the ER gene by Green et a l24,25 led to the identification of the 
properties and the location of the functional domains of the ER protein.
The ER belongs to a superfamily of ligand-activated transcription factors, known as 
the steroid hormone nuclear receptor family, that can initiate or enhance the
Oftranscription of genes containing specific hormone response elements. These 
nuclear receptors all share the same structural features: they are located 
predominantly in the nucleus and function as homo- or heterodimers. Biochemical 
and mutational analyses have indicated that the ER gene can be subdivided into 
several functional domains labelled A to F. The most important regions are C and E 
which are highly conserved and contain the DNA and hormone binding domain, 







Figure 1.6 Schematic representation of the ER and its mode of action: (1) diffusion o f the steroid (E2) 
through the cellular membrane; (2) formation of the ER-steroid complex (ER-E2); (3) conformational 
changes and dimerisation of the complex followed by binding to EREs; (4) transcription o f a 
regulatory gene; (5) production of regulatory proteins.
Tissue localisation studies have shown that the ER was located in the hypothalamic- 
pituitary axis, liver, cardiovascular system, bone cells, uterus, vagina and in some 
breast cancers. In these target organs and tissues, the ER is the key mediator of 
estrogen action, which generally affects the growth and differentiation of target 
cells.28 When an estrogen binds, it induces a conformational change within the ER 
which allows dimerisation of the receptor monomers.29 The homodimer subsequently 
binds with high affinity to DNA-binding sites, the estrogen response elements 
(EREs) located in the transcriptional control regions of target genes. The DNA bound 
receptor activates (up-regulation) or represses (downregulation) the expression of the 
target gene, leading to the subsequent tissue response. A schematic representation of 
these events is depicted in Figure 1.6.
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Hi) A second estrogen receptor
Since the identification and, in the late 1980s, the cloning of the ER, it had been 
accepted that only one ER gene existed. Yet, nearly two decades later, a novel ER, 
the ERp subtype, was cloned from a rat prostate cDNA library; 30 this was closely 
followed by the sequencing of its homologs in human. 31 A comparison of the amino 
acid sequence of the rat ER|3, with that of the first ER cloned, now referred to as 
ERa, showed a high degree of conservation of the DBD (96%) and HBD (58%). 
Similarly to ERa, ERP displays a high affinity and specific binding of E2, and is 
able to stimulate the transcription of an ER target gene in an E2-dependent 
manner. 30 ,3 2 ERa and ERp have an overlapping but non-identical tissue distribution 
and ERP is the predominant subtype expressed in ovary, prostate, testis, spleen, lung, 
hypothalamus and thymus. 33,34
The recent discovery of this new isoform of the ER has added a further level of 
complexity to understanding the mode of action of ERs. There is a need to 
distinguish ERa from ERP pathways and there are many questions concerning how 
each isoform modulates estrogen action and work to stimulate growth responses, 
when both receptors are present in a target cell. 32
1.3 Role of estrogens in the aetiology of breast cancer
The influence of estrogens on the development of breast cancer has long been 
recognised. As early as 1896, at a time when the concept of the hormone had not yet 
been developed, Beatson observed that advanced breast cancer could be induced to 
regress in premenopausal women by removing the ovaries. 35 Later on, Lacassagne 
was the first to indicate that a correlation probably existed between hormones and the 
development of cancer since the administration of estrogen could induce mammary
o r
cancer in rodents. However, the precise mechanism of estrogen action at the 
cellular level and the influence of such hormones in carcinogenesis was only 
elucidated, at least partially, with the discovery of the ER and its subsequent isolation
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in some breast cancer cells. By ER, we will be referring to ERa unless otherwise 
specified.
1.3.1 Molecular basis of estrogen action
i) Agonism and antagonism: some definitions
The ER is capable of binding a diverse set of ligands, that are broadly categorised as 
agonists or antagonists depending on their ability to induce or inhibit a 
transcriptional response. Agonists can bind the ER with different affinities, which, in 
the case of estrogens is correlated with their biological potency or estrogenicity. 
Additionally, the binding affinity of different estrogens to the ER parallels their 
ability to stimulate uterine growth and the uterine weight assay is a common way to 
asses the estrogenicity of a compound in vivo. Of the three major naturally occurring 
estrogens (E2, E3 and El), E2, the most abundant estrogen released from the ovaries, 
is also the most biologically potent. The ability of a given compound to induce 
uterotrophic response is generally compared to that of E2. Intriguingly, estrogenic 
activity is not restricted to the steroid structure and compounds such as the synthetic 
estrogen diethylstilbesterol or the phytoestrogen coumestrol have a potent estrogenic 
activity. 37
Compounds which antagonise the action of E2 are called antiestrogens. They are 
able to bind the ER competitively with E2 and with the same affinity, but do not 
elicit estrogen-related effects such as uterotrophic growth. These compounds 
represent an important class of drugs which aim at preventing endogenous E2 from 
exerting its effects on target cells, by blocking its access to the ER.
Some compounds also possess a mixed agonist/antagonist profile: they manifest ER 
agonist activity in some tissues, but oppose estrogen action in others. The properties 
of such compounds, called selective estrogen receptor modulators (SERMs), are 
exemplified by Tamoxifen. This drug, which was developed some 30 years ago and 
is currently used as a first line treatment for HDBC, was initially believed to act as an 
antiestrogen. It was subsequently shown to have estrogen-like effects on bone and
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lipid metabolism (lower serum lipids) while remaining an estrogen antagonist in 
breast tissue. 38,39 The potentially beneficial effects of partial ER agonists in 
postmenopausal women, i.e. prevention of bone mass loss and reduction in cardiac 
diseases, led to the development of more SERMs to be used as hormone replacement 
therapy (HRT).
ii) Structural basis o f agonism and antagonism
The cloning of the ER, followed by the determination of the crystal structure of its 
ligand binding domain (LBD) in complex with several molecules, have greatly 
contributed to the understanding of the mechanism of agonism and antagonism at the 
ER level.40
The crystal structure of the ERa-LBD in complex with either E2 , 41 the synthetic non 
steroidal estrogen diethylstilbesterol,42 and the antagonist raloxifene41 has been 
determined. No crystal structure of the ERp-LBD has been resolved with a natural or 
synthetic estrogen. It has however been determined in presence of the partial agonist 
genistein43 The data collected showed that the ability of ER ligands to act as agonist 
or antagonist can be related to their binding mode in the vicinity of the LBD. For 
each ligand, the receptor forms a dimer and, although agonist and antagonist bind at 
the same site within the hydrophobic core of LBD, the binding modes are 
dramatically different for the two classes of compounds.40,41 In fact, each class of ER 
ligand induces a distinctive orientation of the LBD’s carboxy terminal helix, helix 12 
(H12). In the presence of agonists, H12 is oriented across the cavity so that the bound 
ligand is completely buried within the core of LBD. In contrast, the large side-chain 
substituent of tamoxifen cannot be accommodated within the binding cavity. Instead, 
the substituent protrudes from this cavity and prevents the correct alignment of 
H 1 2  40,41 This is also the case for the full antagonist ICI 164,384, where the ligand 
side-chain induces a displacement of H12 and a consequent disordered conformation 
of the LBD.
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1.3.2 Endogenous estrogens and risk of breast cancer
Many well recognised risk factors for breast cancer are estrogen-related and assert 
the involvement of the female sex hormone in carcinogenesis.44 ,45 An early onset of 
menstruations (women less than 1 2  years old) or a late menopause (women older 
than 55) increase the risk of breast cancer, suggesting that the duration of exposure to 
ovarian estrogens is an important factor. This view is corroborated by the fact that an 
early menopause or removal of the ovaries early in life decreases the risk. In 
postmenopausal women, high estrogen levels have been correlated with an increased 
relative risk of breast cancer.44
Mutations in high risk genes such as BRCA1,46 BRCA2 and p53 have also been 
correlated with an increased risk of breast cancer. These tumour suppressor genes are 
involved in repairing oxidative DNA damage and help maintain the integrity of the 
genetic material. They also play a role in cell differentiation and apoptosis in normal 
cells. In particular, mutations in the p53 gene have been associated with poor 
prognosis in breast cancer patients 47 Somatic mutations in BRCA1 are extremely 
rare and the mutant gene appears to cause breast cancer only when present in the 
germ line, accounting for the higher risk of the disease for women who have a 
history breast cancer in their family. It is estimated that 70% of the mutation carriers 
will develop breast cancer by the age of 70.
Additional factors may also contribute to individual variation in exposure to 
estrogen. Obese postmenopausal women have a 2-fold increased risk of breast 
cancer48 as a result of an increase in bioavailable E2. Although no correlation 
between E2 metabolism and nutrition has yet been strongly supported, the current 
hypothesis is that alcohol may affect the risk of breast cancer by increasing the 
endogenous E2 level.49
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F igure 1.7 Schematic representations of the mechanisms by which estrogens increase the risk of 
breast cancer.
Although the precise role of estrogens in the genesis of breast cancer is unclear, 
several hypotheses have been put forward in an attempt to explain how these 
hormones exert their effects (Figure 1.7).46’50 Estrogens are generally believed to act 
as promotors of cancer, since they are able to stimulate the growth and development 
of existing malignant cells in the breast. However, they may also act as initiators, by 
promoting cell proliferation in breast tissue and subsequent genetic instability. The 
potential genotoxicity of estrogens and some of its metabolites can also affect breast 
cancer risk. For instance, the catechol 4-hydroxyestradiol is highly estrogenic and 
might cause direct and indirect DNA damage through the formation of free 
radicals.51
1.3.3 Exogenous estrogens and risk of breast cancer
The effect of exogenous estrogens such as oral contraceptives or HRT on the risk of 
breast cancer has attracted much public concern. Although this topic will not be 
discussed in detail, it is interesting to note that in a recent study, the use of oral 
contraceptives was not associated with a significant increased risk among women 
aged 35 to 64. " In contrast, the results of a cohort study (the ‘Million Women 
Study’) established a relationship between the use of HRT and a higher breast cancer 
incidence and mortality.53
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1.3.4 ER and breast cancer
ERs are present in both normal and tumour breast tissues as well as in estrogen- 
dependent and independent cell lines. ER levels vary from one woman to another, 
however, high levels have been directly correlated with an increased risk of breast
54cancer.
A patient with high concentration of the receptor protein (at least 10 fmol ER per mg 
cytosol protein) is designated as being ER positive (ER+), while one with less than 
this value is regarded as ER poor or ER negative (ER- ) . 55 ,56 More than 70% of 
primary breast cancers in women are ER (i.e. ERa) positive and show estrogen 
dependent growth. It is estimated that up to 60% of ER+ breast cancers will respond 
to endocrine therapy (vide infra) while only 10% of ER- tumours will show a 
response. The assessment of the ER status is currently used to select patients for 
hormone-related treatments, although other biological factors may correlate with 
therapeutic response.57 ,58
A number of investigations have been carried out in order to establish a relation 
between the ER content and some intrinsic properties of tumours. Attempts to
correlate ER content with tumour size, or the time of onset or incidence of distant
0(\metastases have been largely unsuccessful. However, a close correlation has been 
observed between ER expression and the tumour growth rate: tumours with low or 
undetectable levels of ER proliferate more rapidly than when the ER content is 
higher.54
A correlation between the ER status of a patient and rate of recurrence of the disease 
also exists: women with ER+ tumours have a better prognosis with longer disease
r o
free intervals and ER- tumours tend to recur earlier and are also more aggressive. 
Therefore the ER status, besides influencing the choice of treatment for a given 
patient, is a crucial prognostic indicator.
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1.4 Hormone-Dependent Breast Cancer
It is now widely acknowledged that breast cancer is a hormone-dependent disease. 
E2 has a well established role in carcinogenesis of the breast and it is generally 
believed that most breast tumours rely on estrogens for their growth and 
development, at least in their early stage. The process which takes the disease from a 
cancer cell to a detectable tumour can take many years, during which time some 
tumours become estrogen independent. Overall, one third of all breast carcinoma 
remain hormone-sensitive.
1.4.1 Treatments: a brief overview
The treatment of breast cancer depends on many factors, including the characteristics 
of the tumour, its stage at diagnosis, its sensitivity to hormonal treatment or 
chemotherapy and the age and menopausal status of the patient. An early detection 
of breast cancer is critical to effective disease management as treatment options are 
greater for primary tumours. Campaigns to promote routine mammography and 
breast screening in women aged 50 years and older are aiming to reduce the overall 
mortality associated to the disease. 59
i) Primary breast cancer
In the earliest stages of breast cancer, surgery is the treatment of choice. In most of 
the cases, breast conserving surgical techniques, such as local excision of lump(s) in 
the breast(s) (lumpectomy), are employed rather than mastectomy. To prevent any 
recurrence of the disease, adjuvant radiotherapy is often prescribed, particularly if 
breast conservation surgery has been involved. 59 There is generally no need for major 
surgery in patients with primary breast cancer, and in a recent trial comparing 
women undergoing mastectomy versus breast conservative surgery plus 
radiotherapy, no significant difference was observed in the overall 1 0 -year survival. 60 
Radiotherapy is also used to reduce large tumours to an operable size so that 
conservational surgery can be carried out.
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Adjuvant hormone therapy57 or chemotherapy, or a combination of both, can also be 
used to eliminate and prevent the recurrence of micrometastases after surgery. 
Chemotherapy is generally given to premenopausal women, while tamoxifen is the 
hormonal treatment of choice for postmenopausal women and ER+ patients of any 
age. Overall, the risk of recurrence can be decreased by 30% with adjuvant 
therapy. 55,56
ii) Secondary breast cancer
For advanced breast cancers, when the tumour has spread or recurred, the aim in the 
treatment is no longer to cure, but to reach a palliative control. This is the case when 
metastases of the tumour have reached the bone, skin, lymph node or the brain.
Temporary regression of the lesions can be achieved by the use of endocrine therapy 
or chemotherapy and some treatments can produce a worthwhile symptom-free 
extension of the patient’s life. The treatment strongly depends on the hormonal and 
ER status of the patient and the prognosis is determined primarily by the ER status.
Endocrine ablation is a treatment alternative, generally recommended in 
premenopausal women, whose tumour show estrogen dependency. Chemical 
ablation, with the use of luteinising hormone-releasing hormone (LHRH) analogues 
which act as pituitary downregulators, is generally given since their action is
cn f. 1
potentially reversible, unlike radiotherapy or surgical removal of the ovaries. ’
1.4.2 Endocrine therapy: one answer to HDBC
Endocrine or hormone therapy is characterised by the use of drugs specifically 
designed to deprive tumour cells of estrogenic stimulation, by either antagonising 
estrogen action at the receptor, or by blocking estrogen production pathways.
Endocrine therapy is particularly effective in women who suffer from HDBC, i.e. 
half of premenopausal women and two-thirds of postmenopausal women with breast 
cancer. Paradoxically, the incidence of HDBC is higher in postmenopausal women,
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where circulating estrogen levels are relatively low, with plasma levels of E2 5- to 
60-fold lower than in premenopausal women. In fact, estrogen concentration in 
tumour tissues is much higher than in the plasma, suggesting that tissue levels do not 
reflect circulating hormone levels. In situ production of E l and E2 from inactive 
precursors is a possible explanation for this tissue:plasma gradient. Inhibition of the 
enzymes involved in the synthesis of active estrogenic steroids therefore represents 
an attractive approach for the treatment of HDBC.64
i) Antiestrogens
The treatment of estrogen-dependent breast cancer by antiestrogen therapy has been 
the front line defence against the disease for the past 30 years. Antiestrogens are able 
to bind competitively to the ER, thus preventing access of endogenous estrogens to 
their specific binding site. Since they induce a different conformation in the ER to 
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Figure 1.8 Structure o f non steroidal antiestrogens and SERMs.
Antiestrogens were initially developed in the late 1950s, as a result of a search for 
orally effective non-steroidal contraceptives. The first non-steroidal antiestrogen 
MER 25 (Figure 1.8) led to the discovery of compounds such as Clomiphene and 
Tamoxifen, both sharing a triphenylethylene skeleton. 39 While Clomiphene is now 
marketed for treating infertility, Tamoxifen has become the endocrine treatment of 
choice for all stages of breast cancer39 ,55 ,56 offering a safe and simple alternative to 
ablative surgery, reducing the risks of recurrence and prolonging the survival of 
women affected by the disease. Interestingly, Tamoxifen itself does not bind to the 
ER but its metabolite, 4-Hydroxytamoxifen (Figure 1.8), has a 100-fold higher 
affinity for the receptor and is able to compete with E2 for binding.
Results of randomised trials of adjuvant Tamoxifen versus no Tamoxifen in women 
with breast cancer before recurrence have shown that the drug is optimally effective 
with a 5 year course treatment. 56 For women with ER+ tumours, receiving adjuvant 
Tamoxifen for 5 years, a 47% reduction in recurrence was observed during a 10-year 
follow up, with a corresponding 26% reduction in mortality. Patients with ER+ 
tumours did respond better to the treatment than those with ER- tumours and, overall, 
Tamoxifen was found to improve the 10-year survival for women with early breast 
cancer55 irrespective of age, menopausal status, and whether previous chemotherapy 
has been administered to the patient. Today, several clinical trials are assessing the 
possible use of Tamoxifen as a preventive treatment for breast cancer. However, 
there are still some serious unanswered problems: ’
(a) Tamoxifen is a partial agonist on the endometrium and long-term use was found 
to be associated with an increased incidence of endometrial carcinoma.
(b) Although 70-80% of breast cancers are ER+, only half of these will respond to 
tamoxifen. This phenomenon might be due to the polymorphism of the ER since the 
presence of ERp can potentially allow estrogen-regulated growth, even in the 
presence of an antiestrogen.
(c) Over time, some tumours can become resistant to the treatment by becoming 
hormone-independent; in responding patients, the disease ultimately progresses to a 
resistant phenotype, because of the presence of an efficient growth control pathway 
independent of estrogen signalling.
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The mixed agonist/antagonist properties of Tamoxifen prompted the development of 
a new type of antiestrogens, the selective estrogen receptor modulators or SERMs. 
These drugs, which emerged in the 1990s, combine the potentially beneficial effects 
of estrogens in postmenopausal women (i.e. maintain bone density and decrease 
circulating low-density lipids), while reducing a patient’s risk of breast cancer. 65 ,66
Raloxifene (Figure 1.8) was the first SERM to be used clinically on the basis that it 
could reduce the incidence of breast cancer as a beneficial side-effect of the 
prevention of osteoporosis. Results of trials (Multiple Outcome of Raloxifene 
Evaluation or MORE) confirmed this hypothesis, with a 70% decrease in risk of
z:o
breast cancer observed after a 3-year treatment in postmenopausal women. 
Additionally, Raloxifene was not associated with an elevated risk of endometrial 
cancer. Toremifene, Droloxifene and Idoxifen (Figure 1.8) are a new class of SERMs 
derived from Tamoxifen that posses a weaker agonist activity on the endometrium. 
Only Toremifene (Fareston) is available for treatment of advanced breast cancer in











Figure 1.9 Structure o f pure antiestrogens.
The search for new endocrine agents, such as pure antiestrogens, was initiated in an 
effort to find an alternative to Tamoxifen for patients who did not respond or 
developed resistance to the treatment. The first pure antiestrogen, ICI 164,384, was 
discovered in the late 1980s by Wakeling and Bowler.70 This 7a-undecanamide 
derivative of E2 was found to be completely devoid of estrogenic activity in rat and 
mouse uterus, in vitro and in vivo, while retaining its affinity for the ER. The poor
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bioavailability and biological profile of this compound consequently led to the design 
of new antiestrogens, from which ICI 182,780 (Faslodex) and RU 58,668 emerged 
(Figure 1.9). Similarly to ICI 164,384, they have no estrogen-like effects and can 
inhibit the growth of breast cancer. 71 ICI 182,780 is currently used as second-line 
treatment in the United States and Great Britain for advanced breast cancer, 
following Tamoxifen failure.71
Pure antiestrogens were initially believed to block dimerisation of ER complexes, 
consequently preventing the binding to DNA. Mechanistic investigations have 
however revealed that such compounds target the ER to provoke its rapid 
destruction, preventing tumour cell survival.
ii) Aromatase inhibitors
The use of therapeutic agents that inhibit one or several enzymes of the steroid 
biosynthetic pathway represents another important strategy to control the 
development of estrogen-dependent tumours. The enzyme aromatase, which converts 
androgenic C19 steroids to estrogenic C18 steroids, has been the prime target for 
reducing estrogen levels. This enzyme complex, which contains a cytochrome P450  
haemoprotein, catalyses the aromatisation of the androgen A-ring with subsequent 
loss of the C-19 methyl group to yield estrogens.
In premenopausal women, aromatisation principally occurs in the ovaries while in 
postmenopausal women, estrogen synthesis from adrenal androgens takes place 
extraglandularly in the adipose tissue, muscle, liver and skin. 18 The aromatase 
enzyme is also present in more than 70% of breast tumours, 72 where estrogen levels 
are found to be generally higher than in normal breast tissue. There is strong 
evidence to suggest that in situ aromatisation of androgens may account for the high 
estrogen content found within some breast tumours; 73 this is supported by the fact 
that 1 0 - 2 0  times greater levels of estrogens are found in tumour tissue vs. plasma.
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AG Formestane Fadrazole
Figure 1.9 AG and second generation arom atase inhibitors Form estane (type I) and Fadrazole (type 
II).
Aminoglutethimide (AG, Figure 1.9) was the first aromatase inhibitor used for the 
treatment of breast cancer. However, its use was correlated with adrenal 
insufficiency and a number of undesirable side effects given its wide spectrum of 
action on other P4 5o-dependent enzymes.74,75
Attempts to improve on the original structure and increase the therapeutic index have
no 7 4  nf\ _led to a number of compounds entering clinical trials. ’ ’ The new molecules, 
more selective, more active and less toxic than AG, can be classified into two types, 
depending on the manner in which the molecule binds to the active site. Type I 
compounds are steroidal, irreversible mechanism-based inhibitors derived from the 
natural substrate for the enzyme: androstenedione. 4-Hydroxyandrostenedione 
(Formestane, Figure 1.9), the first type I inhibitor to be used clinically proved to be 
30-60 times more potent than AG. Its poor oral bioavailability however limited its 
use. Type II inhibitors are non-steroidal molecules (e.g. AG) and contain moieties 
such as phenylamines, imidazoles and triazoles. They act as reversible competitive 
inhibitors and their major interaction with the active site results from the chelation of 
their heteroatom(s), usually a nitrogen, to the iron heme in the enzyme, while the rest 
of the molecule aligns with the substrate binding domain. Fadrazole (Figure 1.9), was
nf\found to be 500-times more potent than AG in vivo.
Letrozole Anastrozole Vorozole Exemestane
Figure 1.10 Third generation arom atase inhibitors: Letrozole, Anastrozole, V orozole and Exem estane.
The last generation of aromatase inhibitors includes compounds such as Letrozole 
(Femara), Anastrozole (Arimidex) and Vorozole (Rivizor) 77 (Figure 1.10), which are 
type II inhibitors. These 1,2,4-triazoles are selective reversible inhibitors of 
aromatase: they combine high potency, being 103 to 104-fold more potent than AG, 
high selectivity for the enzyme and are also better tolerated. Anastrozole and 
letrozole are active in vivo and reduce serum levels of estrogens by 97% and 99% 
respectively. Exemestane is the latest type I inhibitor to enter clinical trials.77
Traditionally, aromatase inhibitors are reserved as second line treatment for 
advanced HDBC in postmenopausal patients whose disease is no longer controlled 
by tamoxifen. However, because of the extremely good toxicity profile of some of 
the latest aromatase inhibitors, recent clinical trials have been conducted to assess 
their suitability as first line treatment for HDBC. Anastrozole is one such drug, now 
licensed for use in the USA.
1.5 Latest strategies
In post-menopausal women, in whom breast cancer most frequently arises, peripheral 
and iotra-tumoral synthesis of estrogens were initially considered to occur almost 
exclusively via the aromatase pathway. However, strong evidence has emerged over 
the past decade, both biochemically and clinically, that the sole inhibition of the 
enzyme aromatase cannot afford an effective reduction of estrogenic stimulation to 














F igure 1.11 Origin of estrogens in tumour cells: the sulfatase pathway. AR, aromatase; ST: steroid 
sulfotransferase; STS, steroid sulfatase; 17P-HSD, 17(3-hydroxysteroid dehydrogenase; 3[THSD, 3(3- 
hydroxysteroid dehydrogenase; A5-A4-IS, A5-A4-isomerase; ER, estrogen receptor; E1S, estrone-3-O- 
sulfate; DHEAS, dehydroepiandrosterone-3-O-sulfate.
The sulfatase pathway is now considered to be the major route for breast tumour 
estrogen synthesis since the sulfatase activity was found to provide 10-fold more El 
than the aromatase activity.73'78 In this pathway, estrogens are synthesized from the 
highly available precursor E1S, via two enzymes (Figure 1.11): steroid sulfatase 
(STS) which hydrolyses E1S into E l, and 17p-hydroxysteroid dehydrogenase (17p- 
HSD) which reduces E l into E2. Both the higher availability in plasma and longer 
half-life of E1S compared with that of unconjugated estrogens have suggested that 
the former may act as a reservoir for the synthesis of active steroids in 
postmenopausal women.63 STS and 17p-HSD, the two enzymes responsible for the 
conversion of E1S into the potent estrogen E2 therefore represent valuable 
therapeutic targets for estrogen deprivation strategies.
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1.5.1 STS inhibitors
Steroid sulfatase is one of 11 sulfatase enzymes capable of cleaving sulfate esters 
into the corresponding alcohol or phenol. In humans, STS is a membrane bound 
enzyme which is responsible for the conversion of inactive 3-O-sulfated molecules 
into their corresponding potent 3-hydroxy form. The presence of STS activity has 
been demonstrated in human breast cancer tissue and in a number of cells lines.79  
Although STS is mainly targeted because of its pivotal role in regulating estrogen 
biosynthesis, it is also able to convert latent androgens into DHEA, the direct 
precursor of androstenediol (A5-diol, Figure 1.11). Recently, this potent androgen 
was found to be able to bind to the ER and stimulate the growth of tumour cells in 
vitro80 and carcinogen-induced mammary tumours in v/v<?.81 Similarly to E2, Adiol is 
therefore an important metabolite for the growth and development of hormone- 
dependent breast tumours. 82 There is strong evidence to suggest that the sulfatase 
enzymes which convert E1S and DHEAS into their respective 3-hydroxy compounds
QO
are identical. Therefore, as sulfated precursors can be converted into potent 
androgens and estrogens via one sulfatase enzyme, the development of STS 
inhibitors offers a viable approach for reducing estrogenic stimulation to tumours and 
combating HDBC . 84
i) Steroidal inhibitors
The androgen Danazol (Figure 1.12), developed in the 1970s as a treatment for 
endometriosis, was the first sulfatase inhibitor to be reported. 85 Since then, several 
potent inhibitors have been identified for STS, some of which are progressing into 
clinical trials. They all share the common structural feature of an aromatic ring that 
mimics the phenolic A-ring of the enzyme natural substrate, E l S.
In the search for E1S analogues, a wide variety of chemical groups have been 
introduced at C3, of which the 3-O-sulfamate was found to be the most potent for the
o z
El skeleton. The resulting compound, estrone-3-O-sulfamate (EMATE, Figure
1.12) inhibited STS activity with respective IC5 0S of 80 nM and 65 pM in placental
Q /T Qn
microsomes and in intact MCF-7 breast cancer cells. This led to the identification
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of the aryl-O-sulfamate moiety as an active pharmacophore required for potent 
inhibition of STS. EM ATE was also shown to inhibit steroid sulfatase activity in a
oo
time- and concentration-dependent manner and was active in vivo on oral 
administration. 89 The mechanism proposed for the inactivation of the enzyme by 
EMATE suggests that E2 is released during the irreversible inhibition of the enzyme, 
which is in agreement with the later findings that EMATE was highly estrogenic in 
rodents. 90,91
h 2n o 2s o h 2n o 2s o
Danazol EMATE
R = OCH3 2-MeO-EMATE 
R = OCH2CH3 2-Et-EMATE
Figure 1.12 Structure o f  Danazol, EM A TE and C2 analogues o f EM ATE.
Most of the compounds which were subsequently developed emerged from the 
search for non-estrogenic inhibitors of STS. Using EMATE as a template, several 
modifications were introduced on the A- and D-ring, mainly at C2 and C17. Since 2- 
methoxy-estrogens are substantially less estrogenic than their unsubstituted parents, 92 
2-methoxy-EMATE (2-MeO-EMATE, Figure 1.12) was synthesised. 93 It was found 
to be a potent irreversible inhibitor of STS, although 8 -times less active than 
EMATE in placental microsomes. This C2 analogue of EMATE was also found to 
possess potent anti-mitotic properties and induced tumour regression without 
displaying any estrogenic activity in vivo.93,94 Its ethyl analogue (2-Et-EMATE, 
Figure 1.12), which was later developed, was as potent as the 2-methoxy analogue 
and had antiproliferative and antiangiogenic activity in human breast cancer cells.95
Molecules combining features of both STS inhibitors and antiestrogens have also 
been developed. Relying on the existing knowledge that an alkylamide side-chain 
can block the estrogen receptor activation, 70 ,96 ,97 Li et al. synthesised 3-O-sulfamates 
derivatives of E2 bearing long hydrophobic A-alkylcarbamoyl and A-alkanoyl side- 
chains at C-17.98 The 17p-alkyl/alkanoyl group, presumably designed as membrane 
insert, increases the affinity of the compound for the enzyme through hydrophobic
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interactions. The heptyl analogues (1.1 and 1.2, Figure 1.13) were found to inhibit 
STS with the same potency as EMATE at 10 nM, without being estrogenic at 1 pM.
Figure 1.13 C-17 derivatives o f EM ATE: introduction o f hydrophobic side-chains with a  or P 
orientation.
Recently, the validity of targeting hydrophobic interaction at C17 of E l, E2 or 
EMATE was further demonstrated by Poirier and coworkers. 9 9 ’ 102 A series of 17a- 
benzyl (or te/t-butylbenzyl) derivatives of EMATE was found to inhibit STS activity 
in transfected HEK-293 cells. 100 In particular, two derivatives (1.3 and 1.4, Figure
1.13) were highly potent, with respective IC5 0S of 0.39 nM and 0.15 nM, being up to 
14-times more potent than EMATE. These irreversible inhibitors were designed 
subsequent to the finding that their precursors, the corresponding D-ring derivatives 
of E2 (1.5 and 1.6, Figure 1.13), could also inhibit STS activity.99 ,102 Their ability to 
do so without the presence of a sulfamate at the C-3 position suggests the presence of 
a hydrophobic pocket in the enzyme, in the region neighbouring the D-ring of these 
steroid substrates. Although 5-8 times less potent than EMATE, they remain the only 
steroidal STS inhibitors known to act via a reversible mechanism.
ii) Non steroidal inhibitors
To avoid the problems linked to an active steroid nucleus, non steroid-based 
inhibitors have been synthesised. Coumarin sulfamates, such as 4-methylcoumarin-7- 
O-sulfamate (COUMATE, Figure 1.14), were among the first inhibitors of that type 
to be identified. 87 Since the coumarin skeleton mimics the A/B ring system of 
estrogens, the aryl-O-sulfamate pharmacophore is present in coumarin sulfamates. 
Although COUMATE was found to be less potent than EMATE in vitro, it was 
active in vivo with the advantage of being non estrogenic. 103
1.1 R = NHCO(CH2)6CH3
1.2 R = CONH(CH2)6CH3
1.3 R = S 0 2NH2 R1 = H 1.5 R = H R = H
1.4 R = S 0 2NH2 R1 = feu 1.6 R = H R1 = feu
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COUMATE n = 7 667 COUMATE 
n = 10 6610 COUMATE
Figure 1.14 Structure o f potent non-steroidal STS inhibitors: C O U M A TE and tricyclic analogues.
In an attempt to improve the activity of coumarin derivatives, several modifications 
were considered. Increasing the hydrophobicity at C3 and/or C4 was found 
beneficial103 and some tricyclic coumarin sulfamates turned out to be more potent 
than COUMATE, while retaining its non estrogenic characteristic. 104 Compounds 
bearing an extra 7- or 10-membered ring (667 and 6610 COUMATE, Figure 1.14) 
were the most active with respective IC5 0S of 8  nM and 1 nM in placental 
microsomes. These COUMATE analogues were therefore up to 800 times more 
potent than COUMATE and some 25 times more potent than EMATE in vitro. 
Investigations of 667 COUMATE in vivo revealed that it could inhibit STS activity 
by 93% after administration of a single dose (10 mg/kg, p.o.) and was devoid of 
estrogenicity.95 Complete recovery of STS activity occurred 7 days after drug 
administration. 95 This potent inhibitor also caused regression of ElS-stimulated 
tumour growth in a dose dependent manner95 and is now being evaluated in a Phase I 
clinical trial in post menopausal women with HDBC . 84
H 0
h 2n o 2s o ^ ^  0  h 2n o 2s o ^ ^  h 2n o 2s o
1.7 1.8 R = C8H17 1.9n = 6
Figure 1.15 M onoarylsulfam ate-based inhibitors o f STS.
In parallel to the development of coumarin-based inhibitors, Li et al. synthesised the 
first monocyclic potent STS inhibitor, p-O-sulfamoyl-A-tetradecanoyl tyramine (1.7, 
Figure 1.15), whose activity was found comparable to that of EMATE in placental 
microsomes. 105 Several compounds based on the monoarylsulfamate structure were 
then developed. Ahmed et a l 106 reported a series of irreversible inhibitors possessing 
a 4-sulfamated phenyl alkyl ketone structure. The best inhibitor (1.8, Figure 1.15)
(CH2)n
was up to 3 times more potent than COUMATE and 7 times weaker than EMATE 
for the inhibition of STS in placental microsomes. 106 Additionally, a strong 
correlation was established between the IC50 of these compounds and their logP 
values, suggesting hydrophobicity as a crucial factor for potent inhibition. 107 Very 
recently, Poirier et al.m  reported some 4-substituted monoarylsulfamates to be more 
potent than EMATE. These compounds, where the B, C and D rings of a steroid have 
been replaced with a mobile chain, are structurally related to the family of C17 
derivatives of EMATE previously reported. 100 The optimum side-chain length was 
found to be of 6  carbon atoms and the resulting compound (1.9, Figure 1.15) was 
more than twice as active as EMATE against STS activity in transfected HEK-293 
cells.
Non steroidal inhibitors based on the chromenone core structure have also been 
reported by Billich and Nussbaumer. 109 ,110 These compounds, which are substituted 
chromenone sulfamates were found to be up to 170-fold more potent than EMATE 
(e.g. 1.10, Figure 1.16) against the purified human enzyme. 109 When the series was 
tested for their ability to induce the proliferation of estrogen-dependent MCF-7 cells, 
the «-nonyl derivative (1.11, Figure 1.16) was the most promising. This compound 
was devoid of estrogenicity at 1 pM while only 7 times less potent than EMATE. 110
n- n
y s  y
H2N0 2S0 ^ ^ ^ ^ N^ y ^ j
1.10 X = S, R = 1-adamantyl 1.12 R = Br
1.11 X = 0 ,R  = C9H19 1.13 R = H
Figure 1.16 Adam antyl and nonyl chrom enone sulfam ates (1.10 and 1.11) as STS inhibitors and 
structure o f  two potent D A SI inhibitors (1.12 and 1.13).
Recently, Woo et a l reported the first dual aromatase-steroid sulfatase inhibitors. 111 
These compounds, which are sulfamoylated derivatives of a known aromatase 
inhibitor, should achieve a more effective blockade of estrogen production in tumour 
cells by inhibiting two enzymes responsible for the biosynthesis of E l. In vitro, the 
bromo derivative (1.12, Figure 1.16) had IC5o values of 0.82 nM and 39 nM for
H2N02S 0 ‘
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aromatase and STS inhibition respectively in JEG-3 cells. One dual inhibitor (1.13, 
Figure 1.16) was potent against both enzymes in vivo.
Hi) Investigations o f the catalytic mechanism for hydrolysis
Until a few months ago, the crystal structure of the human STS enzyme had not been 
resolved. In order to gather information on the mechanism of action of this enzyme, 
its active site has been extensively studied via analogy with other soluble mammalian 
sulfatase enzymes, arylsulfatase A (ASA) and arylsulfatase B (ASB). These 
enzymes, whose crystal structures are available, share extensive homology and 
structural similarity with the human form . 112,113 Several mechanisms for the 
hydrolysis of sulfate esters by sulfatase enzymes have been proposed, 113"115 from 
which the model for the mechanism of action of irreversible inhibitors such as 
EMATE was derived. 8 7 ’116’117
ASA
C-OH R O -S -O
t ROH
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Figure 1.17 Proposed reaction scheme for sulfate ester cleavage by ASA and ASB. A dapted from
W oo et al. 1 1 8
Woo et al. recently published a review of the latest mechanistic studies on STS118 
and proposed several updated catalytic mechanisms. At the core of the catalytic 
cascade, a formylglycine (FGly) moiety, which results from post-translational 
modification of a cysteine residue of the active site, is coordinated to a metal ion, 
supposedly Ca2+. The FGly moiety, which can be present as an aldehyde (ASB) or its 
hydrated form (ASA), dictates two different routes for the sulfate ester cleavage 
(Figure 1.17). For ASA, one of the FGly hydroxyl groups attacks the sulfur atom of 
the substrate, yielding the hydrolysed product and a sulfate adduct. FGly is then
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regenerated after elimination of a sulfate group from the adduct. In the case of ASB, 
the mechanism proposed involves the nucleophilic attack of an oxygen atom of the 
substrate on the carbonyl group of FGly to form a sulfate ester. This is then 
decomposed by water into the product and a sulfate adduct.
From these studies, two mechanisms were proposed for the inhibition of STS activity 
by 667 COUMATE. 118 They should be applicable to any other related active site 
directed sulfamate inhibitor. Similarly to the hydrolysis of the substrate, these 
mechanisms involve a nucleophilic attack of either the hydroxyl of FGly on the 
sulfamoyl group or the attack of the N-atom of the sulfamate group on the carbonyl 
group of FGly (Figure 1.18A and 1.18B). Both mechanisms are irreversible and 
inactivate the enzyme. Inhibition may also occur by random specific or non-specific 
sulfamoylation of an essential amino-acid residue (lysine or histidine) in the STS 
active site.
R O -S-N H 2
O H20
'C -N -S -O R
C=N—S-O R
C - N - S - 0  
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C-OH r o - s - n h 2
^ * 0
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Figure 1.18 Proposed mechanism s o f STS inhibition by a sulfam ate inhibitor. A dapted from  W oo et
a l 11 8
A recently constructed homology model of STS has offered further insight into the 
understanding of enzyme-inhibitor interactions. 119 Docking studies with the substrate 
and known STS inhibitors confirmed the predictive power of the model. These 
studies were however made redundant with the resolution of the crystal structure of
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the human STS enzyme by Ghosh and coworkers. 120 The newly published three 
dimensional structure will be discussed in Chapter 2.
1.5.2 170-HSD inhibitors
In HDBC, tumour cells possess all the enzymes necessary for the production of 
estrogens in situ, thus supporting their own growth and development. The 17p-HSD 
enzyme, which catalyses the final step in estrogen and androgen biosynthesis is 
therefore a valid target to deprive these cells of their estrogen supply. 121,122
The human hydroxysteroid dehydrogenases, which include 3a-, 3p-, lip -, 17p- and 
20a-HSD, catalyse the stereospecific oxido-reduction reactions of alcohols or 
carbonyls using NADP(H) or NAD(P) as a cofactor. The 17p-HSD enzymes catalyse 
the reversible interconversion of the oxidised and reduced forms of steroids at the 17- 
position123 and are the only reversible enzymes of the steroidogenesis. However their 

















Figure 1.19 M ain isotypes o f 17J3-HSD and the reactions they catalyse in the hum an steroidogenesis 
(unidirectional reactions shown only). (A), 3 (3-hydroxysteroid dehydrogenase/A5-A4-isom erases; (B), 
aromatase.
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17p-HSD belongs to a family of isoenzymes, 11 of which have been identified to 
date. 125 The cloning of the pure 17p-HSD isoenzymes has shown that eight 17P-HSD
1 Of*isoforms exist in humans (Figure 1.19). While they all require NADP(H) or 
NAD(P) as a cofactor, each type has a selective substrate affinity, directional activity 
and a particular tissue distribution. 17p-HSD type 1, which interconverts E l and E2, 
and to a minor extent DHEA and A5-diol, is found in the ovaries, endometrium, 
placenta and in normal and cancerous breast tissue. 123 Since it preferentially reduces 
its substrate, 124 its activity directly supports the growth and development of estrogen- 
dependent tumours. 122 ,127,128
17p-HSD type 1 is the best known and most studied of all the isotypes. Although the 
other isoforms of 17p-HSD are not discussed in detail here, it is important to note 
that 17p-HSD type 3 and 5 represent valid therapeutic targets for blocking the 
biosynthesis of testosterone and its effects on androgen sensitive diseases, such as 
prostate cancer. Because of the presence of several isoforms of the enzyme, it is 
important to achieve selectivity of drug action when targeting any 17p-HSD 
isoenzyme. Type 2, which is involved in the degradation and regulation of active 
estrogens and androgens, is more commonly used as a measure of selectivity over 
type 1 .
Unlike STS, only few 17p-HSD type 1 inhibitors have been reported. They can be 
classified into irreversible and reversible inhibitors and most of the steroidal 
inhibitors for 17p-HSD type 1 have in common a D-ring modified structure.
i) Irreversible inhibitors
Mechanism-based inhibitors were the first irreversible inhibitors of 17P-HSD type 1 
to be described in the literature. 129 These compounds, initially developed by Covey
| -| OO
and Tobias, ' are a,(3-unsaturated alcohols steroidal derivatives at C20 or C17 (or 
pseudo C l7) (Figure 1.20). Upon enzymatic oxidation, the unsaturated alcohol is 
converted into the corresponding a,(3-unsaturated ketone (a Michael acceptor) that
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can bind covalently to the enzyme through 1,4-addition of an amino-acid residue. 




Figure 1.20 M echanism -based inhibitors o f 17J3-HSD type 1.
Unfortunately, the compounds developed were either poor substrates for the enzyme 
or had a weak oxidation rate (or both). 16-Methylene-estradiol (1.14, Figure 1.20) 
was the most promising compound of this class, being oxidised at about the same
period of 24 hours but turned out to work synergistically with E2 to produce an
1.20 R = Br
1.21 R = CH2Br
Figure 1.21 C16 derivatives o f E2 as potent 17p-HSD type 1 inhibitors (1.17 and 1.18) and ‘dual­
action’ inhibitors (1.19-1.21) with reduced estrogenicity.
Derivatives of E2 bearing a side-chain with a good leaving group at the 16a-position
i - i r  1 o/C
have been reported as a potent class of inhibitors. ’ In particular, 16a- 
bromoalkyl-estradiol derivatives, where the side-chain exhibits reactivity towards 
nucleophilic amino-acid residues in the active site, were found to irreversibly inhibit 
17p-HSD type 1 activity. 136 138 Compounds containing short bromoalkyl moieties at
rate as the natural substrate. 131 In vivo, this inhibitor was not estrogenic after a short
enhanced uterine response. 134
'(CH2)4Br
'(CH2)10CONBuMe
1.17 n = 3




C16 exhibited the highest activity and a comparative study revealed that 16a
1 ^ 6derivatives were more potent than their corresponding 17a analogues. 16a- 
Bromopropyl-estradiol and 16a-bromobutyl-estradiol (1.17 and 1.18, Figure 1.21) 
were the most potent with IC5 0 S of 0.46 pM and 0.97 pM respectively in human 
placental cytosol. The bromopropyl analogue (1.17, Figure 1.21) was found to act by
a competitive mechanism and inhibited enzymatic activity in a time-dependent
116manner. However, it turned out to be a pure agonist of the estrogen receptor and 
stimulated the growth in the estrogen-dependent breast cancer cell line ZR-75-1.
In an attempt to eliminate the intrinsic estrogenicity of steroidal inhibitors and 
possibly at the same time engineer antiestrogenic properties into the molecule, an 
antiestrogenic C7a-alkylamide side-chain was introduced into the potent bromobutyl 
analogue 1.18 (Figure 1.21) . 138 The resulting compound (1.19, Figure 1.21) was a 
weak inhibitor of 17|3-HSD type 1, being some 40 times less potent than 1.18. When 
tested on the ZR-75-1 cell line at 1 pM, 1.19 was devoid of estrogenic activity and 
displayed some antiestrogenic properties. Since introduction of a large side-chain at 
C-7a was detrimental to the activity, another approach to the design of ‘dual action’ 
inhibitors was to introduce a bromoalkylamide side-chain at the 16a position of 
E2  139 resulting compounds (1.20 and 1.21, Figure 1.21) had disappointing 
respective IC5 0 S of 14 pM and 5.7 pM for the inhibition of placental 17p-HSD type 
1. However 1.20 and 1.21 were not estrogenic and displayed antiestrogenic activity 
at 1 pM.
ii) Reversible inhibitors
Few reversible inhibitors of 17(3-HSD type 1 have been reported and most of the 
studies to develop such compounds have been focusing on phytoestrogens. These 
natural products which are structurally similar to estrogens possess a broad range of 
biological properties and may have a protective role against breast cancer, possibly 
by acting as antiestrogens. Their action on aromatase activity is well documented and 
in recent studies they were found to reduce the conversion of E l into E2 catalysed by 
17P-HSD type l . 140
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Coumestrol
Apigenin (R1 = H; R2 = R3 = R4 = OH)
Luteolin (R1 = R2 = R3 = R4= OH) 
7-Hydroxyflavone (R1 = R2 = R4 = H; R3 = OH)
Figure 1.22 Phytoestrogens with activity against 17p-HSD type 1.
Coumestrol (Figure 1.22) was the most active of a broad range of phytoestrogens, 
with an ICsoof 0.2 pM in human placental cytosolic 17|3-HSD type l . 140 SAR studies 
were also carried out on flavanoids, and Apigenin (4’,5,7-trihydroxyflavone, Figure
1 .2 2 ) emerged as a promising compound with an IC50 of 0.3 pM, without being 
estrogenic at the inhibitory concentration. 141 ' 143 Other natural deriatives provided 
interesting inhibition data such as Luteolin, 7-Hydroxyflavone and Genistein (Figure





n = 8 EM-1745
Figure 1.23 Structure o f the hybrid inhibitor E M -1745.
Recently, high affinity inhibitors of 17p-HSD type 1 in the form of E2-adenosine 
hybrids have been reported. 144 Both moieties (E2 and adenosine), respectively 
designed to interact with the substrate and cofactor binding domains, are linked by an 
alkyl chain tether. The optimal length of the tether was found to be of 8  methylene 
units (EM-1745, Figure 1.23) and the resulting compound had an IC5 0  of 52 nM in 
transfected HEK-293 cells. This hybrid molecule, which is the most potent 17(3-HSD 
type 1 inhibitor to date, was also shown to act via a reversible competitive 
mechanism, with a Ki of 3.0 nM.
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in) Crystal structure and catalytic mechanism
The determination of the three dimensional structure of the human enzyme nearly 10 
years ago has led to an atomic level description of the E2 binding pocket145 and has 
shed light on its mechanism of action. More recently, crystal structures of binary 
complexes of 17p-HSD type 1 with E2 , 146,147 C19 steroids, 147 and a dual site 
inhibitor147 as well as that of a ternary complex with E2 and NADP+ have been 
resolved. 146 The corresponding data have afforded valuable insight into the molecular
14Rdeterminants of substrate (estrogen) specificity and have provided the basis for 
rational design of specific inhibitors. 149
A Tyr-X-X-X-Lys sequence, characteristic of the enzymes of the short chain 
dehydrogenase family, was identified in the active site. The biochemically active 
form of the enzyme is a dimer and the core of the structure of each monomer is a 
seven-stranded parallel P-sheet surrounded by 6  parallel a-helices, three on each side 
of the P-sheet. E2 binds in a narrow hydrophobic tunnel, with critical residues at 
each end. The ternary complex E2-NADP-17p-HSD type 1 shows the presence of a 
triangular hydrogen-bond network between the amino acid residues Tyrl55, Seri42 
and 017 (Figure 1.24). In the A-ring, the 3-hydroxyl group makes specific binding 
interactions with His221 and Glu282. Active site-directed mutations150 together with 
the construction of recombinant chimeric enzymes151 have contributed to the 
identifications of the crucial residues involved in catalysis and substrate recognition. 
Surprisingly, the role of Glu282 could not be confirmed. 151
The androgen A4-dione is also a substrate for 17p-HSD type 1 although the enzyme 
has more affinity for E l. C19 steroids bind in a slightly different position to E2 in the 
active site to accommodate the bulk created by the extra angular methyl group, 
although the orientation in the active site remains similar. 147 The planar shape of the 
A-ring of E2, the hydrophilic interactions at C3 and C17 as well as a large 
hydrophobic core appear to be crucial for affinity binding in the active site.
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Figure 1.24 Proposed m echanism  for the reduction o f E l  to E2. The hydrogen bond network between 
the substrate and critical residues o f the active site is shown. R = adenine dinucleotide.
The putative mechanism for the reduction of E l to E2145’146 involves the transfer of 
the pro-S hydride from the nicotinamide to the a-face of the steroid at C17, while 
017 forms a strong hydrogen bond with the hydroxyl end of Tyrl55 (Figure 1.24). 
Subsequent proton transfer from Tyrl55 to E l could be facilitated by the close 
proximity of protonated Lysl59 and associated water molecules which lower the pKa. 
of the hydroxyl proton.
1.6 Aims
Drugs that antagonise the ER or inhibit estrogen biosynthesis occupy a central role in 
the treatment of HDBC. Data concerning the benefits of endocrine agents such as 
antiestrogens and aromatase inhibitors continue to accumulate, yet there is a clear 
need to find alternative treatments for patients who do not respond or become 
resistant to these therapies. The steroidogenic enzymes STS and 17p-HSD type 1 
have emerged as attractive therapeutic targets in recent years, since their inhibition 
can potentially achieve an efficient depletion of peripheral and local estrogen levels. 
This project aimed broadly to investigate the design and synthesis of a range of 
steroidal molecules that might possess activity against either (or both) these key 
enzymes.
1.6.1 Design of novel, potent, non estrogenic STS inhibitors
The development of STS inhibitors for the treatment of HDBC is still at an early
stage although substantial progress has been made in recent years. At the time this
project was initiated, precedent work in the area of STS inhibition suggested that:
(a) while non-steroidal STS inhibitors are based on the coumarin skeleton, most of 
the steroidal inhibitors result from modification of the A and/or D-ring of E l or 
E2;
(b) the active pharmacophore for potent STS inhibition, an aryl-O-sulfamate moiety, 
is associated with an irreversible inhibition of the enzyme and has been 
incorporated in all potent inhibitors to date;
(c) hydrophobicity of the inhibitor around the steroidal D-ring or at an equivalent 
position is a determining factor for potency;
(d) EMATE, the landmark STS inhibitor is highly estrogenic in rodents;
(e) steroidal inhibitors are not necessarily agonists of the ER and it is possible to 
abolish/reduce the intrinsic estrogenicity of steroidal compounds with carefully 
chosen structural modifications.
retain carbonyl or isostere




Figure 1.25 Proposed strategy to design steroidal inhibitors o f STS based on EM ATE.
To design potent steroidal inhibitors of STS that can be used in the treatment of 
HDBC, the challenge is clearly to find the best compromise between activity, 
estrogenicity and structural modifications on a chosen template. In a new approach to 
exploiting the activity of EMATE, we proposed to transform the steroidal D-ring into 
a functional scaffold while retaining key features, such as the aryl-O-sulfamate
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pharmacophore and the carbonyl group at C17 (Figure 1.25). The structural 
modifications should allow the exploitation of hydrophobic interactions in the active 
site while possibly reducing the intrinsic estrogenicity of the template.
1.6.2 Design of novel, potent, non estrogenic 17P-HSD type 1 
inhibitors
Inhibition of 17|3-HSD type 1 is a relatively newly explored area and no 
pharmacophore has been identified for the generation of selective inhibitors of this 
enzyme isotype. The D-ring, and in particular the 16-position of the E1/E2 nucleus 
has emerged as a crucial location for the introduction of key functionalities. The 
molecular determinant responsible for high affinity binding of substrates or ligands 
in the active site have also been identified and have suggested the importance of 






retain carbonyl or isostere
Figure 1.26 Proposed strategy to design steroidal inhibitors o f 17|i-HSD type 1 based on E l.
The design of novel steroidal inhibitors was therefore envisaged starting from the 
natural substrate for the enzyme, El. A series of structural modifications were 
envisaged at C l 6 , and more generally around the D-ring, while the essential features 
for binding in the active site were conserved (Figure 1.26). The synthesis of 
compounds having activity against 17P-HSD type 1 should contribute to extending 





2.1 Rationale for design
It is now acknowledged that breast tumour estrogen biosynthesis mainly occurs via 
the sulfatase pathway, 7 3 ’78 wherein the successive action of STS and 17P-HSD 
converts inactive precursors (E1S and DHEAS) into potent androgens and estrogens. 
STS activity therefore significantly contributes to the growth and development of 
estrogen-sensitive tumours and its inhibition may thus help reduce estrogen levels in 
patients suffering from HDBC.
Over the past 15 years several generations of STS inhibitors have been developed. 
The most advanced compound, 667 COUMATE (Figure 2.1), is a non steroidal drug 
which inhibits STS activity with an IC50 of 8  nM in placental microsomes. 104 It has 
the advantage of being active in vivo by oral administration and has just entered 
Phase I clinical trials. 84 Although several steroidal inhibitors were found to parallel 
the activity and properties of 667 COUMATE, no candidates could potentially be 
developed for the treatment of HDBC as they were also found to be agonists of the 
estrogen receptor. EMATE (Figure 2.1), the first highly potent steroidal inhibitor of 
STS to be discovered was also found to be more estrogenic than 17 a- 
ethynylestradiol (2.1, Figure 2.1) on oral application in rodents.90
Figure 2.1 Structure o f 667 CO U M A TE, EM ATE and 17a-ethynylestradiol 2.1.
In order to reduce the intrinsic estrogenicity of active steroidal compounds while 
retaining their activity, several structural modifications have been investigated in 
both the E2 and EMATE series. The steroidal D-ring was mainly targeted and 16/17- 
substituted compounds were synthesised in order to build an SAR. Early studies on 
derivatives of E2 substituted at C16 indicated that the ER has a moderate tolerance 
for bulky substituents152 and the introduction of 17a-alkynylamide side-chain on E2
H2N02S0 '
667 COUMATE EMATE 2.1
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decreased its estrogenicity.97 More recently, a series of 17a and 17p alkylamide 
derivatives of E2 and EMATE proved to be less estrogenic than their parents, while 
retaining their STS inhibitory activity. 98,101 Moreover, hydrophobicity of the 
substituents at C l7 a  was found to be crucial for powerful inhibition of the 
enzyme.99 ,100 ,102 These results indicate that modifications in the D-ring region of 
E2/EMATE not only reduce or abolish estrogenicity, but also create some favourable 
interactions within the active site when the side-chain is hydrophobic or bulky. This 
suggests the presence of a hydrophobic pocket in the active site around the steroidal 
D-ring.
In order to develop non estrogenic steroidal inhibitors of STS and expand the SAR 
around the steroidal D-ring, we decided to design and synthesise new derivatives of 
EMATE, where the D-ring is structurally modified. Ideally, the target molecules 
should retain EMATE-like properties against STS and allow the best compromise 
between activity, lack of estrogenicity and accessibility.
Literature reports of structurally modified D-ring on estrogen templates mostly deal 
with the expansion of the 5- into a 6 -membered ring, accompanied by the 
introduction of an heteroatom, yielding lactams and lactones. 153”157 In particular, 
azasteroids have been found of biological interest, with reported antibacterial158,159 
and antifungal activities. A structural modification of interest was the conversion of 
the cyclopentane D-ring into a piperidinedione moiety resulting in a \6,\l-seco- 
estra-l,3,5(10)-triene-16,17-imide derivative. 156,160 Converting the D-ring of 
EMATE into such a moiety would therefore yield 3-sulfamoyloxy-16,17-seco-estra- 
l,3,5(10)-triene-16,17-imide (Figure 2.2, R = H), a molecule which can serve as a 
template for the design of novel STS inhibitors. This new EMATE derivative 
combines:
(a) structural modification of the D-ring into an imide moiety: it was envisaged that 
this may help reduce intrinsic estrogenicity of the molecule and enable an easy 
introduction of a variety of side-chains onto the D-ring;
(b) retention of EMATE-like features, namely the 3-O-sulfamate pharmacophore at 
the A-ring end and the isosteric C17 carbonyl at the D-ring end, that should 
ensure recognition and inhibition of STS ;
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(c) facility and rapidity of access from E l: according to the literature , 156' 160 such D- 







F igure 2.2 General structure for proposed STS inhibitors (R = side-chain).
It was therefore decided to synthesise a series of compounds of the above general 
structure (Figure 2.2), where R corresponds to side-chains designed to enhance 
hydrophobic interactions with the active site of STS. The combination of a D-ring 
modified template with bulky/hydrophobic side-chains should generate compounds 
devoid of estrogenic activity.
2 .2  S y n th e s is
In order to allow versatility, the synthesis was designed around a common 
intermediate, from which the series of 7V-alkylated compounds was easily generated 
(Figure 2.3). This precursor was protected at the 3-position to avoid competing O- 
alkylation during functionalisation of the imido group. The synthesis of the target 
compounds therefore required (a) the design of a short, reliable, high yielding 
pathway to access the key synthetic intermediate in large quantities; (b) an efficient 
introduction of diversity to yield a series of analogues in a rapid manner. This 








Figure 2.3 Synthetic strategy for access to target com pounds (P = protecting group). The key steps are 
shown above the arrows.
D-ring modification 
3-O-protection
2.2.1 Access to the synthetic intermediate
Since the discovery of E l, a number of structurally modified steroids have been 
developed and synthesised. Although there has been considerable interest in the 
synthesis of aza- and other heterocyclic steroids, few synthetic routes have been 
reported for the preparation of 16,17-s£C0-estra-l,3,5(lO)-triene-16,17-imide 
derivatives. On the development of such structurally modified D-ring estrogens, two 
major synthetic approaches have been used over the years: (a) Beckmann 
rearrangement of estrone oximes; (b) oxidative cleavage of the D-ring with 
subsequent cyclisation by condensation, using a nitrogen nucleophile.
i) Beckmann rearrangement
The rearrangement of oximes into amides was first reported in steroids in 1951.154 
17-Ketosteroid oximes were shown to rearrange into 6 -membered D-ring lactams of 
steroids (Figure 2.4A) upon reaction with p-acetylaminobenzenesulfonyl chloride in 
pyridine.
Figure 2.4 Structural m odifications o f the steroidal D-ring via 17- and 16-oxime derivatives (the 
steroidal skeleton is not shown).
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Shortly afterwards 17-keto-16-oximino steroids were found to yield \6,ll-seco- 
estra-l,3,5(10)-triene-16,17-imide (Figure 2.4B) when reacted with an excess of 
thionyl chloride in benzene, 155 and 16-oximino-estrone rearranged into the 6 - 
membered imido derivative using thionyl chloride in dioxane. 156 Recently, Gupta et 
a l reported the synthesis of such D-ring imido derivatives of El protected at C3 in 
two steps from E l , 160 which prompted us to investigate this pathway for the synthesis 













Schem e 2.1 Synthesis o f 2 via Beckm ann rearrangem ent. Reagents: (a) K O C(CH 3)3,
(CH 3 )2 CH (CH 2 )2 0 NO; (b) A c2 0/A cO H , reflux; (c) SOCl2, dioxane or THF, rt or reflux.
16-Oximino-estrone 1 was prepared using an adaptation of the method of Litvan and 
Robinson. 161 E l was stirred with a freshly prepared solution of potassium tert- 
butoxide in tert-butyl alcohol and the resulting enolate reacted with excess isoamyl 
nitrite to give the expected oxime in 63% yield (Scheme 2.1). A Beckmann 
rearrangement of 1 was then carried out following the procedure of Gupta and 
coworkers, 160 which involves refluxing in a mixture of acetic acid and acetic 
anhydride. This afforded the imido derivative 2 in a 65% yield (cf. lit. ’ 60 53%). 
While the Beckmann rearrangement step afforded concomitant D-ring 
functionalisation and 3-O-protection, the overall yield of 40% from E l for the 
synthesis of the intermediate 2 was only moderate. Attempts to perform the 
rearrangement of 1  using thionyl chloride in dioxane failed to give the expected 
product 17, which contrasted with the report of Matkovics and coworkers. 156 
Changing the solvent to THF, or the reaction conditions from room temperature to
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reflux was equally unsuccessful. This however confirmed Kaufmann’s earlier 
observation that the rearrangement did not proceed unless the steroidal 3-hydroxy 
group was esterified. 154 An alternative pathway was therefore investigated.
ii) Sequential D-ring cleavage/D-ring closure
Oxidative cleavage of the D-ring of steroids has been reported as early as 1932. 
When E2 or E3 were fused with alkali, a mono- (doisynolic acid) and dicarboxylic
1 69acid (marrianolic acid) steroid derivative were respectively obtained. Several other 
methods were then investigated in order to cleave the cyclopentanone ring: the D-
163ring of 16-ketoestradiol was opened using lead tetraacetate, or via alkaline 
hydrolysis; 164 acidic or alkaline hydrogen peroxide cleaved the D-ring of El at room 
temperature. 153,165 In 1945, Heer and Miescher reported the direct conversion of 3- 
benzyl-O-estrone (3, Scheme 2.2) into 3-benzyl-O-marrianolic acid (4, Scheme 2.2) 
using a hypoiodite mediated oxidative cleavage. 166
It was envisaged that the condensation of dicarboxylic compounds such as 
marrianolic acid or 4 with an amine would yield 16,17-sea?-estra-l,3,5(10)-triene- 
16,17-imide derivatives. In a study on the synthesis of 16-azaestrones and 17-aza-D- 
homoestrones, Back et al. reported the reaction of a marrianolic acid derivative with 
liquid ammonia in methanol (100°C, pressure reactor) to yield a D-ring lactam . 157 
Although, to the best of our knowledge, the conversion of carboxylic acid precursors 
to D-ring imides has not been reported in the literature, we decided to investigate this 
pathway as an alternative to the Beckmann rearrangement to access our synthetic 
intermediate. Since the 3-hydroxyl group needs to be protected for the second part of 
the synthesis, we decided to follow the exact procedure of Heer and Miescher, where 











Scheme 2.2 A lternative m ethod to Beckm ann rearrangem ent for the synthesis o f D -ring modified 
derivatives o f E l .  Reagents: (a) NaH/DM F, BnBr (b) I2, KOH, M eOH  then KOH reflux; (c) urea, 
180°C.
1A7The benzyl ether 3 was prepared by an adaptation of a reported procedure, by 
reacting E l with NaH and benzyl bromide in DMF. Oxidative cleavage of the 
cyclopentanone moiety was then performed as described in the literature, 166 using an 
alkaline solution of potassium hypoiodite (Scheme 2.2). This reaction, which is an 
adaptation of the iodoform reaction (also called Lieben’s test), is mostly known for 
its application in the characterisation of methyl carbinols and methyl ketones. 168 
However, haloform reactions are also occasionally used as a synthetic method to 
access carboxylic acids166 and have been performed with sodium hypobromite169 and 
sodium hypochlorite. 170
2 KOI
-2  KOH BnO'BnO'
3
OKKOI 
2 KOH OK2 KOH
BnO'
Scheme 2.3 Key steps for the iodoform  reaction on 4.
By reacting 3 with an excess of KOH and iodine, the methylene ketone function at 
C16 was bishalogenated, oxidised and cleaved following the steps depicted in 
Scheme 2.3. Since the reaction was carried out in methanol, the crude product was
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refluxed in an alkaline solution to cleave any methyl ester formed as a side-product. 
After purifications, the dicarboxylic acid 4 was isolated with an optimised yield of 
75%.
Thermal cyclisation of 4 was carried out with urea as the nitrogen source (Scheme 
2.2). After briefly fusing the reagents together at 180°C, a 6 -membered ring was 
formed from the condensation of urea and the dicarboxylic acid moiety of 4. The 
synthetic intermediate 5 was obtained in high yield (80-89%), with an overall yield 
of 55% from E l and its structure was assigned by analogy with that of 2. The 
presence in the 'H  NMR spectrum of a characteristic peak for NH at 8  10.63 as well 
as peaks for two carbonyls at 8  172.1 and 8  178.9 in the 13C NMR spectrum were 
indicative of the imide function. Despite the presence of an additional step, the 
alternative pathway to access to the intermediate 5 represents a significant 
improvement over the literature method for the preparation of imides derivatives of 
E l. Both the synthesis of 4 and 5 could be carried out on multi-gram scale, affording 
a generous supply of the intermediate within a few steps. Interestingly, compound 4 
can also serve as a synthetic intermediate and may readily react with alkylamines to 
yield TV-alkylated products (see section 2.2.2).
2.2.2 Synthesis of the target compounds
The conversion of 5 into the final compounds was easily achieved following a three- 
step sequence: TV-alkylation, 3-O-deprotection and 3-O-sulfamoylation (Scheme 2.4).
The TV-alkylated derivatives were obtained after conversion of 5 into its conjugate 
base and reaction with various alkyl halides. In this manner, a variety of side-chains 
were successfully introduced on the D-ring affording 6-16 (Table 2.1) in yields 
ranging from 75 to 97%. The use of an alkylation reaction to introduce diversity at 
this stage proved expedient due to the broad range of commercially available alkyl 
halides and the relative reliability and simplicity of the reaction. However, for the 
introduction of l-pyridin-3-ylmethyl and benzyl side-chains, yields for the A-alkyl 
compounds were surprisingly low and the corresponding products were accessed 
directly from 4 (Scheme 2.4). When heating the dicarboxylic acid with 3-
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picolylamine and benzylamine, 15 and 16 were respectively obtained in 77% and 
65% yields. This represents an alternative pathway for the synthesis of those 
derivatives where the alkyl halides are commercially unavailable or unreactive 
towards /V-alkylation of 5.
NR
R O'
6-16 R1 = Bn 
18-28 R1 = H 





30 R1 = TBDMS2917
NH
32
Scheme 2.4 Synthesis o f the target com pounds 32-45. Reagents: (a) RNH2, 180°C; (b) NaH/DM F, 
RX; (c) Pd/C, H 2, M eOH/THF; (d) C1S0 2 NH2/D M A  or N aH/DM F, C1S0 2 NH2; (e)
TBD M SCl/Im idazole, DM F; (f) NaH/DM F, C H 2 CH CH 2Br; (g) TBAF/THF.
The benzyl ethers of 6-16 were then cleaved by catalytic hydrogenation using Pd/C 
to afford the corresponding phenol derivatives 18-28 (Table 2.1) in high yields. For 
the introduction of an unsaturated side-chain onto the D-ring, a different protecting 
group had to be used since the debenzylation step is likely to hydrogenate the 
unsaturated group concurrently. Compound 5 was debenzylated to give 17, then re­
protected as a ZerZ-butyldimethylsilyl ether to give 29 in 78% yield (Scheme 2.4). 
Alkylation of 29 with allyl bromide afforded 30 in 92% yield, and subsequent 
deprotection using TBAF in THF gave 31. This particular approach, which was 
developed for the introduction of an allyl moiety on the D-ring, should also be 
applicable to the introduction of other unsaturated groups.
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Table 2.1 Numbering of the 16,17-sm?-estra-l,3,5(10)-triene-16,17-imide derivatives synthesised.
0
R 1
R Bn TBDM S H s o 2 n h 2
H 5 29 17 32
c h 3 6 18 33
c h 2 c h 3 7 19 34
(CH 2 )2 CH 3 8 20 35
(CH 2 )3 C H 3 9 21 36
(CH 2 )4 C H 3 10 22 37
(CH 2 )5C H 3 11 23 38
(CH2)4Br 12 24 39
CH2cyclopropyl 13 25 41
CH 2 Ar'Bu 14 26 42
C H 2 pyrid-3-yl 15 27 43
CH 2Ar 16 28 44
CH 2 CH =CH 2 30 31 45
Sulfamoylation of the phenols was then performed following a recent procedure 
described by Okada et in which the sulfate ester of various phenols was formed 
in the absence of base, in the aprotic solvent N,TV-dimethylacetamide (DMA). With 
the growing interest in the biological properties of sulfamic acid esters, several
or
methods have been investigated for the synthesis of sulfamates. Howarth et al. have 
reported the sulfamoylation of El to proceed in high yields via its sodium salt, using 
NaH in DMF and a large excess of sulfamoyl chloride. Esterification of E l was 
reported to be equally successful in dichloromethane (DCM), using 2,6-di-terf-butyl- 
4-methylpyridine as a base. 100,172 While in our group, sulfamoylation was usually 
carried out using Howarth’s method, the newly reported procedure was of interest for 
several reasons.
57
h2n o 2s h n o 2s o
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Scheme 2.5 A, Side-reactions occurring during sulfam oylation in DMF, in the presence o f a base (B ): 
(a) CISO 2 N H 2 ; (b) DMF. Only the A-ring o f the steroid backbone is shown. B, Proposed m echanism 
for the reaction betw een sulfam oyl chloride and DMF.172
First, the absence of a base in the reaction mixture reduces the risk of forming by­
products, as a result of the deprotonation of the 3-O-sulfamate moiety. Such 
nucleophilic species can readily react with either sulfamoyl chloride, yielding a 
sulfamoyl sulfamate, or with the solvent DMF to give an azomethine type of adduct 
(Scheme 2.5A) . 172 Second, the competing reaction between sulfamoyl chloride and 
DMF (Scheme 2.5B), which results in the formation of NJSf- 
dimethylaminomethylene sulfamic acid as a by-product, 172 does not occur in
171DMA. This reaction, which has been reported to proceed via electrophilic addition 
of azasulfene to the carbonyl oxygen of DMF to yield a cyclic intermediate, 172 can 
conceivably take place with sulfamoyl chloride. Higher yields and shorter reaction 
times were reported when DMA was used as a solvent instead of DMF, and only 2 
equivalents of sulfamoyl chloride were required for optimal yields. Using these 
conditions, the sulfamates 32-38, 41, 42, 44 and 45 (Table 2.1) were obtained mostly 
in high yields after a short reaction time.
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171When 24 was subjected to Okada’s sulfamoylation conditions, an unexpected side- 
product was formed in greater amount than the anticipated sulfamate, 39. Despite 
only one apparent C I 8 -H 3 signal, the presence of two deshielded triplets around 8  
3.4-3. 6  in the *H NMR of the chromatographed mixture, as well as mass peaks of m/z 
469.2 and 513.1 suggested that 39 {m/z = 513.1) and a structurally related compound 
were formed. The structure of the side-product 40 was found to be identical to that of 
39, except for the replacement of the bromine by a chlorine atom in the side-chain. 
Attempts to separate both products by flash chromatography or recrystalisation 
failed; however, the compounds could be separated by HPLC (Figure 2.5) and they 
were finally isolated using preparative HPLC. From the corresponding traces, the 
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Figure 2.5 HPLC chrom atogram  o f the m ixture o f 39 and 40. Elution with M eO H /H 2 0 ,  68:32; =
267.5 nm.
o / r
When the sulfamoylation of 24 was carried out using Howarth’s method, 39 was 
isolated with a yield of 81% as the sole product of the reaction. Clearly, under 
Okada’s conditions, a halogen exchange takes place on the side-chain between the 
bromine and a chlorine atom. The fact that 39 only is obtained using Howarth’s 
conditions excludes the possibility of unreacted sulfamoyl chloride being the source 
of chlorine for the side-reaction. Presumably, the absence of a base in Okada’s
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conditions leads to the formation of HCI during the sulfamoylation, whereas any free 
chlorine is trapped as NaCl under Howarth’s conditions. The halogen exchange 
might therefore occur between 24 or 39 and the HCI formed as a result of the 
sulfamoylation reaction.
Similarly, sulfamoylation of 27 was achieved with better yields of 43 when
Qzr
Howarth’s method was used. This was consistent with the difficulties that we have 
observed in the past in sulfamoylating compounds possessing pyridine groups using 
Okada’s procedure.
2.2.3 Crystal structure of compound 35
In order to elucidate the orientation of the atoms in the D-ring and in the side-chains, 
as well as to gain structural information for potential molecular modelling studies, 
the crystal structure of 35 was determined.
A crystal (approx. dimensions 0.20x0.17x0.08 mm) obtained from slow 
recrystalisation in acetone/hexane, was used for data collection. The ORTEX173 plot 
of the asymmetric unit of 35 is shown in Figure 2.6, along with the labelling scheme 
used. The sulfamate group, all four rings, and the key features of the modified D-ring 
are clearly visible. The stereochemistry at C13 was also confirmed. All C-C bond 
lengths were in the range 1.375-1.545 A and both C-N bonds of the imide group had 
similar lengths (1.397 A and 1.398 A). The bond between the imido N-atom and C l’ 
of the propyl side chain measured 1.476 A and the C-O bonds of the C16 and C17 
carbonyl measured respectively 1.215 A and 1.225 A. For full details see Appendix 
1.
As expected, the D-ring is in a half chair conformation since the imide functionality 
is planar. Molecules are hydrogen-bonded to each other via two interactions: 













F igure 2.6 O RTEXm  plot o f the X-ray crystal structure o f 35. Ellipsoids are shown at the 30% 
probability level.
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2.2.4 Further modifications on the D-ring
With the aim to expand the SAR on D-ring modified compounds and probe the 
pharmacological importance of several molecular features, we carried out further 
modifications on the 16,17-seco-estra-l,3,5(10)-triene-16,17-imide template. It was 
initially decided that the imido function would be reduced (totally or partially) in 
order to assess the role of the carbonyl groups and their effect on inhibitory activity.
In their study on steroidal D-ring lactams and imides, Matkovics et al. have reported 
a procedure for the reduction of 17 (cf. Table 2.1 p57) using LiAIFU in refluxing 
dioxane, in a Soxhlet extraction apparatus. 156 We decided to investigate this reaction 
on the benzylated precursor 5, a more soluble substrate than the unprotected 
derivative 17 and therefore not requiring the use of a Soxhlet apparatus. Starting 
from compound 5 was also advantageous in that the reduced product can be 
selectively A-alkylated if desired. An attempt carried out in THF at room temperature 
only yielded a complex mixture of compounds from which no product could be 
isolated. Under refluxing conditions, the desired piperidine derivative 46 was 
obtained in disappointingly low 7% yield with separation from other reaction 
products proving problematic (Scheme 2.6). Its structure was assigned on the basis of 
!H NMR and mass spectrometry evidences, and confirmed by IR spectroscopy where 
the two anticipated characteristic imide carbonyl absorption bands of 5 at v 1700 and 
1720 were not seen. Switching solvent to dioxane, as reported in the original 
procedure, did not lead to any improvement in yield and therefore other reducing 
agents were evaluated for this reaction. Under milder conditions we hoped that a 
partially reduced derivative of 5, where one or both carbonyls would have been 
converted to the corresponding alcohols would be available. Unfortunately, reactions 
of 5 with either BH3 .THF in THF or NaBH4 in MeOH were unsuccessful. 
Alternatively, the stronger reducing agent ‘super hydride’ (LiBEtsH in THF) was 


























50 R = H
Schem e 2.6 Synthetic pathw ay to reduced derivatives o f 17. (a) LiAlHVTHF, reflux; (b) Law esson’s 
reagent/toluene, reflux; (c) Ra-N i/H 2 0 ,  EtOH; (d) B B r3/DCM ; (e) N aH/DM F, C 1S0 2N H 2.
Because of the apparent difficulty in reducing the imide function of 5, another 
pathway was envisaged to access the desired product(s). Carbonyl compounds can be 
reduced to alkanes via their corresponding thione under the action of Raney nickel, 
in particular this reaction can be applied to thioamides for the synthesis of amines. 174 
It was therefore decided to convert the imide function of 5 into a dithioimide and 
then subject it to hydrogenolysis to effect simultaneous desulfurisation of the D-ring 
and debenzylation.
Lawesson’s reagent (LR, Scheme 2.7) was used to thionate the imide carbonyl 
groups of 5. This arylthionophosphine sulfide reagent is known to be an effective 
thiation agent, and affords high yield synthesis of thioketones and thioamides from 
the corresponding carbonyl compounds. 175,176 Recently, cyclic dithioimides were 
prepared using LR in boiling toluene. 177 Although the thiation of such imides was
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reported to proceed rapidly using an excess of LR, it was noted that the thiation of 
sterically hindered carbonyls was slower.
The mechanism of the reaction is similar to that of the Wittig reaction, involving a 4-
that a highly reactive dithiophosphine ylide, rather than LR itself, is the active 
thiation agent. The cyclic intermediate may be accessed via two possible 
mechanisms: addition of the sulfur atom to the carbonyl group or attack of the 
carbonyl oxygen on the electrophilic phosphorus atom. The latter mechanism seems 
the most likely since it has been supported by structural, kinetic and spectroscopic 
studies.178
Schem e 2.7 Postulated mechanism  for thiation o f carbonyls using Law esson’s reagent, LR (R = 
ArOM e). The ylide m ay be the active thiation agent . 1 7 6
When imide 5 was subjected to reaction with an excess of LR in refluxing toluene, 
two products of significantly different polarities were obtained. They were easily 
separated by flash chromatography and analysis of the two fractions by mass 
spectrometry indicated that the less polar compound was the expected dithioimide 
47, while the most polar fraction was that of a monothionated product. This was 
supported by 13C NMR spectra analysis, where two highly deshielded C=S peaks 
could be seen at 8 202.03 and 8 214.03 for 47, while peaks at 8 207.57 and 8 175.75 
were observed for the other monothionated reaction product. Intuitively, this 
compound was assigned the structure 48, where the less sterically hindered C=0 has 
reacted with LR. An HMBC experiment, where 2-3 bond heteronuclear (!H and I3C)
■I 'TZ
membered cyclic intermediate (Scheme 2.7). Mechanistic studies have suggested
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correlations can be seen, confirmed this hypothesis since a strong correlation was 
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F igure 2.7 HMBC spectra of 48 (CDCI3 , 400 MHz). The arrow shows the cross peak between C = 0  
and CI8-H3.
Both 47 and 48 were subjected to reaction with Raney nickel, in an aqueous 
ethanolic solution at room temperature overnight. While desulfurisation and 
deprotection of 48 afforded the D-ring lactam 50 in 73% yield, reaction of 47 under
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the same conditions unexpectedly led to the formation of the iV-ethyl piperidine
derivative 49 in a low 24% yield. The presence of a triplet at 8  0.99 for a CH3 group
in the JH NMR spectrum of 49 as well as a characteristic 28 mass unit difference
between the expected (NH) and the isolated (N-ethyl) product led to its structural
identification. Examination of the literature provided an example of such side-
reaction occurring between an amine and the solvent EtOH in the presence of Raney
nickel. 179 An acetaldehyde resulting from oxidation of the solvent was postulated to
react with an amine to yield an imine, which is then reduced in situ to a N-ethyl-
amine. 179 In the reduction of 47, a secondary amine is formed (R R ^H , Scheme 2.8),
affording an enamine upon reaction with the acetaldehyde. The latter can then be
reduced to yield 49. Changing solvent might therefore prevent the formation of 49 to





EtOH ---------► H3C-CH + RR1NH -----
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Schem e 2.8 S ide-reaction occurring in the Raney nickel (Ra-Ni) reduction o f 47 in EtOH.
The lactam derivative 50 was then sulfamoylated, affording 51 in 31% yield. The 
synthetic pathway developed here to access 50 represents a shorter and more 
convenient synthesis of 6 -membered D-ring lactam derivatives of E l than the route 
proposed by Back et al.157 In a synthetic study on novel 16-azaestrones and 17-aza- 
D-homoestrones, the authors reported the synthesis of the 3-methoxy derivative of 50 
within 7 steps. Although the yields were in excess of 8 8 % for each step, the forcing 
reaction conditions and the length of the synthesis made it less favourable for highly 
functionalised E l derivatives.
The precursors 47 and 48 were also debenzylated using boron tribromide in DCM to 
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derivatives should serve as precursors for the synthesis of sulfur isosteres of the 
sulfamate 32 (cf. Table 2.1 p57). The activity of such compounds, as well as that of 
51 should provide useful information on the role and importance of the carbonyl 
functionalities in the D-ring of these modified EM ATE derivatives.
2.2.5 A-ring modification
Although the 16,17-secc>-estra-l,3,5(10)-triene-16,17-imide template proved 
synthetically accessible for the rapid generation of target compounds, it was not 
known whether the resulting D-ring modified EMATE derivatives would be 
estrogenic. In a limited study on 3-hydroxy-16,17-.sec0-estra-l,3,5(lO)-triene-16,17- 
imide derivatives, Gupta and Jindal reported that the D-ring modification did not 
suppress in vitro estrogenic activity.160 A-ring modification of EMATE proved to be 
a successful strategy for the production of non-estrogenic STS inhibitors, as 
exemplified by 2-MeOEMATE (Figure 2.8) which was devoid of estrogenic activity 
in vivo.93,94 This compound was only 8 times less active than EMATE in vitro93 and 
we were thus drawn to investigate the synthesis of 2-methoxy derivatives of our D- 
ring modified estrogens (Figure 2.8). In a preliminary study, it was anticipated that 
one example (R = H) would be synthesised and its biological activity evaluated.
MeO. MeO.
2-MeOEMATE Target compounds
Figure 2.8 Structure o f 2-M eO EM A TE and A-ring m odified target com pounds (R = H or side-chain).
2-Methoxy estrogens are natural metabolites which have very low affinity for the
1 fif)ERs. Considerable interest has emerged in recent years due to the wide range of 
biological activities exhibited by these compounds. For instance, 2-methoxy 
derivatives of E2 or analogues were found to display not only cytotoxic activity in 
cancer cells cultures,92 but also antiangiogenic activity in vivo.m  2-MeOEMATE 
displayed similar biological properties, albeit at lower concentration. It induced G2-
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M cell cycle arrest, was an antimicrotubule agent in vitro95 and was found to induce 
breast tumour regression in vivo in rats.94
The first synthetic approach to 2-methoxyestrogens was reported by Fishman,182,183 
wherein the final products were accessed with very low overall yield and an 
excessive number of steps. Most subsequent syntheses involved the direct conversion 
of 2-halogenated (2-iodo or 2-bromo) estrogens into the 2-methoxylated species. 
Mercury, thallium184 and copper acetate185 catalysed iodinations of E2 were 
investigated. Although several groups reported having achieved selectivity for 
halogenation and obtained 2-halo products in high yields, reproducibility of some
1 fiAresults (selectivity and/or yield) was found to be problematic. The conversion of 2- 
iodo estrogens into the corresponding 2-methoxy derivatives was studied by 
Numazawa et a/.187 wherein the reaction was reported to proceed in excellent yields 
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Schem e 2.9 Synthesis o f 2-methoxy derivatives o f D-ring m odified estrogens, (a) H g(O A c)2, I2, 
AcOH, 55°C to rt; (b) NaOM e/M eOH, CuCl2, pyridine, reflux; (c) N aH/DM F, BnBr; (d) I2, KOH, 
M eOH  then KOH reflux; (e) urea, 180°C; (f) Pd/C, H2, M eOH /TH F; (g) N aH/DM F, C 1S0 2N H 2.
In our group, 2-iodoestrone was recently obtained regioselectively from E l using 
mercury acetate188 as a catalyst (unpublished results). The regioselective 
halogenation was carried out in acetic acid at room temperature and was complete 
within 2 hours (Scheme 2.9). The ]H NMR spectrum of the crude product indicated
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the presence of the 4-iodo isomer and the starting material in minor proportions, and 
both were removed after two recrystallisations (in AcOH and EtOH), affording 54 in 
a 56% yield. The latter was reacted with a large excess of freshly prepared sodium 
methoxide in MeOH, in the presence of CuCl2 in refluxing pyridine. 2- 
Methoxyestrone 55 was obtained with a yield of 78% and an overall yield of 44% 
from E l. This method is therefore highly effective, affording 2-methoxyestrone in 
two steps from E l, with a reasonable overall yield.
After benzylation of 55, the resulting compound 56 was subjected to the haloform 
reaction, (cf. Scheme 2.2 p54). The limited solubility of the substrate in MeOH 
combined with difficult purification of the crude material led to a disappointing yield 
of 18% for 57. Ring closure in presence of urea gave the imide derivative 58 in a 
59% yield which, after subsequent debenzylation and sulfamoylation, was converted 
to the desired sulfamate 60. A lack of reactivity was observed when the 
sulfamoylation was carried out in DMA, following Okada’s procedure. 171 When 
conducted in DMF, in presence of NaH and a large excess of sulfamoyl chloride, the 
product 60 was isolated with a yield of 79%. This result could be due to steric 
hindrance at C3, resulting from the presence of the methoxy group at C2, although 
such lack of reactivity towards sulfamoylation in DMA is not seen with other 2- 
methoxy derivatives prepared in our group.
2.3 Results
2.3.1 In vitro inhibition of STS
The ability of the sulfamates synthesised to inhibit STS activity in vitro was 
examined in placental microsomes and the I C 5 0  value for each compound is 
presented in Table 2.2. EMATE was used as a reference in this assay.
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Table 2.2 IC 5 0  values for inhibition o f hum an placental steroid sulfatase by various D -ring m odified steroid 
sulfam ates and EM ATE. Results are expressed as m eans o f at least two determinations.
H2N02S0
0
R Compound IC 5 0  (nM) R Com pound IC 5 0  (nM)
H 32 2 0 (CH2)4Br 39 1 2
c h 3 33 1 2 CH 2cyclopropyl 41 74
c h 2 c h 3 34 52 CH 2 Ar'Bu 42 23
(CH 2 )2 CH 3 35 1 CH 2 pyrid-3-yl 43 1
(CH 2 )3 CH 3 36 382 CH2Ar 44 3
(CH 2 )4 CH 3 37 150 CH 2 CH =CH 2 45 75
(CH 2 )5 CH 3 38 288
EM ATE 18
Of the different compounds tested, the steroids bearing a propyl 35, a l-pyridin-3- 
ylmethyl 43 and a benzyl 44 side-chain on the D-ring were the most potent, with IC5 0S 
ranging from 1 to 3 nM. These compounds were found to be more potent than EMATE 
in the assay, with 35 and 43 being 18 times more active. In general, most of the 
analogues showed potent inhibition of STS activity.
Compound 32, which has no side-chain at the A-atom, as well as 33 and 34, the A-methyl 
and A-ethyl derivatives were found to be of similar potency to EMATE, with IC5 0S 
between 12 and 52 nM. Unexpectedly, compounds 36, 37 and 38 whose side-chains are 
respectively a n-butyl, «-pentyl and n-hexyl moiety, showed a dramatic decrease in 
potency (>10 fold) with IC50 values above 150 nM. This rather steep loss of potency 
suggests that the optimum hydrophobic interactions have been exceeded and steric 
hindrance is playing a role. Overall, good potencies were observed for compounds 
bearing non-linear side-chains and terr-butyl-benzyl 42, l-pyridin-3-ylmethyl 43, and 
benzyl 44 derivatives had IC5 0S below 25 nM. This indicates that restricted hydrophobic 
groups with less degrees of freedom are tolerated in the active site.
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2.3.2 A-ring modification
Since 2-methoxy estrogens are less estrogenic than their parent, and in particular, 3- 
sulfamoylated derivatives were shown to additionally affect cell growth in vitro,95 
both 59 and 60 were assessed for their antiproliferative activity on MCF-7 breast 
cancer cells (Table 2.3).
Table 2.3 IC 5 0  values for inhibition o f M CF-7 cell growth by 59 and 60, and inhibition o f STS in 
placental m icrosom es by 60. Results are expressed as means o f at least two determ inations (± S.D. for 
inhibition o f M CF-7 cell growth).
Com pound
IC 5 0  pM  
(inhibition o f cell growth)
IC 5 0  nM 
(inhibition o f STS)
59 42.19 ±  17.43 nd
60 24.28 ±  14.50 309
667 CO U M A TE Nd 3
2-M eO EM A TE
£U- -  . . ",93 '
0.15 ± 0 .0 5 30a
Unfortunately, 59 and 60 showed poor growth inhibitory properties, with IC50 values 
of 42 and 24 pM respectively, making them at least 160 fold less active than 2- 
MeOEMATE. When examined in placental microsomes for activity against STS, 60 
had an IC50 of 309 nM and 667 COUMATE, with an IC50 of 3 nM, was 100 times 
more active.
2.3.3 In vitro estrogenicity
In order to determine whether the compounds developed could be potentially used 
for the treatment of estrogen-sensitive breast cancer, their estrogenic potency was 
initially assessed in vitro. Given that hydrolysis of the sulfamate moiety might occur 
in vivo by (a) chemical hydrolysis or metabolism or (b) after irreversible inhibition of 
STS by the sulfamate moiety,88’90,91,118 both the sulfamates and their corresponding 
phenolic derivatives were assessed for estrogenicity.
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A luciferase reporter gene assay was used to determine the ability of each compound 
to bind to the ER. The compounds were screened at four concentrations: 100 pM, 1 
nM, 10 nM and 100 nM alongside E2 concentrations of 1 pM, 10 pM, 100 pM and 1 
nM. The results, summarised in Table 2.4, give the lowest concentration at which 
estrogenic activity was detected for each compound i.e. the lowest concentration for 
which above background level of luciferase-induced luminescence was observed.
T ab le  2.4 Low est concentration at which estrogenic activity was detected (low est conc.) for the 
phenolic derivatives 17-28 and 31, their corresponding sulfam ates 32-39 and 41-45 and EM ATE.
PHEN O LS SULFAM ATES
C om pound low est conc. (nM) Com pound low est conc. (nM)
17 1 32 1 0 0
18 1 0 0 33 > 1 0 0
19 1 0 0 34 1 0 0
20 > 1 0 0 35 > 1 0 0
21 > 1 0 0 36 1 0 0
22 n.d. 37 > 1 0 0
23 > 1 0 0 38 > 1 0 0
24 > 1 0 0 39 > 1 0 0
25 > 1 0 0 41 > 1 0 0
26 > 1 0 0 42 1 0 0
27 > 1 0 0 43 > 1 0 0
28 nd 44 > 1 0 0
31 1 0 45 > 1 0 0
E2 0 . 0 1 EM A TE 1 0
Most of the compounds tested displayed estrogenicity at concentrations of 100 nM or 
above and can therefore be considered as weak estrogens. They are 104-fold less 
estrogenic than E2, whose activity was detected at 10 pM. The most estrogenic 
compounds were the phenolic derivatives 17 and 31, with activity detected at 1 and 
10 nM respectively. In this assay, their estrogenic potency was comparable to that of 
EMATE, which is highly estrogenic in vivo 90,9]
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The assay was repeated for the compounds which had a detectable activity at a 
concentration of 100 nM or lower, namely the phenolic derivatives 1 7 , 1 8 ,  1 9  and 3 1  
the sulfamates 3 2 ,  3 4 ,  3 6  and 4 2  (Figure 2.9). The compounds were tested at three 
concentrations: either 1 nM, 10 nM and 100 nM or 10 nM, 100 nM and 1 (iM. The 
results are expressed as a percentage of the activity of E2 at 10 pM for each 
concentration tested (Figure 2.10). 2-Methoxy-estradiol-3-0-sulfamate (2- 
MeOE2MATE, Figure 2.9), which recently showed to be non estrogenic in vivo, 84 
was used as a reference in this assay.
Figure 2.9 Structure o f the com pounds tested for their estrogenic activity at three concentrations.
Clearly, only one compound ( 1 7 )  displayed high estrogenic activity in vitro. At a 
dose as low as 1 nM, compound 1 7  was already as potent as 10 pM of E2. Its 
sulfamate 3 2  was also a potent estrogen, although to a lesser extent, since its 
estrogenicity was comparable to that of 10 pM of E2 at a concentration of 10 nM. 
The other compounds tested were all less active than 2-MeOE2MATE, which was 
estrogenic at 10 nM. Compounds 1 8 , 1 9 ,  3 4 ,  3 6  and 4 2  are therefore at least 103-fold 
less estrogenic than 10 pM of E2.
H2N02S 0 '
o
17 R = H
18 R = CH3
19 R = CH2CH3
31 R = CH2CH=CH;
32 R = H
34 R = CH2CH3 
36 R = (CH2)3CH3 
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F igure 2.10 Estrogenicity of 17-19. 31, 32, 34. 36 and 42 expressed as a percentage of the activity of 
E2 at 10 pM. Results are expressed as means ± S.D. triplicate measurements.
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The ability of some compounds to inhibit the effect of 100 pM of E2 was also 
examined in order to assess their anti-estrogenic potential in the luciferase assay 
(Figure 2.10). Eight compounds, including the two most potent STS inhibitors 35 and 
43, were tested at three different concentrations (1 nM, 10 nM, 100 nM). Raloxifene 
(Ral), a known antiestrogen was used as a reference in this assay.
PH E N O L S
100  pM E 2 + in h ib ito r
S U L FA M A T E S
O'
A
■ N*5 . j P
1 0 0  pM  E 2 + in h ib ito r
F igure 2 .10 Inhibition of the estrogenic effect of 100 pM of E2 by the phenols 20. 27. 28, 24 and their 
sulfamates 35, 43. 44. 39 at 1, 10 and 100 nM. Raloxifene is used as a reference. Results are expressed 
as means ± S.D. triplicate measurements.
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While Raloxifene could inhibit the activity of the 100 pM dose of E2, none of the 
tested compounds displayed clear antiestrogenic properties to the same degree. The 
only potential antiestrogen is 20, where a reduction in estrogenic activity is observed 
at 100 nM. The luciferase activity drops from a level comparable to that of E2 (at 
100 pM) to a near background level upon application of 100 nM of 2 0 .
2.3.4 In vivo studies
In vitro evaluation of the D-ring modified compounds identified two highly potent 
STS inhibitors. With I C 5 o  values of 1 nM, 3 5  and 4 3  were 18-times more active than 
EMATE in placental microsomes. These compounds were selected for in vivo studies 
in order to assess their inhibitory activity on rat liver STS and examine their ability to 
stimulate uterine growth in the ovariectomised animals as a measure of their 
estrogenic potential.
After treatment of ovariectomised rats with an oral dose of 10 mg/kg/day of either 
inhibitor for 5 days, an almost complete inhibition of liver STS activity (99%) could 
be observed (Figure 2.11 A). EMATE, which was tested at a 200-fold lower dose (50 
pg/kg/day) subcutaneously gave a 73% inhibition of STS activity in the liver.
Both 3 5  and 4 3  were not estrogenic in vivo. Unlike EMATE, they had no effect on 
uterine growth in ovariectomised rats and the ratio of the uterine weight/body weight 
was the same as in the animals receiving vehicle only (Figure 2.1 IB). The much 
lower dose at which EMATE was tested was sufficient to produce a marked increase 
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(73%)
% Inhibition of 
STS activity
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F igure 2.11 A, Inhibition of rat liver STS activity by 35 and 43, means ± S.D. (for 35 and 43 the S.D.s 
were <10%). Basal sulfatase activity in liver homogenates of untreated animals was 8.75 nmol/h/mg 
protein. Figures in parentheses represent the percent inhibition compared with the control. B. Effect of 




2.4.1 STS inhibition in vitro
The most advanced steroid sulfatase inhibitor to date, 667 COUMATE, has just 
entered phase I clinical trials and has the potential to be the first in class to reach the 
market. So far, no steroidal inhibitor has achieved the same degree of inhibition in 
vivo, combined with non estrogenic properties and oral availability. Efforts have 
therefore been concentrated on developing potent, non estrogenic, steroidal inhibitors 
of STS, as back-up clinical candidates to 667 COUMATE with a similar or improved 
drug profile.
A report in the literature that D-ring modifications to EMATE could reduce its 
estrogenicity, without loss of potency prompted us to investigate further such D-ring 
derivatives.98 The established pharmacophore for STS inhibition, an aryl-3-O- 
sulfamate moiety, was retained and a template was chosen so that rapid investigation 
of the SAR around the D-ring would be achieved. Several published SAR on STS 
inhibitors have stressed on the importance of the hydrophobicity of the side-chains 
introduced on the D-ring for inhibition.99 ,100 ,102 It is believed that such moieties 
enhance the activity of the compounds by increasing their affinity for the enzyme and 
the active site, which presumably contains a hydrophobic pocket. A number of D- 
ring modified analogues were prepared from the 16,17-seco-estra-1,3,5(10)-triene- 
16,17-imide template chosen for our inhibitors and the activity of the corresponding 
sulfamates was examined in placental microsomes.
A series of linear alkyl side-chains of increasing length (Ci to C$) was first 
introduced on the D-ring, resulting in compounds 32-38. A plot of their IC5 0S vs. the 
number of CH2 units in the side-chain is depicted in Figure 2.12. Derivatives bearing 
short side-chains (33-35) were found to be potent inhibitors of STS, with IC5 0S in the 
range of that of EMATE. In particular, the rc-propyl analogue 35 was found to be 
highly potent with an IC50 of 1 nM, being 18-times more active than EMATE in the 
in vitro assay. In contrast, a sharp decrease in potency was observed for 36-38, with
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IC5 0S above 150 nM. A 400-fold drop in activity was observed when the number of 
carbon atoms in the side-chain increased from C3 to C4 . We were pleased to see that 
the non alkylated derivative 32 was equipotent to EMATE, suggesting that the 
replacement of the D-ring of EMATE with a six-membered piperidinedione ring has 
not been detrimental to its inhibitory activity. No doubt a major factor for the 
potency of this series of compounds is the aryl-3-O-sulfamate moiety, but activities 
higher than that of EMATE for 33 or 35 indicate that the D-ring substituents might 







EMATE ICso= 18 nM
(3 2 ) (33) (35)
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s id e -c h a in  CH* n u m b er
F igu re  2.12 Effect of various side-chain lengths on the inhibitory potency of 3-sulfamoyloxy-16,17- 
sece>-estra-l,3,5(10)-triene-16,17-imide derivatives 32-38 (R = H or linear alkyl side-chain; 
compounds numbers are in parentheses).
Two factors might explain the decrease in potency observed for n-butyl compounds 
onwards: steric bulk and hydrophobicity. Higher conformational flexibility of longer 
alkyl groups might have prevented adequate fitting of inhibitors such as 36-38 into 
the active site. It is also possible that the hydrophobic pocket which these alkyl 
substituents are probably exploiting has in fact a limited capacity where only short 
side-chains (up to C3 ) can fit. If steric clashes occur between the alkyl side-chain and 
a part of the enzyme active site, this results in destabilisation of the enzyme-inhibitor 
complex and therefore lowers the affinity, hence the activity of the inhibitor.
79
Most likely, the nature of the interaction of the side-chains of 32-38 with the active 
site is hydrophobic. In a recent study on a series of 4-sulfamoylated phenyl ketones, 
Ahmed et a l confirmed the importance of hydrophobicity for potent STS inhibition. 
The authors also showed a strong correlation between the IC5 0S for STS inhibition (in 
placental microsomes) and logP values of the phenyl ketones inhibitors. 107 The 
presence of an optimum logP value for these analogues is indicative of an alkyl chain 
length limit beyond which the potency of the inhibitors decreases. If logP is too high, 
entry of the sulfamates into the STS active site is disfavoured, which consequently 
lowers the inhibitory activity. On the other hand, a too hydrophilic character 
diminishes the ability of the compounds to partition into a non-polar environment.
For the derivatives 36-38, it is therefore possible that too high logP values are 
reached for these inhibitors to enter the active site. It is also conceivable that the 
hydrophobicity of the substituents increases the inhibitory activity of the D-ring 
imide derivatives, but the steric factors contribute to the opposite effects for those 
more bulky side-chains. In particular steric clashes might be too important for linear 
substituents where the number of carbon atoms exceeds 3. Clearly, the best 
compromise between hydrophobicity and steric bulk is obtained with the propyl side- 
chain (35, Figure 2.12).
Several other SAR have been reported where similar patterns were observed. On the 
development of non steroidal inhibitors, Woo et a l synthesised a series of tricyclic 
coumarin sulfamates in order to optimise the size of the third ring . 104 The best 
inhibitors had a 7- and a 10-membered ring, and a marked reduction in activity was 
observed for larger ring sizes. Derivatives of E2 bearing linear side-chains at C17a 
reached a maximum of activity for the octyl moiety. 9 9 ’102 Li’s 17(3-alkanoyl and 
alkycarbamoyl derivatives of EMATE had a side-chain length limit and the best 
inhibitors had a total of 8  carbon atoms. 98
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T ab le  2.5 IC 5 0  values for inhibition of placental STS by the D-ring m odified com pound 39, 41-45.
H g N O jS O ^ ^
0
R Com pound IC 5 0  (nM) R Com pound IC 5 0  (nM)
(CH2)4Br 39 1 2 CH 2 pyrid-3-yl 43 1
C H 2cyclopropyl 41 74 CH2Ar 44 3
CH 2 Ar'Bu 42 23 CH 2 CH =CH 2 45 75
In light of the encouraging results obtained for the linear alkyl side-chain derivatives, 
we decided to introduce different moieties while retaining the overall hydrophobic 
character of the side-chains. To examine the effects of increasing hydrophobicity 
without increasing the length, we synthesised the A-bromobutyl analogue 39. With a 
side-chain length similar to that of 36, its activity was more than 30 times higher, 
indicating the importance of hydrophobic interactions in this region of the active site. 
The iV-allyl derivative 45 was also prepared. Although not as potent as 35, the 
additional rigidity conferred by the allyl moiety was not too detrimental to the 
activity (IC50 = 75 nM). This was also exemplified by compound 41, the cyclopropyl 
analogue, whose inhibitory activity was similar to that of 45. We then undertook the 
synthesis of the A-benzyl derivatives 42 and 44, relying on the fact that a benzyl 
group (a) contains an allylic portion (cf. 45) (b) is more hydrophobic and less 
sterically restrictive with its total of seven carbons than would be a linear heptyl side- 
chain. Both 42 and 44 proved the validity of this approach as they were found to 
inhibit STS activity with IC5 0S of 23 nM and 3 nM respectively. This further asserts 
that the hydrophobic pocket around the D-ring in the active site tolerates steric bulk 
in a certain conformation, as already demonstrated by Poirier et a l with their potent 
17a-benzyl derivatives of E2.99’102 Compound 43 was also prepared on the basis that 
the nitrogen atom of the pyridyl moiety would possibly enhance the affinity for the 
active site via hydrogen bonding. With an IC5 0 of 1 nM, 43 was as potent as 35, 
proving that the effect of a linear propyl side-chain is equivalent to that of a pyridyl 
moiety in the vicinity of the STS active site. It is likely that the nitrogen-containing
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part of the side-chain of 43 points away from the hydrophobic region, while the 
hydrophobicity is due to rest of the side-chain.
With 35 and 43 being 18 times more potent than EMATE and 8  times more potent 
than 667 COUMATE in vitro, our study resulted in two novel and potent lead 
compounds with side-chains which differ both chemically and sterically. Although 
there is no definitive proof of the nature of inhibition, it is anticipated that the 
sulfamate moiety leads to an irreversible type of inhibition of STS. Clearly, the 
modified D-ring and its substituents have a role in the inhibition and the overall 
result can be seen as a combination of the effects of the pharmacophores present at 
both ends of the molecule. Similarly, in the development of 17a-benzyl derivatives 
of EMATE, Ciobanu et a l  observed an ‘additive-like’ inhibitory effect of the two 
kinds of substituents on the A- and D-ring. 100 The authors postulated that the 
substituents at C l7 a  facilitate the rate of binding, leading to more potent inactivation 
of the enzyme. It was also suggested that one molecule of the inhibitor may act on 
two molecules of enzyme, because hydrolysis of the inactivating sulfamate group 
leads to the corresponding phenol that can then exert its inhibitory effect on 
neighbouring free enzymes, resulting in an overall better efficacy. 100 Whether this is 
the case or not for our inhibitors is not known at present, but it is conceived that once 
the irreversible type of inhibition is established, the phenol derivatives 17-28 and 31 
could be tested for STS inhibition.
Finally, when the activity of 60 (the 2-methoxy analogue of 32) was examined in 
placental microsomes, it was found to be a poor inhibitor of STS. With an IC50 of 
309 nM, it was 100-fold less active than 667 COUMATE in the same assay and 
some 15 times less potent than its non-methoxylated analogue 32. It is possible that 
the methoxy group causes a displacement of the sulfamate group in the active site 
resulting in a low affinity binding. The 2-methoxy moiety may also conceivably 
shield the sulfamate group, possibly via hydrogen bonding.
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2.4.2 Estrogenicity and antiestrogenicity studies in vitro
Because of the intrinsic estrogenicity of EMATE, we introduced D-ring 
modifications on the estrone-3-O-sulfamate skeleton that were, to some extent, 
intended to reduce this problem. So far, it has not been elucidated whether the 
estrogenicity of EMATE is a direct effect of the sulfamate moiety or of E l and its 
metabolites, although it is not expected that sulfamates directly bind to the ER. This 
was corroborated by the findings of Eiger et al., which indicated that estradiol-3-0- 
sulfamate, and possibly estrogen sulfamates in general, did not have affinity for the 
ER in vitro.91 In a recent study on chromenone-sulfamate-based STS inhibitors, 
Nussbaumer et al. observed that EMATE stimulated the growth of MCF-7 cells but 
had a weak affinity for ERa and ERP, whereas the corresponding phenol, E l and its 
metabolite E2, showed high affinity for the ERs. 110 Since E l may be formed from 
hydrolysis of EMATE in vivo, it is important to take into account the phenolic 
derivatives 17-18 and 31 as well as the sulfamates 32-39 and 41-45 in our study on 
estrogenicity.
The assay was carried out using the MCF-7 human breast cancer cell line, which 
contains ER and is estrogen responsive. By ER, we imply ERa although a second 
isoform, ERp, has recently been discovered. 30 It is still unclear how each isoform 
modulates the estrogenic response and interacts with different compounds in various 
tissues, therefore our study was limited to ERa. In the series of phenols, the most 
estrogenic compound was the unsubstituted analogue 17, with activity detectable at 1 
nM (Table 2.4 p72). It was 10 times more estrogenic than EMATE in the same assay 
and therefore displayed high affinity for the estrogen receptor. The fact that the non­
alkylated template was found much more estrogenic than the compounds bearing a 
side-chain corroborates the hypothesis that the introduction of a hydrophobic moiety 
on the D-ring can contribute to reducing the estrogenicity of the precursor. The 
compounds bearing small and non-bulky side-chains (18, 19 and 31) had a higher 
estrogenic activity than others, with activity detectable at 10 nM for the A-allyl 
analogue and at 100 nM for the A-methyl and A-propyl derivatives. Again, this is in 
accordance with literature reports, where length and bulkiness are important factors 
when aiming at no estrogenic activity.97 ,101 ,152 As expected, none of the sulfamates
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were estrogenic and it is assumed that they do not bind to the ER. In particular, we 
were pleased to see that our two lead compounds, 35 and 43 did not display any 
estrogenic activities at concentrations as high as 100 nM.
When the compounds that displayed estrogenic activities at 100 nM and below were 
re-examined against the estrogenicity of 10 pM of E2, all the analogues except one, 
were less estrogenic than 2-MeOE2MATE, used as a reference in the assay. Given 
that 2MeOE2MATE is not estrogenic in vivo,S4 none of these compounds would be 
expected to bind strongly to the ER if used in living models. Clearly, the compound 
with no substitution on the D-ring was an agonist of the ER, be it in its phenolic 17 
or sulfamoylated form 32. In particular, at a concentration of 1 nM, 17 was already 
as estrogenic as 10 pM of E2. Interestingly, with 32 being estrogenic, we can assume 
that this D-ring modified estrogen sulfamate does bind to the ER, and its affinity for 
the ER is possibly driven by interactions of the receptor with the D-ring moiety. It is 
also conceivable that 32 is hydrolysed into 17 during the assay.
We were interested to see if some of the compounds that did not display estrogenic 
properties did bind to the ER, and thus behaved as antagonists. To this end, 
increasing doses of each inhibitor were assessed for their ability to inhibit the activity 
of 100 pM E2. For comparison, the antiestrogen Raloxifene was also tested in this 
assay. None of the compounds tested (the phenols 20, 27, 28, 24 and the sulfamates 
35, 43, 44, 39) were clearly antiestrogenic. While raloxifene could block the 
estrogenicity of 100 pM of E2, for most of the compounds, the luciferase activity 
recorded at various concentrations of inhibitor was similar or higher than that of 100 
pM of E2. The only compound displaying signs of antagonism of the ER was the 
phenol derivative 20. Unlike all the other compounds tested, this A-propyl analogue 
does bind to the ER and prevents the access of E2 at a concentration of 100 nM. 
From the previous test results, we also know that 20 is not estrogenic at such a 
concentration. Further testing would be required to assess the full potential of this 
derivative as an antiestrogen.
From the different sets of data, it appears difficult to rationalise the ability of our 
compounds to elicit an estrogenic response. Clearly, most of the STS inhibitors
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synthesised are devoid of intrinsic estrogenic activity, which further asserts the 
validity of the D-ring modified template we chose. However, it is still unclear 
whether the apparent lack of estrogenicity of the compounds is the result of their lack 
of affinity for the ER, or the effect of a weak antagonistic behaviour. Examination of 
the recent literature could provide some insight into the mechanisms involved in 
modulation of the ER.
With the resolution of the three-dimensional structure of the ER-LBD bound with 
agonists and antagonists,41,42 several groups have now proposed a structural basis for 
agonism and antagonism 40,41 From the crystal structure, it appears that the binding of 
E2 and other agonists of ERa is mediated through a combination of specific 
hydrogen bonds and that a tight complementarity exists between the binding cavity 
and the steroid’s non-polar surfaces. Both extremities of the steroid establish direct 
hydrogen bonds with critical residues of the LBD, the 3-OH with Glu353 and 
Arg394 and the 17-OH with His524. Mutagenesis studies have shown that residue 
Glu353 plays an important role in the binding of the A-ring phenolic group of E2,189 
thus explaining the higher affinity of phenolic derivatives for the ER as compared to 
that of sulfamates. Comparison of the crystal structure of the LBD of ERa in 
complex with E2 and raloxifene showed that both agonists and antagonists bind at 
the same site within the LBD, but the binding mode is different.41 Whether ER 
ligands are agonists or antagonists depends on the position adopted by one of the a- 
helices of the protein (HI2) which is important for hydrophobic interactions. 
Steroidal or non-steroidal antiestrogens that possess a long hydrophobic or bulky 
side-chain displace this helix, therefore disrupting the overall topography of the 
complex. It is therefore anticipated that compounds such as 17 can bind to the ER 
without disrupting H12 (i.e. in a similar mode to that of E2), as exemplified by its 
estrogenic activity. On the other hand, at concentrations up to 100 nM, compounds 
bearing long or bulky side-chains, such as the phenolic derivatives 27, 28 or 24, do 
not bind to the ER. It is assumed that the propyl side-chain of 20 is short enough to 
afford binding, yet long enough to disrupt H12 and thus results in an antagonist.
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2.4.3 In vivo evaluation of 35 and 43
Being 18 times more active than EM ATE in placental microsomes and devoid of 
estrogenic activity in preliminary in vitro testing, 35 and 43 were selected for in vivo 
studies. Oral administration of both inhibitors in ovariectomised rats at 10 mg/kg/day 
for a period of 5 days resulted in a complete inhibition (99%) of liver sulfatase 
activity. At a 200-fold lower dose, EMATE achieved a 73% inhibition of STS 
activity. These results are in agreement with the excellent in vitro potencies observed 
for the selected inhibitors. At the high dose of 10 mg/kg/day, sulfatase activity is 
completely inhibited by both compounds and further studies employing a range of 
lower doses will be required in order to fully evaluate the comparative potencies of 
35 and 43.
EMATEControl
F igure  2.13 Uteri o f ovariectomised rats treated with EM ATE (50 gg/kg/day, s.c.), 35 (STX 213) and 
43 (STX 237) (10 mg/kg/day, p.o.) for 5 days. Control animals received vehicle only.
In the same study, using an ovariectomised rat uterus weight gain assay, the in vivo 
estrogenicity of the compounds was studied. In animals receiving vehicle only, the 
average uterine weight ratio (expressed as a percentage of uterine weight/total body 
weight) was found to be 0.05. Upon treatment with EMATE for 5 days at 50 
jag/kg/day (s.c.), a 2 0 0 % increase in uterine weight could be observed (ratio > 0 . 1 0 ) 
in comparison with control group. Both 35 and 43 lacked estrogenicity when applied
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orally at 10 mg/kg/day, resulting in uterine weight ratios similar to or lower than the 
controls. A picture of the uteri excised of fat gives a visual account of the effects 
induced by a highly estrogenic compound such as EMATE (Figure 2.13).
To be successfully developed as anti-cancer drugs, it is advantageous if compounds 
are active on oral administration. Although the in vivo results obtained for 35 and 43 
tend to indicate that they are both orally active, we do not have any data attesting of 
their bioavailability. To ensure that such compounds reach the systemic circulation 
without undergoing significant degradation, metabolic studies would be required. 
Nevertheless, it is conceivable that such D-ring modified estrogens are orally 
available because they also are sulfamates. Natural estrogens have a poor oral 
bioavailability, whereas sulfamoylated derivatives of estrogens, such as EMATE, 
have enhanced oral availability.90,91 In their investigations on estrogen sulfamates 
and their potential application in oral hormone therapy as prodrugs of their parent 
estrogens, Eiger and coworkers found that sulfamoylation of E2 increased its activity 
by 100-fold on oral application. This property of sulfamates is thought to result from 
their ability to be taken up by red blood cells (rbcs) after absorption and transported 
through the liver without undergoing metabolism.91 This also explains why EMATE 
is active at low doses orally, in contrast to other estrogens that undergo substantial 
metabolism and inactivation, necessitating the use of high doses to achieve biological 
effectiveness. Possibly, 35 and 41 might achieve a high level of inhibition of STS at 
lower doses and further testing will be required.
Recent reports in the literature suggest that the partitioning of EMATE into rbcs may 
be due to its reversible binding to carbonic anhydrase II (CA II), which is present in 
the cytosol of erythrocytes.190)191 As several CA II inhibitors posses a sulfonamide 
group, it was reasoned that compounds such as EMATE or 667 COUMATE might 
inhibit the enzyme, while being transported in rbcs. Both these sulfamates were 
found to inhibit CA II activity with similar potencies to that of Acetazolamide, a 
known inhibitor of CA II191 and the X-ray crystal structure for the adduct of human 
CAII with EMATE has been resolved.192 Since CAs are highly expressed in several 
tumours and may have a role in supporting their growth, it is conceivable that 
EMATE and 667COUMATE act in vivo by other mechanisms in addition to STS
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inhibition. It would be interesting to see if our compounds act in a similar fashion on 
CA and 43 is currently being evaluated for its activity against CAII.
2.5 Recent advances and further discussion
2.5.1 X-ray crystallography of STS
At the time of writing, the crystal structure of the human steroid sulfatase had not 
been resolved and it is only very recently that the data have been published and made 
available from the Protein Data Bank (PDB).193 In 2003, Hemandez-Guzman 
reported the crystal structure of the full-length active STS, purified from human 
placenta, as determined by X-ray crystallography at 2.60 A resolution.120 Elucidation 
of this crystal structure represents a major breakthrough in the area as scientists have 
been trying to isolate and purify this membrane bound enzyme for many years. Study 
of the three dimensional structure with molecular modelling tools should now help 
understand the interactions involved at the active site and assist in the future design 
of potent inhibitors.
As described by the authors, the tertiary structure of the enzyme is a ‘mushroom­
like’ shape and can be divided into two domains (Figure 2.14): (a) a polar domain 
that contains the catalytic site; it resembles in shape, size and fold the two known 
structures of ASA and ASB; (b) a putative transmembrane domain that consists of 
two antiparallel hydrophobic a-helices, probably inserted into the lipid bilayer of the 
endoplasmic reticulum where the enzyme is bound. The catalytic site, which is 
buried deep in a cavity, seems to be located near the membrane surface, suggesting a 
role for the lipid bilayer in catalysis. Substrates and products may pass the membrane 
before and after catalysis via a hydrophobic tunnel created by the transmembrane 
helices. Three flexible loops, that may open to allow a steroid to enter or exit the 
active site, have also been identified. Figure 2.14 depicts the potent inhibitor 




F igure 2.14 Diagram of the crystal structure of STS in association with the lipid bilayer. Adapted 
from Hernandez-Guzman et al.120 EMATE was docked as a ligand using Gold194 v2.1.
In the active site, the catalytic FGly is covalently linked to a sulfate moiety. This 
was also observed in the crystals of ASB, although it has been proposed that this 
sulfated derivative of FGly could be in equilibrium with its free form . 112 The most 
likely cation present in the reported structures of STS and ASB is Ca2+, although 
Mn2+ and Mg2+ are possibilities that cannot be completely excluded. Most of the 
catalytic residues are conserved among the three mammalian sulfatases, suggesting 
that the mechanism of sulfate hydrolysis by human STS is similar to that previously 
proposed for ASB . 118
2.5.2 Docking studies and QSAR analysis
In an attempt to rationalise the activities observed for the compounds synthesised and 
to gain some insight into their interaction at the active site, molecular modelling 
studies were carried out in collaboration with Mr J.J. Robinson, using the crystal
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structure of the human STS. The use of docking algorithms can provide useful 
information regarding the preferred binding site of ligands in a protein. This can help 
identify and decide which feature(s) of a molecule give rise to its activity (i.e. 
pharmacophore identification) and assist in the design of compounds with enhanced 
properties. Quantitative structure-activity relationship (QSAR), where numerical 
properties of a set of molecules are related to their activity via a mathematical model 
can be used to predict the activity of compounds which have not been tested or 
synthesised as yet.
i) Docking studies
Docking methods can be used to predict energetically favourable conformations and 
orientations of ligands in the interior structure of a protein. These methods combine 
algorithms to generate different poses of a ligand (docking) and scoring functions to 
consider the tightness of protein-ligand interaction. GOLD194 (Genetic Optimisation 
for Ligand Docking) is an automated docking program that uses a genetic algorithm 
to explore the full range of ligand conformational flexibility with partial flexibility of 
the protein. Once a conformation of minimum energy has been determined for each 
ligand-protein complex, the ligands can be ranked using a scoring function. The 
fitness score, which represents the protein-ligand interaction energy, is taken as the 
negative of the sum of the component energy terms, so that larger fitness scores 
represent higher affinity binding.
1 Q-2
The crystal structure used for the study was obtained from the Protein Data Bank 
and has the code 1P49. The PDB file deposited corresponds to that of the enzyme 
bound to a sulfate moiety which, along with all the water molecules, was removed 
from the structure. No energy minimisation was performed on the enzyme. For each 
of the compounds, 50 independent GOLD runs were performed and the best docking 
scores were selected. The GOLD fitness scores (GOLDScores) are presented in 
Table 2.6 as well as the IC5 0S of each compound for STS inhibition in placental 
microsomes.
90
Table 2.6 STS inhibition data com pared with docking scores for com pounds 32-39, 41-45 and
EM ATE.
Com pound IC 5 0  (nM) GOLDScore Com pound IC 5 0  (nM) GOLDScore
32 2 0 60.07 39 1 2 67.87
33 1 2 60.92 41 74 65.26
34 52 61.71 42 23 69.10
35 1 63.20 43 1 67.53
36 382 64.13 44 3 67.78
37 150 65.38 45 75 63.92
38 288 68.76 EM ATE 18 57.96
Each compound gave a large positive docking score, within the same range. This 
suggests that the D-ring modified sulfamates synthesised fit well in the active site of 
STS, with scores similar to that of EMATE. Since these scores vary with the 
physicochemistry of protein-ligand interactions, they do not necessarily correlate 
with the activity observed for the inhibitors, although the values obtained indicate 
that compounds belonging to this series should be active.
All the compounds docked so that the atoms of the sulfamate moiety available for 
ionic interaction are within coordination distances of Ca2+. The positioning of the 
sulfamate group, pointing towards the central Ca2+ ion, dictates one major binding 
mode for the 14 compounds docked (Figure 2.15A and 2.15B). The steroid backbone 
is surrounded by mostly hydrophobic residues and the sides chains coming off the D- 
ring point toward the highly hydrophobic transmembrane domain (Figure 2.15A). 
The location of the active site, close to the membrane, might require passage of the 
ligands through a hydrophobic tunnel formed by the hydrophobic helices, which 
could explain the importance of hydrophobicity in substrate recognition and 
therefore enzyme inactivation.
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ca ta ly tic  site
tran sm em b ran e  helices
F igu re  2.15 A, Docking results of the highest score solution for 32-39, 41-45 and EMATE, shown in 
the tertiary structure of human STS. B, Close-up view of the active site with the docked structures and 
coordination of the sulfamate moieties to Ca2+.
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In agreement with previous reports , 195 the interaction of the sulfamate moiety with 
key residues in the active site and the metal ion Ca2+ is dominant. In their study on 
non steroidal phosphate esters as potential inhibitors of STS, Anderson et al. 
suggested that tight binding of a compound in the active site did not require a steroid 
nucleus . 195 The only essential molecular determinant important for binding appears 
to be the A-ring of the steroidal nucleus and an appropriately positioned charged 
group. Such findings contrast with other published studies, where hydrophobic 
interactions with the entire skeleton are required for optimal inhibition of sulfatase 
activity . 86,196 Both views however indicate the necessity for a negatively charged 
group for tight binding, which none of our inhibitors or EMATE possess. This issue 
was addressed by Howarth et al. in a docking study on estrone-3-sulfate mimics , 119 
where it was postulated that the presence of a potentially cleavable group in EMATE 
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F igure 2.16 Flat projection of 35 and 43 docked in the active site of STS with surrounding amino acid 
residues. Dotted lines represent hydrogen bonding.
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In an attempt to rationalise the high activities observed for 35 and 43, we examined 
the residues around the D-ring and the side-chains of these two inhibitors docked in 
the active site of STS (Figure 2.16). Each inhibitor interacts in the active site via (a) 
the NH2 group of the sulfamate moiety and the metal ion (b) the imide carbonyl at 
C16 and Arg98. Surprisingly, the imide carbonyl at C17 does not appear to 
participate in hydrogen bonding with catalytic residues, although such interactions 
could also be relayed by surrounding molecules of water (which have been removed 
prior to docking). The D-ring of each inhibitor is surrounded by hydrophobic 
residues (Leu, Phe, Trp) which illustrates previous reports98'100,102 and our findings 
that hydrophobic interactions are favoured in this region. It is possible that Trp550 
interacts with the pyridyl moiety of 43 via pi-pi interaction. This would in turn 
explain the high activity observed for the benzyl derivatives 42 and 44.
ii) QSAR analysis
The QSAR equation uses a series of parameters to describe the properties of a 
molecule, which are then correlated to its biological activity. Generally, most of the 
parameters (or descriptors) are designed to represent the hydrophobic, electronic or 
steric characteristics of a molecule. The most widely used technique for deriving 
QSAR equations is multiple linear regression, which uses least-squares fitting, to 
find the best combination of coefficients for the equation.197 To achieve statistically 
significant results, there should be at least five compounds for each parameter 
included in the regression analysis. In our case, the number of samples (14 
compounds including EMATE) is too limited and this method could not be used.
Partial least squares (PLS) is a statistical method in which the original variables are 
replaced by a small set of their linear combinations. It is an extension of multiple 
regression analysis which is particularly useful in cases in which the number of 
descriptors is higher than the number of samples. PLS enables the use of many 
descriptors and still remains predictive.
Docked structures were used and several QSARs were derived using different sets of 
descriptors. The best relationship (Equation 1) had a correlation coefficient (R2)
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value of 0.9995 (Figure 2.17). The descriptors used to build this equation take into 
account the polar character of each molecule (Van der Waals surface area and 
volume), its hydrophobicity (logP value) and its hydrogen bond donor potential, as 
well as physical properties such as its weight or number of atoms.
QSAR prediction = - 4589.92 + 3.60985 PEOE-VSA-POL + 3.6628 SlogP-VSA5
- 5.45559 Weight - 19.3155 a-count + 5417.6 Petitjean + 15.9715 Vol
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F igu re  2.17 Plot o f the QSAR prediction vs. IC 5 0  for each compound. The equation o f the trend line is 
y = 0.9995x + 0.0502; the correlation coefficients are R2 = 0.9995 and Q 2 = 0.9213.
The predicting potential of the final QSAR equation was evaluated by the Leave- 
One-Out (LOO) method. Using LOO, each compound of the list was deleted once 
from the data set and the regression equation thereby obtained was used to predict 
the activity of the deleted compound. The cross validated correlation coefficient Q2 is 
therefore a measure of the ‘wellness’ of the prediction.
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T able  2.7 Experim ental vs. correlated (QSAR) IC 5 0  values for 32-39, 41-45 and EM A TE determined 
using LOO.
Com pound IC 5 0  (nM)
QSAR-IC 5 0
(nM)
Compound IC 5 0  (nM)
QSA R-IC 5 0
(nM)
32 2 0 20.0092 39 1 2 12.1566
33 1 2 12.0069 41 74 71.2865
34 52 49.9671 42 23 22.4933
35 1 3.0043 43 1 2.1707
36 382 379.0415 44 3 1.4218
37 150 146.3974 45 75 79.5856
38 288 293.4210 EM ATE 18 14.1761
With a Q2 value of 0.9213, the predictive power of the QSAR equation was 
confirmed, as shown by the clear trend obtained in Figure 2.17. LOO predicted IC50S, 
as well as experimentally determined IC50S are given in Table 2.7 for comparison.
2.6 Conclusion
We have successfully designed a template for the rapid generation of potent STS 
inhibitors. Starting from EMATE, with the aim to reduce its intrinsic estrogenicity 
while retaining its activity, we introduced crucial modifications into the D-ring. The 
resulting 16,17-seco-estra-l,3,5(10)-triene-16,17-imide skeleton proved to be a 
valuable template for the introduction of a variety of side-chains on the D-ring, that 
allowed us to probe the STS active site. The importance of the hydrophobicity of the 
D-ring moieties (at C16/C17 on E2 or EMATE) is well documented98'100,102 and it 
was envisaged to explore the capacity of the potential corresponding hydrophobic 
pocket in the active site.
Of the analogues synthesised, three compounds were found to be highly active in 
vitro against STS, namely the propyl 35, the pyridin-3-ylmethyl 43 and the benzyl 44 
derivatives. In particular, 35 and 43 were 18 times more potent than EMATE, with 
IC50S of 1 nM in placental microsomes. While hydrophobic residues seemed to 
contribute to the high activity observed, steric bulk had a major effect and long linear
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alkyl side-chains led to steric clashes. Both 35 and 43 were also active in vivo when 
tested orally on a 5 day course, at 10 mg/kg/day. Their full potential as future drug 
candidates for estrogen-dependent diseases was confirmed when they were found to 
inhibit liver sulfatase activity by 99%, with no residual estrogenic activity at this 
dose. Metabolic studies might however be necessary to confirm the bioavailability of 
such inhibitors. Like EMATE, 35 and 44 might be transported by rbcs in vivo and 
thus may not undergo metabolism before they reach their target. At present, we do 
not have the direct proof that our inhibitors act via an irreversible mechanism, but it 
is believed that the A-ring pharmacophore might act synergistically with the D-ring 
to enhance their potency. All sulfamates so far studied are assumed to act irreversibly 
by way of established precedent and we do not anticipate that these will be any 
different.
In order to rationalise the activity of this series of inhibitors, molecular modelling 
studies were carried out using the recently published crystal structure of the human 
STS.120 Docking experiments identified one major binding mode for all the 
compounds, illustrating the importance of the sulfamate moiety for binding, as 
reported in the literature.119,195 Key interactions that may be involved in stabilising 
the inhibitor-enzyme complex have also been identified and evidence for a 
hydrophobic pocket in the D-ring region confirmed. A QSAR was established on the 
basis of the hydrophobic and polar character of the molecules as well as their 
physical properties. Its predictive power was confirmed and it may therefore be used 






Foreword: Isotypes and selectivity
The 17P-hydroxysteroid dehydrogenases are an important class of steroidogenic 
enzymes that are involved in the regulation of steroid hormones such as estrogens 
and androgens.127,128 Several isotypes which differ in substrate specificity, catalytic
19Sdirection (oxidation or reduction) and tissue distribution have been identified. 
Previous investigations have mainly focused on 17p-HSD type 1 and type 2, the 
enzymes responsible for the interconversion of E l and E2. In particular, 17p-HSD 
type 1 the isoenzyme responsible for the production of the potent estrogen E2 
represents an attractive target for the treatment of estrogen-dependent pathologies, 
such as HDBC.
Contrary to isotype 1, 17p-HSD type 2 catalyses preferentially the oxidative process
i ' I ' l  i 2 3(E2 to the less estrogenic E l) thereby reducing exposure of tissues to estrogens. ’ 
Inhibition of 17p-HSD type 2 might result in an increase in the intracellular level of 
E2 and therefore it is important to achieve selectivity when inhibiting 17P-HSD type 
1. Both 17p-HSD type 1 and type 2 accept estrogenic as well as androgenic 
substrates, although 17P-HSD type 2 is less specific for C 18 steroids than the isotype 
1. To design compounds that have little or no affinity for other 17P-HSDs, in 
particular for 17P-HSD type 2, it is crucial to identify the molecular determinant 
responsible for substrate specificity. Unfortunately, the three dimensional structure of 
17p-HSD type 2 remains unknown and investigation of the topology of the active 
site have been carried out via the design of inhibitors.198,199
All the potential 17P-HSD type 1 inhibitors synthesised as part of this work have 
therefore been tested against both isotypes 1 and 2. The inhibitory potency of 
compounds against type 2 was used as a measure of selectivity and selective 17p- 
HSD type 1 inhibitors were characterised by a lack of (or a weak) inhibition of 17P- 
HSD type 2.
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3.1 Mechanism-based inhibitors of 17J3-HSD type 1
3.1.1 Enzyme-generated alkylators: how and why?
Although the therapeutic value of inhibiting 17P-HSD type 1 has been known for 
many years, * relatively few selective inhibitors have been reported in the 
literature.72,121 Early work on inhibition was carried out by Covey and co-workers131' 
133 in the 1980’s, with the development of irreversible inhibitors. Prompted by the 
report that a yeast alcohol dehydrogenase was inactivated by allylic alcohols, the 
authors decided to investigate steroid molecules bearing an a,p-unsaturated alcohol 
moiety as potential suicide substrates for 17p-HSD type 1. Given that 17p-HSD type 
1 has a bidirectional activity, the allylic alcohol functionality (latent Michael 
acceptor) can be enzymically oxidised in the active site to an a,P~unsaturated ketone 
(active Michael acceptor or affinity alkylator) which can then undergo 1,4-addition 
of a nucleophilic amino acid residue to form covalently inactivated enzyme (Figure
3.1).
Enz-X
allylic alcohol Michael acceptor inactivated enzyme
F ig u re  3.1 Irreversible inhibition o f 17(3-HSD type 1 by enzym e-generated M ichael acceptor. (A) 
enzym atic oxidation; (B) attack by a nucleophilic am ino acid and form ation o f an adduct; (C) proton 
abstraction. (Enz-X  =  nucleophilic residue o f the active site; R l ,  R2 and R3 = any groups of the 
substrate).
Enzyme-generated alkylators represent an appealing concept for the development of 
selective inhibitors of 17p-HSD type 1 and have an increased specificity over 
irreversible inhibitors or affinity labelling agents. Conceivably, Michael acceptors 
can be attacked by any available nucleophile within a biological system, however, 
this is avoided by the use of non reactive precursors, which are only converted to 
reactive species by a specific enzyme. Additionally, since generation of the affinity 
alkylator occurs within the enzyme active site, specific alkylation of active site
1 0 0
amino acid residues is favoured. Finally, as one molecule of steroid is expected to 
remain bound to each sub-unit of the enzyme, de novo synthesis is required for the
• • 129enzyme to recover its activity.
Introduction of an a,|3-unsaturated alcohol at C20, C17 or pseudo C17 of a steroid 
nucleus resulted in the suicide inhibitors depicted in Figure 3.2 (1.15, 1.16 and 65) 
that can potentially be oxidised to the corresponding enones (3.1, 3.2 and 63, Figure
3.2) by 17|3-HSD type 1. Both 1.15 and 1.16 were found to cause time-dependent 
inactivation of the enzyme in a concentration-dependent manner, and enzyme 
inhibition occurred only in the presence of a cofactor, indicating that turnover to the 
corresponding ketone was essential.130,132 Unfortunately, these compounds were poor 
substrates for the enzyme and had a weak oxidation rate; the half-life of 1.15 was 
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F ig u re  3.2 Latent (1 .15 ,1 .16 , 65) and active (3.1, 3.2, 63) M ichael acceptors as irreversible inhibitors 
o f 17J3-HSD type 1.
The most promising compound was found to be 16-methylene-estradiol (65, Figure
3.2) since it could be oxidised at about the same rate as the normal substrate. The low 
reactivity of the enzyme-generated product (63, Figure 3.2) was however 
problematic. When the acetylenic derivatives were tested in their active form (3.1 
and 3.2, Figure 3.2), the enzyme was rapidly inactivated (limiting ti/2 , <1 min for
3.2), which suggested that, contrary to 63, the electrophilic moiety generated in situ 
had sufficient reactivity towards residues of the active site. The high reactivity of 3.2
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toward the active site was exploited to study the structure of enzyme-steroid adducts.
Using solution- and solid-state 13C NMR, Auchus and Covey200,201 identified cysteine





F ig u re  3.3 Structure o f the affinity m arker 3.3 and general structure for 17(3-HSD type 1 inhibitors 
developed in our laboratories (3.4 and 3.5, R = aryl, 2-, 3- or 4-pyridyl).
In an attempt to optimise the oxidation rate and/or reactivity of these inhibitors, a 
trifluoroacetylenic alcohol derivative of secoestradiol was prepared ( 3 . 3 ,  Figure
3.3).133 Unfortunately, it was proven to be reactive enough to inactivate the enzyme 
without the oxidation step, and behaved therefore as an affinity alkylator.
To the best of our knowledge, no new enzyme-generated irreversible inhibitor of 
17P-HSD type 1 has been reported in the literature since these studies. Our interest in 
such compounds arose when some derivatives of E2 and E l ( 3 . 4  and 3 . 5 ,  Figure 3.3) 
developed in our laboratories displayed interesting biological activity. These 
compounds were found to inhibit 17p-HSD type 1 activity in T-47D cells, and in 
particular one E2 derivative ( 3 . 4 ,  R = 4-pyridyl, Figure 3.3) had an IC50 of 4.1 jliM. 
However, the mechanism through which these compounds exert their effect was not 
investigated and whether the E2 derivatives could be substrates for the enzyme 
remains unclear. Interestingly, there is no precedent in the study of 16-alkylidene 
derivatives of E1/E2 as inhibitors of 17p-HSD type 1, which prompted us to 
investigate their potential. Therefore, we decided to synthesise 16-alkylidene 
derivatives of E1/E2 bearing small hydrophobic moieties at C l6, and in a 
preliminary study we aimed to prepare the propylidene, isobutylidene and dimethyl- 
propylidene derivatives of El and E2. To the best of our knowledge, such derivatives 
of E l and E2 have not been synthesised before.
1 0 2
3.1.2 Synthesis
i) Synthesis of the 16-methylene derivatives 63 and 65
In order to test the newly synthesised compounds against a reference in the 
enzymatic assay, we first prepared the 16-methylene derivatives of El and E2 (63 
and 65, Figure 3.2). a-Methylene ketones can be prepared by direct methylene 
transfer, via a Mannich reaction followed by elimination of an amine. Most of the 
procedures involve the use of dimethylamine hydrochloride and formaldehyde in an 
aprotic solvent.
Schem e 3.1 The M annich reaction on E l as reported by K in d  and G arcia : 2 0 2  (a) (HCHO)n, 
HN M e 2 .HCl, isoamyl alcohol, reflux; (b) steam  distillation, and as reported by Patton : 2 0 3  (a) 
(HCHO)n, HNR-2 , benzene, EtOH, reflux.
The Mannich reaction on E l was first studied by Kind and Garcia.202,204 Using the 
above mentioned conditions in refluxing isoamyl alcohol, the reaction was reported 
to yield a 16-dimethylaminomethyl intermediate (Mannich base), which was then 
converted into 16-methylene-estrone in good yields (Scheme 3.1). Shortly after Kind 
and Garcia’s report, Patton203 suggested that the Mannich base could be formed by 
reaction on the A-ring of estrogens. This was substantiated by a series of experiments 
where El or E2 were exclusively converted to their corresponding 2- 
dialkylaminomethyl derivatives under Mannich conditions in a refluxing mixture of 
benzene and EtOH (Scheme 3.1). Later, Gonzalez et a l used this method (i.e. 
Patton’s variation) to prepare a 2-dimethylaminomethyl derivative of E2.205 The 




the difference in the solvents used, however we felt it necessary to ensure that 
methylenation occurred at C16 when repeating the procedure of Kind and Garcia.202
A preliminary attempt to apply Kind and Garcia’s conditions to El failed to yield 
the expected product, and protection at C3 was envisaged. Acetylation of the 
phenolic function of E l was achieved in quantitative yields following a literature 
procedure (Scheme 3.2).156 The resulting compound 61 was then reacted with a large 
excess of dimethylamine hydrochloride and paraformaldehyde in refluxing isoamyl 
alcohol. After an acidic workup, the remaining isoamyl alcohol was distilled off 
using a Kugelrohr and purification of the residue by flash chromatography afforded 
62 in 51% yield. Some deprotected product 63 was also recovered from the column 















Schem e 3.2 Synthesis o f the 16-methylene derivative o f E l and E2 63 and 65. (a) Ac2 0 /P y , reflux; (b) 
(HCHO)n, H N M e2 .HCl, isoam yl alcohol, reflux; (c) KOH/EtOH; (d) N a B H ^ O ,  M eOH/THF.
The acetate protecting group was then cleaved using KOH in ethanol although it was 
anticipated that nucleophilic conditions might affect the enone functionality of 62 (or 
that of 63 after deprotection). Using a minimal excess of KOH, our first attempt 
successfully afforded 63 as the sole product of the reaction in 58% yield, after
1 0 4
stirring the reagents at room temperature for 30 minutes. When repeating the reaction 
at 0°C, 64 was isolated as a side-product in 13% yield along with 63 (29%). The 16- 
ethoxymethyl derivative 64 was formed from the 1,4-addition of an ethoxide anion to 
the a,p-unsaturated ketone of 62 or 63. The absence of low field methylenic signals 
in the *H NMR spectrum of 64 confirmed that the methylene functionality had 
reacted. The presence of a triplet at 8  1.16, accompanied by two signals accounting 
for two protons each at 8  3.4-3.7 further asserted the structure of this side-product 
which was formed as a single diastereoisomer. The conditions in which 64 was 
formed indicate that ester hydrolysis at C3 is the favoured reaction and occurs faster 
than nucleophilic addition at the D-ring end. Performing the deprotection at room 
temperature seemed sufficient to prevent the side-reaction. Reduction of the 17-keto 
function of 63 was then achieved using an aqueous solution of NaBFU in 
MeOH/THF . 204 This conventional method for the selective reduction of the ketone of 
E l afforded the corresponding 17p-hydroxy compound 65 in 48% yield after 
recrystallisation.
Based on its H NMR spectrum, 62 was assigned the structure of a 16-methylene 
derivative. All the aromatic protons, as well as the couplings between H1-H2 and 
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F igure  3.4 Part of the ‘H NMR spectrum of 62 (CDCI3, 400 MHz).
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F igure 3.5 ORTEX173 plot of the X-ray crystal structure of 62. Ellipsoids are shown at the 30% 
probability level.
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Unambiguous proof of this structure was later provided by X-ray crystallography. A 
crystal (approximate dimensions 0.35x0.28x0.25 mm) was obtained from slow 
crystallisation of 62 from hexane and used for data collection. The resulting 
ORTEX173 plot is presented in Figure 3.5. As expected, the D-ring features an oc,p- 
unsaturated ketone with an exocyclic methylene function at C l6. Accordingly, the 
C=C bond has a length of 1.3245 A while that of the conjugated carbonyl bond is of 
1.2175 A. For full details see Appendix 2. To the best of our knowledge, this is the 
first report of an X-ray crystal structure of an a,p-unsaturated D-ring derivative of 
E l. The data collected are expected to be useful for future molecular modelling 
studies.
ii) Synthesis of 16-alkylidene analogues
Two general methods have been described in the literature for the efficient 
conversion of the steroid ketone to an ot,p-unsaturated moiety. The first synthetic 
approach involves the generation of a 16-(A7V-dimethylethylene) intermediate, 
which can directly be reacted with alkyllithiums or Grignard reagents to form 
unsaturated ketones (Figure 3.6).205 This Vilsmeier type of intermediate can be 
prepared by reacting protected E l with Bredereck’s reagent ’ or with N,N- 
dimethylformamide dimethylacetal.207 Alternatively, the enamine can be accessed in 
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F ig u re  3.6 Synthetic strategies to access 16-alkylidene derivatives o f E l .  (B redereck’s reagent is 




The synthesis of 16-alkylidene derivatives of E l can also be achieved in one step via 
an aldol condensation between the steroid enol and an aldehyde (Figure 3.6). The 
cross-aldol reaction, which involves the use of aldehydes which do not possess an 
enolisable proton, has been successfully applied to E l previously164 as well as in our 
laboratories. Even when the aldehyde has an enolisable proton, the reaction proceeds 
via addition of the a-carbon of the ketone to the carbonyl of the aldehyde because of 
the lower reactivity of ketones vs. aldehydes towards nucleophiles. This was 






















Schem e 3.3 Synthesis o f 16-alkylidene derivatives o f E l.  (a) LDA/THF, -78°C then (CH 3 )2 CHCHO, 
-78°C to rt; (b) N aBH 4 /H 2 0 ,  M eOH /TH F; (c) LDA/THF, -78°C then rBuCHO, -78°C to rt; (d) 
LD A/THF, -78°C then CH 3C H 2 CHO, -78°C to rt.
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El was deprotonated at C16 using LDA in THF and the resulting enol was reacted 
with a series of aldehydes (Scheme 3.3). Condensation of E l with isobutyraldehyde 
gave 66 with a yield of 79% as the sole product of the reaction. Among other peaks 
characteristic of the isobutylidene moiety in the lH NMR spetrum of 66, a deshielded 
signal was observed at 8 6.46 for the vinylic proton. The signal for the corresponding 
carbon was seen at 8 144.2 in the 13C NMR spectrum. Examination of the NMR 
spectra also suggested that one regioisomer was exclusively formed and the double 
bond configuration was assigned by analogy with literature reports205,209 and was in 
accordance with the formation of the thermodynamically more stable E  isomer.
The reaction of E l with 2,2-dimethyl-propionaldehyde was found to proceed slower, 
possibly due to the diminished reactivity of the more hindered aldehyde, and 
unexpectedly resulted in the formation of two non isomeric products. After 2 days, 
the expected product 68 was obtained in 42% yield along with a side-product which 
was identified as 69 (Scheme 3.3). The presence of a peak for an additional tert-butyl 
group in the NMR spectrum of 69 suggested the formation of an adduct between 
El and two molecules of the aldehyde, which was confirmed by mass spectrometry. 
Presumably, an excess of base in the reaction mixture was able to deprotonate one 
hydroxyl of the intermediate aldol, which then reacted further with the aldehyde 
(Figure 3.7). Deprotonation of the phenol to yield 69 was most likely because of its 
lower pKa (pKa ~ 9-11) compared with that of the secondary alcohol at the D-ring 
end (pKa ~ 15-19). The formation of 69, as opposed to 3.7 (Figure 3.7), was also 
corroborated by the presence of a doublet of doublets at 8 3.23 which gave a doublet 
upon D2 O exchange in the *H NMR spectrum. Such a signal can only be seen for the 










F ig u re  3.7 Formation o f a side-product in the aldol condensation o f E l  with 2,2-dim ethyl- 
propionaldehyde. Bold arrows indicate the sites o f deprotonation and condensation.
Finally, attempts to perform the condensation between El and propionaldehyde 
failed to yield the expected product (3.6, Scheme 3.3). Instead, the aldol 71 was 
obtained in 60% yield, and too little of 3.6 was recovered to allow its purification. 
Although the !H NMR spectrum showed 71 as a single compound, its 13C NMR 
indicated that it was formed as an inseparable mixture of diastereoisomers. 
Reduction of the 17-ketones of 66 and 68 into the corresponding 17p-alcohols 
proceeded smoothly using the same conditions as for the reduction of 63 (cf. Scheme 
3.2). The derivatives 67 and 70 were obtained in respective yields of 60% and 79% 
after recrystallisation.
3.1.3 Results and discussion
i) Inhibition of 17fj-HSD type 1 in vitro
The compounds prepared were examined for their ability to inhibit 17p-HSD type 1 
activity in the human hormone-dependent breast cancer cell line T-47D. For each 
compound, 17p-HSD type 2 activity was also assessed as a measure of selectivity of 
inhibition. The percentage of inhibition achieved for a concentration of 10 pM of 
inhibitor is given in Table 3.1 and 3.2. The 16-methylene and 16-alkylidene 
derivatives were evaluated in both their latent and active Michael acceptor forms.
Table 3.1 Inhibition o f 17J3-HSD type 1 (and type 2) by the a ,P -unsaturated  ketone derivatives 63, 6 6 , 
6 8  and the allylic alcohols derivatives 65, 67 and 70. Results are expressed as a percentage o f 
inhibition at 10 pM  (± S.D. triplicate).
X o &
%  inhibition at 10 pM
R Com pound 17P-HSD type 1 17p-HSD type 2
H 63 70.3 ± 3 .8 9.7 ± 5 .9
CH(CH 3 ) 2 6 6 71.4 ± 2 .7 17.8 ± 4 .6
C(CH 3 ) 3 6 8 81.8 ± 1.3 31.3 ± 3 .3
1
% inhibition at 10 pM
R Com pound 17p-HSD  type 1 17P-HSD type 2
H 65 63.7 ± 2.3 19.9 ± 0 .7
CH(CH 3 ) 2 67 68.3 ± 1.4 7.1 ± 5 .9
C(CH 3 ) 3 70 83.9 ± 2.2 27.1 ± 2 .4
All the compounds tested inhibited 17P-HSD type 1 activity to more than 60% at a 
concentration of 10 pM and displayed selectivity for the type 1 isoenzyme, i.e. they 
were weak inhibitors of 17p-HSD type 2. In the a,p-unsaturated ketone series, the 
best inhibitor was the dimethylpropylidene derivative 68, which achieved 82% 
inhibition of type 1 activity. Its corresponding allylic alcohol 7 0  was the best 
inhibitor among the latent Michael acceptors with 84% inhibition of 17p-HSD type 1 
activity. Disappointingly, 6 3  and 6 5  proved to be moderate inhibitors of 17p-HSD 
type 1 at 10 (iM, with respective levels of inhibition of 70% and 64%. The activity of 
6 3  was however consistent with reports that this enone had low reactivity towards the
131active site.
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Table 3.2 Inhibition o f 17J3-HSD type 1 (and type 2) by the E l derivatives 64 and 71. Results are 
expressed as a percentage o f  inhibition at 10 pM  (± S.D. triplicate).
j o S ’6 '
OR
R R 1 Com pound
% inhibition at 10 pM  
17p-HSD type 1 17p-HSD type 2
Et H 64 92.0 ± 0 .1 19.2 ± 7 .2
H Et 71 79.7 ± 0 .1 -17.5 ± 2 .0
Both 64 and 71 were comparatively good inhibitors of 17|3-HSD type 1. In particular, 
64 was the best inhibitor of all the compounds tested and 71 was highly selective for 
the type 1 isoenzyme, with a total lack of inhibition of 17p-HSD type 2. However, 
these compounds do not enter the scope of the present study and their activity will be 
addressed in another chapter.
The a,p~unsaturated ketones and their corresponding allylic alcohols (Table 3.1) 
were found to be equipotent for the inhibition of 17P-HSD type 1, with the exception 
of 63/65. For this pair of active and latent Michael acceptors, the level of inhibition 
achieved by the allylic alcohol 65 was lower than that of the enone 63. To some 
extent, a difference of activity between active and latent Michael acceptors is 
expected since the latter needs to be oxidised before being able to irreversibly 
alkylate the enzyme. It is conceivable that after a short incubation time (30 minutes 
in this assay) the enzymatic oxidation of 65 to 63 was not complete. Using higher 
concentrations of 63 or 65 in the assay should afford a faster inactivation of the 
enzyme since the reported Km values for these compounds were 2.7 pM and 8.0 pM 
respectively.131
The moderate activities observed for the pair of inhibitors 63/65, and in particular the 
lower activity of 65 might also be related to the pH at which the assay was performed 
(pH 7.4). For the alkylator to be generated enzymically, 17p-HSD type 1 oxidative 
activity needs to be sufficiently high in the assay conditions. Recent reports clearly
1 1 2
state that 17(3-HSD type 1 has a higher specificity towards El reduction than E2 
oxidation at physiological pH,124,210 therefore an inefficient oxidation of 6 5  by the 
enzyme might account for its lower potency. Previous reports also indicate that a 22- 
fold slower inhibition of 17p-HSD type 1 at physiological pH vs. pH 9.2 was 
observed with 6 3 / 6 5 . 131 An enhanced nucleophilicity of residues such as cysteine, 
lysine or histidine at higher pH values was proposed to rationalise this observation. 
Finally, it is conceivable that the ketone 6 3  is reduced back to 6 5  faster than the 
inactivation occurs, accounting for the disappointing 70% inhibition at 10 pM.
Unlike 6 5 ,  it is not known whether 6 7  or 7 0  are substrates for the enzyme. Moreover, 
no reversibility study or kinetic data support the inhibition results, and it is therefore 
difficult to anticipate how these compounds inhibit 17p-HSD type 1. Four possible 
scenarios can be envisaged to rationalise their moderate activities:
(a) 6 7  and 7 0  are substrates for 17p-HSD type 1, but as in the case of 6 5 ,  the
turnover of the oxidation reaction is too low (due to the pH, the length of the assay or 
the concentration of inhibitor used);
(b) 6 7  and 7 0  are substrates for 17p-HSD type 1, but as in the case of 6 3 ,  the
reactivity of the Michael acceptor generated in situ is not very high;
(c) 6 7  and 7 0  are not substrates for 17p-HSD type 1 and the level of inhibition seen 
is the result of another mechanism, possibly inhibition via reversible interactions;
(d) a combination of (a) and (b).
Upon examination of the biological results, it is not possible to conclude whether the 
new inhibitors 6 7  and 7 0  are actual substrates of the enzyme and whether their 
corresponding enones (66 and 68) inhibit the enzyme via an irreversible mechanism. 
The presence of a bulky moiety at C 16 in these compounds might prevent access of 
the cofactor to the active site or its correct positioning for hydride transfer to occur at 
C17. It is however interesting to notice that if 6 7  and 7 0  do behave as enzyme­
generated inhibitors, they are more potent than 6 5 .  This might be explained by the 
fact that their respective a,p-unsaturated ketones 66 and 68 are better inhibitors than 
6 3 ,  suggesting that the enzyme-generated products exhibit a higher reactivity towards 
the active site.
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ii) Reversibility study on 63
Before investigating further the new inhibitors synthesised, we wanted to assess 
whether 6 3  could be used as a control or reference, and therefore whether it inhibited 
the enzyme via an irreversible mechanism in our assay. To this end, a reversibility 
study was carried out in which T-47D cells were pretreated with the inhibitor 6 3  (at 
10 or 20 pM) overnight. 17P-HSD type 1 activity was then measured in four 
different cases (Figure 3.8):
(a) the cells were washed and the inhibitory activity of 6 3  (at 10 p M )  was measured 
under standard assay conditions (P+W+I);
(b) the cells were not washed and the inhibitory activity of 6 3  (at 10 jiM) was 
measured under standard assay conditions (P+NW+I);
(c) the cells were not washed and activity was measured in the absence of inhibitor 
(P+NW+S);
(d) the cells were washed and activity was measured in the absence of inhibitor 
(P+W+S).
A standard assay measurement was also carried out at 20 pM and Figure 3.8 
summarises the results.
Clearly, a loss of inhibition can be observed upon washing the pretreated cells, 
whether 6 3  was tested at 10 or 20 p M .  The remaining inhibitory activity in cells 
which have been pretreated but not washed (P+NW+S) is much higher than for those 
which undergo washing (P+W+S). Indeed, the level of inhibition falls from 57% to 
35% at 10 p M  and from 85% to 62% at 20 p M .  This means that the recovery of the 
enzymatic activity upon washing is of 23%, irrespectively of the concentration of 
inhibitor used.
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Figure 3.8 Inhibition of 17|3-HSD type 1 activity in T-47D cells. Results are shown as percentage 
inhibition (± S.D. duplicate) of the control. The control was not pretreated with inhibitor overnight. P 
= pretreatment with 63 (10 pM  or 20 pM ) overnight; W = cells washed five times with assay medium: 
NW = cells not washed (assay medium removed); I = assay medium + 3 H-E1 + 63 (10 pM ) followed 
by 30 minutes incubation; S = assay medium + 3 H-E1 followed by 30 minutes incubation; In assay = 
inhibition under standard assay conditions, i.e. without overnight pretreatment, after 30 minutes 
incubation with 3 H-E1 + 63 (20 pM).
As expected, washing of the cells does not significantly affect the level of inhibition 
when they are pretreated overnight and their activity measured in presence of the 
inhibitor. In both cases (P+W+I and P+NW+I) a high level of inhibition is observed 
(81 to 8 8 %), with no significant difference. Maximum level of inhibition (98%) is 
reached when the cells are tested in presence of 63 at a concentration of 20 pM, 
under standard assay conditions.
Although the influence of washing seems to indicate that the inhibitor 63 may not be 
tightly bound to the enzyme, the recovery of enzymatic activity does not exceed 
23%, which is conceivable, even for an irreversible inhibitor. To some degree, a loss 
in inhibition is expected upon washing the cells as it is not possible to ascertain 
whether all the enzyme molecules are irreversibly inactivated the moment the 
washing procedure is started. As mentioned earlier, the rate of inactivation is greatly 
enhanced at higher pH values and in previous experiments , 131 1 hour was necessary
1 1 5
for 63 (at 100 jllM) to inhibit half the enzymatic activity (ti/2) at pH 9.2 vs. 25 hours 
at pH 7.4. Given that our assay is carried out at physiological pH, this might explain 
why only 35% and 62% of inhibition are achieved for 10 and 20 JiM of 63 
respectively after overnight incubation and washing.
Compound 63 therefore appears to behave as an irreversible inhibitor but the 
conditions of the assay need to be adjusted to observe an optimal effect of this 
inhibitor on the enzyme after overnight pre-treatment.
3.1.4 Towards a mechanism of irreversible inhibition
Irreversible inhibition using enzyme-generated inhibitors is thought to occur by 
Michael addition of an enzymic nucleophile to the electrophilic moiety of the ligand. 
Although kinetic studies corroborate such a mechanism, there is no clear proof as to 
whether such an attack occurs, and if so, which amino acid(s) is(are) involved. Our 
aim was to investigate the active site of 17p-HSD type 1 using molecular modelling 
in order to identify putative nucleophilic amino acid(s) thought to be involved in 
irreversible inhibition by 63.
i) Literature precedent
The first evidence in support of a nucleophile-mediated irreversible inhibition of 
17p-HSD type 1 was reported by Auchus and Covey, in their study on the enzyme­
generated acetylenic ketone 2 (Figure 3.9).200
OH
HO'HO'HO'
lysyl enaminone adduct3 .93 .8
F ig u re  3.9 Proposed irreversible inhibition o f 17(5-HSD type 1 by the enzym e-generated ketone 3.9 
via attack o f a lysine residue (Enz-Lys-N H 2) (' = 1 3C). A dapted from  Auchus and C ovey . 2 0 0
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To elucidate the structure of the potential enzyme-steroid adduct formed during 
irreversible inhibition, 13C-enriched allylic alcohol (3.8, Figure 3.9) was prepared 
and incubated with purified 17(3-HSD type 1 at pH 9.2.200 Analysis of the inactivated 
enzyme by solution-state 13C NMR, revealed the presence of a lysyl enaminone 
adduct (Figure 3.9). It is not excluded that other adducts between the steroid and the 
enzyme may have been formed, only they were not detected in the experiment. A 
follow-up study confirmed the previous findings using solid-state 13C NMR.201 From 
a spectra of lyophilised intact inactivated enzyme, a lysine- as well as a cysteine- 
Michael adducts were identified.
Although these studies have provided valuable insight into the irreversible inhibition 
of 17p-HSD by enzyme-generated inhibitors, they do not entirely reflect what would 
happen at physiological pH. In both cases the incubations were performed at pH 9.2, 
which may have led to an ‘artificial’ deprotonation of some residues such as lysine, 
resulting in an enhanced nucleophilicity. We believed that the use of the now 
available crystal structure of 17p-HSD type 1 might provide an alternative way of 
identifying the particular residues involved in covalent bonding with the steroid.
ii) Docking in the active site o f 17fi-HSD type 1
Docking studies were performed on 63 in order to predict the energetically 
favourable conformations of this ligand in the active site and allow the identification 
of key residues surrounding the steroid. The docking programme GOLD194 and the 
crystal structure of 17P-HSD type 1 at 1.70 A resolution in complex with E l, in the 
absence of cofactor (1 FDS146 in the Protein Data Bank193) were used for this study. 
This particular crystal structure was chosen since a preliminary experiment using the 
crystal structure of 17P-HSD type 1 in complex with E2 and NADP+146 did not allow 
the identification of residues of the active site within proximity of the steroidal D- 
ring, due to the presence of the cofactor in this region. In addition, kinetic studies on 
the acetylenic derivative 3.9 (Figure 3.9) have shown that inactivation of the enzyme 
by Michael acceptors cannot occur in the ternary complex formed between the 
enzyme, the inhibitor and NAD.132
117
F igure 3.10 Docking solutions for 63 in the active site of 17(3-HSD type 1 (1 FDS).146 The potential 
nucleophilic amino acid involved in irreversible inhibition, Cysl85, is shown (sulphur atom in yellow) 
and the white arrows point towards the D-ring.
A model of 63 was built based on the X-ray crystal structure of 62 (the 3-O acetyl 
precursor, cf. section 3.1.2) and docking was performed using G OLD.194 The 
docking modes of higher score (i.e. lower energy) obtained for 63 after 50 
independent GOLD runs are shown in Figure 3.10. Clearly, two major binding 
modes of low energy can be identified for this steroid.
Examination of the active site within a 7 A radius around the steroidal binding cleft 
identified only one candidate for nucleophilic attack on the a,(3-unsaturated ketone 
63: a cysteine residue, namely Cysl85 which is shown in Figure 3.10. Although 
Cysl85 appears to be at quite a distance from the putative site of attack, it is 
conceivable that its side-chain comes within close contact of the steroidal D-ring as a 
result of conformational changes occurring in the protein. No other potential 
nucleophilic amino acids (His, Lys, Ser) were observed within a radius of 10 A
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around the steroid, suggesting that Cysl85 is the most likely candidate for the 
formation of a Michael adduct with 63. This is in agreement with the findings of 
Auchus et al., where cysteine and lysine adducts were identified between a steroidal




Figure 3.11 Proposed irreversible inhibition o f  17(3-HSD type 1 by the enzym e-generated ketone 63 
via attack o f a cysteine residue Cys 185 (Enz-Cys-SH).
We therefore propose a putative mechanism for the irreversible inhibition of 17p- 
HSD type 1 by 63 involving Cys 185, as depicted in Figure 3.11. The 1,4-addition of 
the thio-group of Cys 185 onto the a,p-unsaturated system of 63 results in the 
covalently modified enzyme.
3.1.5 Conclusions and perspectives
In a limited study on enzyme-generated Michael acceptors as potent selective 
irreversible inhibitors of 17P-HSD type 1, we successfully synthesised a series of 16- 
alkylidene derivatives of E l and E2.
In vitro evaluation of the new derivatives in a routine assay led to inconclusive 
results. The isobutylidene and dimethyl-propylidene analogues (66/67 and 68/70) 
had similar or better potency than the known 16-methylene derivatives of E l and E2 
(63 and 65) when tested at 10 pM, however, their mechanism of action was not 
elucidated. Reversibility studies indicated that 63 behaved as an irreversible inhibitor 
of 17P-HSD type 1, although the assay conditions clearly need to be adjusted in 
order to observe total inactivation of the enzyme by this inhibitor. Similar 
investigations on 66 and 68 should contribute to elucidating how these compounds 
inhibit the enzyme and further kinetic studies may help determine whether the allylic 
alcohols 67 and 70 are substrates for 17(3-HSD type 1. Time- and concentration-
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dependent curves should also help establish if the inhibitors are irreversible and 
competitive. Reports that inactivation was enhanced at higher pH values prompted us 
to investigate inhibition at pH ~ 9, and this is currently being addressed.
With the help of molecular modelling, we were able to identify a potential amino 
acid that might be involved in covalent binding of the steroid to the enzyme. A 
cysteine (Cys 185) residue was the only nucleophilic candidate found in the vicinity 
of the steroid after docking in 17(3-HSD type 1 active site and a putative mechanism 
of irreversible inhibition is proposed. To confirm covalent bond formation and 
support these data, analysis of the reacted enzyme by mass spectrometry and 
calculation of the molecular mass of the enzyme-inhibitor adduct would be required. 
Proteolytic digestion of the inactivated enzyme and analysis of the fragments should 
also help confirm the nature of amino acid(s) involved in the nucleophilic attack on 
the inhibitor.
1 2 0
3.2 Heterocyclic derivatives of El
3.2.1 Identification of new lead structures
i) Background
Following the purification211 and later the cloning of the cDNA sequence of 17(3- 
HSD type l,212 the first insights into the topography of the active site and the
identification of its critical residues were achieved thanks to affinity labelling
investigations of the enzyme catalytic mechanism, producing the first active site-
directed irreversible inhibitors of 17p-HSD type i .131-133 From these early studies, the
steroidal D-ring emerged as a promising location for the introduction of structural
modifications able to block the enzymatic activity and this concept was further
explored by Poirier’s group in the 1990’s. Investigations around a series of 16a and
17a-substituted E2 derivatives showed that better inhibition was obtained for
1compounds bearing a good leaving group at the end of a C l6 a  side-chain. This 
was exemplified by the 16a-bromobutyl derivative (1.18, Figure 3.12), the lead 
compound of these studies, which had an IC50 of 0.46 pM in human placental 
cytosol.135 It was found to irreversibly inhibit the enzyme in a time-dependent
1 ' X f imanner and was later found to be an agonist of the estrogen-sensitive human 
breast tumour cell line ZR-75-1.138
F ig u re  3.12 Structure o f steroidal inhibitors o f 17P-HSD type 1 developed by Poirier et  a / . 1 3 5 ,1 3 6 ,1 3 8







With the growing awareness of the implication of 17p-HSD type 1 in estrogen
metabolism, and, in particular, the potential benefit of inhibiting its activity to treat
estrogen-dependent diseases, attention has shifted towards the design of inhibitors
devoid of estrogenic activity. Having identified a potential lead, Poirier et aV  s
strategy was to introduce the bromobutyl pharmacophore in a known antiestrogen
(ICI 164,384) and in a concurrent approach, to introduce an antiestrogenic side-chain
in a potent 17P-HSD type 1 inhibitor (e.g. 1.18, Figure 3.12). Unfortunately, the
bulky antiestrogenic side-chains proved to be detrimental to the inhibitory activity,
and a drop of potency by at least 10-fold was observed for the resulting compounds
(1.19 and 1.20, Figure 3.12). However, one bromoalkylamide derivative (1.20,
1Figure 3.12) had antiestrogenic properties at 1 pM.
To the best of our knowledge, no lead compound has been reported since 16a- 
bromobutyl-estradiol (1.18, Figure 3.12). Given that attempts to optimise its 
properties were only partially successful, we wanted to identify new substrate-based 
structures that would inhibit 17p-HSD type 1 activity and which could potentially be 
modified in case of residual estrogenicity.
ii) Preliminary work, results and choice of a new template
In an initial approach to the identification of novel potent inhibitors of 17p-HSD type 
1, we decided to assess the inhibitory activity of two synthetic intermediates, namely 
the 16-oximino and 16-hydroxymethylene derivatives of E l (1 and 97, Figure 3.13). 
Both compounds possess small hydrophilic moieties which can potentially interact 
with hydrogen bond donors or acceptors in the active site. We also hoped that these 
compounds, which are structurally related to 69 and 72 (Figure 3.13) synthesised 





64 R = H, R1 = Et971
71 R = Et, R1 = H
Figure 3.13 Structure o f  the synthetic interm ediates 1 and 97 and the 17|5-HSD type 1 inhibitors 64 
and 71. C om pound 1, 64 and,71 were prepared in the course o f this work, while 97 was synthesised in 
our laboratories by Dr. C. Bubert.
When tested at 10 pM for the inhibition of 17(3-HSD type 1 in T-47D cells, 1 and 
97 inhibited the enzymatic activity in excess of 95% (Table 3.3). Both compounds 
were found to inhibit selectively the isotype 1, as they displayed low activities 
against type 2. With respective IC50 values of 1.10 pM and 0.11 pM, 1 and in 
particular 97 emerged as a highly potent inhibitors of 17P-HSD type 1, which further 
confirmed the validity of targeting the D-ring to introduce functionalities and identify 
potential pharmacophores.
Table 3.3 Inhibition o f  17|3-HSD type 1 (and type 2) activity by 1, 97, 64 and 71. Results are 
expressed as percentage o f inhibition at 10 pM  (± S.D. triplicate). IC 5 0  values are given as means o f at 
least tw o determ inations.
% inhibition at 10 pM IC50 (pM )
Compound 17p-HSD type 1 17(3-HSD type 2 17p-HSD type 1
1 95.7 ± 1.0 5.0 ± 4 .2 1 . 1 0
97 96.6 ± 0.2 17.4 ±1.9 0 . 1 1
64 92.0 ± 0 .1 19.2 ± 7 .2 0.32
71 79.7 ± 0 .1 - 17.5 ± 2.0 nd
Although the geometries of C=C and C=N bonds at C16 for compounds 1 and 97 has 
not been investigated, it is anticipated that intramolecular hydrogen bonding could 
stabilise both compounds in the cis geometry, where a 6-membered ring system can 
be formed (Figure 3.14) as a result of hydroxy-keto interactions. Alternatively, the 
lower activity of 1 compared with 97 could be explained by its inability to form such 
a cyclic hydrogen bond network if the oxime exists in the trans geometry and
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suggests that such a requirement may be crucial for activity. This is corroborated by 
the results obtained previously for compound 71, where such a hydrogen bonded 
system can potentially be formed between the hydroxyl group of the side-chain and 
the carbonyl at C l7. Conceivably, a pseudo 6-membered ring hydrogen bond 
network can also be created via the assistance of a hydrogen bond donor residue or a 
molecule of water in the vicinity of the D-ring (Figure 3.14), which might be the case 
in 64. Therefore, it appears that compounds which are able to mimic a D-ring fused 


















F ig u re  3.14 Exam ples o f bioisosteric replacem ents and proposed targets to mim ic cyclic hydrogen 
bonding in 1 (X  = N) and 97 (X = C). Enz-YH is a hydrogen bond donor residue o f the active site.
Heterocycles have been used in the past as bioisosteric replacements of cyclic 
intramolecular hydrogen bond networks. A pyrimidine ring was shown to be a 
valuable functional substitution for the hydroxy-keto intramolecular hydrogen bond
0 1 fiin a salicylic acid derivative (3.10, Figure 3.14) and a similar bioisosteric 
relationship (between 3.12 and 3.13, Figure 3.14) was applied to the design of
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tyrosine kinase inhibitors.217 In light of these considerations, we decided to 
investigate the synthesis of D-ring fused heterocyclic derivatives of El (Figure 3.14).
Pyrazole-based inhibitors
Two precedents in the literature deal with heterocyclic fused systems as inhibitors of 
17P-HSD. A series of 2,3- and 3,4-fused ring steroidal pyrazoles were shown to 
inhibit bacterial 17p-HSD type 3 activity via tight binding interactions.218 The 
putative mechanism of inhibition involves a ternary complex inhibitor-enzyme- 
NAD+ stabilised by hydrogen bonding between the pyrazole moiety and the 
imidazole group of a histidine.
F ig u re  3.15 Sites o f  functionalisation o f the pyrazole nucleus o f 98 and future target com pounds. (R = 
side-chain)
More recently, in an attempt to exploit potential pyrazole-histidine hydrogen bonding 
at the catalytic site, some D-ring fused pyrazole and isoxazole derivatives of El were 
prepared as inhibitors of 17p-HSD type l.219 Compound 98 (Figure 3.15) was shown 
to inhibit human placental 17p-HSD type 1 competitively with a Ki value of 4.1 fiM 
which was better than the natural substrate used as an inhibitor (Ki = 9.5 pM). The 3- 
methoxy analogue of 98 was 3 times less potent than its parent, indicating the 
importance of the hydroxyl at C3 for affinity binding to the active site. This is
R
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consistent with the fact that most steroidal inhibitors of 17(3-HSD type 1 developed 
to date possess a free hydroxyl at C3. A model was proposed for the inhibitor- 
enzyme complex, where stabilisation occurs via specific hydrogen bonding between 
the phenol and the pyrazole groups of the steroid and histidyl residues of the active
219site.
Although these studies were made obsolete by the later resolution of the three 
dimensional structure of human 17p-HSD type l ,145 the pyrazole nucleus remains an 
attractive template for further investigation. With a basal inhibitory activity and a 
good affinity for the enzyme, it was anticipated that functionalisation of this moiety 
could result in an increased inhibition 17p-HSD type 1. It was therefore decided to 
investigate the SAR of a series of D-ring fused pyrazole analogues of E l. To this 
end, we investigated modifications of the heterocycle at the 1', 2' and 5' positions in 
order to probe the space around the pyrazole nucleus in three directions (Figure 
3.15).
Other heterocycle-based inhibitors
Unlike pyrazole-based derivatives of El (or other steroids), the biological activity of 
6-membered fused heterocyclic steroidal derivatives is not well documented. 
Nevertheless, the interest in steroids bearing heterocycles fused to the A- or D-ring 
has led several groups to investigate the synthesis of steroidal pyrimidines with the 
heterocycle fused to the position 2,3 or 16,17.220'225 We principally wanted to assess 
the potential activity against 17p-HSD type 1 of those derivatives where a nitrogen is 
incorporated as an isostere of the C17 carbonyl, and where the rest of the cyclic 
system mimics the putative hydrogen bond network described previously (cf. Figure 













F ig u re  3.16 Target com pounds for pyridine- and pyrim idine-fused heterocyclic derivatives o f E l .  The 
arrow  indicates a potential site o f functionalisation (R = side-chain)
Pyridine and pyrimidine heterocycles fused at the 16,17-position of E l were 
therefore chosen as targets (Figure 3.16). Given that literature reports exclusively 
deal with C2'- and/or C4'-substituted pyrimidines (amino, alkoxy, thiacyanato) fused 
to the steroidal nucleus, a possible functionalisation at C2' was also envisaged.
3.2.2 Synthesis
i) N-alkylated pyrazoles
The synthesis of 1,2-azoles is generally performed via condensation of 1,3-diketones 
with hydrazine. In the case of E l derivatives, early reports describe the preparation 
of l,3,5(10)-estratrien-[17,16-c]-pyrazoles by reaction of hydrazine with 16- 
hydroxymethylene-estrone. " The latter can be obtained by condensation of El 
with ethyl formate.229,230
In order to access the desired /V-alkyl derivatives, two pathways were initially 
envisaged starting from a protected 16-hydroxymethylene precursor (Figure 3.17): 
(a) formation of the pyrazole nucleus with hydrazine followed by iV-alkylation 
(method A); (b) direct condensation of an alkyl hydrazine with a 16- 
hydroxymethylene derivative of E l (method B). While method B represents a more
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efficient approach to substituted pyrazoles, the TV-alkylation reaction offers more 
flexibility with the greater range of alkyl halides commercially available, compared 
with fewer alkyl hydrazines.






F ig u re  3.17 The two pathways to access TV-alkylated pyrazoles. (P =  protecting group, R = side-chain, 
RX  = alkylating agent)
From a mechanistic point of view, it is anticipated that two regioisomers are formed 
during the TV-alkylation reaction, in proportions reflecting either the predominance of 
one of the tautomers of the pyrazole {Y-H  or 2 Figure 3.17), or only the 
difference in sterical hindrance of the substituents introduced, possibly clashing with 
the C18 angular methyl group. If the regioisomers prove to be easily separable, two 
target compounds can be synthesised via this method.
Similarly, the reaction of unsymmetrical 1,3-diketones with alkylhydrazines 
generally gives a mixture of regioisomers, and their proportion depends on the nature 
of the substituents, as well as on the solvent and the reaction conditions.231 However, 
in the particular case of El derivatives, the reaction is expected to commence at C l' 
(the aldehyde carbon) due to the more reactive nature of the aldehyde vs. the C17 
ketone, therefore only one product, the 2'-alkylated isomer may be formed using 








R O R O
, R1 = Bn 74-81
d [”  i— R = H 82-69
Schem e 3.4 Synthesis o f TV-alkyl D -ring fused pyrazole derivatives o f  E l .  (a) KO C(CH 3 )3 /toluene, 
H C 0 2 Et; (b) H 2 N N H 2 .H2 0 ,  EtOH, reflux ; (c) NaH/DM F, RX  ; (d) Pd/C, H 2, M eOH/THF.
Starting from 3-benzyl-O-estrone 3, formylation at C16 was performed following an 
adaptation of the literature conditions (Scheme 3.4) . 2 29 ’230 Using potassium tert- 
butoxide as a base, the resulting enolate of 3 was reacted with ethyl formate in 
toluene to give 72 in 8 6 % yield. Subsequent condensation of 72 with hydrazine 
monohydrate in refluxing EtOH rapidly yielded 73 almost quantitatively. N- 
Alkylation was performed under standard conditions, using NaH in DMF, followed 
by treatment with the desired alkyl halide. As expected, each alkylation yielded two 
regioisomers, which were easily separated by flash chromatography in most cases.
We anticipated that for each alkylation reaction the same isomer would elute first 
from the chromatography column and decided to call the less polar compound 
(eluting first) ‘regioisomer A’ and the more polar (eluting second) ‘regioisomer B’. 
Table 3.4 summarises the different isolated yields of regioisomers A and B for each 
reaction. As exemplified by the yields for the isomers 76/77 and 78/79, the A:B ratio 
increases with steric hindrance. However, such an effect is not observed for 80/81 as 
total separation of the isomers by flash chromatography could not be achieved, thus 
the yields isolated do not reflect the proportions in which these compounds were 
formed. For the isomers 74/75, the A:B ratio is close to 1, as predicted from the 
lower steric hindrance of a methyl substituent. Interestingly, a downfield shift of ca. 
0.2 ppm was observed for the heterocyclic proton (8 5 ^ ,  Table 3.4) in the regioisomer 
B. It is therefore envisaged that regioisomers can be differentiated on the basis of this
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chemical shift difference, in addition to their difference in polarities. This may be 
particularly useful for the determination of the proportion of regioisomer A vs. 
regioisomer B formed during A-alkylation reactions, by examination of the *H NMR 
spectrum of the crude mixture. However, these observations did not allow to 
determine which alkylated product (T or 2') corresponded to which regioisomer (A 
or B).
T ab le  3.4 Isolated yields and chem ical shift o f the heterocyclic proton (C5'-H) for regioisom ers A and 
B in /V-alkylated pyrazoles derivatives o f E l .  The substituent R  is either at N T  or N 2 \
L y s 'H
R 10 '
regioisom er A regioisom er B











c h 3 Bn 74 33 6.97 75 35 7.15 0.94






2 . 2 1
c h 2 c o 2 c h 3 Bn 78 48 7.07 79 2 0 7.25 2.40




(CH2)2CN TBDM S 93 8 7.10 94 1 2 7.25 0.67
aM ultiplet or under another signal
Subsequent deprotection of each regioisomer via hydrogenolysis gave the final 
products 82-89 in moderate to good yields after recrystallisation. A summary of the 
different A-alkylated pyrazole derivatives synthesised along with their numbering is 
presented in Table 3.5. Structural assignment for each regioisomer (T- or 2- 
alkylated) is explained later.
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f y j J
C l j
2-alkylated
R 1 R 1
R Bn TBDM S H Bn TBDM S H
c h 3 74 82 75 83
C H 2C H (C H 3)2 76 84 77 85
c h 2c o 2c h 3 78 86 79 87
(CH2)2O C H 3 80 88 81 89
(CH 2)2CN 93 95 94 96
While the TV-methyl, N-isobutyl, iV-methylacetate and 7V-(2-methoxyethyl) pyrazole 
derivatives could be easily accessed following the reaction sequence in Scheme 3.4, 
the synthesis of the 7V-cyanoethyl analogue proved to be problematic. The use of 
bromopropionitrile to alkylate 73 only yielded mixtures in which the starting material 
was predominant. Conceivably, base-catalysed a-elimination on this halo-nitrile may 
have occurred, however this was not believed to be the major reason behind the lack 
of reactivity, as only a slight excess of base was used. On the other hand, a proton 
exchange between the deprotonated pyrazole and the alkylating agent may have 
promoted the formation of acrylonitrile, while regenerating the starting material.
These considerations prompted us to investigate the reaction of the pyrazole nucleus 
with acrylonitrile under basic conditions (Scheme 3.5). The expected reaction is a 
Michael-type 1,4-addition on the unsaturated system of the alkylating agent. For this 
pathway, the hydroxyl at C3 was protected with a TBDMS group since previous 
observations suggested that a cyanoalkyl moiety may be unstable under the 












TBDMSO' R O'R O'
93,94 R1= TBDMS 
95, 96 R1 = H
Scheme 3.5 Synthesis o f /V-cyanoethyl derivatives, (a) Imidazole, TBDMSC1, DM F; (b) 
N aO M e/toluene, H C 0 2Et; (c) H2N N H 2.H20 ,  EtOH, reflux; (d) K OC(CH3)3/toluene, CH2CHCN; (e) 
TBAF/THF.
Protection of the 3-hydroxyl of E l with a TBDMS group was achieved following a 
reported procedure, using imidazole and TBDMSC1 in DMF. 232 The resulting 
compound 90 was obtained quantitatively and its formylation was performed 
following an analogous procedure to that described for the synthesis of 72 to afford 
91 in 98% yield (crude material). Condensation of 91 with hydrazine monohydrate 
yielded the 16,17-fused pyrazole intermediate 92 with a yield of 81%, and 
subsequent reaction with acrylonitrile gave two regioisomers 93 and 94. 
Unfortunately, the yields for this reaction were very poor and the separation of the 
products by flash chromatography was difficult, thus only small quantities of each 
regioisomer were isolated. Subsequent deprotection using TBAF in THF afforded the 







Scheme 3.6 Synthesis o f 3-hydroxy-estra-l,3,5(10)-triene-[17,16-c]-pyrazole 98. (a) TBA F/THF; (b) 
H 2N N H 2.H20 ,  EtOH, reflux.
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From the precursor 91, it was also possible to access the deprotected and 
unsubstituted pyrazole derivative 98 which will be used as a reference compound for 
biological testing. Deprotection of 91 using TBAF in THF gave 97 in 69% yield, and 
subsequent annulation with hydrazine monohydrate afforded 98 with a yield of 64%.
Because of the poor yields for 93/94 following the procedure described in Scheme 
3.5,* we tried to access the corresponding final compounds 95/96 via Method B (see 
Figure 3.17 pl28), which employs the condensation of a 16-hydroxymethylated 
precursor with an alkylhydrazine (Scheme 3.7). As discussed earlier, we expected the 
2 '-alkylated compound to be formed exclusively or at least predominantly.
S chem e 3.7 Synthesis o f  the /V-cyanoethyl derivative 96 via M ethod B. (a) H2N N H (CH 2)2 CN, EtOH; 
(b) TBA F/THF.
Compound 91 was therefore reacted with cyanoethylhydrazine in ethanol at room 
temperature and yielded a single product whose spectroscopic data did not match the 
structures of either 93 or 94. The presence of an exchangeable proton at 8  5.97 and 
the absence of deshielded signals around 8  4.2-4.5 for the N-CH2 moiety in the *H 
NMR spectrum of the product indicated that the condensation did not yield a fully 
aromatised heterocycle. Analysis by mass spectrometry showed an 18 mass unit 
difference between the mass of the product and that of 93 or 94, suggesting that one 
molecule of water remained to be eliminated. The absence of a peak for the C17 
carbonyl in the 13C NMR spectra confirmed that cyclisation did occur. Assuming that 
the product obtained is a 2 '-alkylated derivative, the presence of an inexchangeable, 
deshielded doublet at 8  6.74 in the ]H NMR spectrum indicated that a double bond 
between C5' and NT was formed. From these findings, the product was assigned the 
molecular structure of 99 which was formed in 73% yield, as a single 
diastereoisomer as evidenced by its !H and 13C NMR spectra. Rapid conversion of 




of 91 with cyanoethylhydrazine by TLC, suggesting that heating was not necessary. 
However, since partial condensation occurred to yield 99, it is anticipated that 
heating the reagents in a refluxing solution of EtOH might promote water elimination 
and yield directly the fully aromatised product (96). Simultaneous deprotection and 
water elimination occurred when treating 99 with TBAE in THF overnight. The final 
product, obtained in 62% yield, was identical to isomer B (96) obtained in the 
synthesis described in Scheme 3.5.
Structural assignment o f the regioisomers
Structural assignment was undertaken before deprotection of the precursors 74-81 
and 93, 94 as it was necessary to unambiguously determine which molecular 
structures corresponded to the regioisomers A and B. With the exception of 82/83, 
the synthesised derivatives have not been reported previously and no NMR data were 
available for the A-methyl derivatives. On the basis of the yields reported in Table 
3.4, we tentatively assumed that isomer A was the l'-alkylated product since the A:B 
ratio was shown to increase with steric bulk. This was also consistent with the fact 
that deprotection of 99, a 2'-alkylated compound, gave 96, a regioisomer B.
These findings were further corroborated by !H NMR-NOE difference experiments 
for compound 74 and 75. This particular technique allows the detection of groups 
which are close in space to each other. Irradiation at the resonance frequency of a 
proton (or group of protons) of interest produces a signal enhancement for the 
protons nearby. The signal enhancement can be seen on a difference spectrum. 
Irradiation of a sample of 74 (regioisomer A) at the resonance frequency of the Cl 8 - 
H3 signal only yielded background noise (Figure 3.18 p 136). The same experiment 
over 75 (regioisomer B) yielded a significant peak at 6  3.81, corresponding to the 
enhancement of the signal of the A-methyl group. In both experiments, the angular 
methyl was also coupled in space with two protons (or group of protons) of the 
steroidal backbone around 8  1.7 and 8  2.3, asserting the reproducibility of the 
experiment between 74 and 75. The NOE effect is only noticeable over short 
distances, generally 2-4 A, and was therefore only expected to occur between the 
methyl groups in a 2'-alkylated compound. Using a model in the three dimensional
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molecule viewer Chem3D, the average distance betweens these protons was found to 
be of 4.3 A for isomer B, while it exceeded 6  A in the l'-alkylated isomer. The N- 
methyl pyrazole derivative 75 was therefore assigned the structure of a 2'-alkylated 
compound.
Structural assignment of the other members of the A-alkylated pyrazole series was 
made by analogy with 74 and 75. Besides the fact that for each alkyl motif the 
regioisomers A and B could be differentiated by their polarities, the *H NMR shift 
for the heterocyclic proton (Ss-.h, Table 3.4 p i30) was always around 0.2 ppm higher 
in the B regioisomer. This provided an easy way to rapidly ascertain the structure of 
these A-alkylated products. Contrary to what we expected, the position of the alkyl 
group on the pyrazole nucleus did not considerably influence the chemical shift of 
C18-H3.
The final piece of evidence for assigning the structures of the regioisomers A and B 
was provided by the X-ray crystal structure of the A-isobutyl derivative 84. This 
compound was obtained after deprotection of the regioisomer A isolated after N- 
alkylation of 73 with isobutyl bromide. The experiment was performed on a crystal 
(approximate dimensions 0.50x0.50x0.30 mm) obtained by recrystallisation from 
MeOH. As predicted from the NMR experiments on 74/75, 84 was found to 
correspond to the l'-alkylated product (Figure 3.19 p i37). The ORTEX173 plot shows 
all four steroidal rings with the additional heterocyclic system fused to the 16 and 17 
positions. The presence of a molecule of MeOH in the asymmetric unit indicates that 
84 co-crystallised with the solvent, to which it hydrogen-bonds via O l. The 
hydrogen atom H2 of each unit (84-MeOH) is hydrogen bonded to N2' of the next 
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F igure 3 .18  NOE difference spectra for 74 and 75. and part of the ‘H NMR spectrum for 75 (400 
MHz, CDCI3). The bold arrows on the first two spectra indicate the signal whose frequency was 
chosen for irradiation (only the D-ring of the steroidal backbone is shown).
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F igure 3.19 ORTEX173 plot of the X-ray crystal structure of 84. Ellipsoids are shown at the 30% 
probability level.
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The bond lengths between the carbon atoms in the aromatic pyrazole system were 
1.374 A for C16-C5' and 1.394 A for C16-C17. The bonds between carbon and 
nitrogen atoms measured 1.359 A and 1.334 A for C5-N1' and C17-N2' respectively, 
while N l'-N 2 ' measured 1.375 A (for full details see Appendix 4). This is the first 
report of a crystal structure of a pyrazole fused D-ring derivative of E l and this 
provides unambiguous proof of the molecular structure of these compounds and their 
regioisomers.
iii) C-alkylated pyrazoles
In order to fully explore the SAR around the pyrazole nucleus, we undertook the 
synthesis of C5'-substituted pyrazole derivatives of E l. Linkage with an alkyl group 
at C5' can be achieved by condensing Cl'-substituted 16-hydroxymethylene 
derivatives with hydrazine monohydrate. Presumably, these 16-hydroxymethylene 
compounds can exist in four different tautomeric forms as shown in Figure 3.20. 
Because of the established preference to locate double bonds in an exocyclic rather 
than endocyclic position relative to a five membered ring, the predominant enol form 
is believed to be B. For clarity, such compounds will be referred to as tautomer B 
and their enol-ketone ratio in solution will be discussed later.
F ig u re  3.20 Tautom eric forms for 16-hydroxymethylene and 16-(r-substituted)-hydroxym ethylene 
derivatives o f E l (R = H or side-chain; only the D-ring o f the steroidal backbone is shown).
A B c D
Literature precedents for the synthesis of Cl'-substituted 16-hydroxymethylene 
compounds include 16-acetylation233 and 16-trifluoroacetylation234 of 3-methoxy- 
estrone. Interestingly, not only can such compounds be used as synthetic
intermediates but their corresponding 3-hydroxy derivatives are analogues of 97 (16- 
hydroxymethylene-estrone) and therefore represent potential 17p-HSD type 1 
inhibitors. The synthetic sequence envisaged includes the synthesis of C l'- 
substituted 16-hydroxymethylene intermediates, their deprotection and subsequent 
annulation into pyrazole derivatives (Scheme 3.8) to afford two series of compounds: 
16-(l'-substituted)-hydroxymethylene and C5'-substituted pyrazole derivatives of El. 
The hydrophobic methyl and trifluoromethyl moieties were chosen for preliminary 
SAR investigations. A 3-pyridyl group was also selected since high activity against 
17p-HSD type 1 was observed for derivatives synthesised in our laboratories 
containing such a moiety around the D-ring.





100 R = Bn, R1 = CH; 104 R1 = CH'
101 R = TBDMS, R1 = CF3
102 R = TBDMS, R1 = 3-pyridyl






107 R1 = CH
108 R1 =CF3
109 R1 = 3-pyridyl
Schem e 3.8 Synthesis o f  5 '-substituted pyrazole derivatives o f E l .  (a) KOC(CH 3 )3 /toluene, R ]C 0 2 Et; 
(b) Pd/C, H 2, M eOH /TH F; (c) TBAF/THF; (d) H 2N N H 2 .H 2 0 ,  EtOH, reflux.
Following an adaptation of the procedure reported by Yoshioka et al. , 233 3 was 
reacted with potassium tert-butoxide and ethyl acetate under refluxing conditions in 
toluene, to give 100 in 80% yield. Subsequent deprotection via hydrogenolysis 
afforded 104 which was then heated in a refluxing solution of EtOH in the presence 
of hydrazine monohydrate. The resulting product, the 5'-methyl pyrazole derivative 
107 was obtained in a yield of 35%. An analogous sequence was applied for the 
synthesis of the 5'-trifluoromethyl derivative, starting from 90. The 16-substituted
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intermediate 101 was obtained quantitatively as a pure crude product from reaction 
of 90 with ethyl trifluoroacetate. The resulting product was deprotected with TBAF 
in THF to afford 105 in 60% yield. Reaction of the latter with hydrazine 
monohydrate, under the same conditions as for the synthesis of 107, gave 108 in a 
yield of 60%.
Synthesis of the pyridinyl analogue was also carried out on the TBDMS-protected 
precursor 90. Reaction of the latter with ethyl-nicotinate went to completion at room 
temperature affording 102 in a yield of 77%. Its deprotection gave 103 in 50% yield 
as a highly insoluble product, which prompted us to perform the subsequent 
condensation with hydrazine monohydrate on the protected precursor 102. The 
product of this reaction was however not the expected aromatised heterocyclic 
derivative but the partially condensed product 106, which was obtained in a yield of 
89%, as a single diastereoisomer. The structure of this product was assigned after 
examination of its *H NMR spectra, where the signals for two exchangeable protons 
(OH and NH) could be seen at 8  5.97 and 8  7.26. Analysis by mass spectrometry also 
indicated an extra 18 mass unit for 106 compared to that of the expected aromatised 
product. As in the case of 99 (cf. Scheme 3.7 p i33), deprotection using TBAF in 
THF afforded the deprotected and dehydrated product 109 in 75% yield.
Tautomerism in solution
As mentioned previously, the derivatives 100-102 and 103-105 may exist in several 
tautomeric forms and an enol-ketone equilibrium was seen for some derivatives in a 
solution of deuterated solvent, when collecting their *H NMR spectra. To the best of 
our knowledge, none of the 3-hydroxy derivatives 103-105 (or 107-109) have been 
reported previously.
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Compounds 100 and 104 were found to exist as a mixture of two tautomers in a 
solution of CDCI3 . While the protected compound 100 showed a high enol content 
vs. the ketone form (6:1), the derivative 104 displayed an equal proportion of each
9 3 3
form. For the 3-methoxy derivative of 104, Yoshioka et al. reported a mixture of 
two enols in C D C I3 . In both 100 and 104, however, we could clearly identify the 
peaks corresponding to C16-H, suggesting the presence of the ketonic and enolic 
tautomers (Figure 3.21).
I C I 8 -H3
F igure 3.21 Part of the ‘H NMR spectrum of 104 in CDCf (400 MHz).
For the trifluoro derivatives 101 and 105, the data of the 'H  NMR spectra were in 
accordance with the literature, where a 3-methoxy derivative of 105 was found to 
exist predominantly in the enol form . 234 As the enolic protons were not seen in our 
spectra (too broad), the structure of 101 was confirmed by 13C NMR, where only one 
highly deshielded quaternary carbon signal was seen at 5 216.0. This peak was not 
coupled to the fluorine atoms of the trifluoro group, which confirmed the enolic 
character of 101. If the structure had been ketonic (A or C, Figure 3.20) a signal 
corresponding to the second carbonyl at C l ' would have been expected, with 
coupling to the trifluoro group. It is believed that the electronegative character of the 
trifluoromethyl group, as well as the increased possibility for hydrogen bonding due
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to the ability of fluorine atoms to bond OH, are involved in the stabilisation of the 
enolic form . 234,235
Finally, the pyridyl derivatives 102 and 103 were also found to be totally enolised in 
CDCI3 . Collection of a spectrum for 103 was particularly difficult as this compound 
was sparingly soluble in CDCI3 . When the experiment was repeated in DMSO-d6 , the 
two enolic forms were seen as well as the ketonic form(s). Interestingly, when 
studying the !H NMR spectrum of the corresponding pyrazole derivative 109, the 
two pyrazole tautomers could be seen. While one single C I8 -H3 peak was observed, 
the peaks of the pyridyl protons were broadened with a shoulder effect. The signal 
for the NH moiety consisted of two singlets at 8  12.65 and 8  12.72, indicating that 
intramolecular hydrogen bonding possibly prevented free rotation of the pyridyl 
moiety around the C5'-C3" bond, allowing as a result the observation of the two 
tautomeric forms of the pyrazole within the time of the acquisition of the ]H NMR 
spectrum.
iii) Other heterocyclic derivatives
The synthesis of the [17,16-b]-pyridine derivative of E l was envisaged via the 
thermal rearrangement of an O-allyl oxime precursor. We were prompted by the 
apparent extensive use of this method to generate pyridine heterocycles, although the
O'Xfi O'XQyields reported for the corresponding reactions were generally moderate to low. 
Recent approaches to annulation of a pyridine ring vary from one-pot240,241 to 
microwave assisted procedures, 2 42 yet the development of a straightforward method 
to access such compounds still constitutes a synthetic challenge.
1 4 2
OVOH 






S chem e 3.9 Postulated mechanism s for the therm al rearrangem ent o f O-allyl oxim es into pyridines. 
Pathway A proposed by Kusumi et al. and Pathway B proposed by K oyam a et  al.
There is no clear report on the mechanism of the unusual thermolysis reaction of O- 
allyl oximes. It is thought to proceed via a multistep rearrangement, the first step 
being a [2,3]-sigmatropic rearrangement of the oxime to the corresponding nitrone 
(Scheme 3.9) . 243 ,244 The investigation carried out by Koyama et al.12>1 indicated that 
oxygen participated in the reaction in an ionic manner after nitrone formation 
(Pathway B), although this was not suggested in the earlier studies of Kusumi and
9  'Xfxcoworkers (Pathway A). In both cases, the nitrone is rearranged into an allylidene 






Schem e 3.10 Synthesis o f the [17 ,16-b]-pyridine derivative o f E l .  (a) H2N 0 C H 2CHCH 2.HC1, 
NaOAc, M eOH/H20 ;  (b) 230°C.
To the best of our knowledge, this reaction has never been applied to steroids, and it 
was anticipated that E l could ideally be converted to a pyridine-fused derivative in
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two steps. Following the adaptation of a literature procedure for the conversion of 
ketones to oximes , 155 the O ally l oxime derivative 110 was easily obtained in 94% 
yield after treatment of E l with O-allylhydroxylamine hydrochloride and sodium 
acetate in a mixture of MeOH and H20 . The latter was then heated neat to 230°C for 
46 hours to give a dark crude material from which 111 was isolated in 
spectroscopically pure form after repeated column chromatography. The harsh 
conditions required for this reaction, which resulted in loss of material through 
decomposition and a consequent tedious separation of 111 from the crude material 
might explain the low yield of 6 % for this final product. It was envisaged that milder 
conditions would lead to better yields. An alternative would be to consider the 
annulation of a 1,5-diketone derivative of E l (e.g. 16-propionaldehyde-estrone) in
presence of ammonium acetate. 239
The structure of 111 was assigned on the basis of spectroscopic evidences: a total of 
three additional aromatic signals were observed in the 'H NMR spectrum of 111 
around 5 7.0-8.4 which accounted for the aromatic protons of the pyridine nucleus 
(Figure 3.22); the absence of a peak for a C17 carbonyl above 200 ppm in the 13C 
NMR spectrum of 110 and 111 was indicative of the conversion of C = 0  to C=N, 
with corresponding C=N peaks being observed in the 5 170 region. Mass 







F igure 3.22 Aromatic region of the 'H NMR spectrum of 111 (CDCI3, 400 MHz).
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However, attempts to access our next target, the [17,16-d]-pyrimidine derivative of 
E l were met with little success. While examination of the literature provided several 
methods for the synthesis of steroidal fused pyrimidine derivatives substituted at C2' 
and C4 ' , 22 0 ' 225 no reports accounted for the annulation of an unsubstituted pyrimidine 
ring. Using analogous procedures to that employed for 1,3-diketone substrates,245 we 
used the 16-hydroxymethylene derivative 72 as a starting material and attempted 
several condensation reactions without success. Treatment of 72 with formamidine 
hydrochloride in ethanol, in the presence of a base or in a pressure tube heated to 
110°C only led to recovery of the starting material. Attempts to perform similar 
reactions with acetamidine hydrochloride or formamidine acetate also failed to yield 
the expected pyrimidine-fused product.
As an alternative to the study of steroidal fused-ring systems containing several 
nitrogen atoms, we envisaged the condensation of 16-hydroxymethylene derivative 
of El with several aminoazoles. Such reactions have been extensively studied at the 
A-ring of androgens by Bajwa and Sykes. 2 4 6 ' 249 The authors also investigated these 
condensation with 3-methoxy-16-hydroxymethylene-estrone. It was expected that the 
corresponding 3-hydroxy azolopyrimidines derivatives of E l would provide useful 
information on the extent of hydrophilic and pi-pi interactions at the active site of 
17p-HSD type 1 and we therefore decided to undertake their synthesis. Three 
aminoazole substrates were chosen for this study: 5-aminotetrazole, 3-amino-1,2,4- 
triazole and 3-aminopyrazole (Figure 3.23).
H H
/ N"N / N"N
h 2n —<^JJ H2N <xn J
h2n H ' K  h W NJ h h2n ^-N)nN N
H
5-aminotetrazole 3-aminopyrazole 3-amino-1,2,4-triazole
Figure 3.23 Structure and tautom eric form s o f the am inoazoles substrates for condensation reactions.
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Given that 16-hydroxymethylene derivatives of E l are asymmetric P-diketones and 
that both 3-amino-1,2,4-triazole and 3-aminopyrazole can exist in tautomeric forms, 
we anticipated that a number of products may be formed as the result of each 
condensation reaction. The structure of the final product(s) depends on (a) the 
preferred site of attack of the primary amino group of the aminoazole to begin the 
reaction; (b) the nucleophilic nitrogen involved in the second condensation to form 
the final ring system. Depending on (a), the resulting product has either a linear or 
angular structure (Figure 3.24).
F ig u re  3.24 Condensation o f a 16-hydroxym ethylene derivative o f E l with an am inoazole. The linear 
structure results from  a prim ary attack o f N H 2 at C17, while the angular structure is form ed after 
attack at C l '.  (P = protecting group; X = CH or N).
As mentioned previously, a higher reactivity of the hydroxymethylene group vs. the 
carbonyl in 16-hydroxymethylene derivatives of E l is expected to direct the 
condensation of the primary amino group towards Cl'. This was corroborated by a 
literature report, 250 where the condensation of a 1,3-diketone with aminoazoles was 
proposed to yield angular products. In the case of 5-aminotetrazole, only one 
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Schem e 3.11 Synthesis o f azolopyrim idine derivatives o f E l .  General conditions: am inoazole, EtOH, 
reflux, (a) 5-am inotetrazole; (b) 3-am inopyrazole; (c) 3-am ino-1,2,4-triazole ; (d) TBAF/THF.
The condensation reactions were performed on the TBDMS protected precursor 91, 
in a refluxing solution of ethanol in presence of a small excess of the aminoazole 
(Scheme 3.11). Upon reaction with 5-aminotetrazole hydrate, two products were 
unexpectedly formed. The heterocyclic fused derivative 113 was isolated in a yield 
of 32% along with a side-product which was identified as 112 (43% yield). The 
formation of 112 is believed to result from the action of 5-aminotetrazole as a base, 
which promoted a side reaction between the enol moiety of 91 and the solvent. 
Deprotection of 113 with TBAF in THF gave 114 in moderate yields. The latter was 
particularly difficult to purify as a result of its poor solubility in organic solvents.
Assignment of the molecular structure of 113 on the basis of its lH NMR spectrum 
alone faces the difficulty that the presence of only one additional aromatic signal at 8 
8.74-8.75 provides little information about its spatial arrangement. Moreover, 
conflicting reports have been published on the condensation of 5-aminotetrazole with 
a P-diketone (such as 2-hydroxymethylene-cylcopentanone 3.14, Figure 3.25). While 
Cook et al.250 suggested that the product had an angular structure, Bajwa and 
Sykes248 established with the aid of !H and 13C NMR spectroscopy that the product 
was linear. In particular, it was established that in the *H NMR of the angular product
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3.15, a sharp singlet was seen for C5-H, while the corresponding C8 -H in 3.16 
showed a small long range coupling with the protons at Cl.
7
angular 3 .1 5  linear 3 .16
3 .1 7
F ig u re  3.25 Reaction o f 5-am inotetrazole with 2-hydroxym ethylene-cylcopentanone 3.14 and 
putative products. The two products 3.15 and 3.16 may be interconverted via an azido-pyrim idine 
3.17.
Extensive structural studies on azolopyrimides by Bajwa and Sykes24 6 ' 249 however 
indicated that the condensation product of aminoazoles with 3.14 afforded mainly 
angular fused products. In the case of tetrazolo-pyrimidine derivatives, the angular 
structure may be formed from the linear initial product via an azido-pyrimidine 
intermediate (3.17, Figure 3.25).248 Such investigations were extended and verified in 
steroidal substrates and the authors synthesised several D-ring fused 
azolopyrimidines derivatives of 3-methoxy-estrone. The structure of 113 was 
therefore assigned by analogy with the linear structure reported for the 3-methoxy 
analogue. 248 Interestingly, in the *H NMR spectrum of 113, the signal for the 
heterocyclic proton (C7'-H) was a multiplet, which was in accordance with the linear 
fused product. This was not seen in *H NMR spectrum reported for the 3-methoxy 
derivative, possibly because of the lower resolution provided by the spectrometer 
used (100 MHz vs. 400 MHz in our case).
Condensation of 91 with 3-aminopyrazole gave 115 as the sole product of the 
reaction in 77% yield (Scheme 3.11). Although 3-aminopyrazole exists in two 
tautomeric forms, we anticipated the form protonated at N2 to react more readily 
with a |3-diketone than the N 1 -protonated isomer, yielding the more favoured 6 -
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membered pyrimidine ring as opposed to a less stable 7-membered ring. Subsequent
deprotection of 115 gave 116 in 91% yield. The structure of 115 was assigned by
analogy with the 3-methoxy analogue reported in the literature. 249 In contrast to the 
condensation involving 5-aminotetrazole, the product obtained resulted from an 
angular fusion of the heterocyclic ring to the steroidal D-ring. The *H NMR spectrum 
of 115 (and 116) showed characteristic doublets for C2'-H and C3'-H in the aromatic 
region while C5'-H was a singlet.
O H
Jl OH N -nQ = /  + h2nH nj
3.14 3.18
F ig u re  3.26 Reaction o f 3-am ino-1,2,4-triazole with 2-hydroxym ethylene-cyclopentanone 3.14.
Condensation of 3-amino-1,2,4-triazole has not been reported on steroidal 
precursors. Taking into account that both tautomeric forms of this aminoazole might 
condense with the p-diketone functionality, four possible isomeric products were 
envisaged. However, reaction of 2-hydroxymethylene-cyclopentanone (3.14, Figure 
3.26) with 3-amino-1,2,4-triazole was shown to yield exclusively one angular fused 
product (3.18, Figure 3.26).247 Accordingly, when the reaction was carried out on 91, 
one azolopyrimidine derivative 117 was isolated in a yield of 50%. It was 
deprotected to afford 118 in 6 6 % yield. The structure of 117 was assigned by 
analogy with the data reported for the non steroidal analogues, 247 in the same way as 
Bajwa et a l assigned the structure of other steroidal fused azolopyrimidines from 
NMR data on non steroidal related analogues. The additional aromatic signals of the 
heterocyclic system were seen as singlets at 8  8.50 and 8  8.72 in the *H NMR 
spectrum, which was in agreement with the chemical shifts of C2-H and C5-H in 
3.18 (Figure 3.26) respectively of 8  8.42 and 8  8.65. However, it is anticipated that 
further structural investigations need to be carried out to fully establish the proposed 
structure for 117 (and 118).
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3.2.3 Results
i) Inhibition o f 17fi-HSD type 1 in vitro
The compounds synthesised were tested for their ability to inhibit 17(3-HSD type 1 
activity in T-47D cells. As a control of selectivity, type 2 activity was also measured 
for each compound in MDA-MB-231 cells. Table 3.6 gives the percentage of 
inhibition achieved for a 10 pM concentration of the inhibitor. The data for the 
unsubstituted pyrazole derivative 98 are also included.
Table 3.6 Inhibition o f 17(3-HSD type 1 (and type 2) by pyrazole derivatives o f E l and 105. Results 
are expressed as a percentage o f inhibition at 10 |iM  (± S.D. triplicate).
N
% inhibition 17p-HSD k f - 4  J
at 10 pM
% inhibition 17p-HSD 
at 10 pM
R Com pound type 1 type 2 Com pound type 1 type 2
H 98a 97.2 ± 0.4 32.1 ± 3 .0
c h 3 82 94.3 ± 1.3 24.2 ± 3 .9 83 42.5 ± 8.3 32.3 ± 6.4
CH 2CH (CH 3)2 84 76.9 ±  2.5 60.8 ± 3.2 85 70.2 ± 3.5 44.1 ± 5 .7
c h 2c o 2c h 3 86 95.1 ± 0 .4 18.6 ± 1.3 87 79.0 ± 1.1 29.8 ± 1.4
(CH2)2OCH 3 88 94.6 ± 0.8 47.9 ± 3 .5 89 82.9 ± 1.1 55.2 ± 1.7
(CH2)2CN 95 95.1 ± 1.2 43.8 ± 3 .9 96 nd nd
k U p n i I /^ 'NH
CF3 105 86.5 ± 0 .3  -1 .5  ± 7 .6  108 74.5 ± 0 .9  35.7 ± 1 .9
aM ay exist as a 1 '-H or T- H  tautom er
In the A-alkylated pyrazole series, all the l'-substituted compounds significantly 
inhibited 17P-HSD type 1 activity. An inhibition of 94% or higher is observed at 10 
pM for 82, 8 6 , 8 8  and 95. The isobutyl analogue 84 was less potent than the other 
derivatives with a 77% inhibition of 17P-HSD type 1 at 10 pM. This compound was 
also the least selective for the isotype 1, with nearly 61% inhibition of 17p-HSD type
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2. The most selective compound for the T-alkylated series were 82 and 86, while 88 
and 95 inhibited 17p-HSD type 2 in excess of 40%. The unsubstituted pyrazole 
precursor 98 was highly potent at 10 pM (97% inhibition) which was in agreement 
with the literature. 219
Interestingly, the activity of the 2'-alkylated derivatives was significantly lower than 
that of the corresponding l'-alkylated compounds, with inhibitory activities of 83% 
or below at 10 pM. Positioning the same side-chain at N2' was detrimental for the 
activity against 17P-HSD type 1, especially in the case of 83. While its NT analogue 
82 achieved a level of inhibition close to 95%, compound 83 inhibited a mere 42% of 
type 1 activity at 10 pM. However, for bulkier side-chains, the difference between 1' 
and 2'-substitution was less marked. The selectivity for type 1 was also worse for 2'- 
alkylated compounds.
In the series of the 5'-alkylated pyrazole derivatives and their hydroxymethylene 
precursors, one motif has been tested so far. The trifluoromethyl derivatives 105 and 
108 were moderately potent against 17P-HSD type 1 at 10 pM. Compound 105 was 
particularly selective for type 1, with a total lack of activity against 17p-HSD type 2.
T ab le  3.7 IC50 values for inhibition o f 17(THSD type 1 by several pyrazole derivatives o f  E l .  Results 







The I C 50  values were determined for those derivatives whose potency was 
sufficiently high at 10 pM, namely the 1' derivatives 82, 86, 88 and 95 along with 
that of 98 (Table 3.7). Clearly, the substitutions on the pyrazole nucleus were 
detrimental to the inhibitory activity, since the unsubstituted pyrazole 98 remained
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the most potent derivative, with an IC50 of 180 nM. Unexpectedly, a methyl side- 
chain provoked the highest drop of activity with 82 being 15 times less potent than 
98. The methoxyethyl analogue 8 8  was the best inhibitor of the A-alkylated series 
(IC50 = 530 nM), and was only 3 times less active than 98.
ii) Estrogenicity in vitro
Although the compounds synthesised in the course of this study proved to be less 
potent than the precursor 98, we were interested in evaluating their estrogenicity to 
compare the effects of a side-chain vs. no side-chain. For this study, the best inhibitor 
of the A-alkylated series 8 8 , and a compound bearing a small moiety (82) were 
chosen. Their estrogenicity was assessed in a luciferase reporter gene assay, and the 
results are given as a percentage of the maximum activity observed for E2, at four 
different concentrations (Figure 3.27).
f
HO
98 R = H
82 R = CH3
88 R = (CH2)2OCH3
rh
100 nM 10 nM 1 nM 100 pM 100 nM 10 nM 1 nM 100 pM 100 nM 10 nM 1 nM 100 pM
F igure  3.27 Estrogenic activity of 98, 82 and 88 given as a percentage of E2?s maximum activity.
From the data presented in Figure 3.27, it is clear that the side-chains contribute to a 
reduced estrogenicity of the pyrazole derivatives. While at 1 nM, the unsubstituted 
compound 98 is already half as estrogenic as E2, the estrogenic activity of 
derivatives 82 and 8 8  is less than 3% of that of E2 at the same concentration. In 
particular, 88 does not display any estrogenicity even at a concentration of 100 nM,
1 5 2
for which 82 and 98 are clearly estrogenic. Although 8 8  is 3 times less effective than 
98 at inhibiting 17P-HSD type 1 activity, its estrogenic profile in vitro is highly 
encouraging, suggesting that it could be used to treat estrogen-dependent 
pathologies.
iii) Metabolic studies
Since it was anticipated that one or several of our inhibitors would be examined in 
vivo, a preliminary assessment of their biological profile was desirable. Metabolism 
mainly takes place in the liver, where cytochrome P450 catalysed-oxidation converts 
drugs to more polar conjugates for excretion. This however may take place before 
the drug has reached its site of action and elicited the desired response. A set of 
potential inhibitors was incubated with hepatic microsomes and their degradation 
monitored by HPLC (Table 3.8). The stability towards metabolism in the mouse and 
in the human hepatic systems was assessed and the half life (ti/2) and hepatic 
clearance (Cl) for each compound were determined in both systems.
T ab le  3.8 H alf life and hepatic clearance for the pyrazole derivatives 82, 86, 88 and 89 in the mouse 
and human. All incubations were carried out in duplicate.
M ouse Hum an
Com pound ti / 2  (min) Cl (mL/min/kg) t1/2(min) Cl (m L/m in/kg)
82 < 3 0 > 2 3 < 3 0 > 2 3
86 < 3 0 > 2 3 < 3 0 > 2 3
88 > 60 (225) < 11 (3.1) 39.9 17.4
89 45.6 15.2 > 60 (199) <11 (3.5)
From these data, 82 and 8 6  appear to be metabolically unstable in both human and 
mouse, with both compounds having a half life below 30 minutes, and a 
corresponding hepatic clearance above 23 mL/min/kg. In contrast, the most 
promising alkyl-pyrazole inhibitor 8 8  was metabolically stable in the mouse and 
displayed moderate stability in the human system. Its regiosiomer 89 showed an even 
higher stability towards human microsomes, with a half life exceeding 60 minutes
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and a hepatic clearance lower than 11 mL/min/kg. This compound was moderately 
stable in the mouse.
3.2.4 Discussion
i) Inhibition o f 17/3-HSD type 1 (and type 2) in vitro
The inhibition of 17p-HSD type 1 represents an important option in the search for 
endocrine agents to treat HDBC, yet this is a relatively recently explored area. There 
is a considerable need to identify lead structures and pharmacophores, and in an 
effort to develop new potent inhibitors of 17p-HSD type 1, we synthesised D-ring 
fused pyrazole derivatives of E l. Not only should the ideal 17P-HSD inhibitor be 
highly potent against its target, it also needs to be selective towards other 17p-HSD 
isotypes and devoid of estrogenic activity. All these requirements have resulted in 
only few candidates being identified, none of which has entered the clinic.
Preliminary work in our laboratory has identified the 16,17-fused pyrazole derivative 
of El 98 as a potentially useful template for the design of 17p-HSD type 1 inhibitors. 
This compound, which was previously shown to inhibit the enzyme with a Ki of 4.1 
pM , 219 was functionalised at the 1', 2' and 5' positions in order to build a 
comprehensive SAR. A series of V and 2' derivatives was synthesised 
simultaneously by A-alkylating the pyrazole nucleus. Small or bulky hydrophobic 
moieties and polar side-chains were introduced on the heterocycle with the aim to 
probe the active site for interactions that would enhance the affinity of the enzyme- 
receptor complex.
In vitro evaluation of the derivatives against 17p-HSD type 1 revealed a clear 
difference between the activity of the 1'- and 2 -substituted compounds. While the 
inhibitory activity of most l'-alkylated pyrazoles was ca. 95%  at 10 |LiM , the highest 
level of inhibition for 2' derivatives was 83%. Surprisingly, the change of position of 
the substituents from N l' to N2' was the most detrimental to the activity for a small 
moiety, as exemplified by the 2'-methyl derivative 83, which displayed a poor 42%
154
of inhibition of type 1 at 10 pM (vs. 94% for 82). This clearly indicates that the 
active site has a limited tolerance for substituents pointing in the 2' direction, where 
such moieties prevent the steroid from binding in a high affinity orientation. To some 
extent, this is in agreement with Poirier and coworkers’ early findings that C16 
derivatives of E2 are more potent inhibitors than their corresponding C17 
analogues. 136 Unexpectedly, the drop in activity was less marked for the N2' 
derivatives 85, 87 and 89 (compared with 84, 8 6  and 8 8 ) indicating that a long 
flexible side-chain at NT or N2' can be equally accommodated in the active site. The 
ability of such side-chains to interact in the active site via hydrophobic and/or polar 
interactions might also explain the higher activity of 85, 87 and 89 compared with 
that of 83. The methyl group in 83 might be too small to pick up hydrophobic 
interactions which could compensate with the steric clashes generated by this moiety 
at N2'.
In the l'-substituted series, compounds bearing a polar side-chain exhibited the 
highest level of activity (~ 95% at 10 pM), with IC5 0S ranging from 530 nM to 920 
nM. The choice of side-chains bearing no more than 3 or 4 carbons was mainly 
driven by previous SAR135’136 on E1/E2, where the active site showed a good 
tolerance for short moieties at the Cl 6 -position. A bulky hydrophobic group was 
however not well tolerated, as suggested by 84, which was the weakest inhibitor of 
the series. Moreover, the //-methyl derivative 82 had a disappointing IC50 (2.75 pM) 
despite good inhibition of the enzyme at 10 pM, indicating that hydrophobic 
moieties placed at NT of a D-ring fused pyrazole nucleus do not contribute to 
specific binding/interactions with the active site.
The requirement for a polar moiety at NT to inhibit 17p-HSD type 1 might suggest 
that the side-chains of 84, 8 6 , 8 8  and 95 interact with some residues of the cofactor 
binding domain. With the resolution of the three dimensional structure of 17P-HSD 
type 1 , alone or complexed with substrate and/or cofactor, 145’146 it has been possible 
not only to identify the residues involved in high specificity binding of C l 8  steroids, 
but also those interacting with the cofactor. While several residues that interact with 
the substrate are hydrophobic (Val, Met, Leu, Pro, Phe), most of the residues that 
bind to the cofactor are polar (Cys, Ser, Arg, Asp, Asn, Lys). Such an observation
155
recently constituted the basis for the design of a series of 16p-propylaminoacyl 
derivatives of E2 , where side-chains containing both hydrophobic and hydrophilic 
components were expected to interact with both the steroid and cofactor binding 
domains. 251 Unfortunately, the resulting compounds did not prove the validity of 
such an approach as they displayed very low inhibitory potency on 17P-HSD type 1 
activity. In the case of the pyrazole derivatives 84, 8 6 , 8 8  and 95, it is conceivable 
that the pyrazole scaffold contributes to correctly orientate the polar moieties 
affording a good point of contact in the enzyme pocket.
Most of the pyrazole-based inhibitors showed selectivity for 17P-HSD type 1 
inhibition. Poor selectivity was however observed for the derivatives 8 8  and 95 
which inhibited isotype 2 activity by more than 40% at 10 pM. The isobutyl 
derivative 84, which was the weakest inhibitor of 17p-HSD type 1 in the l'-alkylated 
series, was the best type 2  inhibitor with more than 60% inhibition achieved at 1 0  
pM. Since the three dimensional structure of 17p-HSD type 2 has not been resolved, 
it is difficult to assess which molecular features are likely to enhance the selectivity 
of a type 1 inhibitor towards type 2. From the activity observed for 84, it is clear that 
hydrophobic interactions are important in the region of 17P-HSD type 2 active site 
corresponding to a N 1 ' substituent.
However, although most of the l'-alkylated derivatives had IC50 values below 1 pM, 
it is clear that the alkylation of the pyrazole template has been detrimental to the 
activity. With an IC50 of 180 nM, the parent pyrazole 98 is more potent than any of 
its 1- or 2'-alkylated analogues. The fact that 8 8  remains 3 times less potent than 98 
suggests that the active site does not accommodate well the side-chains and/or a 
crucial interaction with the NH group is perturbed as a result of the alkylation. Both 
nitrogen atoms on the pyrazole nucleus may constitute a hydrogen bond donor 
(HBD) and acceptor (HBA) system, which interacts with the catalytic triad (Tyrl55, 
Seri42 and Lysl59) of 17p-HSD type 1 to result in a high affinity enzyme-inhibitor 
complex. Although polar interactions are favoured in this region of the active site, as 
demonstrated by the activity of 8 6 , 8 8  and 95, they do not overcome the negative 
steric effect or compensate the loss of NH as HBD. We therefore hoped that
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compounds of the 5' series, where the HBA and HBD character of the heterocycle 
are conserved, would exhibit a higher level of activity. Unfortunately, too little data 
is available at present to draw a conclusion for such derivatives.
ii) Estrogenicity in vitro
Although 98 was reported to be a potent inhibitor of 17p-HSD type 1, there are no 
estrogenicity data available for this compound. In T-47D cells, this 16,17-fused 
pyrazole derivative of E l was shown to inhibit 17P-HSD enzymatic activity with an 
IC50 of 180 nM and its l'-methoxyethyl analogue 8 8  had an IC50 of 530 nM. Before 
undertaking further studies on compounds derived from the pyrazole template, it was 
necessary to assess their estrogenicity. Along with 98, the estrogenic activity of 82 
and 8 8  was evaluated.
Unexpectedly, 98 proved to be a full agonist of the ER, displaying estrogenic activity 
at concentrations as low as 100 pM. Although none of the alkylated derivatives were 
designed with the intention to decrease the potential estrogenicity of the template, we 
were pleased to see that the introduction of side-chains on the pyrazole nucleus 
considerably reduced its estrogenicity. Even a small moiety, such as a methyl group, 
introduced at the l'-position dramatically decreased the agonist activity of the 
template. In particular, the analogue 8 8  was totally devoid of estrogenic activity over 
the range of concentrations tested, and therefore emerged as a strong candidate for 
further studies, being only 3 times less active than 98 against 17p-HSD type 1 
activity.
Conceivably, the NH group of the heterocycle might be involved in the binding of 98 
to the ER. In the same way as A-alkylation generates weaker inhibitors of 17p-HSD 
type 1 (vs. 98), A-alkylation might result in compounds having a lower affinity for 
the ER. In addition, the A-methyl derivative 82 is estrogenic at concentrations above 
10 nM, while 8 8  is not, suggesting that longer side-chain prevent binding to the ER. 
However, we cannot exclude that 8 8  might be an antagonist at the receptor. Such a 
possibility needs to be further investigated since a compound displaying both 
inhibition of 17p-HSD type 1 and antiestrogenic properties would be an ideal drug
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for the treatment of HDBC. In this respect, Poirier and coworkers’ attempts to design 
such a compound (i.e. dual action inhibitor) were not entirely successful. The 
derivatives that emerged from such investigations were moderately potent against
1 o o
17p-HSD type 1 and not entirely antagonistic.
iii) Metabolic studies
Given that alkyl substitution on a heterocyclic nitrogen is likely to give rise to 
metabolic instability due to dealkylation reactions and oxidation, some metabolic 
studies were undertaken on the N-alkyl pyrazole derivatives 82, 86, 88 and 89.
Compounds 82 and 86 were unstable in presence of both human and mouse hepatic 
microsomes. The most likely metabolic pathway was iV-demethylation for 82, while 
the methyl acetate side-chain of 86 was expected to undergo rapid hydrolysis. To 
assess the influence of the location of the substituents of the heterocycle, the two 
regioisomers 88 and 89 were also assessed. While the l'-alkylated derivative was 
moderately stable in the human system and stable in the mouse, the N2' regioisomer 
had a greatly enhanced stability in the human system. This indicates that N2' 
compounds are less likely to be metabolised in vivo than their NT analogues. 
Unfortunately, none of the 2'-alkylated derivatives was potent against 17|3-HSD type 
1. Nevertheless, this information is useful for the design of future inhibitors of the 
same series. So far, compound 88 seems to have several characteristics of a suitable 
candidate for in vivo studies: it is a potent inhibitor of 17p-HSD type 1 in vitro, with 
an IC50 of 530 nM in T-47D cells, totally devoid of estrogenicity in vitro and stable 
towards mice hepatic microsomes.
3.2.5 Conclusion
To address a growing need for agents able to block estrogen production in hormone- 
dependent cancer cells, we designed and synthesised a series of D-ring heterocyclic- 
fused derivatives of El as potential inhibitors of 17p-HSD type 1. In particular, a 
comprehensive SAR was built around the pyrazole nucleus fused at C16,C17.
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Functionalisations were performed at the 1', 2' and 5' positions, to probe the available 
space in three directions.
Efficient synthetic pathways were devised in order to access the target compounds in 
a minimum number of steps. In the pyrazole series, the 1' and 2'-alkylated derivatives 
were isolated from the same reaction. While synthesising C5'-alkylated compounds, 
a series of Cl'-substituted 16-hydroxymethylene derivatives of El could also be 
prepared.
In vitro testing of the 1' and 2'-alkylated analogues indicated that (a) N l' was clearly 
the preferred position for the introduction of side-chains; (b) moieties with a polar 
character gave better inhibition of 17p-HSD type 1 than hydrophobic ones. It is 
suggested that substituents at N2' contribute to negative steric effects which lower 
the activity of the corresponding derivatives while polar moieties at N l' might 
interact with the cofactor binding domain. A methylacetate and a cyanoethyl 
derivative, 88 and 95, were the most potent alkylated pyrazoles with respective IC50 
values of 530 nM and 730 nM in T-47D cells. However, they were found to be less 
potent than their parent 98, which had an IC50 of 180 nM in the same assay.
The introduction of a side-chain on the pyrazole nucleus did not yield better 
inhibitors of 17P-HSD type 1 than 98, however this approach proved valuable when 
examining the estrogenicity data for some of the derivatives prepared. While 98 was 
a full agonist of the ER, the estrogenicity of its methyl 82 and methoxyethyl 88 
analogues was comparatively low. The derivative 88 was also metabolically stable in 
mouse hepatic microsomes. Such results are highly encouraging as they indicate that 
TV-alkylated derivatives of 98, although less potent than their parent, might offer 
pharmacokinetic advantages and can be used in the treatment of hormone-dependent 
pathologies. However, before investigating further such compounds (e.g in vivo), it 
would be interesting to elucidate their mechanism of inhibition (tight binding, 
reversible) and whether a derivative such as 88 displays any antiestrogenic 
properties. The biological data for the C5'-alkylated compounds and the pyridine and 
pyrimidine-based heterocyclic derivatives should also bring further insight into 
understanding the molecular determinants responsible forl7P-HSD type 1 inhibition.
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3.3 Small modifications on the estra-l,3,5(10)-triene nucleus
3.3.1 Rationale for novel targets
Since Poirier and coworkers’ findings that 16a-bromobutyl-estradiol (1.18, Figure 
3.28) was a potent inhibitor of 17p-HSD type l / 35 ,136 most of the investigations 
dedicated to the search of agents blocking the activity of this enzyme have revolved 
around the D-ring, and in particular the 16 position of E1/E2. In a preliminary study 
aimed to identify pharmacophores or functionalities that could be exploited or 
optimised for the design of inhibitors, we evaluated the synthetic intermediates 1  and 
97 (Figure 3.28) for their activity against 17p-HSD type 1. Both compounds emerged 
as potent inhibitors, with respective IC5 0S of 1.10 and 0.11 pM in T-47D cells, which 
confirmed the validity of investigating the steroidal D-ring. As a result, part of our 
work was dedicated to the synthesis of pyrazole-based inhibitors of 17P-HSD type 1 
(cf. section 3.2), where the D-ring fused heterocyclic system mimics a putative 








Figure 3.28 Structure o f 17(I-HSD type 1 inhibitors. Com pounds 1 and 97 are intermediates 
synthesised in our laboratories.
In a concurrent approach, we wanted to identify another position of the steroidal 
backbone which would allow the introduction of functionalities designed to interact 
with residues of the active site. We therefore decided, prior to chemical synthesis, to 
examine the three dimensional crystal structure of 17P-HSD type 1 in complex with 
E2 , 146 with a particular focus on the amino acids within close contact of the steroidal 
backbone. In order to narrow the area of space we intended to probe, several 
restrictions were applied regarding:
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(a) the type of interaction desired between the target(s) amino acid(s) and the moiety 
to be introduced on the steroid. In general, an enzyme-inhibitor complex can be 
stabilised by electrostatic or hydrophobic interactions as well as hydrogen or 
covalent bonds. Although covalent bonds contribute to a higher stabilisation, 
hydrogen bonds or hydrophobic interactions are more easily achieved, and require 
the introduction of polar/hydrophilic or non polar/lipophilic moieties respectively on 
the inhibitor.
(b) the region of the steroid to target. We wanted to introduce a functionality at a 
position other than the D-ring which would not disrupt the high complementarity of 
the binding of the steroid to the active site. While E2 binds in a narrow hydrophobic 
tunnel, specific hydrogen bonds between residues of the active site and the hydroxyl 
functions at C3 and C17 contribute to stabilising the enzyme-substrate 
complex. 145 ,146,148 Structural modifications on the A-ring were therefore not 
envisaged, as any substitution in close proximity to C3 might be detrimental to 
hydrogen bonding at this position. We therefore focused on the steroidal B- and C- 
rings, for the introduction of moieties of small to medium size.
(c) the type of moiety to be introduced. In order to rapidly generate inhibitors, the 
structural modification envisaged had to be easily achieved. For the B- and C-rings, 
reports in the literature mostly deal with chemical synthesis of 6 , 7 or 11 derivatives 
of E1/E2.
Therefore, our search was restricted to identifying potential residue of 17p-HSD type 
1 that could interact via hydrophobic or hydrophilic interactions with a putative 
moiety or functional group situated at the 6 , 7 or 11 position of E2.
The crystal structure of 17p-HSD type 1 in complex with E2 and NADP+ was used 
for this study (code 1 FDT146 in the Protein Data Bank193). From the examination of 
the amino acids present around the B and C ring, and in particular around the 6 , 7 
and 11 position, a serine residue in the vicinity of C6  clearly emerged as an attractive 
target. As shown in Figure 3.29, the distance between C6  in E2 and the p-hydroxyl 
moiety of Ser2 2 2  was found to be about 5 A and it was anticipated that a small polar 







Figure 3.29 View of part of the active site of 17(3-HSD type I in complex with E2 and NADP+ 
(NADP+ not shown). Critical residues and Ser222 are labelled as well as the distance between C6  in 
E2 and (3-OH in Ser222.
Further to these observations, we decided to synthesise the keto derivative of E l at 
C 6 , a known compound that can be accessed from E l in a limited number of 
steps . 252’254 In addition, it seemed worthwhile investigating whether a moiety at C 6  
could potentially act synergistically with a functionality at C16 to enhance the 
inhibitory effect against 17p-HSD type 1, and 6,16- as well as 6,17-modified 
derivatives of E l were also prepared. Estrogenic activity is undesired in endocrine 
therapy, therefore we chose to introduce modifications on the E l template (3- 




i) Preparation o f 6-oxoestrone
The oxidation of the C6  benzylic position of El or E2 can be achieved using 
potassium permanganate or chromium (VI) derivatives. 252,253 However, low yields 
are reported for such reactions due to a number of side products being formed by 
cleavage of the B and C rings. 253 Few methods have been applied to steroids, 
especially to E l or E2, and among recent procedures the use of tert-butyl 
hydroperoxide in the presence of chromium hexacarbonyl in refluxing acetonitrile 
was reported. 25 4 Although the yields for the oxidation of 3-methoxy-estrone were 
claimed to be higher than those obtained via previous methods, the difficulty of 
performing the reaction on a large scale prompted us to use an adaptation of 








Schem e 3.12 Synthesis o f  6-oxoestrone 120. (a) C r0 3, A cOH/H20 ;  (b) KOH/M eOH.
In order to prevent simultaneous oxidation at C3, the hydroxyl function of E l was 
protected with an acetate group, 156 which was reported to be stable under oxidative 
conditions using chromic acid. 253 The resulting derivative 61 was then reacted with 
chromium trioxide in a mixture of acetic acid and water, below room temperature 
(ca. 15°C), so that the oxidation was relatively slow and mild. The oxidised product
119 was obtained in a yield of 2 0 % after recrystallisation, which was consistent with 
previously reported yields.254 Hydrolysis of the acetate group was then performed 
using KOH in MeOH to give 120 in 58% yield. The position of the carbonyl group in
120 was confirmed by the downfield shift of the C4-H signal in the !H NMR 
spectrum to 5 7.77 (vs. 8  6.81 in 61), due to the deshielding of the benzylic carbonyl 
group.
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ii) Combination o f substituents at C6 and C l 6
In order to assess whether the putative effects of the ketone group at C6  would work 
in synergy with a moiety at C 16 to inhibit 17p-HSD type 1, we decided to synthesise 
6 -oxo, 16-hydroxymethylene-estrone (124, Scheme 3.13). Since the formylation of 
120 (or a protected analogue) can take place at C l or C16 due to the presence of two 
enolisable positions, the oxidation at C6  had to be performed after functionalisation 



















S chem e 3.13 Synthesis o f 6,16-substituted E l derivatives, (a) Ac20/pyrid ine , reflux; (b) C r0 3, 
A cO H /H 20 ;  ( c )  KOH/EtOH; (d) K2C 0 3/M e0 H
Starting from E l, 97 was obtained in three steps following the sequence described 
previously (see section 3.2.2, overall yield 6 6 %). The latter was then subjected to 
reaction with a large excess of acetic anhydride in refluxing pyridine in order to 
protect the derivative at C3. As predicted from the totally enolised character of 97, 
C3-protection was accompanied by esterification of the enolic hydroxyl. The 
resulting bis-acetylated product 121 was isolated in a yield of 47%. As indicated by 
TLC (CHCl3/EtOAc, 8:2) a second more polar product was also formed during the 
reaction. However, we were unable to isolate this product in a pure form after
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purification of the crude material by flash chromatography due to the similarity 
between its Rf  (0.85) and that of 121 (R /=  0.91). Too little of this side-product was 
recovered to attempt further purification and examination of its !H NMR spectrum 
indicated the presence of two acetyl groups with corresponding methyl signals at 8
2.09 and 8 2.28 vs. 8 2.24 and 8 2.29 in 121. Conceivably, a bis-acetylated derivative 
may also have been formed as a result of the esterification of the less stable enolic 
form of 97 (where the double bond is endocyclic). Subsequent oxidation of 121, 
using the same conditions as described for 61 (Scheme 3.12), gave 122 in a yield of 
10%. The poor yield of this reaction may be attributed to the high number of side- 
products formed, due to the reactivity of the substrate.
Attempts to deprotect 122 using KOH in EtOH did not yield the expected product 
124, but a compound which was identified as 123. Examination of its *H NMR 
spectrum indicated that both acetate groups were cleaved during the reaction. The 
presence of a triplet integrating for three protons at 8 1.35 and a deshielded signal for 
two protons around 84.1 suggested that an ethoxy function was added to the 
molecule. These findings were corroborated by mass spectrometry and it is suggested 
that 123 was formed as a result of a nucleophilic attack at C l', occurring most likely 
on the protected enol, since AcO" is a better leaving group than OH". Treatment of 
122 under milder conditions (K2CO3 in MeOH) gave 124 in 54% yield. Mainly due 
to the low-yielding oxidation step (121 to 122), the final product 124 was obtained in 
only small quantities. Although the yields for this sequence can most likely be 
optimised, it would be of interest to investigate a more efficient and reliable method 
for the benzylic oxidation of E l or E2.
Hi) Combination of substituents at C6 and C17
To further explore the potential of functionalisation at the 6  position, we decided to 
convert the 6 -keto group of 1 2 0  into another small moiety which would retain the 
hydrogen bonding properties of a carbonyl. An oxime group was particularly suitable 
for this purpose, given that it can easily be introduced in one step from a carbonyl 
compound without requiring any protection of the precursor. Moreover, the large
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number of hydroxylamines available offers the possibility for further diversification 





1X = 0  >  127 X = H, H " \
) effect of oxime at C17 ) effect of oxime at C6
128 X = N O H -/ 125 X = N O H -/
Figure 3.30 Structural m odifications on the estra-l,3 ,5(10)-triene tem plate and com parison o f the 
effects o f introducing an oxim e at C17 and at C6.
Although we initially wanted to assess the effects of converting the carbonyl at C6  
into an oxime, it was anticipated that starting from 6 -oxoestrone, oximation would 
occur at both C6  and C17 carbonyl to yield 125 (Figure 3.30). Being unable to access 
selectively and in a short sequence the 6 -oximino compound, two additional 
derivatives were prepared in order to gain information on the biological effects of 
adding and relocating oxime moieties around the estra-1,3,5(lO)-triene ring system 
(Figure 3.30):
(a) 128, a 16,17-bisoximino derivative, whose activity can be directly compared with 
that of 1 to assess the effects of replacing the carbonyl by an oxime at C17;
(b) 127, a 17-oximino derivative which will allow evaluation of the effects of 
introducing an oxime at C6  by comparing its activity with that of 125. It is 
anticipated that the activity of 127 can also be compared to that of the natural 
susbtrate for the enzyme, E l.
Both 127 and 128 were obtained after treatment of their respective precursors El and 
1 with hydroxylamine hydrochloride and sodium acetate in a mixture of MeOH and 
H2O (Scheme 3.14), following an adaptation of a literature procedure. 155
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125 R = H
126 R = CH3
S chem e 3.14 Synthesis o f oxim e derivatives o f E l .  (a) NHROH.HC1, N aOAc, M eO H /H 20 ;  (b) and 
(c) same conditions as in (a), w ith R = H.
Reaction of 120 with hydroxylamine hydrochloride or methoxylamine hydrochloride 
under the same conditions gave the analogues 125 and 126. Compound 125 was 
highly polar and purification of the crude product by flash chromatography only 
afforded the product in 41% yield, while 126 was obtained with a yield of 92%. All 
these oxime derivatives existed as single geometrical isomers, as inferred from their 
*H NMR spectra. The derivative 127 is known to be formed as the anti-isomer, from 
the resolution of its crystal structure. No further experiments were carried out on 
the synthesised derivatives to assess the configuration of the different oxime 
functionalities, although this could be worthwhile investigating if some of these 
compounds turn out to be potent inhibitors of 17p-HSD type 1.
3.3.3 Results and discussion
i) Inhibition of 17fi-HSD type 1 in vitro
The inhibitory activity of the different estra-l,3,5(10)-triene derivatives synthesised 
was assessed in vitro. Inhibition of 17p-HSD type 1 and 17|3-HSD type 2 were 
examined in T-47D cells and MDA-MB-231 cells respectively. As in previous 
sections, the activity of the compounds against 17P-HSD type 2 was determined as a 
measure of selectivity of the inhibitors for the isotype 1. Table 3.9 gives the 
percentage of inhibition achieved for a 10 pM concentration of each compound as
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well as the IC50 for some of the potent inhibitors. The data for E l, 1 and 97 were also 
included for comparison between structurally related analogues.
T ab le  3.9 Inhibition o f 17(3-HSD type 1 (and type 2) by estra-l,3 ,5(10)-triene derivatives. Results are 














0 H,H H,H E l nd nd 0.33
0 NOH H,H 1 95.7 ± 1.0 5.0 ± 4 .2 1.10
0 CHOH H,H 97 96.6 ± 0.2 17.4 ± 1.9 0.11
0 H,H O 120 98.4 ±  0.2 7.9 ±  10.7 0.34
0 CHOEt O 123 84.7 ± 0.7 8.1 ± 6 .4 nd
0 CHOH O 124 97.3 ± 0.3 nd 0.70
NOH H,H NOH 125 83.1 ± 0 .8 26.5 ± 0.5 1.90
NOM e H,H NOM e 126 31.3 ± 2 .9 15.0 ± 4 .3 nd
NOH H,H H,H 127 20.4 ± 6.5 nd nd
NOH NOH H,H 128 54.9 ± 2.0 -2 .1  ± 4 .9 nd
At 10 jiM, most of the compounds tested displayed a high inhibitory activity against 
17p-HSD type 1. In particular, the percentage of inhibition achieved by derivatives 
120, 123, 124 and 125 was above 80% and therefore comparable to the reference 
compound 97. Derivatives 120 and 124 were the most potent with ca. 97% of type 1 
activity inhibited, and respective IC 5 0 S of 340 nM and 700 nM. Although this 
indicates that targeting the 6-position alone or in combination with a functionality at 
C16 was not too detrimental to the activity, these derivatives are less potent than 97. 
Compound 120 was equipotent to the natural substrate indicating that the 6-keto 
group was tolerated but did not enhance binding in the active site.
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Overall, the oxime derivatives 125-128 were less potent than the other estra- 
l,3,5(10)-triene analogues synthesised in this study. In particular, they were less 
active than 16-oximinoestrone 1 which had an IC50 of 1.10 pM in T-47D cells. The 
best oxime analogue in this series was the 6,17-bisoximino derivative 125, which 
achieved an 83% of inhibition of 17p-HSD type 1 at 10 pM. The presence of an 
oxime group at C6 and C17 did not abolish the activity of the template although with 
an IC50 of 1.90 pM, 125 was clearly less potent than 1. The 16,17-bisoxime 128 had 
a weak inhibitory activity against 17P-HSD type 1 (55% inhibition at 10 pM), while 
126 and 127 were practically inactive. Interestingly, introduction of an oxime at C17 
in place of the carbonyl yielded the weakest inhibitor 127.
Although type 2 activity was not determined for all the derivatives, a good selectivity 
was achieved for most of the analogues tested. The least selective compound was 
125, which inhibited the activity of type 2 by 26% at 10 pM.
Effect o f a ketone at C6 and combination with a functionality at Cl 6
From the activity data, it is apparent that the introduction of a ketone at C6 was not 
detrimental nor beneficial to the activity against 17p-HSD type 1 since 120 was 
found equipotent to E l. Nevertheless, the inhibitory activity of 6-oxoestrone 120 
against 17p-HSD type 1 indicates that there is a potential small pocket in the active 
site to be exploited. As indicated by molecular modelling studies, polar groups at C6 
might contribute to favourable interactions in the active site by hydrogen-bonding (as 
HBA) the hydroxyl group of Ser222 (a HBD). To some extent, the inhibitory activity 






E1 97 120 124
IC50 = 0.33 nM IC50 = 0.11 |iM IC50 = 0.34 |iM IC50 = 0.70
F ig u re  3.31 IC50 values for 6-, 16- and 6,16-m odified com pounds
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Having identified C6 as a potential site of structural modifications, the next step was 
to determine whether the effect of a substituent at C6 and that of a moiety at C16 
would be additive. To verify this possibility, the El derivative 124 (6-oxo,16- 
hydroxymethylene-estrone) was prepared. With an IC50 of 700 nM, 124 was found to 
be respectively 2-fold and 6-fold less potent than 120 (6-oxoestrone) and 97 (16- 
hydroxymethylene-estrone), suggesting that a synergistic or additive effect was not 
created by combining the two structural modifications. The drop in activity observed 
for 124 vs. 120 and 97 indicates that the ketone at C6 and the enol at C16 might be 
involved in mutually exclusive interactions in the active site. Conceivably, hydrogen 
bonding between Ser222 and the carbonyl at C6 may displace the inhibitor from the 
position adopted by 97 in the active site, resulting in the loss of the interaction 
between the side-chain of C16 and a putative hydrophilic residue. The enol moiety in 
124 might also point towards a hydrophobic region of the enzyme. Conversely, an 
alignment of 124 which enhances interactions at the enol end might prevent 
hydrogen bonding between the C6 ketone and Ser222, or position the ketone in a 
hydrophobic environment.
Effect o f an oxime at C6 and/or C17
We used the facile conversion of carbonyls to oximes to further investigate 6, 16 and 
17 modifications on the estra-1,3,5(lO)-triene nucleus. Given that the direct 
oximation of 120 yielded a 6,17-bisoximino derivative, we were unable to directly 
compare the effects of a carbonyl vs. an oxime moiety at C6, this requiring the 
selective oximation of 120 at C6. Nevertheless, the preparation of compounds 127 
and 128 afforded some valuable insights into the potential of adding or relocating 
oxime functionalities around the estratriene ring system.
Conversion of the C l7 carbonyl group into an oxime clearly reduced the activity of 
the corresponding derivatives. This was exemplified by 128, a 16,17-bisoximino 
compound that was only half as active against 17p-HSD type 1 as its 16-oximino 
analogue 1. Again, such a loss in activity might be explained by mutually exclusive 
interactions involving either oxime group in the active site.
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NOH
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83% at 10 )iM
IC50 = 1.90 [iM
F ig u re  3.32 IC5o values for 6-, 17-, 16,17- and 6,17-m odified com pounds
However, the 17-oximino derivative 127 was found to be a poor inhibitor of 17P- 
HSD type 1 indicating that the replacement of the carbonyl at C17 by an oxime 
moiety was detrimental to the activity. As described by Ghosh et a l, the molecular 
basis for estrogen recognition involves highly specific interactions of the steroidal C3 
hydroxyl and C17 carbonyl (or C17p-hydroxyl in E2) of E l with residues of the 
active site.148 While the hydroxyl at C3 is hydrogen bonded to His221 and possibly 
Glu282, the keto group at C17 interacts with Tyrl55 and Serl42, which are part of 
the catalytic triad. It is therefore conceivable that the oxime moiety is unable to make 
specific interactions at the D-ring end and/or disrupts the triad, resulting in a less 
stable enzyme-inhibitor complex. This might be because of the bigger size of the 
oxime compared with that of a carbonyl group. Alternatively, if hydrogen bonding 
occurs between the oxime and residues of the active site, the steroid might be shifted 
to a position where interaction at the C3-end are no longer stabilising. The presence 
of an oxime functionality at C16 did not impart on the activity to the same extent as 
an oxime at C l7, and the activity of 1 (vs. 127) indicates that the carbonyl at C17 is 
crucial for binding while an oxime at C16 is tolerated.
Interestingly, 125 was found to be a better inhibitor of 17p-HSD than 127, 
suggesting that the addition of an oxime functionality at C6, and the corresponding 
electronic interactions created in the active site, did overcome the inactivating effects 
of the oxime at C17. Similarly, when comparing the activity of 127 and 128, it 
appears that the presence of an oxime at C16 in 128 contributes to a higher activity. 
When the oxime groups in 125 were replaced by O-methyl-oximes (cf. 126), the 
activity dropped to 31% inhibition at 10 pM. This loss in activity may result from
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steric clashes in restricted size pockets at C6 and/or C17, possibly combined with the 
HBA-only character of the moieties of 126 (vs HBA and HBD for the oximes in 
125).
Investigating the effects of introducing or relocating small isosteric functionalities on 
the estra-1,3,5(lO)-triene ring system proved valuable as this contributes to a better 
understanding of the structural features that are involved in high affinity binding of a 
potential inhibitor to the active site of 17P-HSD type 1. At this stage, it is however 
not known whether the inhibitors designed act via a reversible or irreversible 
mechanism at the active site.
Hi) Estrogenicity in vitro
To evaluate the potential of 6-, 16- and 17-modified estra-l,3,5(10)-triene inhibitors 
of 17p-HSD type 1 for their application as endocrine agents in hormone-dependent 
diseases, the estrogenic activity of some of the derivatives was assessed in vitro. 
Compounds 1, 97, 120 and 125 were tested in a luciferase reported gene assay and 
the results are presented in Figure 3.33. For each compound, the estrogenicity was 
measured at four concentrations (100 pM, 1 nM, 10 nM and 100 nM) and expressed 
as a level of luciferase activity. The luciferase level for background cells was also 
recorded and E2 was used as a reference in a 1 pM-1 nM concentration range. The 
derivatives 97, 120 and 125 were tested side by side, while the activity of 1 was 
examined separately.
The 16-oximino derivative 1 was the most estrogenic compound of the series, being 
as estrogenic as 10 pM of E2 at a concentration of 100 pM. Its 16-hydroxymethylene 
analogue 97 was however less active at the ER, displaying pronounced agonist 
activity at a concentration of only 100 nM. Introduction of a ketone at C6 on the El 
template yielded 120 which was as estrogenic as E2 at a 100-fold lower 
concentration. Given that E l was found to be about 100 times less estrogenic than E2 
in our assays, the agonist activity of 120 was comparable to that of E l. Interestingly, 
125 was devoid of estrogenic activity at concentrations up to 10 nM. Its level of
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estrogenicity at 100 nM was comparable to that of 1 pM of E2, suggesting that 125 















Figure 3.33 Estrogenicity in vitro for derivatives 1, 97, 120 and 125 tested at four concentrations. E2 
was used as a reference. Results are expressed as mean ± S.D. of triplicate measurements.
All the compounds tested displayed some estrogenic activity, albeit at different 
concentrations and the strong disparity between the estrogenicity of estra-1,3,5(10)- 
triene derivatives bearing subtle structural modifications was noteworthy. For 
instance, 1 was found to be a potent agonist of the ER whereas 97 only showed a 
moderate level of estrogenic activity in the luciferase reporter gene assay. Given the
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similarity in the structure of the two compounds such results are unexpected, in 
particular as both 1  and 9 7  bear small isosteric hydrophilic moieties at C l6. 
However, in the same way as a potential different binding mode of 1  and 9 7  to the 
active site of 17(3-HSD type 1 results in different levels of inhibition, both 
compounds may interact differently with the ER. This suggests that the oxime and 
the enol groups at C16 of E l interact in a clearly distinctive way in biological 
systems, possibly because of the different electronic densities of the atoms in both 
moieties. A difference in the configuration of the hydroxyl groups relative to C=N 
and C=C bonds in the side-chains of 1  and 9 7  may also account for distinct affinities 
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Figure 3 .34  Structure o f  com pounds previously investigated for their estrogenic activity.
Interestingly, the low estrogenicity of 9 7  may be correlated to the findings of Fevig 
et al. in their study on the ER binding tolerance of 16a-substituted derivatives of 
E2.152 Although the ER had displayed a good tolerance and high affinity for small 
substituents at C l6, the authors reported that highly polar derivatives, such as a 16a- 
hydroxymethyl analogue of E2 ( 3 . 1 9 ,  Figure 3.34), did not bind to the ER efficiently. 
While the enol moiety of 9 7  does not strictly cover the same area of space compared 
with that of a 16a-hydroxymethyl group, these results suggest that there is a region 
of the ER where substituents of high polarity are not well tolerated. This was further 
corroborated by the recent study of Labaree et al., which demonstrated that 16a- 
carboxylic acids derivatives of E2 were devoid of estrogenic activity as a result of a 
weak affinity for the ER.257 More recently, the examination of the affinity of the four 
possible isomers of 16-hydroxymethyl-estradiol for the ER indicated that none of the 
compounds did bind the ER efficiently.258 Yet, the reasons behind the estrogenicity 
of 1 are still unclear, and most likely the oxime moiety points towards an area of the
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ER where hydrophilic interactions are favourable and contribute to stabilising the 
ligand-receptor complex.
While targeting the 6-position of El with small polar moieties was a potential 
approach for the design of potent inhibitors of 17p-HSD type 1, the estrogenicity of 
the potent derivative 120 was a major drawback to its further development as an 
endocrine agent to treat estrogen-dependent diseases. Oxygenated derivatives of El 
or E2 at C6 have been studied comparatively early, with 6p-hydroxyestradiol, 6- 
oxoestradiol and 6P-hydroxyestrone ( 3 . 2 0 ,  3 . 2 1  and 3 . 2 2 ,  Figure 3.34) being 
identified as metabolites of E2.259 Although the activity of such compounds at the ER 
is well documented, ’ ’ to the best of our knowledge, no data were available for 
1 2 0 .  In a study on some 40 derivatives of E2, Wiese et a l demonstrated that the 
introduction of a hydroxyl group at C6 (equatorial or axial) of E2 yielded compounds 
with weak affinity for the ER whereas 6-oxoestradiol displayed a 10-fold higher
0 f \  1affinity than its hydroxylated analogues. Clearly, a keto group placed at C6 of El 
(or E2) did not prevent high affinity binding to the ER, as exemplified by the 
estrogenicity of 1 2 0  at a concentration of 1 nM in our assay. Besides correlating our
a /:  i
findings for 120, these reported data indicate that the estrogenicity of such 
compound could be abolished by reducing the carbonyl at C6 into a hydroxyl 
function. Whether this would be detrimental to the inhibitory activity of the 
derivative is unclear, although we expect the hydrogen bonding properties to be 
retained.
Interestingly, the conversion of both C6 and C17 carbonyl of 1 2 0  into oxime 
moieties (cf. 1 2 5 )  did not produce an agonist of the ER. This was in agreement with 
a previous report where 1 2 7 ,  the 17-oximino analogue, was found to be about 40
A /T A
times less estrogenic than El on oral administration. These results confirm the 
requirement of a carbonyl (or hydroxyl) at C17 for high affinity binding to the ER 
and suggest that an oxime moiety does not mimic this group at the ER.
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3.3.4 Conclusion
A small series of estra-1,3,5( 10)-triene analogues was generated by the addition or 
relocation of ketone and oxime functionalities around the steroidal ring system. 
These compounds were designed and synthesised as potential inhibitors of 17P-HSD 
type 1. Further to investigations using the three dimensional crystal structure of the 
enzyme in complex with E2 and‘NADP+, we primarily focused on introducing small 
modifications at the C6 position of E l. It was anticipated that a polar moiety at C6 
would potentially interact with the hydrophilic residue Ser222, which was shown to 
come within close contact of the B-ring of E2, and in particular C6. In order to 
rapidly gain information on the structural features that would be crucial for high 
inhibitory activity, easy and convenient transformations were envisaged starting from 
E l and most of the compounds were synthesised in a minimum number of steps.
Of the derivatives synthesised, 6-oxoestrone 120 was the most potent with an IC50 of 
340 nM in T-47D cells for the inhibition of 17p-HSD type 1. However, no synergy 
was observed when the 6-keto group was combined with a functionality at C16 and 
6-oxo, 16-hydroxymethylene-estrone 124 had a disappointing IC50 of 700 nM. 
Mutually exclusive interactions between the moieties at C6 and C16 and the active 
site residues might explain the loss in activity in 124 compared with 120 and 97. 
More importantly, in vitro estrogenicity studies revealed that 120 was an agonist of 
the ER, suggesting that some structural modifications should be envisaged before 
further investigating this template. Although these limited studies were not entirely 
successful in generating a potent inhibitor of 17p-HSD type 1, in particular 120 was 
3-times less potent than 97, the tolerance of the active site for a small polar moiety at 
C6 was demonstrated.
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3.4 Potential dual inhibitors
3.4.1 Dual action agents: concept
A number of protein targets involved in estrogen production or action at the cellular 
level have now been identified. Besides agents that are designed to act as antagonists 
at the ER, inhibitors of steroidogenic enzymes represent a valuable alternative to 
treat hormone-dependent diseases such as HDBC by depleting estrogen levels . 72 In 
particular, the P450 aromatase, STS and 17(3-HSD type 1 enzymes play a pivotal role 
in the biosynthesis of active estrogens by transforming inactive or androgenic 
precursors to E2 and A5-diol, two potent agonists of the ER (Figure 3.35).










F igure 3.35 Schematic representation of the biosynthetic pathways leading to E2 and A5-diol in 
normal and breast cancer cells (STS, steroid sulfatase; 17(3-HSD, 17(3-hydroxysteroid dehydrogenase; 
AR, aromatase).
While early investigations focused on blocking the conversion of androgens to 
estrogens via the inhibition of aromatase activity, it progressively became clear that
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local production of estrogens from inactive precursors was an equally or even more 
important pathway.73,78 The efforts therefore shifted towards the design of agents that 
could inhibit the estrogenic enzymes STS and 17p-HSD type 1, responsible for the 
activation of latent precursors to potent estrogens (Figure 3.35).
Most of the endocrine agents developed so far, or currently under investigation, 
solely target the ER or one of the steroidogenic enzymes in Figure 3.35. Yet, it can 
be conceived that a more effective reduction of estrogen levels could be achieved by 
the use of (a) a combination of two distinct inhibitors or (b) an inhibitor and an 
antagonist of the ER. However, previous experience of combining aromatase 
inhibitors with antiestrogens has not been convincing, partly due to pharmacological 
interactions between the drugs. Dual action agents, which might be capable of 
providing the effects of a combination therapy as a single drug represent an attractive 
alternative.
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F ig u re  3.36 Structure o f  dual action agents: com bined 17(3-HSD type 1 inhibitor and antiestrogen 
(1.20), com bined 17fi-HSD type 1 inhibitor and arom atase inhibitor (Apigenin), com bined STS and 
arom atase inhibitor (1.13).
There are few examples in the literature of dual action agents interfering with
estrogen production or its action at the ER. In 1998, Tremblay et al. reported the
synthesis and biological evaluation of 17P-HSD type 1 inhibitors that possessed
1antiestrogenic activity. The best candidate (1.20, Figure 3.36) inhibited placental 
cytosolic 17p-HSD type 1 activity with an IC50 of 14 jliM  while being antiestrogenic 
at 1 pM. Several flavonoids were found to inhibit the activity of both 17p-HSD type 
1 and aromatase enzymes, as exemplified by Apigenin (Figure 3.36) which inhibited 
by 78% and 95% respectively the activity of these enzymes in placental 
microsomes.141,143 Recently, Woo et a l synthesised the first dual aromatase-STS
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inhibitors (DASI) and validated their concept, with one compound (1.13, Figure 
3.36) being potent against both enzymes in vivo.ni
These findings prompted us to determine whether a similar concept could be applied 
to the dual inhibition of 17(3-HSD type 1 and STS. Despite resulting in some potent 
inhibitors, our work and that of others failed to clearly identify a systematic 
functionality that would be the key to 17P-HSD type 1 inhibition. Nevertheless, most 
of the potent steroidal 17(3-HSD type 1 inhibitors were shown to possess D-ring 
modifications in the form of a side-chain at C 16 or more complex features such as a 
heterocycle fused at the 16,17-positions. In contrast, the pharmacophore for STS 
inhibition has long been identified as an aryl-O-sulfamate moiety87 and it was 
anticipated that its introduction into a potent steroidal 17p-HSD type 1 inhibitor 
should confer some inhibitory activity against STS to the corresponding molecule, 
while possibly retaining the potency against 17p-HSD type 1 (Figure 3.37).
This approach seemed attractive for several reasons:
(a) the STS pharmacophore is easily introduced on a phenolic functionality, which 
all steroidal 17P-HSD type 1 inhibitors possess;
(b) the presence of a sulfamate at C3 may help decrease the intrinsic estrogenicity of 
the molecule;
(c) the phenolic precursor (i.e. the 17p-HSD type 1 inhibitor) may be released as a 
result of irreversible inhibition of STS via sulfamoylation of the enzyme resulting in 
an enhanced 17p-HSD type 1 inhibition;
(d) as shown on Figure 3.38, there is reasonable space in the active site of 17P-HSD 
type 1 to accommodate a sulfamate at the 3-position on an El-based molecule.
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F igure 3.37 Approach to design of dual inhibitors of 17p-HSD type 1 and STS, structure of target 
compounds and corresponding precursors.
s tru c tu ra l fea tu re  
for 17p-H SD  type 1 inhibition
sk e le to n  of 
17p-H SD  type 1 inhibitor
p h a rm aco p h o re  
for S T S  inhibition
\
F igure 3.38 Three dimensional structure of 17[3-HSD type 1 in complex with E2 and NADP+, code 
1FDT. 146
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The 17p-HSD type 1 inhibitors 64, 1 and 98, with respective IC5 0S of 320 nM, 1.10 
pM and 180 nM in T-47D cells were chosen for this study. The structure of the 
corresponding sulfamoylated targets is presented in Figure 3.37. It was anticipated 
that the steroidal skeleton of these potential dual agents would ensure favourable 
hydrophobic interactions with the active site of both 17p-HSD type 1 and STS 
enzymes, while the A- and D-ring functionalities would provide additional affinities 
for the active site of STS and 17P-HSD type 1 respectively. However, it could not be 
ruled out that these pharmacophore manipulations might be detrimental to both 
activities, and although high activity is desired, a compromise situation where 
moderate potencies against the two enzymes are observed would be encouraging.
3.4.2 Synthesis
i) Preparation of the 16-ethoxy ethyl derivative
Compound 64, a side-product of the deprotection reaction of 62 (Scheme 3.15), 
emerged as a potent inhibitor of 17p-HSD type 1 at a time when we were 
investigating mechanism-based irreversible inhibition of this enzyme (see section 
3.1). The high activity of this derivative might be attributed to the 16-ethoxymethyl 
side-chain that can interact via polar (cf. ether oxygen) and hydrophobic interactions 
in the active site of 17P-HSD type 1. In turn, this seems to indicate a certain potential 
for ether-type side-chains at C16 of E l (or E2), and such a compound may also 
constitute the basis of new investigations. The moiety at C16 could be optimised by 
either modifying the length of the alkoxy group or that of the spacer between C16 
and the oxygen atom of the ether functionality. However, for the time being, we were 
interested in exploiting the activity of 64 to design a dual inhibitor of 17p-HSD type 
1 and STS.
As evidenced by *H and 13C NMR spectroscopy, 64 was formed as a single 
diastereoisomer, however at this stage, the stereochemistry at C16 was unknown and 











S chem e 3.15 Synthesis o f com pound 64, as a side-product o f the deprotection reaction o f  62. (a) 
KOH/EtOH.
Before further investigations, the orientation of the ethoxymethyl side-chain at C16 
was unambiguously determined by X-ray analysis of a crystal of 64 (approximate 
dimensions 0.40x0.13x0.04 mm) obtained from recrystallisation in EtOH. The 
ORTEX173 plot in Figure 3.39 clearly shows the side-chain on the P-face of the 
steroid, with /^-configuration at C16 (for full details see Appendix 3). To some 
extent, a p-stereochemistry may have been expected for the ethoxymethyl moiety of 
64 since this product was formed as a result of the 1,4-addition of an ethoxide ion to 
the enone moiety of 62 (or 63). In this reaction, the proton abstraction step occurs 
predominantly on the less sterically hindered face of the enone, i.e. away from the 
18-methyl group.
Given that 64 was never obtained in yields higher than 10%, a new synthetic 
pathway was designed in order to provide sufficient quantities of this derivative for 
our present study and for possible future investigations. The aim was to 
stereospecifically introduce the ethoxymethyl side-chain with /^-stereochemistry at 
C l6. Examination of the literature confirmed that alkylation in the a  position of the 
steroidal C17 ketone does not result in the desired stereochemistry since the C18 
methyl group on the p-face directs the attack of any incoming electrophile towards
1 'IS  1 'JA 1 'JQ 9*29the less hindered a-face. ’ ’ ’ Although Poirier et al. developed a methodology
to access 16P-compounds stereoselectively,135,138 we decided to exploit the directing 
effects of the angular methyl in a different way, namely through a hydrogenation 
reaction of an alkenyl group at C l6.
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F igu re  3.39 ORTEX173 plot of the X-ray crystal structure of 64. Ellipsoids are shown at the 30% 
probability level.
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Building on the synthesis of several 16-hydroxymethylene derivatives of El (see 
section 3.2), it was anticipated that under catalytic hydrogenation conditions these 
enols would be selectively converted into the 16(3-alcohols by syw-addition of two 
hydrogens on the less sterically hindered face of the double bond. Similar effects of 
angular methyl groups towards reduction of alkoxymethylene moieties have been 
observed in the literature.264 Given that alkenes are more reactive than other 
functional groups toward catalytic hydrogenation, we did not expect any side-product 













i—  64 R = H 130 and 131
C L— 132 R = 0 S 0 2NH2
Schem e 3.16 A lternative pathway for the synthesis o f 64. (a) K2C 0 3/DM F, EtI; (b) Pd/C, H2, 
M eOH /TH F; (c) C1S02NH2/DM A.
To access 64 in a minimum number of steps, we decided to first alkylate the enol 
function of the benzylated precursor 72 to form the ethoxymethylene derivative 129. 
Subsequent hydrogenation was expected to reduce the double bond at C16 as well as 
cleave the protecting group at C3 (Scheme 3.16). The intermediate 72 was obtained 
in 61% overall yield in two steps from E l. Treatment of this enol according to a 
literature procedure152,257 with potassium carbonate and ethyl iodide in acetone easily 
afforded 129 in 80% yields. Unexpectedly, hydrogenation of the latter for 48 hours at 
room temperature gave a mixture of three products, all of which were debenzylated 
at C3. Separation of the crude mixture by flash chromatography afforded 64 in 46% 
yield as the least polar compound. Examination of the !H NMR spectra of the two 
more polar products isolated from the column indicated that they corresponded to 16- 
ethoxymethyl derivatives of E2 (130 and 131 in increasing polarity), which was
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corroborated by mass spectrometry. Because of the new two chiral centres at C16 
and C l7, these two compounds could theoretically be any of four possible isomers. 
Determination of the coupling constants between C16-H and C17-H was expected to 
help assigning the structures of 130 and 131 since in the cyclopentane ring system, 
the coupling constant between cfs-protons is higher than for trans-protons. In 130, 
C17-H and C16-H were coupled with a constant of 9.9 Hz, however, we were unable 
to compare this value with the corresponding coupling constant in 131, as the signal 
for C17-H was within the multiplet for the methylene protons of the ethoxymethyl 
side-chain, in the 8 3.3-3.6 region. Since the reduction was expected to occur 
preferably on the a-face, it can be surmised that isomer 131, which was present in 
larger quantities (19% yield vs. 9% for 130), contains the p,p arrangement of the C16 
and C17 substituents. Compound 64 was then sulfamoylated following a literature
171procedure using sulfamoyl chloride in DMA to give 132 in quantitative yield.
The determination of the stereochemistry of 130 and 131 was not further investigated 
given that these compounds were formed in relatively minor proportions. However, 
the formation of side-products during the hydrogenation step suggests that this 
pathway (Scheme 3.16) for the synthesis of 64 is not ideal, although it allowed 
synthesis of the product in larger quantities than in the previous method. Another 
sequence might be developed to access 64, or alternatively, it might be useful to 
investigate the hydrogenation conditions, in order to prevent reduction at C17. 
Monitoring of the hydrogenation reaction by TLC however indicated that for shorter 
reaction times, some starting material was still present, while longer exposure to H2 
and the catalyst lead to reduction of the ketone at C l7.
ii) Other derivatives
Access to the remaining target compounds 133 and 135 was achieved through 
sulfamoylation of the respective phenolic precursors 1 and 98 (Scheme 3.17). 
Reaction of 1 with sulfamoyl chloride in DMA gave 133 as a single product, 
however, loss of material through purification led to a yield of 37%. Comparison of 
the ]H NMR spectrum of and 1 and 133 confirmed that sulfamoylation occurred at 
the phenolic end and not at the oxime moiety. In 133, the oxime signal (8 12.41) was
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unchanged (cf. 1), while the peak for C3-OH was not seen. The sulfamate NH2 group 





1 R = H
133 R = 0 S 0 2NH2
E1
4 steps
98 R = Rt = HP  '
I , 134 R = Ri = 0 S 0 2NH2 
135 R = 0 S 0 2NH2l Rt =H
S chem e 3.17 Synthesis o f the sulfam oylated derivatives 133 and 135. (a) C1S02N H 2/DM A.
Treatment of 98 under the same conditions gave a mixture of two products of distinct 
polarities, which were identified as 134 and 135. The more polar product 135 was 
obtained with a yield of 57% while 134 was formed in smaller quantities and was 
recovered in 32% yield. Compound 134 was identified as a bis-sulfamoylated 
product on the basis of *H NMR and mass spectrometry evidence. The signals for the 
NH2 group of each sulfamate moiety were seen at 8 7.88 and 8 8.30 in the NMR 




/  134 135
5 7.88 87.89
F ig u re  3.40 'H  NM R shifts for characteristic protons in 134 and 135 (DM SO-d6, 400 M Hz).
When a sample of 134 was kept for several hours in DMSO-d6 at room temperature 
and a new spectra collected we observed that:
(a) one sulfamate peak (8 8.30) decreased in intensity while the other (8 7.88) was 
unchanged;
(b) the signal for C5'-H disappeared;
(c) a peak at 8 7.25 appeared.
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This was indicative of the rapid degradation of 134 into 135, for which C5'-H and 
NH2 resonated respectively at 8 7.25 and 8 7.89 (Figure 3.40). Cleavage of the 
sulfamate at the heterocyclic nitrogen (vs. C3) in aprotic polar solvents was strongly 
supported by the shift observed for C5'-H before and after degradation. In 134, the 
sulfamate group was assumed to be directed at the least hindered nitrogen (NT) 
because of the steric effects of the 18-methyl group, although we do not have any 
experimental evidence to support this assumption.
3.4.3 Results and discussion
i) Inhibition of 17p-HSD type 1 and STS in vitro
Compound 133 was tested for its activity against both enzymes in separate assays. 
While 17p-HSD type 1 and type 2 activities were assessed in T-47D and MDA-MB- 
231 cells respectively, STS activity was assessed in placental microsomes. Table
3.10 summarises the data collected. The activity of 1, the precursor of 133 and potent 
17(3-HSD type 1 inhibitor, is also reported here as both compounds were tested in the 
same assay. 667 COUMATE was used as a reference for STS inhibition.
T ab le  3.10 Inhibition o f 17(1--HSD type 1 (and type 2) and STS by 133 and reference com pounds.
170- HSD STS
Com pound 17 p-HSD type 1 17p-HSD type 2 IC50 (nM)
133 47.1 ± 0 .9 7.6 ±  2.4 414
1 95.1 ± 1.0 5.0 ± 4 .2 nd
667 COUM ATE nd nd 5.5
The inhibitory data for 133 indicate that the structural modifications introduced at C3 
were detrimental to its activity against 17p-HSD type 1. At a concentration of 10 
pM, 133 inhibits only half of the activity of 17p-HSD type 1 while its phenolic 
precursor 1 achieved a 95% inhibition. With an IC50 of 414 nM in placental 
microsomes, 133 was also a 75 times less potent STS inhibitor than 667 COUMATE.
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Although clearly not as effective as 667 COUMATE, 133 remains a moderately 





effect of sulfamate at C3 effect of oxime at C16
(2 fold loss of activity against 17|5-HSD type 1) (30-40 fold loss of activity against STS)
F ig u re  3.41 Structures o f  1, 133 and EM A TE and com parison o f the structural features influencing 
the biological activity.
When comparing the activities of 1 and 133 (Figure 3.41), it is clear that the 
introduction of a sulfamate moiety at C3 contributed to decreasing the activity 
against 17(3-HSD type 1. This was to some extent expected, as we previously 
stressed on the importance of the interactions of the 3-hydroxyl moiety of the A-ring 
with key residues of 17p-HSD type 1 active site. This is exemplified by the fact that 
most steroidal inhibitors of 17p-HSD type 1 developed so far possess this feature.121 
A sulfamate group can potentially hydrogen bond to the polar residues surrounding 
the A-ring, yet, 133 only inhibits 47% of 17P-HSD type 1 activity at 10 pM. It is 
possible that despite favourable interactions of the sulfamate group in the active site, 
the D-ring moiety imparts negatively to the activity. The 16-oxime, which in 1 
interacts favourably in the active site, may be shifted towards a more hydrophobic 
area to accommodate the increased bulk at the A-ring end. The loss of favourable 
interactions, and possibly consequent electrostatic repulsions, might explain the weak 
inhibitory activity of 133 against 17P-HSD type 1.
Concerning the inhibition of STS, it is believed that most of the favourable 
interactions can be attributed to the sulfamate moiety, yet 133 remains considerably 
less potent than 667 COUMATE. We have extensively discussed in Chapter 2 the 
importance of hydrophobic interactions of moieties situated on the D-ring of an 
E1/E2 or EMATE template. Interestingly, 133 is structurally derived from EMATE,
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and the activity of both compounds against STS can be compared (Figure 3.40). 
EMATE, which is known to be 2-3 times less potent than 667 COUMATE in vitro, is 
therefore 30-40-fold more effective than 133 at inhibiting STS activity. The presence 
of the oxime moiety at C16 therefore decrease the activity of the derivative, which 
corroborates the aforementioned requirement for a hydrophobic group at this position 
or around the D-ring.
ii) Estrogenicity in vitro
The ability of some derivatives to provoke an estrogenic response was assessed in 
vitro, in a luciferase reporter gene assay. Figures 3.42 and 3.43 give a representation 
of the estrogenic activity for the sulfamates 132 and 133, as well as for their 
respective phenolic precursors 64 and 1 at four different concentrations. The activity 
of 1, which was discussed in section 3.3 is included for comparison, and E2 was used 
as a reference in all assays
All the compounds, except 132, displayed some estrogenic activity at a concentration 
of 100 nM. While compound 1 was the most estrogenic derivative, its sulfamate 
analogue 133 had a weaker activity at the ER. It was a clear agonist of the ER at 100 
nM, with an activity higher than 10 pM of E2. Both the 16p-ethoxymethyl 
derivatives 64 and 132 had no or weak estrogenic activity. In particular, 132 was not 
an agonist of the ER at 100 nM while 64 was a weak agonist at this concentration. 
The introduction of an ethoxymethyl at C16 therefore provoked a marked reduction 
of the intrinsic estrogenicity of E l, which was generally found to be estrogenic at 10 
nM in our assays.
As predicted, a sulfamate moiety at C3 contributed to a weaker estrogenicity of the 
corresponding derivatives. Extensive studies on ER binding affinities of various 
steroids37 and resolution of the crystal structure of the LBD of ER in complex with 
agonists and antagonists 41-43 have suggested that the 3-hydroxyl group was crucial 
for high affinity binding at the ER. We therefore expected the steroidal sulfamates 
132 and 133 to be weaker agonists than their phenolic precursors 64 and 1. This was 
particularly striking with the 16-oxime derivatives 1 and 133 which were separated
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by a 1000-fold difference in estrogenic concentrations (100 pM and 100 nM 






1 nM 100 pM 10 pM 1 pM
E2
& T








100 nM 10 nM 100 pM1 nM 100 pM 10 pM 1 pM 1 nM
E2 133
Figure 3 .42  Estrogenicity in vitro for the sulfamoylated derivative 133 and its phenolic precursor 1.
Clearly, an oxime moiety at C 16 did not prevent high affinity binding to the ER, as 
exemplified by the high agonistic activity of 1. This contrasts with previous reports 
where the ER was found to have a limited tolerance for polar moieties at C l 6 a , 152,257  
although the difference in orientation between a moiety at C 16 a  and the polar group 
in 1 might be sufficient to explain its estrogenic activity. In contrast, the effects of an
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ethoxymethyl side-chain at C16p were encouraging, with 64 and 132 being 
considerably less estrogenic than 1 and 133. Interestingly, the highly potent 17P- 
HSD type 1 inhibitor 64 (IC5o= 320 nM in T-47D cells) was a poor agonist of the ER 
at 100 nM, which may indicate a low affinity binding of such compounds to the ER. 
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F igure 3.43 Estrogenicity in vitro for the sulfamoylated derivative 132 and its phenolic precursor 64.
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3.4.4 Conclusion
Agents that inhibit more than one enzyme of the steroidogenic pathway may 
contribute to a more efficient blockade of estrogen production in tumour cells. 
Recently, some compounds were shown to successfully inhibit both STS and 
aromatase activity in vitro and in vivo.111 To verify if this concept is also applicable 
to the dual inhibition of 17p-HSD type 1 and STS, a small set of novel compounds 
was synthesised. By introducing the pharmacophore for STS inhibition in known 
17p-HSD type 1 inhibitors, we hoped to engineer into these compounds some 
inhibitory activity against STS, while retaining their 17p-HSD type 1 inhibitor 
properties.
Compounds 132, 133 and 135 were synthesised in one step from their phenolic 
precursors. In vitro, the 16-oximino derivative 133 was found to be a poor inhibitor 
of 17P-HSD type 1 activity with moderate potency against STS. Clearly, the 
modification at the A-ring end reduced the activity of the derivative against 17P- 
HSD type 1, while the moiety at the D-ring end did not contribute sufficiently to 
favourable interactions in STS active site. Examination of the estrogenicity of 132 
and 133 compared with that of their precursors confirmed that the presence of a 
sulfamate moiety was correlated to reduced estrogenicity.
More biological data are however needed to conclude whether the approach chosen 
might lead to potent dual inhibitors of 17p-HSD type 1 and STS. In particular, A- 
ring sulfamates with a variety of D-ring features need to be designed and synthesised 
in order to assess whether a compromise can be reached between the structural 





Estrogens have a well-established role in the aetiology of breast cancer. They directly 
support the growth and development of hormone-dependent forms of carcinoma and 
therapeutic strategies aimed to deprive the tumours of estrogens by either 
antagonising the ER, or by blocking their biosynthetic pathways, have seen an 
accelerated development in the past decade. In particular, steroidogenic enzyme 
inhibitors represent an attractive class of compounds that can potentially deplete 
circulating and tissue levels of active estrogens. While aromatase inhibitors are 
currently used in the treatment of HDBC, drugs that inhibit STS or 17p-HSD type 1 
have not yet progressed to clinical trials. A major difficulty in the design of agents to 
treat hormone-dependent diseases lies in the requirement for a non estrogenic profile 
of the drug. A number of strategies have been adopted to design and synthesise novel 
inhibitors of STS and 17|3-HSD type 1 that would be highly active while being 
devoid of estrogenic activity.
Attempts to develop potent inhibitors of STS were met with success. EMATE 
(Figure 3.44), the highly active, albeit estrogenic, landmark inhibitor was used as a 
structural basis for the design of a new template. To explore the potential of 
hydrophobic interactions around the steroidal D-ring, while possibly overcoming the 
intrinsic estrogenicity of EMATE, structural modifications were envisaged. The 
cyclopentanone steroidal D-ring was transformed into a piperidinedione moiety 
while the active pharmacophore for STS inhibition, an aryl-O-sulfamate moiety, was 
retained. The synthetic strategy developed afforded the resulting 3-sulfamoyloxy- 
16,17-^c<9-estra-l,3,5(10)-triene-16,17-imide template in a minimum number of 
steps, and facile introduction of diversity rapidly yielded a series of TV-alkylated 
analogues. Biological evaluation of these novel derivatives indicated that not only 
most of the compounds synthesised were potent, non estrogenic inhibitors of STS, 
but two analogues (TV-propyl 35 and TV-pyridin-3-ylmethyl 43, Figure 3.44) were 
found to be 18 times more active than EMATE in vitro, with IC5 0S of 1 nM in 
placental microsomes. The importance of hydrophobic interactions in the active site 
was confirmed (e.g. TV-benzyl 44 and TV-'butylbenzyl 42 had IC 5 0 S below 25 nM) 
however, the corresponding pocket did not tolerate long linear side-chains (IC 5 0 S 
above 150 nM for C4 -C6 side-chains).
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In an effort to rationalise the activity of such compounds, molecular modelling 
studies using the recently disclosed three dimensional structure of human STS were 
carried out. Key interactions contributing to high affinity binding of the D-ring 
modified inhibitors in the active site were examined. The pseudo imido-carbonyl at 
C16 was proposed to hydrogen bond to an amino acid of the active site (Arg98), 
however interactions of the sulfamate moiety with catalytic residues and the metal 
ion Ca2+ seemed to dictate one major binding mode for the inhibitors upon docking. 
A QSAR was established for this series of D-ring modified analogues and its 
predictive power confirmed. It is anticipated that this QSAR will assist in the design 
of future potent inhibitors.
EMATE 35 43
IC50 = 18 nM IC5Q = 1 nM IC5Q = 1 nM
Figure 3.44 Structure and IC 5 0  values for EM ATE and D -ring modified STS inhibitors (IC 5 0  values 
determ ined in placental microsomes).
In vivo evaluation of 35 and 43 confirmed their potential as future drug candidates. 
Both compounds were found to inhibit rat liver sulfatase activity by 99% when 
treated orally at a dose of 1 0  mg/kg, while being devoid of estrogenic activity. 
Further investigations need to be carried out to determine in particular whether such 
compounds inhibit the enzyme in an irreversible manner.
The design of 17p-HSD type 1 inhibitors faced the difficulty that relatively few 
potent compounds have been reported and consequently no pharmacophore was 
identified, despite the resolution of the crystal structure of this enzyme nearly 1 0  
years ago. The existence of several isotypes has added a level of complexity to the 
work on inhibition since selectivity of drug action has to be achieved when targeting 
17p-HSDs. The logical approach to the development of inhibitors was therefore to 
carry out substrate-based design.
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In a limited study on mechanism-based inhibitors of 17|3-HSD type 1, we aimed to 
identify new E2 derivatives that would behave as potential substrates for the enzyme 
and be converted in situ to affinity alkylators. In vitro testing of the resulting 16- 
alkylidene compounds led to inconclusive results and their full potential is expected 
to be assessed after optimisation of the biological assay. Unexpectedly, 16- 
ethoxymethyl-estrone ( 6 4 ,  Figure 3.45) emerged from these studies as a highly 
potent inhibitor. Molecular modelling investigations on 16-methylene-estrone, a 
known enzyme-generated inhibitor provided interesting insight into the mechanism 
of inhibition. A cysteine residue (Cysl85) of the active site was proposed as the 





IC50 = 460 nM IC50 = 320 nM IC50 = 530nM
Figure 3.45 Structure and IC 5 0  values for 17p-HSD type 1 inhibitors (IC 5 0  values determ ined in T- 
47D  cells except for 1.18, in hum an placental cytosol).
Despite the lack of a pharmacophore for 17p-HSD type 1 inhibition, the D-ring of 
E 1 /E2  proved to be a crucial location for the introduction of functionalities able to 
block enzymatic activity. Most of the potent 17P-HSD type 1 inhibitors reported are 
C16 or C17 modified E1/E2 derivatives, 16oc-bromobutyl-estradiol ( 1 . 1 8 ,  Figure 
3.45) being among the most active. Further to the identification of the synthetic 
intermediates 16-oximino- and 16-hydroxymethylene-estrone ( 1  and 9 7 )  as potent 
inhibitors of 17p-HSD type 1 (respective IC5 0S of 1.10 pM and 0.11 pM in T-47D 
cells), a series of D-ring fused heterocyclic derivatives of E l were synthesised as 
putative bioisosteres. To probe the active site in several directions, a 16,17-fused 
pyrazole derivative of E l was functionalised at the 1', 2' and 5' position and the 
synthetic routes developed efficiently afforded the final compounds via common 
intermediates. A-Alkylation of the pyrazole nucleus yielded isomers which were 
separated and their regiochemistry unambiguously assigned. In vitro evaluation 
afforded an SAR in which the 1'-alkylated (vs. 2'-alkylated) compounds were more
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potent. Substituents able to make polar interactions were preferred and the N- 
methoxyethyl analogue 8 8  (Figure 3.45) emerged as a promising compound, being 
also devoid of estrogenic activity in vitro.
Investigations aimed to identify other positions of the steroidal nucleus (E1/E2) 
available for functionalisation were not entirely successful. SAR studies in a series of 
keto/oximino derivatives of El at the 6 , 16, 17 or a combination of these positions 
provided interesting results, however no synergy was observed when substituents 
were combined suggesting that they might be involved in mutually exclusive 
interactions at the active site. In vitro activity of 6 -oxo-estrone 120 (IC50 = 340 nM) 
confirmed the potential of the 6 -position for the introduction of a small polar moiety, 
as suggested by the identification of Ser222 in the vicinity of the B-ring in an 
enzyme-E2 complex. Structural modifications need to be implemented to overcome 
the estrogenicity of some of these derivatives.
Building on our investigations in the field of steroidogenic enzymes inhibition, a 
preliminary study focused upon the design of dual inhibitors of STS and 17p-HSD 
type 1 was initiated. Introduction of the pharmacophore for STS inhibition in potent 
17p-HSD type 1 inhibitors proved easy and the validity of this approach needs to be 
further assessed.
A useful template for the design of potent STS inhibitors was proposed and two 
highly active non estrogenic derivatives with in vivo activity emerged from these 
studies. Several new lead structures have been identified for 17p-HSD type 1 
inhibition and it is expected that their optimisation might result in potential drug 
candidates. These investigations should contribute to further the development of 






All chemicals were either purchased from Aldrich Chemical Co. (Gillingham, UK) 
or Lancaster Synthesis (Morecambe, U.K.). All organic solvents of A. R. grade were 
supplied by Fisher Scientific (Loughborough, U.K.). Anhydrous N,N- 
dimethylformamide (DMF) and A,7V-dimethylacetamide (DMA), used for N- 
alkylations and sulfamoylation reactions, were purchased from Aldrich and were 
stored under an atmosphere N2 after use. Sulfamoyl chloride was prepared by an 
adaptation of the method of Appel and Berger and was stored at 5°C under an
9 fifiatmosphere N2 as a solution in toluene as described by Woo et al. An appropriate 
volume of this solution was freshly concentrated under reduced pressure immediately 
before use.
E l was purchased from Sequoia Research Products (Oxford, UK). E1S and NADPH 
(tetrasodium salt) were supplied by Sigma Chemical Co. (Poole, UK). Radiolabelled 
El and E2 (3H and 14C) as well as 3H-E1S were purchased from New England 
Nuclear (Boston, USA) or Amersham Biosciences UK Limited (Amersham, U.K.).
Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC 
aluminium sheets silica gel 60 F 254) . Product(s) and starting material(s) were detected 
by either viewing under UV light and/or treating with an ethanolic solution of 
phosphomolybdic acid followed by heating. Flash column chromatography was 
performed on silica gel (Sorbsil/Matrex C60); for compounds 78 and 79, 
Flashmaster™ was used with prepacked columns of 10 g. IR spectra were recorded 
on a Perkin-Elmer Spectrum RXI FT-IR as KBr discs and peak positions are 
expressed in cm'1. *H NMR and DEPT-edited 13C NMR spectra were recorded with a 
JMN-GX 400 NMR spectrometer at 400 and 100 MHz respectively, and chemical 
shifts are reported in parts per million (ppm, 8) relative to tetramethylsilane (TMS) 
as an internal standard. The following abbreviations are used to describe resonances 
in !H NMR and 13C NMR spectra: br, broad; s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; dd, doublet of doublet etc. Chemical shifts for AB systems 
were approximated by taking the middle of each doublet and the corresponding 
coupling constant labelled J a b  or Jba-  HPLC analyses were performed on a Waters
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Millenium 32 instrument equipped with a Waters 996 PDA detector. A Waters 
Radialpack C l 8 , 8x100 mm column was eluted with a MeOH/tkO gradient at 2 
mL/min. Preparative HPLC was performed on a Waters Nova-Pak C l 8 , 25x100 mm 
column eluted with a MeOH/KbO gradient at 20 mL/min. Mass spectra were 
recorded at the Mass Spectrometry Service Center, University of Bath. FAB-MS 
were carried out using m-nitrobenzyl alcohol (NBA) as the matrix. Elemental 
analyses were performed by the Microanalysis Service, University of Bath. Melting 
points were determined using a Reichert-Jung Thermo Galen Kofler block and are 
uncorrected. The X-ray crystallographic studies of 35, 62, 64 and 84 were carried out 
by Dr. M. F. Mahon in the Department of Chemistry, University of Bath, on a kappa 
CCD diffractometer with area detector.
Molecular modelling was performed in collaboration with Mr. J.J. Robinson on a 
Silicon Graphics Octane 2. The molecular operating environment (MOE) from the 
Chemical Computing Group Inc. was used for model building and QSAR 
determination. The three dimensional molecular viewer ViewerLite 5.0 from 
Accelrys Inc. or MOE were used to construct diagrams. Docking studies and scoring 
were performed using Gold® v2.1.
5.2 Biological assays
In vitro estrogenicity assays were performed at the Cancer Research UK Oncology 
Unit, Southampton General Hospital, Southampton by Drs. L. Wood and G. 
Packham. Metabolic studies were carried out at the Magdalen Centre, Oxford 
Science Park, Oxford in collaboration with Dr. D.J. McCormick. All other assays 
were performed at the Department of Endocrinology and Metabolic Medicine, 
Imperial College School of Medicine, St. Mary’s Hospital, London by and in 
collaboration with Dr. A. Purohit and Prof. M. J. Reed.
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5.2.1 In vitro assays
Inhibition o f STS activity
STS inhibition was assessed as described previously. 88 Placental microsomes 
(100000 g fraction) were incubated with 3H-E1S adjusted to a final concentration of 
20 pM with unlabeled substrate, in the absence or presence of the inhibitor (0.1 nM-
1.0 pM). Product formed was isolated from the mixture by extraction with toluene (4 
mL), using 14C-E1 to monitor procedural losses. The mass of 3H-E1 produced was 
calculated from the 3H counts detected and recovery of 14C-E1.
Inhibition o f 17f-HSD type 1 activity
T47-D human breast cancer cells were incubated with 3H-E1 at a concentration of 5 
pmol per flask, in the absence or presence of the inhibitor (0.1 nM-lpM). After 
incubation of the substrate ± inhibitor for 30 minutes at 37°C, the products were 
isolated from the mixture by extraction with Et2< 3 (4 mL), using 14C-E2 to monitor 
procedural losses. Separation of 3H-E2 from the mixture was achieved using 
preparative TLC (DCM/EtOAc, 4:1) and the mass of 3H-E2 produced was calculated 
from the 3H counts detected and recovery of 14C-E2.
Reversibility assay
T-47D cells were pretreated with 10 pM or 20 pM of the inhibitor at 37°C overnight. 
The flasks were either washed (5 times) with assay medium or had their assay 
medium removed. Each group of flasks (washed and not washed) were then treated 
with either 3H-E1 or 3H-E1 and the inhibitor (10 pM or 20 pM), incubated for 30 
minutes at 37°C and processed as normal.
Inhibition o f 17/3-HSD type 2 activity
MDA-MB-231 human breast cancer cells were incubated with 3H-E2 at a 
concentration of 5 pmol per flask, in the absence or presence of the inhibitor (0.1 
nM-lpM). After incubation of the substrate ± inhibitor for 30 minutes at 37°C, the 
products were isolated from the mixture by extraction with Et2 0  (4 mL), using 14C- 
E1 to monitor procedural losses. Separation of 3H-E1 from the mixture was achieved
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using preparative TLC (DCM/EtOAc, 4:1) and the mass of 3H-E1 produced was 
calculated from the 3H counts detected and recovery of 14C-E1.
Inhibition o f cell growth
This was assessed as described previously. 94 MCF-7 human breast cancer cells (5000 
per well) were incubated in the absence or presence of the test compound (1 nM to 
100 JiM) for 4 days. The effect on cell growth was determined using a Cell Titer 96 
proliferation assay. This assay uses a tetrazolium dye to measure the number of 
metabolically active cells.
Estrogenicity and anti-estrogenicity assay
A luciferase reporter gene assay was used to measure the effect of ER binding 
compounds on gene expression through the activation of ERE. MCF-7 cells (ER 
positive) were transfected with a pERET811uc reporter construct. After 24 hours, the 
cells were exposed to either the candidate estrogen compound (for estrogenicity 
measurement) or the candidate estrogen compound and E2 (for anti-estrogenicity 
measurement). After a further 24 hours, the cells were assayed for luciferase activity 
using a bioluminescence assay. To control for transfection efficiency, cells were 
cotransfected with a control reporter construct containing the P-gal gene, and p- 
galactosidase activity was measured using a colorimetric assay.
Metabolic studies
Hepatic microsomes (47 |iL of a 20 mg/mL sample) were incubated with the test 
compound (final concentration 18 J iM ) for 10 minutes at 37°C. An aliquot, 
corresponding to time 0  was taken and added to an internal standard before addition 
of NADPH (0.1 mL of a 3.6 mg/mL standard solution). Samples were then taken at 
times 10, 30 and 60 minutes and added to the internal standard. Analysis of the 
samples was performed by HPLC. Peak area ratio was determined for the test 
compound and the internal standard, and the ratio (test compound/internal standard) 
was calculated for each time point. The data were used to calculate the half life (ti/2) 
and clearance (Cl) for each compound.
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5.2.2 In vivo studies
Ovariectomised female Wistar rats (200 g) were obtained from Charles River (Kent, 
UK) and kept under conditions meeting institutional requirement with free access to 
food and water. Groups of rats, with 3 rats in each group, were treated with EMATE 
(50 jag /kg, s.c.) or 35 or 43 (10 mg/kg, p.o.) once daily for a 5-day period. Control 
groups of rats were given vehicle (propylene glycol, 200 |iL, p.o.-).
Uterotrophic estrogenicity study
Animals were killed using an approved procedure 24 hours after administration of 
the last dose of compound, and uteri were excised of fat and weighed. Total body 
weights of the rats were also recorded, and the results were expressed as uterine 
weightx 1 0 0 /total body weight.
Inhibition o f STS activity
Samples of liver tissue obtained from animals 24 hours after administration of the 
last dose of the drug, were immediately frozen on solid carbon-dioxide and stored at 
-20°C until assay.89 After homogenisation and centrifugation, aliquots of the 
resulting tissue supernatants were incubated with 3H-E1S adjusted to a final 
concentration of 20 pM with unlabelled ElS, for 1 hour at 37°C. Product formed was 
isolated from the mixture by extraction with toluene (4 mL), using 14C-E1 to monitor 
procedural losses. The mass of 3H-E1 produced was calculated from the 3H counts 
detected and recovery of 14C-E1. The protein concentration in supernatants was 
measured by the method of Bradford.
Statistics
The significance of differences in uterine weight and steroid sulfatase activity in 
tissues from control and treated animals was assessed using Student’s t test.
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5.3 General synthetic procedures
5.3.1 Preparation of sulfamoyl chloride
Freshly distilled formic acid ( 6  mL, 150 mmol) was added dropwise to a stirred 
solution of chlorosulfonyl isocyanate (25 g, 150 mmol) in freshly distilled toluene 
(150 mL) at 0°C under an atmosphere of N2 . The resulting white suspension was 
stirred overnight at room temperature and concentrated under reduced pressure to 
give a light brown crude of sulfamoyl chloride. The product was dissolved in freshly 
distilled toluene (150 mL) and filtered under an atmosphere of N2 using a cannula 
into a 250 mL volumetric flask. The volume of toluene was then completed to 250 
mL, giving a standard solution (ca. 0.70 M) of sulfamoyl chloride which was stored 
in the fridge under N2 .
5.3.2 Method 1. Synthesis of alkylated derivatives 6-16 and 30
NaH (60% dispersion in mineral oil, 1.2 eq.) was added to a stirred solution of 5 in 
anhydrous DMF (15 mL) at 0°C under an atmosphere of N2 . After 20 minutes of 
stirring, the parent alkylating agent ( 2  eq.) was added and the resulting mixture was 
stirred at room temperature. The reaction was monitored by TLC and quenched with 
H2O (50 mL) at completion. The organics were extracted with EtOAc (2x50 mL), 
washed with brine (4x25 mL), dried (MgS0 4 ), filtered and concentrated under 
reduced pressure. The crude product was purified by flash chromatography.
5.3.3 Method 2. Hydrogenolysis
A suspension of Pd-C 10% (ca. 50% w/w of substrate used) in THF (2 mL) was 
added to a solution of the starting material in MeOH/THF. The resulting suspension 
was hydrogenated at room temperature using a hydrogen-filled balloon until TLC 
indicated completion. After removal of the supported catalyst by filtration through 
celite and concentration of the filtrate under reduced pressure, the product obtained 
was purified by flash chromatography and/or recrystallised.
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1715.3.4 Method 3. Sulfamoylation according to Okada et ah
Anhydrous DMA was added to a freshly concentrated solution of sulfamoyl chloride 
(2.2 eq.) cooled to 0°C under an atmosphere of N2 . The phenolic substrate was then 
added and the resulting mixture was stirred at room temperature until TLC indicated 
completion. The mixture was then poured into cold brine (15 mL), and the organics 
were extracted with EtOAc (2x20 mL), washed with brine (5x20 mL), dried 
(MgSC>4), filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography and/or recrystallised.
5.3.5 Method 4. Preparation of the sulfamates 39 ,43,51  and 60
NaH (60% dispersion in mineral oil, 1.2 eq.) was added to a stirred solution of the 
phenolic substrate in anhydrous DMF at 0°C under an atmosphere of N2 . After 15 
minutes, sulfamoyl chloride ( 6  eq.) was added and the resulting mixture was stirred 
at room temperature until TLC indicated completion. The mixture was then poured 
into brine (20 mL), and the organics were extracted with EtOAc (2x20 mL), washed 
with H2O (2x20 mL), brine (2x20 mL), dried (MgSC^), filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography 
and/or recrystallised.
5.3.6. Method 5. Synthesis of alkylated derivatives 74-81
NaH (60% dispersion in mineral oil, 1.5 eq.) was added to a stirred solution of 73 in 
anhydrous DMF at 0°C under an atmosphere of N2 . After 20 minutes of stirring, the 
parent alkylating agent ( 2  eq.) was added and the resulting mixture was stirred at 
room temperature. The reaction was monitored by TLC and quenched with H2O (50 
mL) at completion. The organics were extracted with EtOAc (2x50 mL), washed 
with H2O (2x30 mL), brine (2x30 mL), dried (Na2S0 4 ), filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography.
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5.4 Synthesis
5.4.1 D-ring modified derivatives of EMATE and precursors 
16-Oximino-estrone (1)
E l (200 mg, 740 pmol) was added to a stirred solution of fBuOK, freshly prepared by 
dissolving potassium metal (80 mg, 2.05 mmol) in 2 mL terr-butanol, under an 
atmosphere of N2 . The reaction mixture was stirred for 1 hour at room temperature 
before dropwise addition of isoamyl nitrite (180 |nL, 1.34 mmol). The resulting deep 
red mixture was stirred overnight, then poured into H2O (20 mL). The organics were 
extracted with Et2 0  (2x20 mL) and the aqueous layer was acidified with AcOH 
glacial (10 mL) to give a light yellow precipitate. After standing for 2 hours, the solid 
was isolated by filtration to give 1 as a yellow powder (140 mg, 63%). For analysis, a 
sample was recrystallised from acetone to give white crystals: mp 223-225°C [lit. 160 
(MeOH) 218-220°C]; IR (KBr) 3385 (NOH), 2920-2860 (aliph CH), 1735 (C=0), 
1605-1500 (arom C=C) cm'1; 5r (DMSO-cL, 400 MHz) 0.89 (3H, s, C -I8 -H3), 1.30- 
2.85 (11H, m), 2.70-2.81 (2H, m, C-6 -H2), 6.46 (1H, d, J=  2.3 Hz, C-4-H), 6.52 (1H, 
dd, J = 8.3 Hz, J  = 2.3 Hz, C-2-H), 7.05 (1H, d, /  = 8.3 Hz, C-l-H), 9.05 (1H, s, 
exchanged with D2O, OH) and 12.39 (1H, s, exchanged with D2O, NOH); 8 c 
(DMSO-d6, 100.4 MHz) 14.1 (q, C-18), 25.1 (t), 25.5 (t), 26.2 (t), 29.0 (t), 30.9 (t),
37.2 (d), 43.2 (d), 44.6 (d), 48.5 (s, C-13), 112.7 (d), 114.8 (d), 125.8 (d), 129.6 (s),
136.9 (s), 154.8 (s, C-3 or C-16), 155.2 (s, C-3 or C-16) and 204.6 (s, C=0); MS m/z 
(FAB+) 453.2 [30, (M+H+NBA)+], 300.1 [100, (M+H)+]; MS m/z (FAB-) 451.3 [38, 
(M-H+NBA)'], 298.2 [100, (M-H)']; Acc MS m/z (FAB+) 300.1596, Ci8H2 2N0 3 
requires 300.1600. Found: C, 71.30; H, 7.08; N, 4.35. Ci8H2 iN0 3 .(Ac0 H)i/6 
requires: C, 71.17; H, 7.06; N, 4.53%.
3-Acetoxy-16,17-sm?-estra-l,3,5(10)-triene-16,17-imide (2)
A suspension of 1 (150 mg, 501 pmol) in a mixture of 4.5 mL of AcOH glacial and
7.5 mL of acetic anhydride was heated to reflux under an atmosphere of N2 for 20 
hours. The solvent mixture was then removed under reduced pressure and H20  (20 
mL) added. After cautious addition of 10% aq. NaOH (2-3 drops), the organics were
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extracted with EtOAc (2x20 mL), washed with H2O (2x15 mL), brine (2x15 mL), 
dried (MgS0 4 ), filtered and concentrated under reduced pressure. The crude product 
was purified by flash chromatography (CHCI3) to give 2 as a light yellow solid (97 
mg, 57%): mp 189-193°C [lit. 160 (acetone) 196-198°C]; JR (KBr) 3205 (NH), 2940- 
2860 (aliph CH), 1760, 1725, 1690 (C=0), 1610-1495 (arom C=C) c m 1; 5H (DMSO- 
d6, 400 MHz) 1.11 (3H, s, C -I8 -H3), 1.20-2.72 (11H, m), 2.77-2.84 (2H, m, C-6 -H2), 
2.23 (3H, s, COCH3), 6.81 (1H, d, J  = 2.6 Hz, C-4-H), 6.87 (1H, dd, J  = 8.3 Hz, J =
2.6 Hz, C-2-H), 7.32 (1H, d, /  = 8.3 Hz, C-l-H) and 10.64 (1H, s, exchanged with 
D2 0 , NH); 5C (DMSO-d6 , 100.4 MHz) 16.0 (q, C-18), 20.7 (q, COCH3), 24.8 (t),
24.9 (t), 28.8 (t), 32.2 (t), 32.5 (t), 37.3 (d), -39 (s, under solvent peaks), 40.3 (d),
41.9 (d), 118.6 (d), 120.9 (d), 125.9 (d), 136.5 (s), 137.1 (s), 147.9 (s, C-3), 168.8 (s, 
COCH3), 171.9 (s, C=0) and 178.7 (s, C=0); MS m/z (FAB+) 342.1 [100, (M+H)+],
299.1 [40, (M+H-Ac)+]; MS m/z (FAB-) 493.2 [34, (M-H+NBA)'], 340.1 [100, (M- 
H)']; Acc MS m/z (FAB+) 342.1705, C20H24NO4  requires 342.1705.
3-Benzyloxy-estra-l,3,5(10)-triene-17-one (3)
NaH (60% dispersion in mineral oil, 0.68 g, 20.34 mmol) was added to a stirred 
solution of E l (5.0 g, 18.49 mmol) in anhydrous DMF (50 mL), at 0°C under an 
atmosphere of N2 and the resulting suspension was stirred for 1 hour. Benzyl 
bromide (2.42 mL, 20.34 mmol) was then added and the mixture was heated at 80°C 
for 4 hours. The reaction mixture was poured into ice/H2 0  and the organics extracted 
with EtOAc (150 mL), washed with H20  (4x50 mL), dried (MgS0 4 ), filtered and 
concentrated under reduced pressure. The pale yellow crude product was 
recrystallised from IPA to give 3 as white flaky crystals (4.73 g, 71%): mp 129- 
131°C [lit. 167 126-127°C]; IR (KBr) 3100 (arom CH), 2950-2840 (aliph CH), 1730 
(C=0), 1600, 1500 (arom C=C) c m 1; 5h (CDC13, 400 MHz) 0.91 (3H, s, C -I8 -H3 ), 
1.41-2.54 (13H, m), 2.86-2.93 (2H, m, C-6 -H2), 5.04 (2H, s, OCH2Ar), 6.73 (1H, d, J  
= 2.5 Hz, C-4-H), 6.80 (1H, dd, /  = 8 . 6  Hz, J  = 2.5 Hz, C-2-H), 7.20 (1H, d, J  = 8 . 6  
Hz, C-l-H) and 7.30-7.44 (5H, m, C6H5).
3-Benzyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-dioic acid (4)
A solution of iodine (7.6 g, 29.9 mmol) in MeOH (95 mL) and a solution of KOH 
(13.7 g, 245 mmol) in H2Q (25 mL) and MeOH (60 mL) were added dropwise and
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alternately to a stirred solution of 3 (3.8 g, 10.5 mmol) in MeOH (1 L), at room 
temperature, so that the colour of the mix remains orange/brown. The addition was 
carried out over 45 minutes and the resulting light yellow solution was stirred 
overnight, after which it was concentrated under reduced pressure and poured into 
H2O (800 mL). After acidification with 5M HC1, the organics were extracted with 
Et2 0  (600 mL), washed with aq. Na2S2 0 3  (4x100 mL), H2O (4x100 mL), dried 
(MgSCLO, filtered and concentrated under reduced pressure. The resulting yellow 
foam (4.54 g) was then dissolved in a solution of KOH (7.6 g, 136 mmol) in 
MeOH/H2 0  (1:2, 228 mL) and heated to reflux for 4 hours. The resulting orange 
solution was poured into H2O (800 mL), acidified with 5M HC1, and the organics 
extracted with EtOAc (300 mL). After washing with brine (4x200 mL), the organic 
layer was dried (MgS0 4 ), filtered and concentrated under reduced pressure to give a 
yellow residue (4.32 g). The crude product was recrystallised from CHCL/Hexane 
(5:3) to give 4 as an off-white powder (3.25 g, 75%): mp 212-215°C [lit. 166 (aq. 
MeOH) 226-227°C]; IR (KBr) 3050-2650 (br, C 0 2H, arom CH and aliph CH), 1700 
(C=0), 1600-1500 (arom C=C) cm'1; 8 H (DMSO-cL, 400 MHz) 1.02 (3H, s, C-18- 
H3), 1.20-2.78 (11H, m), 2.72-2.76 (2H, m, C-6 -H2), 5.05 (2H, s, OCH2Ar), 6 . 6 8  
(1H, d, J = 2.5 Hz, C-4-H), 6.75 (1H, dd, J = 8.7 Hz, J = 2.5 Hz, C-2-H), 7.18 (1H, d, 
J = 8.7 Hz, C-l-H), 7.30-7.42 (5H, m, C6H5) and 12.14 (2H, s, exchanged with D20 , 
C 0 2H); 8 c (DMSO-cL, 100.4 MHz) 15.4 (q, C-18), 25.8 (t), 26.5 (t), 29.7 (t), 35.8 (t),
36.1 (t), 40.7 (d), 41.8 (d), 42.5 (d), 46.2 (s, C-13), 68.9 (t, OCH2Ar), 112.3 (d),
114.0 (d), 126.3 (d), 127.3 (2xd), 127.5 (d), 128.2 (2xd), 131.6 (s), 137.2 (2xs),
156.0 (s, C-3), 173.9 (s, C 0 2H) and 178.6 (s, C 0 2H); MS m/z (FAB+) 408.2 [41, 
M+], 91.1 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 408.1940, C25H280 5  requires 
408.1937.
3-Benzyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (5 )
Urea (3.25 g, 54.11 mmol) and 4 (3.25 g, 7.96 mmol) and were heated at 180°C 
under an atmosphere of N2 for 45 minutes. The resulting brown residue was crushed 
and acetone was added (200 mL) to give a brown suspension. This mixture was 
concentrated to ca. 100 mL, silica gel was added and the solvent was removed under 
reduced pressure to give an homogeneous light brown powder which was transferred 
onto a wet packed (CHCI3) flash chromatography column. Elution with
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CHC^/acetone (96:4) gave 5 as a white residue (2.75 g, 89%). An analytical sample 
was recrystallised from EtOH to give colourless needles: mp 225-226°C; JR (KBr) 
3260 (NH), 2900-2870 (aliph CH), 1720 (C=0), 1700 (C=0), 1600-1500 (arom 
C=C) cm'1; 5h (DMSO-do, 400 MHz) 1.09 (3H, s, C-I8 -H3), 1.20-2.72 (11H, m), 
2.76-2.80 (2H, m, C-6 -H2), 5.05 (2H, s, OCH2Ar), 6.72 (1H, d, /  = 2.5 Hz, C-4-H), 
6.76 (1H, dd, J=  8.7 Hz, / =  2.5 Hz, C-2-H), 7.19 (1H, d, / =  8.7 Hz, C-l-H), 7.31- 
7.44 (5H, m, C6H5) and 10.63 (1H, s, exchanged with D20 , NH); 5C (DMSO-d6 ,
100.4 MHz) 16.2 (q, C-18), 25.1 (t), 25.2 (t), 29.2 (t), 32.4 (t), 32.7 (t), 37.8 (d), 40.3 
(d), 40.5 (s), 41.9 (d), 68.9 (t, OCH2Ar), 112.2 (d), 114.1 (d), 126.0 (d), 127.3 (2xd),
127.4 (d), 128.2 (2xd), 131.5 (s), 137.0 (s), 137.1 (s), 156.0 (s, C-3), 172.1 (s, C=0) 
and 178.9 (s, C=0); MS m/z (FAB+) 390.2 [58, (M+H)+], 91.1 [100, (CH2Ar)+]; Acc 
MS m/z (FAB+) 390.2059, C2 5H28N 0 3 requires 390.2069. Found: C, 76.90; H, 6.99; 
N, 3.73. C2 5H27N0 3  requires: C, 77.09; H, 6.99; N, 3.60%.
3-Benzyloxy-iV-methyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (6 )
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with methyl iodide (160 p.L, 2.57 mmol) was 
complete within 45 minutes. The crude product was purified by flash 
chromatography (CHCI3) to give 6  as a white residue (432 mg, 83%). An analytical 
sample was recrystallised from EtOH to give colourless crystals: mp 118-121°C; ER 
(KBr) 3160-3060 (arom CH), 2920-2870 (aliph CH), 1720 (C=0), 1670 (C=0), 
1600-1500 (arom C=C) cm'1; 5H (CDC13, 400 MHz) 1.17 (3H, s, C -I8 -H3), 1.26-3.00 
(11H, m), 2.86-2.91 (2H, m, C-6 -H2), 3.15 (3H, s, N-CH3), 5.04 (2H, s, OCH2Ar), 
6.72 (1H, d, /  = 2.7 Hz, C-4-H), 6.80 (1H, dd, J  = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.21 
(1H, d, J  = 8 . 6  Hz, C-l-H) and 7.32-7.45 (5H, m, C6H5); 6 C (CDCI3 , 100.4 MHz)
16.6 (q, C-18), 25.6 (t), 25.8 (t), 27.0 (q, C-l'), 29.7 (t), 33.5 (t), 33.8 (t), 38.5 (d),
40.4 (d), 41.5 (s, C-13), 42.6 (d), 69.9 (t, OCH2Ar), 112.6 (d), 114.5 (d), 126.1 (d),
126.3 (2xd), 127.7 (d), 128.4 (2xd), 131.5 (s), 137.0 (s), 137.2 (s), 156.8 (s, C-3),
171.8 (s, C=0) and 178.7 (s, C=0); MS m/z (FAB+) 404.4 [79, (M+H)+], 91.1 [100, 
(CH2Ar)+]; Acc MS m/z (FAB+) 404.2217, C26H3oN0 3  requires 404.2226. Found: C, 
77.30; H, 7.22; N, 3.48. C26H29N0 3  requires: C, 77.39; H, 7.24; N, 3.47%.
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3-Benzyloxy-Af-ethyl-16,17-sec0-estra-l,3,5(lO)-triene-16,l'7-imide (7)
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with ethyl iodide (205 |iL, 2.57 mmol) was 
complete within 1 hour. The crude product was purified by flash chromatography 
(CHCI3) to give 7 as a white residue (502 mg, 94%): mp 93-95°C; IR (KBr) 2975- 
2865 (aliph CH), 1715 (C=0), 1665 (C=0), 1605-1500 (arom C=C) cm'1; ^  
(CDCI3 , 400 MHz) 1.11 (3H, t ,J =  1 2  Hz, C-2'-H3), 1.16 (3H, s, C -I8 -H3), 1.31-
2.98 (11H, m), 2.85-2.90 (2H, m, C-6 -H2), 3.81 (2H, m, N-CH2), 5.04 (2H, s, 
OCH2 Ar), 6.72 (1H, d, J = 2.7 Hz, C-4-H), 6.81 (1H, dd, J=  8 . 6  Hz, J=  2.7 Hz, C-2- 
H), 7.22 (1H, d,J =  8 . 6  Hz, C-l-H) and 7.30-7.44 (5H, m, C6H5); 6 C (CDC13, 100.4 
MHz) 13.1 (q, C-2'), 16.4 (q, C-18), 25.5 (t), 25.7 (t), 29.6 (t), 33.5 (t), 33.6 (t), 35.0 
(t, C-l'), 38.5 (d), 40.2 (d), 41.3 (s, C-13), 42.4 (d), 69.8 (t, OCH2Ar), 112.4 (d),
114.4 (d), 126.0 (d), 127.1 (2xd), 127.6 (d), 128.3 (2xd), 131.4 (s), 136.9 (s), 137.0 
(s), 156.7 (s, C-3), 171.1 (s, C=0) and 178.0 (s, C=0); MS m/z (FAB+) 418.3 [90, 
(M+H)+], 91.0 [100, (CH2Ar)+]; A cc MS m/z (FAB+) 417.2306, C2 7H3 iN 0 3 requires 
417.2304.
3-Benzyloxy-iV-propyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (8 )
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with propyl iodide (250 (iL, 2.57 mmol) was 
complete within 2 hours. The crude product was purified by flash chromatography 
(CHCI3) to give 8  as a white residue (524 mg, 94%). An analytical sample was 
recrystallised from EtOH to give white crystals: mp 95-98°C; IR (KBr) 3035 (arom 
CH), 2960-2870 (aliph CH), 1720 (C=0), 1660 (C=0), 1610-1500 (arom C=C) cm'1; 
5h (CDCI3 , 400 MHz) 0.89 (3H, t, J  = 7.6 Hz, C-3'-H3), 1.16 (3H, s, C -I8 -H3), 1.32-
2.98 (13H, m), 2.83-2.88 (2H, m, C-6 -H2), 3.64-3.80 (2H, m, N-CH2), 5.03 (2H, s, 
OCH2Ar), 6.72 (1H, d ,J=  2.7 Hz, C-4-H), 6.80 (1H, dd, J = 8 . 6  Hz, J = 2.7 Hz, C-2- 
H), 7.21 (1H, d, J  = 8 . 6  Hz, C-l-H) and 7.30-7.44 (5H, m, C6H5); 6 C (CDC13, 100.4 
MHz) 11.4 (q, C-3'), 16.6 (q, C-18), 21.3 (t), 25.6 (t), 25.8 (t), 29.8 (t), 33.7 (t), 33.8 
(t), 38.7 (d), 40.4 (d), 41.5 (s, C-13), 41.6 (t, C-l'), 42.5 (d), 70.0 (t, OCH2Ar), 112.6 
(d), 114.5 (d), 126.1 (d), 127.3 (2xd), 127.8 (d), 128.4 (2xd), 131.5 (s), 137.0 (s),
137.2 (s), 156.8 (s, C-3), 171.5 (s, C=0) and 178.4 (s, C=0); MS m/z (FAB+) 432.4 
[8 8 , (M+H)+], 91.1 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 432.2522, C28H34N0 3
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requires 432.2539. Found: C, 77.60; H, 7.68; N, 3.26. C2 8 H3 3NO3 requires: C, 77.93;
H, 7.71; N, 3.25%.
3-Benzyloxy-Ar-butyl-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (9)
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with bromobutane (276 jjJL, 2.57 mmol) was 
complete within 4 hours. The crude product was purified by flash chromatography 
(CHCI3) to give 9 as a white residue (513 mg, 90%). An analytical sample was 
recrystallised from EtOH to give white needles: mp 100-103°C; IR (KBr) 2960-2870 
(aliph CH), 1720 (C=0), 1665 (C=0), 1615-1500 (arom C=C) c m 1; 5h (CDC13, 400 
MHz) 0.92 (3H, t, 7 = 7.2 Hz, C-4'-H3), 1.16 (3H, s, C -I8 -H3), 1.28-2.99 (15H, m),
2.84-2.89 (2H, m, C-6 -H2), 3.75 (2H, m, N-CH2), 5.04 (2H, s, OCH2Ar), 6.72 (1H, d, 
7=  2.5 Hz, C-4-H), 6.81 (1H, dd, 7=  8 . 6  Hz, 7=  2.5 Hz, C-2-H), 7.22 (1H, d, 7=  8 . 6  
Hz, C-l-H) and 7.29-7.45 (5H, m, C6H5); 5C (CDC13, 100.4 MHz) 13.8 (q, C-4'),
16.5 (q, C-18), 20.1 (t), 25.5 (t), 25.7 (t), 29.6 (t), 30.0 (t), 33.5 (t), 33.7 (t), 38.5 (d),
39.7 (t, C-l'), 40.2 (d), 41.3 (s, C-13), 42.4 (d), 69.8 (t, OCH2Ar), 112.4 (d), 114.4 
(d), 126.0 (d), 127.1 (2xd), 127.6 (d), 128.3 (2xd), 131.4 (s), 136.9 (s), 137.0 (s),
156.7 (s, C-3), 171.3 (s, C=0) and 178.2 (s, C=0); MS m/z (FAB+) 446.3 [97, 
(M+H)+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 446.2691, C29H36N03 requires 
446.2695. Found: C, 77.80; H, 7.89; N, 3.13. C29H35N0 3 requires: C, 78.17; H, 7.92; 
N, 3.14%.
3-Benzyloxy-Af-pentyl-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (10)
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with pentyl bromide (318 jiL, 2.57 mmol) was 
complete within 5 hours. The crude product was purified by flash chromatography 
(CHCI3) to give 10 as a white residue (550 mg, 93%). An analytical sample was 
recrystallised from EtOH to give colourless needles: mp 104-107°C; IR (KBr) 3100- 
3000 (arom CH), 2960-2870 (aliph CH), 1720 (C=0), 1660 (C=0), 1610-1500 (arom 
C=C) cm'1; 8 h (CDC13, 400 MHz) 0.89 (3H, t, 7 = 7.2 Hz, C-5'-H3), 1.16 (3H, s, C- 
I 8 -H3), 1.20-2.98 (17H, m), 2.83-2.89 (2H, m, C-6 -H2), 3.66-3.82 (2H, m, N-CH2),
5.03 (2H, s, OCH2Ar), 6.72 (1H, d, 7 = 2.7 Hz, C-4-H), 6.80 (1H, dd, 7 = 8 . 6  Hz, 7 =
2.7 Hz, C-2-H), 7.21 (1H, d, 7 = 8 . 6  Hz, C-l-H) and 7.30-7.44 (5H, m, C6H5); 5C
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(CDC13, 100.4 MHz) 14.1 (q, C-5'), 16.6 (q, C-18), 22.5 (t), 25.6 (t), 25.8 (t), 27.7 (t), 
29.2 (t), 29.7 (t), 33.7 (t), 33.8 (t), 38.7 (d), 40.1 (t, C-l'), 40.3 (d), 41.5 (s, C-13),
42.5 (d), 70.0 (t, O C H 2A r ) ,  112.5 (d), 114.5 (d), 126.1 (d), 127.3 (2xd), 127.8 (d),
128.4 (2xd), 131.5 ( s ) ,  137.0 ( s ) ,  137.2 ( s ) ,  156.8 ( s ,  C-3), 171.4 ( s ,  C=0) and 178.4 
( s ,  C=0); MS m/z (FAB+) 460.2 [78, (M+H)+], 91.1 [100, ( C H 2 A r ) + ] ;  Acc MS m/z 
(FAB+) 460.2845, C 3 0 H 3 8 N O 3  r e q u i r e s  460.2852. Found: C, 78.20; H, 8.08; N, 3.01. 
C 3 0 H 3 7 N O 3  r e q u i r e s :  C, 78.40; H, 8 . 1 1; N, 3.05%.
3-Benzyloxy-jV-hexyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (11)
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with hexyl bromide (360 pL, 2.57 mmol) was 
complete within 1.5 hours. The crude product was purified by flash chromatography 
(CHCI3) to give 11 as a white residue (575 mg, 94%). An analytical sample was 
recrystallised from EtOH to give white needles: mp 108-111°C; IR (KBr) 2960-2860 
(aliph CH), 1720 (C=0), 1665 (C=0), 1615-1500 (arom C=C) cm'1; 6 H (CDC13, 400 
MHz) 0.87 (3H, t, J  = 6 . 6  Hz, C-6 '-H3), 1.16 (3H, s, C -I8 -H3), 1.28-2.98 (19H, m),
2.84-2.89 (2H, m, C-6 -H2), 3.74 (2H, m, N-CH2), 5.04 (2H, s, OCH2Ar), 6.72 (1H, d, 
J = 2.7 Hz, C-4-H), 6.81 (1H, dd, J = 8 . 6  Hz, J = 2.7 Hz, C-2-H), 7.22 (1H, d, J = 8 . 6  
Hz, C-l-H) and 7.29-7.44 (5H, m, C6H5); 6 C (CDC13, 100.4 MHz) 14.1 (q, C-6 '),
16.6 (q, C-18), 22.6 (t), 25.6 (t), 25.8 (t), 26.7 (t), 28.0 (t), 29.8 (t), 31.6 (t), 33.7 (t),
33.8 (t), 38.7 (d), 40.1 (t, C-l'), 40.4 (d), 41.5 (s, C-13), 42.5 (d), 70.0 (t, OCH2Ar),
112.6 (d), 114.5 (d), 126.1 (d), 127.3 (2xd), 127.8 (d), 128.4 (2xd), 131.6 (s), 137.0 
(s), 137.2 (s), 156.8 (s, C-3), 171.4 (s, C=0) and 178.4 (s, C=0); MS m/z (FAB+)
474.3 [6 8 , (M+H)+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 474.2988, 
C31H40NO3 requires 474.3008. Found: C, 78.10; H, 8.16; N, 2.98. C31H39NO3 
requires: C, 78.61; H, 8.30; N, 2.96%.
3-Benzyloxy-iV-(4'-bromobiityI)-16,17-sm>-estra-l,3,5(10)-triene-16,17-imide
(12)
Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with 1,4-dibromobutane (310 jllL , 2.57 mmol) 
was complete within 1.5 hours. The crude product was purified by flash 
chromatography (CHCI3) to give 12 as a white residue (569 mg, 84%). An analytical
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sample was recrystallised from EtOH to give white crystals: mp 113-116°C; IR 
(KBr) 2935-2860 (aliph CH), 1720 (C=0), 1670 (C=0), 1605-1500 (arom C=C) cm' 
5h (CDC13, 400 MHz) 1.17 (3H, s, C -I8 -H3), 1.30-3.00 (15H, m), 2.84-2.90 (2H, 
m, C-6 -H2), 3.42 (2H, t, J  = 6 . 8  Hz, C-4'-H2), 3.79 (2H, m, N-CH2), 5.04 (2H, s, 
OCH2Ar), 6.72 (1H, d, J  = 2.7 Hz, C-4-H), 6.81 (1H, dd, J= 8 . 6  Hz, J  = 2.7 Hz, C-2- 
H), 7.21 (1H, d ,J  = 8 . 6  Hz, C-l-H) and 7.30-7.45 (5H, m, C6H5); 5C (CDC13, 100.4 
MHz) 17.0 (q, C-18), 25.9 (t), 26.1 (t), 27.1 (t), 30.1 (t), 30.5 (t), 33.5 (t), 33.9 (t),
34.1 (t), 39.0 (d), 39.3 (t, C-l'), 40.6 (d), 41.8 (s, C-13), 42.8 (d), 70.3 (t, OCH2Ar),
112.9 (d), 114.8 (d), 126.4 (d), 127.6 (2xd), 128.1 (d), 128.8 (2xd), 131.8 (s), 137.3 
(s), 137.5 (s), 157.1 (s, C-3), 171.8 (s, C=0) and 178.8 (s, C=0); MS m/z (FAB+)
524.1 [42, (M+H)+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 526.1759, 
C2 9H3 5 81BrN0 3 requires 526.1780 and 524.1738, C29H3 5BrN0 3 requires 524.1800. 




Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with bromomethyl-cyclopropane (246 jllL, 2.57 
mmol) was complete within 3 hours. The crude product was purified by flash 
chromatography (CHCI3) to give 13 as a white residue (536 mg, 94%). An analytical 
sample was recrystallised from EtOH to give white needles: mp 96-99°C; IR (KBr) 
2920-2860 (aliph CH), 1720 (C=0), 1670 (C=0), 1610-1495 (arom C=C) cm'1; 6 H 
(CDCI3 , 400 MHz) 0.29-0.34 (2H, m, C-3'-H2), 0.40-0.45 (2H, m, C-4'-H2), 1.15 
(1H, m, C-2'-H), 1.18 (3H, s, C -I8 -H3), 1.25-3.01 (11H, m), 2.85-2.90 (2H, m, C-6 - 
H2), 3.67 (2H, m, N-CH2), 5.04 (2H, s, OCH2Ar), 6.73 (1H, d, J = 2.5 Hz, C-4-H), 
6.81 (1H, dd, J = 8 . 6  Hz, J = 2.5 Hz, C-2-H), 7.22 (1H, d, J = 8 . 6  Hz, C-l-H) and
7.29-7.45 (5H, m, C6H5); 8 C (CDC13, 100.4 MHz) 3.9 (t, C-3'), 4.0 (t, C-4'), 10.5 (d, 
C-2'), 17.0 (q, C-18), 26.0 (t), 26.1 (t), 30.1 (t), 34.0 (t), 34.1 (t), 39.1 (d), 40.6 (d),
41.9 (s, C-13), 42.9 (d), 44.6 (t, C-l'), 70.3 (t, OCH2Ar), 112.9 (d), 114.9 (d), 126.4 
(d), 127.6 (2xd), 128.1 (d), 128.7 (2xd), 131.9 (s), 137.4 (s), 137.5 (s), 157.2 (s, C-3),
172.0 (s, C=0) and 179.0 (s, C=0); MS m/z (FAB+) 887.3 [58, (2M+H)+], 444.1 [98, 
(M+H)+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 444.2525, C29H34N0 3 requires
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Following method 1, 5 (500 mg, 1.28 mmol) was treated with NaH (62 mg, 1.54 
mmol) and the subsequent reaction with l-bromomethyl-4-te/t-butyl-benzene (472 
|iL, 2.57 mmol) was complete within 30 minutes. The crude product was purified by 
flash chromatography (CHCI3) to give 14 as a white residue (667 mg, 97%): mp 199- 
200°C; IR (KBr) 2965-2870 (aliph CH), 1720 (C=0), 1670 (C=0), 1605-1505 (arom 
C=C) cm"1; 8 h (CDC13, 400 MHz) 1.16 (3H, s, C -I8 -H3), 1.28 (9H, s, C(CH3)3),
1.30-3.01 (11H, m), 2.84-2.90 (2H, m, C-6 -H2), 4.88 (1H, d, JBa = 13.7 Hz, N- 
CHaCHe), 4.94 (1H, d, Jab = 14.1 Hz, N-CHACtfB), 5.03 (2H, s, OCH2Ar), 6.72 (1H, 
d ,J  = 2.7 Hz, C-4-H), 6.80 (1H, dd, J = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.21 (1H, d, J =
8 . 6  Hz, C-l-H) and 7.24-7.44 (9H, m, C6H5, C-2"-H, C-3"-H, C-5"-H and C-6 "- 
H); 6 C (CDCI3 , 100 .4 MHz) 16.6 (q, C-18), 25.6 (t), 25.8 (t), 29.7 (t), 31.4 (3 xq, 
C(CH3)3), 33.7 (t), 33.8 (t), 34.5 (s, C(CH3)3), 38.6 (d), 40.1 (d), 41.5 (s, C-13), 42.5 
(d), 42.9 (t, C-l'), 69.9 (t, OCH2Ar), 112.5 (d), 114.5 (d), 125.2 (2xd), 126.1 (d),
127.3 (2xd), 127.8 (d), 128.0 (2xd), 128.4 (2xd), 131.5 (s), 134.2 (s), 137.0 (s), 137.2 
(s), 149.9 (s), 156.8 (s, C-3), 171.4 (s, C=0) and 178.4 (s, C=0); MS m/z (FAB+)
1071.5 [32, (2M+H)+], 536.2 [80, (M+H)+], 91.0 [100, (CH2Ar)+]; MS m/z (FAB-)
534.3 [72, (M-H) ], 195.0 [100], 276.0 [100]; Acc MS m/z (FAB+) 536.3150, 
C36H4 2N0 3  requires 536.3165.
3-Benzyloxy-A-(l"-pyridin-3"-yImethyl)-16,17-s0co-estra-l,3,5(lO)-triene-16,17- 
imide (15)
3-Picolylamine (4.71 mL, 46.24 mmol) and 4 (600 mg, 1.47 mmol) were heated at 
180°C under an atmosphere of N2 for 2 hours. After cooling down, the resulting 
orange mixture was poured into H20  (300 mL) and acidified with 5M HC1. The 
organics were extracted with EtOAc (2x70 mL), washed with H20  (2x50 mL), brine 
(2x50 mL), dried (MgSCU), filtered and concentrated under reduced pressure. The 
crude product was recrystallised from EtOH to give 15 as light yellow crystals (543
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mg, 77%). An analytical sample was further recrystallised from EtOH to give 
colourless needles: mp 170-172°C; IR (KBr) 2925-2870 (aliph CH), 1720 (C=0), 
1670 (C=0), 1610-1500 (arom C=C) c m 1; 5H (CDC13, 400 MHz) 1.14 (3H, s, C-18- 
H3), 1.28-3.04 (11H, m), 2.84-2.88 (2H, m, C-6 -H2), 4.92 (1H, d, JBA= 13.7 Hz, N- 
CHaHb), 4.98 (1H, d, JAB = 14.1 Hz, N-CHAtfB), 5.03 (2H, s, OCH2Ar), 6.71 (1H, d, 
J = 2.7 Hz, C-4-H), 6.79 (1H, dd, J = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.17-7.45 (7H, m, 
C6H5, C-l-H and C-5"-H), 7.69 (1H, dt, J=  7.8 Hz, J=  1.8 Hz, C-4"-H), 8.50 (1H, 
dd, J=  5.1 Hz, J=  1.8 Hz, C-6 "-H) and 8.63 (1H, d, J= 1.8 Hz, C-2"-H); 6 C (CDC13,
100.4 MHz) 16.5 (q, C-18), 25.5 (t), 25.8 (t), 29.7 (t), 33.6 (t), 33.7 (t), 38.5 (d), 40.1 
(d), 40.8 (t, C-l'), 41.6 (s, C-13), 42.4 (d), 69.9 (t, OCH2Ar), 112.5 (d), 114.5 (d),
123.2 (d), 126.1 (d), 127.3 (2xd), 127.7 (d), 128.4 (2xd), 131.3 (s), 132.8 (s), 136.4 
(d), 137.1 (2xs), 148.6 (d), 150.0 (d), 156.8 (s, C-3), 171.4 (s, C=0) and 178.3 (s, 
C=0); MS m/z (FAB+) 481.3 [100, (M+H)+], 91.1 [47, (CH2Ar)+]; Acc MS m/z 
(FAB+) 481.2504, C3 iH33N20 3 requires 481.2491. Found: C, 77.00; H, 6.75; N, 5.73. 
C32H32N20 3 requires: C, 77.47; H, 6.71; N, 5.83%.
3-Benzyloxy-iV-benzyl-16,17-sec0-estra-l,3>5(lO)-triene-16,17-imide (16)
Benzylamine (6.25 mL, 57.22 mmol) and 4 (500 mg, 1.22 mmol) were heated at 
180°C under an atmosphere of N2 for 3 hours. After cooling down, the resulting 
brown mixture was poured into H20  (250 mL) and acidified with 5M HC1. The 
organics were extracted with EtOAc (50 mL), washed with H20  (2x25 mL), brine 
(3x25 mL), dried (MgS0 4 ), filtered and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (CHCl3/hexane, 8:2) to give 16 
as an off-white powder (385 mg, 65%). An analytical sample was recrystallised from 
MeOH to give colourless needles: mp 144-146°C; IR (KBr) 3100 (arom CH), 2940- 
2850 (aliph CH), 1720 (C=0), 1670 (C=0), 1615-1560 (arom C=C) cm 1; 5H 
(CDC13, 400 MHz) 1.15 (3H, s, C-18-H3), 1.25-3.01 (11H, m), 2.84-2.89 (2H, m, C- 
6 -H2), 4.91 (1H, d, JBA = 13.7 Hz, N-CHAHB), 4.98 (1H, d, 7ab = 13.7 Hz, N- 
CHaHb\  5.03 (2H, s, OCH2Ar), 6.72 (1H, d, J = 2.7 Hz, C-4-H), 6.80 (1H, dd, J  =
8.4 Hz, J  = 2.7 Hz, C-2-H), 7.21 (1H, d, J = 8.4 Hz, C-l-H) and 7.24-7.43 (10H, m, 
2xC6H5); 5c (CDC13, 100.4 MHz) 16.5 (q, C-18), 25.6 (t), 25.8 (t), 29.7 (t), 33.7 
(2xt), 38.6 (d), 40.2 (d), 41.5 (s, C-13), 42.5 (d), 43.2 (t, C -lf), 69.9 (t, OCH2Ar),
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112.5 (d), 114.5 (d), 126.1 (d), 127.2 (d), 127.3 (2xd), 127.8 (d), 128.3 (2xd), 128.4 
(4xd), 131.5 (s), 137.0 (s), 137.2 (2xs), 156.8 (s, C-3), 171.4 (s, C = 0)  and 178.3 (s, 
C = 0) ;  MS m/z (FAB+) 480.2 [52, (M+H)+], 91.1 [100, ( C H 2A r ) + ] ;  Acc MS m/z 
(FAB+) 480.2522, C 3 2 H 3 4 N O 3  requires 480.2539. Found: C, 80.10; H, 6.91; N, 2.94. 
C 3 2 H 3 3 N O 3  requires: C, 80.14; H, 6.94; N, 2.92%.
3-Hydroxy-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (17)
Following method 2, a suspension of 5 (350 mg, 899 pmol) and Pd-C (10%, 100 mg) 
in MeOH/THF 1:1 (50 mL) was hydrogenated for 5 hours to give 17 as a white solid 
(246 mg, 91%). An analytical sample was recrystallised from CHC^/Hexane (2:1) to 
give white crystals: mp 297-300°C [lit. 160 (MeOH) 294-296°C]; IR (KBr) 3410 
(OH), 3180-3085 (arom CH), 2955-2870 (aliph CH), 1715 (C=0), 1680 (C=0), 
1615-1500 (arom C=C) cm'1; 8 H (DMSO-cL, 400 MHz) 1.09 (3H, s, C -I8 -H3), 1.15- 
2.66 (11H, m), 2.69-2.73 (2H, m, C-6 -H2), 6.44 (1H, d, J=  2.7 Hz, C-4-H), 6.52 (1H, 
dd, J  = 8.5 Hz, J  = 2.7 Hz, C-2-H), 7.07 (1H, d, J = 8.5 Hz, C-l-H), 9.05 (1H, s, 
exchanged with D20 , OH) and 10.63 (1H, s, exchanged with D20 , NH); 5c (DMSO- 
d6 , 100.4 MHz) 16.2 (q, C-18), 25.2 (t), 25.4 (t), 29.2 (t), 32.4 (t), 32.8 (t), 38.0 (d),
40.4 (d), 40.5 (s, C-13), 41.4 (d), 112.7 (d), 114.5 (d), 125.9 (d), 129.5 (s), 136.7 (s),
154.8 (s, C-3), 172.2 (s, C=0) and 179.0 (s, C=0); MS m/z (FAB+) 300.0 [100, 
(M+H)+], 133.0 [29], 111.1 [36], 97.1 [60]; MS m/z (FAB-) 451.3 [58, (M-H+NBA)" 
], 298.2 [100, (M-H)-]; Acc MS m/z (FAB+) 300.1585, C18H2 2N 0 3 requires 
300.1600. HPLC (MeOH/H20 , 60:40; ^ax  = 279.3 nm) Rt = 3.06 min, 100%. 
Found: C, 61.80; H, 5.85; N, 3.86. Ci8H21N 0 3 .(CHC13)i/ 2 requires: C, 61.88; H, 6.04; 
N, 3.90%.
3-Hydroxy-A-methyl-16,17-sec0-estra-l,3,5(lO)-triene-16,l'7-imide (18)
Following method 2, a suspension of 6  (400 mg, 992 jumol) and Pd-C (10%, 200 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated for 2 hours to give 18 as a white solid 
(253 mg, 81%). An analytical sample was recrystallised from EtOAc to give white 
crystals: mp 328-330°C; IR (KBr) 3460 (OH), 2940-2860 (aliph CH), 1715 (C=0), 
1655 (C=0), 1610-1510 (arom C=C) cm'1; 5H (DMSO-d6, 400 MHz) 1.09 (3H, s, C- 
I 8 - H 3) ,  1.19-2.97 (11H, m), 2.68-2.73 (2H, m, C-6 -H2), 2.98 (3H, s, N-CH3), 6.44
216
(1H, d, J = 2.3 Hz, C-4-H), 6.52 (1H, dd, / =  8.5 Hz, J = 2.3 Hz, C-2-H), 7.06 (1H, d, 
J = 8.5 Hz, C-l-H) and 9.05 (1H, s, exchanged with D2O, OH); 6 c (DMSO-d6 , 100.4 
MHz) 16.3 (q, C-18), 25.2 (t), 26.4 (q, C-l'), 29.1 (t), 32.8 (t), 33.5 (2xt), 37.8 (d), 
-39 (s, under solvent peaks), 40.9 (d), 41.9 (d), 112.7 (d), 114.5 (d), 125.8 (d), 129.4 
(s), 136.7 (s), 154.8 (s, C-3), 171.3 (s, C=0) and 178.2 (s, C=0); MS m/z (FAB+)
314.1 [78, (M+H)+], 97.1 [100]; Acc MS m/z (FAB+) 314.1749, Q 9H24NO3 requires 
314.1756. HPLC (MeOH/H2 0 , 70:30; = 279.3 nm) Rt = 3.24 min, 100%.
Found: C, 72.60; H, 7.16; N, 4.35. C 19H23NO3 requires: C, 72.82; H, 7.40; N, 4.47%.
3-Hydroxy-Af-ethyI-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (19)
Following method 2, a suspension of 7 (470 mg, 1.13 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 4.5 hours to give 19 as a 
white solid (183 mg, 50%). This product was washed with acetone to give a white 
precipitate (121 mg, 33%): mp 306-308°C; IR (KBr) 3450 (OH), 2915-2860 (aliph 
CH), 1715 (C=0), 1655 (C=0), 1610-1505 (arom C=C) cm'1; 6 H (CDC13, 400 MHz) 
1.11 (3H, t, J = 7.0 Hz, C-2-H3), 1.16 (3H, s, C -I8 -H3), 1.22-2.98 (11H, m), 2.81- 
2.87 (2H, m, C-6 -H2), 3.82 (2H, m, N-CH2), 4.62 (1H, s, exchanged with D2 0 , OH),
6.57 (1H, d, J = 2.7 Hz, C-4-H), 6 . 6 6  (1H, dd, J  = 8 . 6  Hz, J = 2.7 Hz, C-2-H) and
7.17 (1H, d, J  = 8 . 6  Hz, C-l-H); MS m/z (FAB+) 328.2 [100, (M+H)+]; Acc MS m/z 
(FAB+) 328.1906, C2 0H26NO3 requires 328.1913. Found: C, 72.90; H, 7.68; N, 4.09. 
C20H25NO3 requires: C, 73.37; H, 7.70; N, 4.28%.
3-Hydroxy-A-propyl-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (20)
Following method 2, a suspension of 8  (400 mg, 927 pmol) and Pd-C (10%, 100 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated for 3 hours to give 20 as a white solid 
(256 mg, 81%). An analytical sample was recrystallised from MeOH to give 
colourless crystals: mp 183-186°C; IR (KBr) 3445 (OH), 3050 (arom CH), 2940- 
2860 (aliph CH), 1725 (C=0), 1655 (C=0), 1585-1500 (arom C=C) cm’1; 6 H 
(CDCI3 , 400 MHz) 0.90 (3H, t, J  = 7.4 Hz, C-3'-H3), 1.17 (3H, s, C -I8 -H3), 1.30-
2.98 (13H, m), 2.82-2.86 (2H, m, C-6 -H2), 3.64-3.80 (2H, m, N-CH2), 4.73 (1H, s, 
exchanged with D20 , OH), 6.58 (1H, d, J = 2.7 Hz, C-4-H), 6 . 6 6  (1H, dd, 7 c - i -h ,c -2-h 
= 8 . 6  Hz, J = 2.7 Hz, C-2-H) and 7.17 (1H, d, /  = 8 . 6  Hz, C-l-H); 6 C (CDC13, 100.4 
MHz) 11.4 (q, C-3'), 16.6 (q, C-18), 21.3 (t), 25.6 (d), 25.8 (t), 29.6 (t), 33.6 (t), 33.7
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(t), 38.7 (d), 40.3 (d), 41.5 (s, C-13), 41.6 (t, C-l'), 42.5 (d), 113.0 (d), 115.0 (d),
126.3 (d), 131.1 (s), 137.4 (s), 153.7 (s, C-3), 171.8 (s, C=0) and 178.6 (s, C=0); 
MS m/z (FAB+) 342.3 [100, (M+H)+], 97.2 [45]; MS m/z (FAB-) 494.4 [43, 
(M+NBA)'], 340.3 [100, (M-H)’]; Acc MS m/z (FAB+) 342.2076, C21H28NO3 
requires 342.2069. HPLC (Me0 H/H2 0 , 70:30; X,max = 279.3 nm) Rt = 6.55 min, 
100%. Found: C, 73.90; H, 7.98; N, 4.20. C21H27NO3 requires: C, 73.87; H, 7.97; N, 
4.10%.
3-Hydroxy-A-butyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (21)
Following method 2, a suspension of 9 (480 mg, 1.08 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 2 hours to give 21 as a white 
solid (361 mg, 94%). This product was recrystallised from MeOH to give colourless 
needles (242 mg, 63%): mp 212-214°C [lit. 160 (MeOH) 210-212°C]; IR (KBr) 3445 
(OH), 2940-2870 (aliph CH), 1715 (C=0), 1655 (C=0), 1585-1500 (arom C=C) cm' 
5 h (CDC13, 400 MHz) 0.92 (3H, t, J  = 7.2 Hz, C-4'-H3), 1.16 (3H, s, C-18-H3), 
1.26-2.99 (15H, m), 2.81-2.88 (2H, m, C-6 -H2), 3.75 (2H, m, N-CH2), 4.75 (1H, s, 
exchanged with D2O, OH), 6.58 (1H, d, J  = 2.7 Hz, C-4-H), 6 . 6 6  (1H, dd, J  = 8 . 6  Hz, 
J = 2.7 Hz, C-2-H) and 7.17 (1H, d, J = 8 . 6  Hz, C-l-H); 5C (CDC13, 100.4 MHz) 13.8 
(q, C-4'), 16.5 (q, C-18), 20.1 (t), 25.5 (t), 25.7 (t), 29.4 (t), 30.0 (t), 33.5 (t), 33.7 (t),
38.6 (d), 39.8 (t, C-l'), 40.2 (d), 41.4 (s, C-13), 42.4 (d), 112.9 (d), 114.9 (d), 126.2 
(d), 131.1 (s), 137.3 (s), 153.5 (s, C-3), 171.5 (s, C=0) and 178.4 (s, C=0); MS m/z 
(FAB+) 356.2 [100, (M+H)+]; MS m/z (FAB-) 508.2 [35, (M+NBA)’], 354.2 [100, 
(M-H)’]; Acc MS m/z (FAB+) 356.2225, C22H30NO3 requires 356.2226. Found: C, 
74.20; H, 8.21; N, 3.88. C22H29NO3 requires: C, 74.33; H, 8.22; N, 3.94%.
3-Hydroxy-/V-pentyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (22)
Following method 2, a suspension of 10 (520 mg, 1.13 mmol) and Pd-C (10%, 100 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 3 hours to give 22 as a white 
solid (347 mg, 83%). An analytical sample was recrystallised from MeOH to give 
white crystals: mp 181-184°C; IR (KBr) 3445 (OH), 2955-2870 (aliph CH), 1715 
(C=0), 1660 (C=0), 1610-1505 (arom C=C) cm’1; 6 H (CDCI3 , 400 MHz) 0.89 (3H, t, 
7 =  7.4 Hz, C-5'-H3), 1.16 (3H, s, C -I8 -H3), 1.20-2.98 (17H, m), 2.81-2.86 (2H, m, 
C-6 -H2), 3.65-3.82 (2H, m, N-CH2), 4.77-4.79 (1H, m, exchanged with D20 , OH),
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6.58 (1H, d ,J =  2.7 Hz, C-4-H), 6.65 (1H, dd, J  = 8.2 Hz, J  = 2.7 Hz, C-2-H) and
7.17 (1H, d, J  = 8.2 Hz, C-l-H); 6 C (CDC13, 100.4 MHz) 14.1 (q, C-5'), 16.6 (q, C- 
18), 22.5 (t), 25.6 (t), 25.8 (t), 27.7 (t), 29.1 (t), 29.7 (t), 33.7 (t), 33.8 (t), 38.7 (d),
40.2 (t, C-l'), 40.3 (d), 41.5 (s, C-13), 42.5 (d), 113.0 (d), 115.0 (d), 126.3 (d), 131.2 
(s), 137.4 (s), 153.6 (s, C-3), 171.7 (s, C=0) and 178.5 (s, C=0); MS m/z (FAB+)
739.1 [50, (2M+H)+], 370.1 [100, (M+H)+]; MS m/z (FAB-) 522.4 [30, (M+NBA)'],
368.3 [100, (M-H)']; Acc MS m/z (FAB+) 370.2394, C2 3H32NO3 requires 370.2382. 
HPLC (MeOH/H20 , 80:20; ^max = 279.3 nm) Rt = 5.42 min, 100%. Found: C, 74.90; 
H, 8.38; N, 3.73. C23H31NO3 requires: C, 74.96; H, 8.46; N, 3.79%.
3-Hydroxy-iV-hexyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (23)
Following method 2, a suspension of 11 (540 mg, 1.14 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF 2:1 (45 mL) was hydrogenated for 3 hours to give 27 as a white 
solid (384 mg, 8 8 %). This product was recrystallised from MeOH to give white 
crystals (263 mg, 60%): mp 157-159°C; IR (KBr) 3435 (OH), 2930-2865 (aliph CH), 
1715 (C=0), 1660 (C=0), 1585-1500 (arom C=C) cm'1; 8 h (CDC13, 400 MHz) 0.87 
(3H, t, J = 6 . 8  Hz, C-6 '-H3), 1.16 (3H, s, C -I8 -H3), 1.23-2.98 (19H, m), 2.81-2.87 
(2H, m, C-6 -H2), 3.74 (2 H, m, N-CH2), 4.68 (1H, s, exchanged with D20 , OH), 6.58 
(1H, d, J  = 2.5 Hz, C-4-H), 6 . 6 6  (1H, dd, J  = 8.4 Hz, J  = 2.5 Hz, C-2-H) and 7.17 
(1H, d, /  = 8.4 Hz, C-l-H); 6 C (CDC13, 100.4 MHz) 14.0 (q, C-6 '), 16.5 (q, C-18),
22.5 (t), 25.5 (t), 25.6 (t), 26.5 (t), 27.8 (t), 29.4 (t), 31.4 (t), 33.5 (t), 33.6 (t), 38.5 
(d), 40.1 (d and t, C-l'), 41.3 (s, C-13), 42.3 (d), 112.8 (d), 114.8 (d), 126.2 (d), 131.0 
(s), 137.2 (s), 153.5 (s, C-3), 171.6 (s, C=0) and 178.4 (s, C=0); MS m/z (FAB+)
767.6 [48, (2M+H)+], 384.3 [100, (M+H)+]; MS m/z (FAB-) 382.2 [100, (M-H)']; 
Acc MS m/z (FAB+) 384.2535, C24H34NO3 requires 384.2539. Found: C, 75.40; H, 
8.65; N, 3.71. C24H33NO3 requires: C, 75.16; H, 8.67; N, 3.65%.
3-Hydroxy-A-(4'-bromobiityl)-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (24)
Following method 2, a suspension of 12 (210 mg, 381 |imol) and Pd-C (10%, 100 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 2 hours to give 24 as a white 
solid (146 mg, 84%). This product was recrystallised from MeOH to give white 
crystals (98 mg, 57%): mp 165-167°C; IR (KBr) 3450 (OH), 2910-2860 (aliph CH), 
1715 (C=0), 1660 (C=0), 1610-1505 (arom C=C) cm'1; 6H (CDC13, 400 MHz) 1.18
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(3H, s, C -I8 -H3), 1.29-3.01 (15H, m), 2.82-2.88 (2H, m, C-6 -H2), 3.42 (2H, t, J  = 6 . 6  
Hz, C-4'-H2), 3.72-3.87 (2H, m, N-CH2), 4.63 (1H, s, exchanged with D20 , OH),
6.58 (1H, d, J  = 2.3 Hz, C-4-H), 6 . 6 6  (1H, dd, J  = 8.5 Hz, J  = 2.3 Hz, C-2-H) and
7.17 (1H, d, J=  8.5 Hz, C-l-H); 6 C (DMSO-d6, 100.4 MHz) 17.0 (q, C-18), 25.9 (t),
26.1 (t), 27.1 (t), 29.9 (t), 30.5 (t), 33.5 (t), 33.9 (t), 34.1 (t), 39.0 (d), 39.4 (t, C-l'),
40.6 (d), 41.9 (s, C-13), 42.8 (d), 113.3 (d), 115.3 (d), 126.6 (d), 131.5 (s), 137.7 (s),
153.9 (s, C-3), 171.9 (s, C=0) and 178.8 (s, C=0); MS m/z (FAB+) 869.2 [64], 587.1 
[46, (M+H+NBA)+], 434.1 [100, (M+H)+]; Acc MS m/z (FAB+) 436.1287, 
C22H29 81BrN03 requires 436.1310 and 434.1282, C22H29BrN03 requires 434.1331. 
HPLC (MeOH/H20 , 70:30; ^ax  = 279.3 nm) Rt = 7.73 min, 98%. Found: C, 61.30;
H, 6.60; N, 3.17. C22H28BrN03 requires: C, 60.83; H, 6.50; N, 3.22%.
3-Hydroxy-A-cyclopropylmethyl-16,17-seco-estra-l,3,5(10)-triene-16,17-imicle
(25)
Following method 2, a suspension of 13 (500 mg, 1.13 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF 2:1 (45 mL) was hydrogenated for 2.5 hours to give 25 as a 
white solid (356 mg, 89%). This product was recrystallised from MeOH to give 
colourless crystals (254 mg, 64%): mp 238-240°C; IR (KBr) 3440 (OH), 2940-2865 
(aliph CH), 1715 (C=0), 1655 (C=0), 1610-1505 (arom C=C) cm'1; 6 H (CDC13, 400 
MHz) 0.29-0.34 (2H, m, C-3'-H2), 0.40-0.45 (2H, m, C-4'-H2), 1.13 (1H, m, C-2'-H),
I.19 (3H, s, C-18-H3), 1.30-3.02 (11H, m), 2.82-2.89 (2H, m, C-6 -H2), 3.66 (2H, m, 
N-CH2), 4.70 (1H, s, exchanged with D20 , OH), 6.58 (1H, d, /  = 2.7 Hz, C-4-H),
6 . 6 6  (1H, dd, / =  8.4 Hz, / =  2.7 Hz, C-2-H) and 7.17 (1H, d, J  = 8.4 Hz, C-l-H); 5C 
(CDC13, 100.4 MHz) 3.9 (t, C-3'), 4.0 (t, C-4'), 10.5 (d, C-2'), 16.9 (q, C-18), 26.0 (t),
26.1 (t), 29.9 (t), 31.1 (t), 34.0 (t), 39.0 (d), 40.6 (d), 41.9 (s, C-13), 42.8 (d), 44.6 (t, 
C-l'), 113.3 (d), 115.3 (d), 126.6 (d), 131.6 (s), 137.7 (s), 154.0 (s, C-3), 172.2 (s, 
C=0) and 179.1 (s, C=0); MS m/z (FAB+) 707.3 [29, (2M+H)+], 507.1 [72, 
(M+H+NBA)+], 354.1 [100, (M+H)+]; MS m/z (FAB-) 505.2 [32, (M-H+NBA)'],
352.1 [100, (M-H)']; Acc MS m/z (FAB+) 354.2069, C22H28N 0 3 requires 354.2069. 




Following method 2, a suspension of 14 (620 mg, 1.16 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 5 hours to give 26 as an off- 
white solid (550 mg). This product was recrystallised from MeOH to give white 
flaky crystals (448 mg, 87%): mp 128-130°C; IR (KBr) 3415 (OH), 2955-2870 
(aliph CH), 1725 (C=0), 1655 (C=0), 1610-1505 (arom C=C) cm'1; 5h (CDC13, 400 
MHz) 1.16 (3H, s, C-I8 -H3), 1.28 (9H, s, C(CH3)3), 1.30-3.02 (15H, m), 2.81-2.87 
(2H, m, C-6 -H2), 4.77 (1H, s, exchanged with D2 O, OH), 4.88 (1H, d, Jba = 14.0 Hz, 
N-C/^Hb), 4.95 (1H, d, 7ab = 14.0 Hz, N-CHAHB), 6.57 (1H, d, J = 2.7 Hz, C-4-H),
6.65 (1H, dd, J = 8.4 Hz, J  = 2.7 Hz, C-2-H), 7.16 (1H, d, J  = 8.4 Hz, C-l-H) and 
7.24-7.32 (4H, m, C-2"-H, C-3"-H, C-5"-H and C-6 "-H); 6 C (CDC13, 100.4 MHz)
16.9 (q, C-18), 25.9 (t), 26.1 (t), 29.9 (t), 31.7 (3xq, C(CH3)3), 34.0 (t), 34.1 (t), 34.9 
(s, C(CH3)3), 39.0 (d), 40.4 (d), 41.9 (s, C-13), 42.8 (d), 43.3 (t, C-l'), 113.3 (d),
115.3 (d), 125.5 (2xd), 126.6 (d), 128.3 (2xd), 131.4 (s), 134.4 (s), 137.7 (s), 150.3 
(s), 153.9 (s, C-3), 172.0 (s, C=0) and 178.8 (s, C=0); MS m/z (FAB+) 891.4 [80, 
(2M+H)+], 599.2 [35, (M+H+NBA)+], 446.2 [100, (M+H)+]; MS m/z (FAB-) 889.5 
[42, (2M-H)-], 751.4 [87, (M+2NBA)'], 598.3 [30, (M+NBA)'], 444.2 [100, (M-H)']; 
Acc MS m/z (FAB+) 446.2690, C29H36N03 requires 446.2695. Found: C, 77.40; H, 
7.67; N, 3.19. C29H35N0 3 .(H2 0 )i/4  requires: C, 77.39; H, 7.95; N, 3.11%.
3-Hydroxy-iV-(l"-pyridin-3"-ylmethyl)-16,17-seco-estra-l,3,5(10)-triene-16,17-
imide (27)
Following method 2, a suspension of 15 (190 mg, 395 pmol) and Pd-C (10%, 100 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 20 hours to give 27 as an off- 
white solid (141 mg, 91%). An analytical sample was triturated with EtOAc to give a 
white powder: mp 199-203°C; IR (KBr) 3380 (OH), 2940-2865 (aliph CH), 1720 
(C=0), 1670 (C=0), 1610-1500 (arom C=C) cm'1; 6 H (DMSO-d6, 400 MHz) 1.11 
(3H, s, C-18-H3), 1.14-2.94 (11H, m), 2.67-2.75 (2H, m, C-6 -H2), 4.82 (1H, d, 7Ba =
14.8 Hz, N-C/^Hb), 4.87 (1H, d, JAb = 14.8 Hz, N-CHAHB), 6.44 (1H, d, J  = 2.3 Hz, 
C-4-H), 6.52 (1H, dd, J = 8.5 Hz, J  = 2.3 Hz, C-2-H), 7.07 (1H, d, J  = 8.5 Hz, C-l- 
H), 7.33 (1H, dd, J = 7.8 Hz, J = 4.7 Hz, C-5"-H), 7.57-7.61 (1H, m, C-4"-H), 8.42-
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8.47 (2H, m, C-2"-H and C-6 "-H) and 9.05 (1H, s, exchanged with D2O, OH); MS 
m/z (FAB+) 391.2 [8 8 , (M+H)+], 156.1 [40], 135.1 [46], 119.1 [48], 95.1 [70]; MS 
m/z (FAB-) 542.3 [50, (M-H+NBA)'], 389.3 [100, (M-H)'], 276.1 [43], 258.1 [37],
195.1 [42], 124.1 [34]; Acc MS m/z (FAB+) 391.2019, C24H2 7N2O3 requires 
391.2022.
3-Hydroxy-A-benzy 1-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (28)
Following method 2, a suspension of 16 (230 mg, 479 pmol) and Pd-C (10%, 100 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 2 hours to give 28 as a white 
solid (170 mg, 91%). This product was triturated with boiling MeOH to give a white 
precipitate (122 mg, 65%): mp 298-301°C; IR (KBr) 3430 (OH), 2950-2890 (aliph 
CH), 1720 (C=0), 1655 (C=0), 1610-1505 (arom C=C) cm'1; 5H (DMSO-d6, 400 
MHz) 1.12 (3H, s, C -I8 -H3), 1.18-2.92 (11H, m), 2.68-2.75 (2H, m, C-6 -H2), 4.79 
(1H, d, 7 Ba  = 14.8 Hz, N-CHAHB), 4.85 (1H, d, JAB =  14.8 Hz, N-CHAHB), 6.45 (1H, 
d, /  = 2.3 Hz, C-4-H), 6.53 (1H, dd, J = 8.5 Hz, J  = 2.3 Hz, C-2-H), 7.07 (1H, d, J =
8.5 Hz, C-l-H), 7.17-7.32 (5H, m, C6H5) and 9.05 (1H, s, exchanged with D2 0 , 
OH); 8 C (DMSO-ds, 100.4 MHz) 16.3 (q, C-18), 25.2 (2xt), 29.1 (t), 32.9 (t), 33.5 
(t), 38.0 (d), -39 (d, under solvent peaks), 41.0 (s, C-13), 41.7 (d), 42.3 (t, C-l'),
112.7 (d), 114.5 (d), 125.8 (d), 126.6 (d), 126.8 (2xd), 128.1 (2xd), 129.4 (s), 136.7 
(s), 137.4 (s), 154.8 (s, C-3), 172.2 (s, C=0) and 178.0 (s, C=0); MS m/z (FAB+)
390.3 [30, (M+H)+], 133.2 [43], 111.2 [57], 97.2 [100]; Acc MS m/z (FAB+) 
390.2062, C25H28NO3 requires 390.2069. Found: C, 75.60; H, 7.01; N, 3.34. 
C25H27NO3 .(H20 ) 1/2 requires: C, 75.35; H, 7.08; N, 3.51%.
3-0-terf-butyl-dimethylsilyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (29)
Imidazole (256 mg, 3.74 mmol) and te/t-butyl-dimethylsilyl chloride (546 mg, 3.63 
mmol) were added to a stirred solution of 17 (350 mg, 1.17 mmol) in anhydrous 
DMF (20 mL) at room temperature under an atmosphere of N2 . The resulting mixture 
was stirred for 4 hours, after which it was poured into H2O (150 mL). The organics 
were extracted with EtOAc (150 mL), washed with H2 O (4x80 mL), dried (MgS0 4 ), 
filtered and concentrated under reduced pressure to give a white solid. The crude 
product was recrystallised from EtOH/H2 0  to give 29 as white crystals (376 mg, 
78%): mp 261-264°C; IR (KBr) 3210 (NH), 3090 (arom CH), 2950-2860 (aliph CH),
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1730 (C=0), 1680 (C=0), 1610-1500 (arom C=C) cm 1; 6 h (CDC13, 400 MHz) 0.19 
(6 H, s, Si(CH3)2), 0.97 (9H, s, C(CH3)3), 1.23 (3H, s, C-18-H3), 1.31-2.96 (11H, m), 
2.80-2.87 (2H, m, C-6 -H2), 6.57 (1H, d, J=  2.5 Hz, C-4-H), 6.64 (1H, dd, 7=  8 . 6  Hz, 
J = 2.5 Hz, C-2-H), 7.13 (1H, d, J  = 8 . 6  Hz, C-l-H) and 7.72 (1H, s, exchanged with 
D20 , NH); 5c (CDC13, 100.4 MHz) -4.2 (2xq, Si(CH3)2), 16.5 (q, C-18), 18.3 (s, 
C(CH3)3), 25.4 (t), 25.8 (3xq, C(CH3)3), 26.1 (t), 29.5 (t), 32.8 (t), 32.9 (t), 38.5 (d),
41.2 (s, C-13), 41.6 (dj, 42.7 (d), 117.5 (d), 119.7 (d), 126.0 (d), 131.5 (s), 136.9 (s),
153.5 (s, C-3), 171.6 (s, C=0) and 178.4 (s, C=0); MS m/z (FAB+) 827.6 [50, 
(2M+H)+], 414.2 [100, (M+H)+], 356.2 [45, (M-C(CH3)3)+], 72.9 [50]; MS m/z 
(FAB-) 412.2 [100, (M-H)']; Acc MS m/z (FAB+) 414.2453, C24H36N 0 5Si requires 




Following method 1, 29 (300 mg, 725 jimol) was treated with NaH (35 mg, 870 
pmol) and the subsequent reaction with allyl bromide (126 pL, 1.45 mmol) was 
complete within 7 hours. The crude product was purified by flash chromatography 
(CHC13) to give 30 as an off-white oil (302 mg, 92%): DR. (KBr) 2930-2860 (aliph 
CH), 1725 (C=0), 1676 (C=0), 1610-1500 (arom C=C) cm'1; 5H (CDC13, 400 MHz) 
0.19 (6 H, s, Si(CH3)2), 0.98 (9H, s, C(CH3)3), 1.19 (3H, s, C-18-H3), 1.29-3.02 (11H, 
m), 2.80-2.86 (2H, m, C-6 -H2), 4.33 (1H, app dd, J  = 14.8 Hz, J  = 5.8 Hz, N- 
CHaRb), 4.42 (1H, app dd, J  = 14.8 Hz, J  = 5.8 Hz, N-CHAHB), 5.11-5.19 (2H, m, C- 
3'-H2), 5.74-5.85 (1H, m, C-2'-H), 6.56 (1H, d, J  = 2.7 Hz, C-4-H), 6.64 (1H, dd, J =
8.3 Hz, J = 2.7 Hz, C-2-H) and 7.13 (1H, d, J  = 8.3 Hz, C-l-H); MS m/z (FAB+)
454.3 [100, (M+H)+], 396.2 [35, (M+H-C(CH3)3)+], 72.9 [54]; MS m/z (FAB-) 606.3 
[32, (M+NBA)'], 452.2 [100, (M-H)'], 412.2 [56, (M -H -C ^)']; Acc MS m/z 
(FAB+) 454.2760, C^HwNOsSi requires 454.2777.
3-Hydroxy-A-allyI-16,17-sec0-estra-l,3,5(lO)-triene-16,l'7-imide (31)
Tetrabutyl ammonium fluoride trihydrate (183 mg, 701 pmol) was added to a stirred 
solution of 30 (265 mg, 584 pmol) in THF (10 mL) at room temperature under an 
atmosphere of N2. After stirring for 2 hours, another 1.2 eq. of TBAF trihydrate was
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added and the reaction was quenched 5 hours later with H2O (40 mL) and acidified 
with 5M HC1. The resulting white precipitate was filtered, washed and air dried to 
give 31 as a white powder (172 mg, 87%). This product was recrystallised from 
EtOAc to give white crystals (114 mg, 58%): mp 246-248°C [lit. 160 (MeOH) 238- 
240°C]; IR (KBr) 3445 (OH), 2920-2860 (aliph CH), 1720 (C=0), 1660 (C=0), 
1610-1505 (arom C=C) cm’1; 6 H (CDCI3 , 400 MHz) 1.18 (3H, s, C -I8 -H3), 1.30-3.02 
(11H, m), 2.82-2.87 (2H, m, C-6 -H2), 4.33 (1H, app ddt, 7Ba = 14.8 Hz, J = 5.6 Hz, J  
= 1.4 Hz, N -C /^ H b), 4.41 (1H, app ddt, 7ab = 14.8 Hz, J  = 5.6 Hz, J  = 1.4 Hz, N- 
CHaHb\  4.72 (1H, s, exchanged with D20 , OH), 5.12-5.19 (2H, m, C-3'-H2), 5.75-
5.85 (1H, m, C-2-H), 6.58 (1H, d, /  = 2.7 Hz, C-4-H), 6.65 (1H, dd, J = 8.3 Hz, Jc.4- 
h ,C-2-h  = 2.7 Hz, C-2-H) and 7.17 (1H, d, /  = 8.3 Hz, C-l-H); MS m/z (FAB+) 340.2 
[100, (M+H)+]; MS m/z (FAB-) 491.1 [50, (M-H+NBA)'], 338.1 [100, (M-H)’]; Acc 
MS m/z (FAB+) 340.1916, C2 iH26N 0 5 requires 340.1913. HPLC (MeOH/H20 , 
70:30; ^max = 279.3 nm) Rt = 3.91 min, 100%. Found: C, 73.90; H, 7.37; N, 4.11. 
C2 ]H25N 0 5 requires: C, 74.31; H, 7.42; N, 4.13%.
3-Sulfamoyloxy-16,17-sec0-estra-l,3>5(lO)-triene-16,17-imide (32)
Following method 3, reaction of 17 (100 mg, 334 pmol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 4 hours. The crude product was washed with 
boiling acetone and the precipitate was filtered to give 32 as a white solid (56 mg, 
44%): mp 242-244°C; IR (KBr) 3250 (NH2), 3090 (arom CH), 2940-2850 (aliph 
CH), 1690 (C=0), 1695 (C=0), 1640-1560 (arom C=C), 1370 (S02), 1170 (S02) cm’ 
!; 5h (DMSO-d6, 400 MHz) 1.10 (3H, s, C-I8 -H3), 1.19-2.72 (11H, m), 2.81-2.85 
(2H, m, C-6 -H2), 6.98 (1H, d, J  = 2.3 Hz, C-4-H), 7.03 (1H, dd, J  = 8 . 6  Hz, J  = 2.3 
Hz, C-2-H), 7.38 (1H, d, J=  8 . 6  Hz, C-l-H), 7.91 (2H, s, exchanged with D20 , NH2) 
and 10.65 (1H, s, exchanged with D20 , NH); 6 C (DMSO-d*,, 100.4 MHz) 16.2 (q, C- 
18), 25.0 (2xt), 29.0 (t), 32.4 (t), 32.7 (t), 37.5 (d), 40.3 (d), 40.5 (s, C-13), 42.1 (d),
119.2 (d), 121.5 (d), 126.4 (d), 137.5 (s), 137.6 (s), 147.8 (s, C-3), 172.1 (s, C=0) 
and 178.9 (s, C=0); MS m/z (FAB+) 379.3 [94, (M+H)+], 157.2 [32], 133.2 [56],
97.2 [100], 82.2 [28]; MS m/z (FAB-) 531.2 [37, (M+NBA)’], 377.2 [100, (M-H)']; 
Acc MS m/z (FAB+) 379.1331, Ci8H23N20 5S requires 379.1328. HPLC 
(MeOH/H20 , 50:50; Xmax = 266.3 nm) Rt = 5.70 min, 100%. Found: C, 56.80; H, 
5.83; N, 7.19. C]8H22N20 5S requires: C, 57.13; H, 5.86; N, 7.40%.
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3-Sulfamoyloxy-./V-methyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide 3^ 3 ^
Following method 3, reaction of 20 (100 mg, 319 jimol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 3 hours. The crude product was recrystallised 
from CHCI3 to give 33 as white crystals (84 mg, 67%): mp 219-222°C; IR (KBr) 
3300, 3230 (NH2), 3100 (arom CH), 2945-2865 (aliph CH), 1710 (C=0), 1655 
(C=0), 1605-1500 (arom C=C), 1390 (S02), 1190 (S02) cm'1; 5h (CDC13, 400 MHz)
1.18 (3H, s, C -I8 -H3), 1.32-3.02 (11H, m), 2.89-2.93 (2H, m, C-6 -H2), 3.16 (3H, s, 
N-CH3), 4.85 (2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J = 2.3 Hz, C-4-H), 
7.11 (1H, dd, J  = 8.5 Hz, J  = 2.3 Hz, C-2-H) and 7.33 (1H, d, J  = 8.5 Hz, C-l-H); 
MS m/z (FAB+) 393.0 [100, (M+H)+], 109.0 [43], 81.0 [64, (S0 2NH2+H)+]; MS m/z 
(FAB-) 545.3 [38, (M+NBA)'], 391.2 [100, (M-H)']; Acc MS m/z (FAB+) 393.1472, 
Ci9H25N2 0 5S requires 393.1484. HPLC (MeOH/H20 , 60:40; A™* = 266.3 nm) Rt =
4.72 min, 100%. Found: C, 58.30; H, 6.17; N, 7.19. Ci9H24N2 0 5 S requires: C, 58.15; 
H, 6.16; N, 7.14%.
3-Sulfamoyloxy-Af-ethyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (3 4 )
Following method 3, reaction of 19 (70 mg, 214 pmol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 1.5 hours. The crude product was recrystallised 
from EtOAc/hexane (1:2) to give 34 as off-white crystals (72 mg, 83%): mp 215- 
217°C; IR (KBr) 3415, 3305 (NH2), 2970-2870 (aliph CH), 1715 (C=0), 1665 
(C=0), 1375 (S02), 1190 (S02) cm'1; 8H (CDC13, 400 MHz) 1.11 (3H, t, J=  7.0 Hz, 
C-2'-H3), 1.17 (3H, s, C -I8 -H3), 1.24-2.99 (11H, m), 2.88-2.95 (2H, m, C-6 -H2), 
3.74-3.88 (2H, m, N-CH2), 4.89 (2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J  =
2.4 Hz, C-4-H), 7.12 (1H, dd, J=  8.5 Hz, J=  2.4 Hz, C-2-H) and 7.33 (1H, d, J=  8.5 
Hz, C-l-H); MS m/z (FAB+) 813.2 [40, (2M+H)+], 560.1 [70, (M+H+NBA)+], 407.1 
[100, (M+H)+]; MS m/z (FAB-) 811.4 [72, (2M-H)'], 712.3 [47, (M+2NBA)'], 559.2 
[30, (M+NBA)'], 405.1 [100, (M-H)']; Acc MS m/z (FAB+) 407.1645, C2oH27N20 5S 
requires 407.1641.
3-Sulfamoyloxy-A-propyl-16,17-sec0-estra-l,3,5(lO)-trieiie-16,17-imide (35) 
Following method 3, reaction of 20 (100 mg, 293 pmol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 6  hours. The crude product was purified by flash 
chromatography (CHCE/acetone, 95:5) to give 35 as a white solid (107 mg, 87%).
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An analytical sample was recrystallised from acetone/hexane (1:2) to give white 
crystals: mp 202-204°C; IR (KBr) 3365, 3255 (NH2), 3095 (arom CH), 2965-2880 
(aliph CH), 1710 (C=0), 1660 (C=0), 1600-1500 (arom C=C), 1380 (S02), 1180 
(S02) cm'1; 8 h (CDC13, 400 MHz) 0.90 (3H, t, J  = 7.4 Hz, C-3'-H3), 1.17 (3H, s, C- 
18-H3), 1.32-3.00 (13H, m), 2.88-2.93 (2H, m, C-6 -H2), 3.64-3.80 (2H, m, N-CH2), 
4.90 (2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J  = 2.5 Hz, C-4-H), 7.11 (1H, 
dd, J  = 8.4 Hz, J  = 2.5 Hz, C-2-H) and 7.33 (1H, d, J  = 8.4 Hz, C-l-H); MS m /z  
(FAB+) 421.0 [100, (M+H)+], 109.0 [52], 97.0 [45], 81.0 [74, (S0 2NH2+H)+], 67.0 
[60]; MS m /z (FAB-) 573.3 [34, (M+NBA)'], 419.3 [100, (M-H)']; Acc MS m /z  
(FAB+) 421.1800, C2 ]H29N20 5S requires 421.1797. HPLC (MeOH/H20 , 70:30; U  
= 266.3 nm) Rt = 4.61 min, 100%. Found: C, 60.00; H, 6.60; N, 6.49. C2 iH28N20 5S 
requires: C, 59.98; H, 6.71; N, 6 .6 6 %.
3-Sulfamoyloxy-Af-butyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (36) 
Following method 3, reaction of 21 (90 mg, 253 pmol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 1.5 hours. The crude product was recrystallised 
from acetone/hexane (1:2) to give 36 as white crystals (78 mg, 71%): mp 194-196°C; 
IR (KBr) 3335, 3250 (NH2), 2940-2870 (aliph CH), 1710 (C=0), 1650 (C=0), 1385 
(S02), 1190 (S02) cm'1; SH (CDC13, 400 MHz) 0.92 (3H, t, / =  7.2 Hz, C-4'-H3), 1.17 
(3H, s, C-18-H3), 1.25-2.99 (15H, m), 2.88-2.92 (2H, m, C-6 -H2), 3.75 (2H, m, N- 
CH2), 4.91 (2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J  = 2.3 Hz, C-4-H), 7.12 
(1H, dd, J  = 8.7 Hz, J  = 2.3 Hz, C-2-H) and 7.34 (1H, d, J  = 8.7 Hz, C-l-H); MS m /z 
(FAB+) 869.2 [78, (2M+H)+], 588.1 [78, (M+H+NBA)+], 435.1 [100, (M+H)+]; MS 
m /z  (FAB-) 587.2 [32, (M+NBA)'], 433.2 [100, (M-H)']; Acc MS m /z  (FAB+) 
435.1960, C22H31N20 5S requires 435.1954. Found: C, 60.50; H, 6 .8 6 ; N, 6.26. 
C2 2H30N2 O5S requires: C, 60.81; H, 6.96; N, 6.45%.
3-Sulfamoyloxy-Af-pentyI-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (37)
Following method 3, reaction of 22 (100 mg, 271 pmol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 3.5 hours. The crude product was purified by 
flash chromatography (CHCl3/acetone, 95:5) to give 37 as a white foam (111 mg, 
92%). An analytical sample was recrystallised from EtOAc/hexane (1:2) to give 
white crystals: mp 159-161°C; IR (KBr) 3345, 3255 (NH2), 3095 (arom CH), 2930-
226
2870 (aliph CH), 1720 (C=0), 1655 (C=0), 1600-1500 (arom C=C), 1385 (S02), 
1190 (S02) c m 1; 5H (CDC13, 100 MHz) 0.89 (3H, t, J  = 1A  Hz, C-5'-H3), 1.17 (3H, 
s, C-18-H3), 1.21-2.98 (17H, m), 2.90-2.94 (2H, m, C-6 -H2), 3.66-3.81 (2H, m, N- 
CH2), 4.94 (2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J  = 2.5 Hz, C-4-H), 7.11 
(1H, dd, J  = 8 . 6  Hz, J = 2.5 Hz, C-2-H) and 7.33 (1H, d, J  = 8 . 6  Hz, C-l-H); 6 C 
(CDC13, 100.4 MHz) 13.9 (q, C-5'), 16.4 (q, C-18), 22.3 (t), 25.3 (2xt), 27.5 (t), 29.0 
(t), 29.3 (t), 33.5 (2 xt), 38.1 (d), 40.0 (t, C-l'), 40.2 (d), 41.2 (s, C-13), 42.5 (d),
119.0 (d), 121.6 (d), 126.5 (d), 138.0 (s), 138.1 (s), 147.8 (s, C-3), 171.3 (s, C=0) 
and 178.1 (s, C=0); MS m/z (FAB+) 449.0 [100, (M+H)+], 133.0 [33], 111.0 [32],
97.0 [46]; MS m/z (FAB-) 601.4 [34, (M+NBA)’], 447.3 [100, (M-H)’]; Acc MS m/z 
(FAB+) 449.2111, C23H33N2 0 5S requires 449.2110. HPLC (MeOH/H20 , 80:20; ^max 
= 266.3 nm) Rt = 3.70 min, 98%. Found: C, 61.70; H, 7.30; N, 6.22. C23H32N20 5S 
requires: C, 61.58; H, 7.19; N, 6.24%.
3-Sulfamoyloxy-A-hexyl-16,17-sm>-estra-l,3,5(10)-triene-16,17-imide (38)
Following method 3, reaction of 23 (130 mg, 339 jamol) with sulfamoyl chloride in 
DMA (2.5 mL) was complete within 2 hours. The crude product was purified by 
flash chromatography (CHCl3/acetone, 9:1) to give 38 as a white foam (127 mg, 
81%). This compound was recrystallised from EtOAc/hexane (1:2) to give colourless 
crystals (77 mg, 49%): mp 112-115°C; IR (KBr) 3310, 3190 (NH2), 2925-2860 
(aliph CH), 1720 (C=0), 1655 (C=0), 1390 (S02), 1185 (S02) cm’1; 6 H (CDC13, 400 
MHz) 0.88 (3H, t, 7 = 6 . 6  Hz, C-6 '-H3), 1.19 (3H, s, C-18-H3), 1.24-2.99 (19H, m), 
2.88-2.94 (2H, m, C-6 -H2), 3.66-3.82 (2H, m, N-CH2), 4.91 (2H, s, exchanged with 
D20 , NH2), 7.06 (1H, d ,J=  2.5 Hz, C-4-H), 7.11 (1H, dd, 7 = 8 . 6  Hz, 7=  2.5 Hz, C-
2-H) and 7.33 (1H, d, J  = 8 . 6  Hz, C-l-H); 6 C (CDC13, 100.4 MHz) 14.1 (q, C-6 '),
16.6 (q, C-18), 22.6 (t), 25.5 (t), 26.7 (t), 27.9 (t), 29.5 (t), 31.5 (2xt), 33.6 (t), 33.7 
(t), 38.2 (d), 40.2 (t, C-l'), 40.3 (d), 41.4 (s, C-13), 42.6 (d), 119.2 (d), 121.7 (d),
126.6 (d), 138.1 (s), 138.3 (s), 147.9 (s, C-3), 171.5 (s, C=0) and 178.2 (s, C=0); 
MS m/z (FAB+) 925.3 [64, (2M+H)+], 463.1 [100, (M+H)+]; MS m/z (FAB-) 1077.5 
[70, (2M+NBA)’], 615.3 [70, (M+NBA)’], 462.2 [100, M’]; Acc MS m/z (FAB+) 
463.2263, C24H35N2 0 5S requires 463.2267. Found: C, 62.60; H, 7.43; N, 6.20. 




Following method 4, a solution of 24 (130 mg, 299 |Limol) in anhydrous DMF (2 mL) 
was treated with NaH (14 mg, 359 |nmol) and the subsequent reaction with sulfamoyl 
chloride ( 6  eq.) was complete within 2 hours. The crude product was purified by 
flash chromatography (CHCVacetone, 9:1) to give 39 as a white foam (154 mg, 
100%). This compound was recrystallised from EtOAc/hexane (1:2) to give white 
crystals (125 mg, 81%): mp 162-165°C; IR (KBr) 3380, 3260 (NH2), 2945-2870 
(aliph CH), 1720 (C=0), 1650 (C=0), 1565-1495 (arom C=C), 1388 (S02), 1180 
(S02) cm'1; 5h (CDC13, 400 MHz) 1.18 (3H, s, C -I8 -H3), 1.22-3.00 (15H, m), 2.86- 
2.97 (2H, m, C-6 -H2), 3.42 (2H, t, J  = 6 . 6  Hz, C-4'-H2), 3.79 (2H, m, N-CH2), 4.89 
(2H, s, exchanged with D20 , NH2), 7.06 (1H, d, J  = 2.5 Hz, C-4-H), 7.12 (1H, dd, J  
= 8 . 6  Hz, J  = 2.5 Hz, C-2-H) and 7.33 (1H, d, /  = 8 . 6  Hz, C-l-H); 6 C (CDC13, 100.4 
MHz) 16.6 (q, C-18), 25.4 (t), 25.5 (t), 26.7 (t), 29.4 (t), 30.1 (t), 33.2 (t), 33.5 (t),
33.7 (t), 38.2 (d), 39.1 (t, C-l'), 40.3 (d), 41.4 (s, C-13), 42.6 (d), 119.2 (d), 121.7 (d),
126.6 (d), 138.1 (s), 138.2 (s), 147.9 (s, C-3), 171.4 (s, C=0) and 178.2 (s, C=0); 
MS m/z (FAB+) 513.1 [100, (M+H)+], 435.2 [46, (M-Br+H)+]; Acc MS m/z (FAB+) 





Following method 3, reaction of 24 (60 mg, 138 pmol) with sulfamoyl chloride in 
DMA (0.8 mL) was complete within 3 hours. The crude mixture was purified by 
flash chromatography (CHC^/acetone, 9:1) to give a white foam ( 6 6  mg) containing 
39 and 40: HPLC (MeOH/H20 , 68:32; Xmax = 267.5 nm) Rt (40) = 5.52 min, 58% 
and Rt (39) = 6.50 min, 42%. The final product 40 was isolated after preparative 
HPLC (MeOH/H20 , 68:32) to give a white solid (18 mg, 28%): mp 162-164°C; IR 
(KBr) 3390, 3245 (NH2), 2940-2865 (aliph CH), 1720 (C=0), 1645 (C=0), 1560- 
1490 (arom C=C), 1385 (S02), 1185 (S02) cm'1; 6 H (CDC13, 400 MHz) 1.17 (3H, s, 
C -I8 -H3), 1.28-3.00 (15H, m), 2.88-2.96 (2H, m, C-6 -H2), 3.54 (2H, t, J=  6.4 Hz, C-
228
4'-H2), 3.79 (2H, m, N-CH2), ~4-5 (2H, br s, NH2), 7.06 (1H, m, C-4-H), 7.11 (1H, 
app dd, J  = 8.5 Hz, J  = 2.1 Hz, C-2-H) and 7.33 (1H, d, J  = 8.5 Hz, C-l-H); MS m/z 
(FAB+) 469.3 [100, (M+H)+]; MS m/z (FAB-) 467.2 [100, (M-H)'], 621.3 [40, 
(M+NBA) ]; Acc MS m/z (FAB+) 469.1540, C22H3oC1N20 5S requires 469.1564.
3-Sulfamoyloxy-iV-cyclopropylmethyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17- 
imide (41)
Following method 3, reaction of 25 (100 mg, 283 jumol) with sulfamoyl chloride in 
DMA (1 mL) was complete within 1.5 hours. The crude product was recrystallised 
from acetone/hexane (1:2) to give 41 as white crystals (112 mg, 92%): mp 202- 
204°C; IR (KBr) 3280 (NH2), 2960 (aliph CH), 1700 (C=0), 1660 (C=0), 1395 
(S02), 1185 (S02) cm 1; 5H (CDC13, 400 MHz) 0.29-0.34 (2H, m, C-3'-H2), 0.40-0.45 
(2H, m, C-4'-H2), 1.08-1.16 (1H, m, C-l'-H), 1.19 (3H, s, C-18-H3), 1.32-3.02 (11H, 
m), 2.88-2.96 (2H, m, C-6 -H2), 3.66 (2H, m, N-CH2), 4.93 (2H, s, exchanged with 
D20 , NH2), 7.07 (1H, d, J = 2.5 Hz, C-4-H), 7.12 (1H, dd, J  = 8 . 6  Hz, J = 2.5 Hz, C-
2-H) and 7.34 (1H, d, J  = 8 . 6  Hz, C-l-H); MS m/z (FAB+) 865.1 [55, (2M+H)+],
586.1 [45, (M+H+NBA)+], 433.0 [100, (M+H)+]; MS m/z (FAB-) 585.2 [30, 
(M+NBA)'], 431.2 [100, (M-H)']; Acc MS m/z (FAB+) 433.1794, C22H29N20 5S 
requires 433.1797. Found: C, 61.00; H, 6.85; N, 5.91. C22H2 8N2OsS requires: C, 
61.09; H, 6.52; N, 6.48%.
3-SuIfamoyloxy-A-(4"-terf-butyl-benzyl)-16,17-sec0-estra-l,3,5(lO)-triene-16,17- 
imide (42)
Following method 3, reaction of 26 (200 mg, 449 pmol) with sulfamoyl chloride in 
DMA (2 mL) was complete within 6.5 hours. The crude product was recrystallised 
from EtOAc/hexane (1:2) to give 42 as white crystals (199 mg, 85%): mp 227- 
230°C; IR (KBr) 3320, 3240 (NH2), 2960-2870 (aliph CH), 1720 (C=0), 1660 
(C=0), 1385 (S02), 1180 (S02) cm'1; SH (CDC13, 400 MHz) 1.16 (3H, s, C-18-H3), 
1.29 (9H, s, C(CH3)3), 1.30-3.02 (11H, m), 2.87-2.93 (2H, m, C-6 -H2), 4.87 (2H, s, 
exchanged with D20 , NH2), 4.87-4.96 (2H, m, N-CHAHB) 7.06 (1H, d, J  = 2.5 Hz, 
C-4-H), 7.11 (1H, dd, J  = 8 . 6  Hz, J  = 2.5 Hz, C-2-H) and 7.24-7.34 (5H, m, C-l-H, 
C-2"-H, C-3"-H, C-5"-H and C-6 "-H); 5C (CDC13, 100.4 MHz) 16.4 (q, C-18), 25.3
229
(2xt), 29.3 (t), 31.2 (3xq, C(CH3)3), 33.5 (2xt), 34.4 (s, C(CH3)3), 38.0 (d), 40.0 (d),
41.3 (s, C-13), 42.5 (d), 42.8 (t, C-l'), 119.0 (d), 1 2 1 . 6  (d), 125.1 (2 xd), 126.5 (d), 
127.8 (2xd), 133.9 (s), 137.9 (s), 138.1 (s), 147.8 (s), 149.8 (s, C-3), 171.2 (s, C=0) 
and 178.1 (s, C=0); MS m/z (FAB+) 1049.3 [70, (2M+H)+], 525.1 [100, (M+H)+]; 
MS m/z (FAB-) 1047.5 [80, (2M-H)'], 523.2 [100, (M-H)']; Acc MS m/z (FAB+) 
525.2405, C29H37N2O5S requires 525.2423.
3-Sulfamoyloxy-A-(l"-pyridin-3"-ylmethyl)-16,17-seco-estra-l,3,5(10)-triene-
16,17-imide (43)
Following method 4, a solution of 27 (45 mg, 115 |Limol) in anhydrous DMF (0.5 
mL) was treated with NaH (5 mg, 230 |nmol) and the subsequent reaction with 
sulfamoyl chloride ( 6  eq.) was complete within 3 hours. The crude product was 
purified by flash chromatography (CHCL/acetone, 8:2) to give 42 as an off-white 
powder (42 mg, 78%). This compound was recrystallised from acetone/hexane (1:2) 
to give colourless crystals (28 mg, 52%): mp 215-218°C. IR (KBr) 3335 (NH2), 
3100-2850 (aliph CH), 1720 (C=0), 1675 (C=0), 1380 (S02), 1190 (S02) cm'1; 5H 
(DMSO-cL, 400 MHz) 1.10 (3H, s, C -I8 -H3), 1.15-2.97 (11H, m), 2.79-2.84 (2H, m, 
C-6 -H2), 4.81 (1H, d, 7 Ba  = 14.8 Hz, N-CHAUB\  4.86 (1H, d, JAB = 14.8 Hz, N- 
CRaHb), 6.96 (1H, d, J  = 2.7 Hz, C-4-H), 7.01 (1H, dd, J  = 8 . 6  Hz, J  = 2.7 Hz, C-2- 
H), 7.31 (1H, dd, J  = 7.8 Hz, J  = 4.7 Hz, C-5"-H), 7.36 (1H, d, J  = 8 . 6  Hz, C-l-H),
7.57 (1H, m, C-4"-H), 7.89 (2H, s, exchanged with D2 0 , NH2) and 8.41-8.44 (2H, m, 
C-2"-H and C-6 "-H); MS m/z (FAB+) 470.3 [48, (M+H)+], 133.2 [38], 111.2 [52],
97.1 [100]; MS m/z (FAB-) 622.3 [52, (M+NBA)'], 468.3 [100, (M-H)'], 276.2 [62], 
198 [48], 139.1 [46], 93.1 [40]; Acc MS m/z (FAB+) 470.1767, C2 4H28N3 O5 S 
requires 470.1750. HPLC (MeOH/H20 , 60:40; A,max = 260.4 nm) Rt = 4.84 min, 
100%. Found: C, 60.00; H, 5.86; N, 8.57. C24H27N3C>5S.(H20)i/2 requires: C, 60.03; 
H, 5.90; N, 8.78%.
3-Sulfamoyloxy-iV-benzyl-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (44)
Following method 3, reaction of 28 (150 mg, 385 pmol) with sulfamoyl chloride in 
DMA (1.5 mL) was complete within 3 hours. The crude product was purified by 
flash chromatography (CHC^/acetone, 9:1) to give 44 as a white powder (151 mg,
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84%). This compound was recrystallised from acetone/hexane (1:2) to give white 
crystals (133 mg, 74%); mp 208-210°C; IR (KBr) 3340, 3230 (NH2), 3100-3050 
(arom CH), 2950-2870 (aliph CH), 1715 (C=0), 1655 (C=0), 1610-1495 (arom 
C=C), 1385 (S02), 1195 (S02) cm'1; 5H (DMSO-d6, 400 MHz) 1.13 (3H, s, C-18- 
H3), 1.17-2.96 (11H, m), 2.81-2.87 (2H, m, C-6 -H2), 4.80 (1H, d, JBa = 14.6 Hz, N- 
C/^Hb), 4.86 (1H, d, Jab = 14.6 Hz, N-CHAHB\  6.99 (1H, d, J  = 2.3 Hz, C-4-H),
7.04 (1H, dd, J = 8.4 Hz, J  = 2.3 Hz, C-2-H), 7.19-7.40 (6 H, m, C6H5 and C-l-H) 
and 7.92 (2H, s, exchanged with D20 , NH2); MS m/z (FAB+) 469.2 [100, (M+H)+]; 
MS m/z (FAB-) 621.3 [38, (M+NBA)'], 467.2 [100, (M-H)']; Acc MS m/z (FAB+) 
469.1789, C25H29N20 5S requires 469.1797. HPLC (MeOH/H20 , 70:30; Amax = 266.3 
nm) Rt = 5.14 min, 100%. Found: C, 63.90; H, 6.12; N, 5.86. C2 5H2gN2 0 5 S requires: 
C, 64.08; H, 6.02; N, 5.98%.
3-Sutfamoyloxy-A-allyI-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (45)
Following method 3, reaction of 31 (150 mg, 345 pmol) with sulfamoyl chloride in 
DMA (2 mL) was complete within 3 hours. The crude product was purified by flash 
chromatography (CHCL/acetone, 9:1) to give 45 as a white foam (85 mg, 99%). This 
compound was recrystallised from acetone/hexane (1:2) to give white crystals (75 
mg, 87%): mp 210-213°C; IR (KBr) 3385, 3275 (NH2), 2935-2870 (aliph CH), 1715 
(C=0), 1670 (C=0), 1600-1495 (arom C=C), 1385 (S 02), 1185 (S02) cm ']; 6 H 
(DMSO-d6, 400 MHz) 1.13 (3H, s, C -I8 -H3), 1.25-2.89 (11H, m), 2.81-2.87 (2H, m, 
C-6 -H2), 4.17 (1H, app ddt, J = 15.0 Hz, J  = 5.1 Hz, J  = 1.7 Hz, N-CT^Hb), 4.27 
(1H, app ddt, J  = 15.0 Hz, /  = 5.1 Hz, J = 1.7 Hz, N-CHAHB), 4.97-5.08 (2H, m, C- 
3'-H2), 5.69-5.79 (1H, m, C-2'-H), 6.99 (1H, d, J = 2.5 Hz, C-4-H), 7.04 (1H, dd, J =
8 . 6  Hz, J  = 2.5 Hz, C-2-H), 7.38 (1H, d, J = 8 . 6  Hz, C-l-H) and 7.91 (2H, s, 
exchanged with D20 , NH2); 6 C (DMSO-d6, 100.4 MHz) 16.3 (q, C-18), 24.8 (t), 25.0 
(t), 29.0 (t), 32.8 (t), 33.5 (t), 37.4 (d), -39 (d, under solvent peaks), 40.9 (s, C-13),
41.1 (t, C-l'), 42.0 (d), 115.6 (t, C-3'), 119.2 (d), 121.5 (d), 126.4 (d), 132.7 (d), 
137.5 (s), 137.6 (s), 147.8 (s, C-3), 170.8 (s, C=0) and 177.6 (s, C=0); MS m/z 
(FAB+) 837.4 [48, (2M+H)+], 572.2 [6 8 , (M+H+NBA)+], 419.1 [100, (M+H)+]; MS 
m/z (FAB-) 571.1 [30, (M+NBA)'], 417.1 [100, (M-H)']; Acc MS m/z (FAB+) 
419.1635, C2 iH27N20 5S requires 419.1641. HPLC (MeOH/H2Q, 70:30; A™* = 266.3
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nm) Rt = 3.25 min, 100%. Found: C, 60.30; H, 6.32; N, 6.56. C2 1H2 6 N2 O5 S requires:
C, 60.27; H, 6.26; N, 6.69%.
5.4.2 Further D-ring modifications
3-Benzyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-amine (46)
A solution of 5 (100 mg, 257 |Limol) in anhydrous THF (3.5 mL) was added dropwise 
to a stirred suspension of LiAlFL (78 mg, 2.06 mmol) in anhydrous THF (3.5 mL) at 
0°C under an atmosphere of N2 . The resulting mixture was allowed to warm to room 
temperature and heated to reflux for 48 hours. After cooling down, H2O (300 jllL )  
was added, followed by 10% aq. NaOH (300 jllL ) and another portion of H2O (900 
jllL ). The mixture was filtered, the filter cake was washed with THF and the filtrate 
was concentrated under reduced pressure to give a brown product. The crude 
material was purified by flash chromatography (CHCh/MeOH, 98:2 to 75:25, 
gradient) to give 46 as an off-white solid (7 mg, 7%): mp 222-225°C; IR (KBr) 3410 
(NH), 2950-2810 (aliph CH), 1615-1500 (arom C=C) c m 1; SH (CDC13, 400 MHz)
1.18 (3H, s, C -I8 -H3), 1.22-2.87 (14H, m), 2.63 ( 1 H, d, Jab = 12.3 Hz, N-CHA/ /B),
3.06 (1H, d, Jba = 12.3 Hz, N-CHAHB), 3.57-3.63 (1H, m, N-CHA7/B'), 5.03 (2H, s, 
OCH2Ar), 6.71 (1H, d, J  = 2.6 Hz, C-4-H), 6.79 (1H, dd, J  = 8 . 6  Hz, J  = 2.6 Hz, C-2- 
H), 7.18 (1H, d, J  = 8 . 6  Hz, C-l-H) and 7.29-7.43 (5H, m, C6H5), NH not seen; MS 
m/z (FAB+) 362.2 [100, (M+H)+], 91.1 [38, (CH2Ar)+J; Acc MS m/z (FAB+) 
362.2498, C25H32NO requires 362.2484.
3-Benzyloxy-16,17-sec0-estra-l,3,5(lO)-triene-16,17-dithioimide (4 7 ) an(j 3 .
benzyloxy-16,17-sec0-estra-l,3,5(lO)-triene-16-one,17-thioimide (48)
Lawesson’s reagent (4.5 g, 11.17 mmol) was added to a stirred suspension of 5 (2.9 
g, 7.45 mmol) in anhydrous toluene (120 mL), under an atmosphere of N2 . The 
resulting mixture was heated to reflux for 4 hours giving a yellow solution. After 
cooling down, the solvent was removed under reduced pressure and the yellow crude 
mixture was purified by flash chromatography (CHCL/Hexane, 7:3 to CHCI3 , 
gradient) to give two products.
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The less polar fraction gave 47 as a yellow solid (-1.5 g) which was recrystallised 
from EtOH to give yellow crystals (1.13 g, 36%): mp 209-211°C; IR (KBr) 3120 
(NH), 2940-2860 (aliph CH), 1610-1600 (arom C=C), 1500 (C=S) c m 1; 5H (CDC13, 
400 MHz) 1.25 (3H, s, C -I8 -H3), 1.30-2.55 (9H, m), 2.65 (1H, dd, J  = 19.5 Hz, J  =
12.9 Hz, C-15-H), 2.84-2.90 (2H, m, C-6 -H2), 3.56 (1H, dd, J  = 19.5 Hz, J  = 4.3 Hz, 
C-15-H), 5.04 (2H, s, OCH2Ar), 6.72 (1H, d, J  = 2.7 Hz, C-4-H), 6.81 (1H, dd, J  = 
8 : 6  Hz, J  = 2.7 Hz, C-2-H), 7.22 (1H, d, J  = 8 . 6  Hz, C-l-H), 7.30-7.44 (5H, m, C6H5) 
and 10.63 (1H, s, exchanged with D20 , NH); 5C (CDCI3 , 100.4 MHz) 19.7 (q, C-18),
26.0 (t), 26.2 (t), 29.8 (t), 37.6 (t), 39.3 (d), 41.6 (t), 42.2 (2xt), 46.1 (s, C-13), 69.9 
(t, OCH2Ar), 112.5 (d), 114.4 (d), 126.2 (d), 127.3 (2xd), 127.8 (d), 128.4 (2xd),
131.4 (s), 136.9 (s), 137.1 (s), 156.8 (s, C-3), 202.0 (s, C=S) and 214.0 (s, C=S); MS 
m/z (FAB+) 422.1 [40, (M+H)+], 90.9 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 
422.1620, C25H28NOS2 requires 422.1612.
The more polar fraction gave 48 as a pale yellow solid (-2  g) which was 
recrystallised from EtOH to give yellow crystals (1.74 g, 58%): mp 204-207°C; IR 
(KBr) 3230 (NH), 2940-2860 (aliph CH), 1720 (C=0), 1605-1470 (C=S and arom 
C=C) cm'1; 5h (CDC13, 400 MHz) 1.21 (3H, s, C -I8 -H3), 1.30-2.66 (9H, m), 2.62 
(1H, dd, J  = 19.4 Hz, 2=  12.7 Hz, C-15-H), 2.83-2.89 (2H, m, C-6 -H2), 3.49 (1H, dd, 
J  = 19.4 Hz, J  = 3.9 Hz, C-15-HP), 5.02 (2H, s, OCH2Ar), 6.71 (1H, d, J = 2.7 Hz, 
C-4-H), 6.80 (1H, dd, J  = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.20 (1H, d, J = 8 . 6  Hz, C-l- 
H), 7.28-7.43 (5H, m, C6H5) and 9.55 (1H, s, exchanged with D20 , NH); 6 c (CDCI3 ,
100.4 MHz) 16.6 (q, C-18), 25.7 (t), 26.3 (t), 30.0 (t), 33.1 (t), 38.5 (d), 40.9 (s, C- 
13), 41.8 (d), 42.8 (d), 43.0 (d), 70.2 (t, OCH2Ar), 112.9 (d), 114.8 (d), 126.5 (d),
127.6 (2xd), 128.1 (d), 128.8 (2xd), 131.7 (s), 137.3 (s), 137.5 (s), 157.1 (s, C-3),
175.7 (s, C=0) and 207.6 (s, C=S); MS m/z (FAB+) 406.0 [59, (M+H)+], 90.9 [100, 
(CH2Ar)+]; Acc MS m/z (FAB+) 406.1846, C2 5H28N 0 2S requires 406.1841.
3-Hydroxy-A-ethyl-16,17-s,^ co-estra-l,3,5(10)-triene-16,17-amine (49)
A suspension of Raney nickel (50% slurry in H20 , 5 g) was added to a stirred 
solution of 47 (200 mg, 474 pmol) in EtOH/THF (1:1, 60 mL) at room temperature. 
The resulting suspension was stirred at room temperature overnight, after which it
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was filtered through celite. The filter cake was washed with several portions of EtOH 
and THF, and the filtrate was concentrated under reduced pressure to give a light 
brown solid. The crude product was recrystallised from acetone/hexane to give 49 as 
off-white crystals (34 mg, 24%): mp 188-191°C; IR (KBr) 3100 (OH), 2925-2825 
(aliph CH), 1610-1505 (arom C=C) c m 1; 5h (DMSO-cL, 400 MHz) 0.95 (3H, s, C- 
18-H3), 0.99 (3H, t ,J =  7.2 Hz, C-2'-H2), 1.10-2.73 (18H, m), 2.95-3.01 (1H, m, N- 
CUaHb), 6.44 (1H, d, /  = 2.7 Hz, C-4-H), 6.52 (1H, dd, J = 8 . 6  Hz, J  = 2.7 Hz, C-2- 
H), 7.06 (1H, d, J  = 8 . 6  Hz, C-l-H) and 9.02 (1H, s, exchanged with D20 , OH); MS 
m/z (FAB+) 300.1 [100, (M+H)+]; MS m/z (FAB-) 298.3 [100, (M-H)'].
3-Hydroxy-16,17-seco-estra-l,3,5(10)-triene-17-one-16,17-amide (50)
A suspension of Raney nickel (50% slurry in H20 , 5 g) was added to a stirred 
solution of 48 (300 mg, 740 pmol) in EtOH/THF (1:1, 60 mL) at room temperature. 
The resulting suspension was stirred at room temperature for 7 hours, after which it 
was filtered through celite. The filter cake was washed with several portions of EtOH 
and THF, and the filtrate was concentrated under reduced pressure to give a white 
solid. The crude product was recrystallised from EtOH to give 50 as white crystals 
(155 mg, 73%): mp 334-337°C (dec.); IR (KBr) 3350 (NH), 3185 (br, OH), 2945- 
2860 (aliph CH), 1635 (C=0), 1585-1500 (arom C=C) cm'1; 6 H (DMSO-cL, 400 
MHz) 1.03 (3H, s, C -I8 -H3 ), 1.18-2.74 (13H, m), 3.08-3.23 (2H, m, N-CHAHB), 6.42 
(1H, d, J  = 2.6 Hz, C-4-H), 6.50 (1H, dd, J  = 8.5 Hz, J  = 2.6 Hz, C-2-H), 7.04 (1H, d, 
J  = 8.5 Hz, C-l-H), 7.10 (1H, s, exchanged with D2 0 , OH or NH) and 9.00 (1H, s, 
exchanged with D20 , OH or NH); 6 C (DMSO-d6, 100.4 MHz) 18.4 (q, C-18), 20.3 
(t), 26.0 (t), 26.4 (t), 29.9 (t), 34.3 (t), 38.4 (d), 40.6 (s, C-13), 40.8 (t, C-16), 43.0 
(d), 44.6 (d), 113.3 (d), 115.1 (d), 126.5 (d), 130.7 (s), 137.5 (s), 155.5 (s, C-3) and
177.4 (s, C=0); MS m/z (FAB+) 286.2 [100, (M+H)+]; Acc MS m/z (FAB+) 
286.1805, CigH24N 0 2 requires 286.1807.
3-Sulfamoyloxy-16,17-seco-estra-l,3,5(10)-triene-17-one-16,17-amide (51)
Following method 4, a solution of 50 (80 mg, 280 pmol) in anhydrous DMF (1 mL) 
was treated with NaH (13 mg, 0.34 pmol) and the subsequent reaction with 
sulfamoyl chloride ( 6  eq.) was complete after stirring overnight. The crude product 
was recrystallised from EtOAc/hexane (1:2) to give 51 as yellow crystals (22 mg,
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21%): mp 217-218°C; IR (KBr) 3300 (br, NH2, NH), 2940-2865 (aliph CH), 1644 
(C=0), 1600-1490 (arom C=C), 1375 (S02), 1170 (S02) cm'1; 6 H (DMSO-cL, 400 
MHz) 1.04 (3H, s, C -I8 -H3), 1.18-2.88 (13H, m), 3.09-3.25 (2H, m, N-CHAHB), 6.95 
(1H, d, J=  2.6 Hz, C-4-H), 7.00 (1H, dd, / =  8.3 Hz, J=  2.6 Hz, C-2-H), 7.12 (1H, s, 
exchanged with D20 , NH), 7.34 (1H, d, J  = 8.3 Hz, C-l-H) and 7.88 (2H, s, 
exchanged with D20 , NH2); MS m/z (FAB+) 365.1 [100, (M+H)+]; Acc MS m/z 
(FAB+) 365.1558, Ci8H25N20 4S requires 365.1535.
3-Hydroxy-16,17-sec0-estra-l,3,5(lO)-triene-16,17-dithioimide (52)
Boron tribromide (1.0 M solution in DCM, 889 pL) was added dropwise to a stirred 
solution of 47 (250 mg, 593 pmol) in anhydrous DCM (10 mL) at -78°C under an 
atmosphere of N2. The resulting brown solution was stirred at -78°C for 4 hours, 
after which H20  (50 mL) was added and the mixture was allowed to warm to room 
temperature. The organics were extracted with DCM (50 mL), washed with sat. 
NaHCC>3 (4x30 mL), H20  (30 mL), then brine (30 mL), dried (Na2S 04), filtered and 
concentrated under reduced pressure to give a yellow product. The crude material 
was purified by flash chromatography (CHCI3) to give 52 as a yellow solid (98 mg, 
50%). This compound was recrystallised from CHCL/hexane to give yellow crystals 
(69 mg, 35%): mp 270-272°C; IR (KBr) 3410, 3230 (OH, NH), 2925-2860 (aliph 
CH), 1605 (arom C=C), 1500 (C=S) c m 1; 6 H (DMSO-ds, 400 MHz) 1.15 (3H, s, C- 
I 8 -H3 ), 1.19-2.80 (12H, m), ~3.35-3.40 (~1H, under solvent peaks, C-15-H), 6.44 
(1H, d, J  = 2.6 Hz, C-4-H), 6.52 (1H, dd, J = 8.3 Hz, J  = 2.6 Hz, C-2-H), 7.06 (1H, d, 
J  = 8.3 Hz, C-l-H), 9.03 (1H, s, exchanged with D20 , C-3-OH) and 13.37 (1H, s, 
exchanged with D20 , NH); MS m/z (FAB+) 332.0 [100, (M+H)+]; Acc MS m/z 
(FAB+) 332.1141, Ci8H22NOS2 requires 332.1143.
3-Hydroxy-16,17-sec0-estra-l,3,5(lO)-triene-16-one,17-thioimide (53)
Boron tribromide (1.0 M solution in DCM, 1.29 mL) was added dropwise to a stirred 
solution of 48 (350 mg, 863 pmol) in anhydrous DCM (15 mL) at -78°C under an 
atmosphere of N2. The resulting brown solution was stirred at -78°C for 5 hours, 
after which H20  (50 mL) was added and the mixture allowed to warm to room 
temperature. The organics were extracted with DCM (50 mL), washed with sat. 
NaHCQ3 (4x30 mL), H20  (30 mL), then brine (30 mL), dried (Na2SQ4), filtered and
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concentrated under reduced pressure to give a brown product. The crude material 
was purified by flash chromatography (CHCh/EtOAc, 9:1) to give 53 as a yellow 
solid (89 mg, 33%). This compound was recrystallised from CHC^/hexane to give 
pale yellow crystals (47 mg, 17%): mp 240-242°C; JR (KBr) 3420-3200 (OH, NH), 
2940-2870 (aliph CH), 1720 (C=0), 1620-1475 (C=S and arom C=C) cm'1; 6 H 
(DMSO-de, 400 MHz) 1.11 (3H, s, C -I8 -H3 ), 1.17-2.74 (12H, m), 3.27 (1H, dd, J  =
19.3 Hz, /  = 4.1 Hz, C-15-H), 6.44 (1H, d, /  = 2.7 Hz, C-4-H), 6.52 (1H, dd, J  = 8.3 
Hz, J  = 2.7 Hz, C-2-H), 7.06 (1H, d ,J=  8.3 Hz, C-l-H), 9.03 (1H, s, exchanged with 
D20 , C-3-OH) and 12.22 (1H, s, exchanged with D20 , NH); MS m/z (FAB+) 316.0 
[100, (M+H)+]; Acc MS m/z (FAB+) 316.1384, Ci8H22N 02S requires 316.1371.
5.4.3 A-ring modified analogues 
2-Iodo-estrone (54)
Mercuric acetate (5.89 g, 18.49 mmol) was added to a stirred solution of El (10 g, 
36.98 mmol) in a mixture of AcOH glacial (570 mL) and THF (280 mL) warmed to 
55°C. After 15 minutes, iodine (8.70 g, 34.37 mmol) was added portionwise and the 
resulting orange solution was stirred for 2 hours at room temperature. The final light 
yellow mixture was concentrated under reduced pressure and a solution of KI (5% 
aq., 300 mL) was added. The organics were extracted with EtOAc (2x300 mL), 
washed with aq. Na2S2C>3 (3x200 mL), then brine (200 mL), dried (MgSCU), filtered 
and concentrated under reduced pressure. The brown crude product was 
recrystallised from AcOH glacial to give 54 as a pale blue powder (6.42 g, 44%) and 
a further crop of the product (3.00 g) was obtained from the residue of the mother 
liquor upon recrystallisation from EtOH (overall ‘crude’ yield 64%). Both crops 
were further recrystallised from EtOH to give light grey flaky crystals (8.20 g, 
overall yield 56%): mp 213-215°C (dec.) [lit. 188 (MeOH) 200-205°C]; IR (KBr) 3400 
(OH), 2920-2855 (aliph CH), 1725 (C=0), 1590-1495 (arom C=C) cm 1; §H (CDC13, 
400 MHz) 0.91 (3H, s, C -I8 -H3), 1.36-2.57 (13H, m), 2.83-2.86 (2H, m, C-6 -H2),
5.09 (1H, s, exchanged with D20 , OH), 6.74 (1H, s, C-4-H) and 7.52 (1H, s, C-l-H); 
MS m/z (FAB+) 396.1 [100, M*], 85.1 [39]; Acc MS m/z (FAB+) 396.0568, 
Ci8H2 i0 2I requires 396.0586.
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2-Methoxy-estrone (55)
2-Iodoestrone 54 (4 g, 10.09 mmol) and copper chloride (452 mg, 3.36 mmol) were 
stirred at room temperature under an atmosphere of N2 in anhydrous pyridine (35 
mL) for 30 minutes. A freshly prepared 5.1 M solution of NaOMe (19.7 mL, 100 
mmol) was then added and the resulting blue solution was heated to reflux for 45 
minutes. After cooling down, the final orange solution was poured into ice and 
acidified with 5M HC1. The organics were extracted with EtOAc (3x200 mL), 
washed with aq. NaHCC>3 (2x200 mL), then brine (2x200 mL), dried (MgSCU), 
filtered and concentrated under reduced pressure. Purification of the crude product 
by flash chromatography (EtOAc/hexane, 3:17 to 5:15, gradient) gave 55 as an off- 
white residue (2.58 g, 78%): mp 167-170°C [lit. 182 (MeOH) 188-191°C]; IR (KBr) 
3415 (br, OH), 2930-2850 (aliph CH), 1725 (C=0), 1520-1460 (arom C=C) c m 1; 5H 
(CDCI3 , 400 MHz) 0.92 (3H, s, C -I8 -H3), 1.38-2.54 (13H, m), 2.80-2.84 (2H, m, C- 
6 -H2), 3.86 (3H, s, OCH3 ), 5.45 (1H, s, exchanged with D20 , OH), 6 . 6 6  (1H, s, C-4- 
H) and 6.79 (1H, s, C-l-H); MS m/z (FAB+) 300.2 [100, M+]; Acc MS m/z (FAB+) 
300.1719, C19H24O3 requires 300.1725.
2-Methoxy-3-benzyloxy-estra-l,3,5(10)-triene-17-one (56)
fBuOK (1.07 g, 9.54 mmol) was added portionwise to a stirred solution of 55 (1.91 g, 
6.36 mmol) in anhydrous DMF (20 mL) at 0°C under an atmosphere of N2 . After 2 
hours, benzyl bromide (1.13 mL, 9.54 mmol) was added and the mixture was stirred 
at room temperature for another 2 hours. The resulting orange solution was poured 
into H2O (50 mL) and the organics were extracted with EtOAc (2x50 mL), washed 
with H2O (2x50 mL), brine (2x50 mL), dried (MgSCU), filtered and concentrated 
under reduced pressure. The crude product was recrystallised from EtOH to give 56 
as a light orange powder (2.3 g). This compound was further recrystallised from 
EtOH to give an off-white powder (1.81 g, 73%): mp 120-123°C [lit. 268 (MeOH) 
152-154°C]; IR (KBr) 2930-2830 (aliph CH), 1735 (C=0), 1605, 1520, 1460 (arom 
C=C), 1255, 1205 (C-O) cm'1; 6 H (CDC13, 400 MHz) 0.92 (3H, s, C-18-H3), 1.36- 
2.55 (13H, m), 2.74-2.85 (2H, m, C-6 -H2), 3.86 (3 H, s, OCH3), 5.11 (2H, s, 
OCH2Ar), 6.64 (1H, s, C-4-H), 6.84 (1H, s, C-l-H) and 7.29-7.46 (5H, m, C6H5); MS 
m/z (FAB+) 390.1 [8 8 , M+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 390.2191, 
C26H3 0O3 requires 390.2195.
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2-Methoxy-3-benzyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-dioic acid (57) 
This was prepared according to the procedure used for the synthesis of 4. A solution 
of iodine (2.8 g, 11.1 mmol) in MeOH (35 mL) and a solution of KOH (5.0 g, 90.2 
mmol) in H2O (10 mL) and MeOH (25 mL) were added dropwise and alternatively 
to a stirred solution of 56 (1.52 g, 3.89 mmol) in MeOH (700 mL). After the workup, 
the resulting crude orange foam (1.80 g) was dissolved in a solution of KOH (2.8 g,
50.0 mmol) in MeOH/H2 0  (1:2, 84 mL) and heated to reflux for 4 hours. The orange 
residue (4.32 g) recovered after the workup was purified by flash chromatography 
(CHCL/MeOH, 95:5) to give 57 as an orange powder (311 mg, 18%): mp 91-93°C; 
IR (KBr) 3430-3000 (br, C 0 2H), 2935-2860 (aliph CH), 1705 (2xC=0), 1610-1455 
(arom C=C) cm'1; 6 H (CDCI3 , 400 MHz) 1.02 (3H, s, C -I8 -H3), 1.21-2.38 (11H, m), 
2.64-2.70 (2H, m, C-6 -H2), 3.72 (3H, s, OCH3), 5.01 (2H, s, OCH2Ar), 6.70 (1H, s, 
C-4-H), 6.85 (1H, s, C-l-H), 7.30-7.45 (5H, m, C6H5) and 12.20 (2H, br s, 
exchanged with D20 , C 0 2H); MS m/z (FAB+) 438.1 [52, M+], 91.0 [100, (CH2Ar)+]; 
MS m/z (FAB-) 437.2 [100, (M-H)']; Acc MS m/z (FAB+) 438.2055, C26H3o06 
requires 438.2042.
2-Methoxy-3-benzyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (5 8 )
This was prepared according to the procedure used for the synthesis of 5 by reaction 
of 57 (300 mg, 684 mmol) with urea (300 mg, 4.99 mmol) at 180°C. Purification of 
the crude product by flash chromatography (CHCL/acetone, 95:5) gave 58 as a light 
yellow powder (170 mg, 59%): mp 84-87°C; IR (KBr) 3415, 3225 (br, NH), 3090- 
2860 (arom and aliph CH), 1720 (C=0), 1695 (C=0), 1610-1510 (arom C=C), 1260 
(C-O) cm'1; 5h  (DMSO-d6, 400 MHz) 1.10 (3H, s, C - I 8 - H 3 ) ,  1.14-2.66 (11H, m), 
2.67-2.72 (2H, m, C-6 -H2), 3.73 (3H, s, OCH3), 5.02 (2H, s, OCH2Ar), 6.73 (1H, s, 
C-4-H), 6 . 8 6  (1H, s, C-l-H), 7.30-7.46 (5H, m, C6H5) and 10.64 (1H, s, exchanged 
with D20 , NH); MS m/z (FAB+) 419.1 [100, M+]; Acc MS m/z (FAB+) 419.2110, 
C2 6H29NO4  requires 419.2097.
2-Methoxy-3-hydroxy-16,17-sec0-estra-l,3,5(lO)-triene-16,17-imide (59)
Following method 2, a suspension of 58 (150 mg, 357 pmol) and Pd-C (10%, 80 mg) 
in MeOH/THF 2:1 (15 mL) was hydrogenated for 4 hours to give 59 as a light 
yellow powder (115 mg, 97%). An analytical sample was recrystallised from MeOH
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to give white crystals: mp 202-205°C; IR (KBr) 3500-3090 (br, OH and NH), 2935- 
2840 (aliph CH), 1725 (C=0), 1685 (C=0), 1515-1460 (arom C=C) cm'1; 5H 
(DMSO-d*, 400 MHz) 1.10 (3H, s, C -I8 -H3), 1.13-2.42 (11H, m), 2.63-2.69 (2H, m, 
C-6 -H2), 3.71 (3H, s, OCH3), 6.45 (1H, s, C-4-H), 6.78 (1H, s, C-l-H), 8.67 (1H, s, 
exchanged with D2O, OH) and 10.63 (1H, s, exchanged with D2 O, NH); MS m/z 
(FAB+) 330.1 [100, (M+H)+]; MS m/z (FAB-) 481.2 [43, (M-H+NBA)'], 328.1 [100, 
(M-H)-]; Acc MS m/z (FAB+) 330.1695, C19H24NO4  requires 330.1705. HPLC 
(MeOH/H20 , 75:25; Xmax = 286.4 nm) Rt = 2.64 min, 100%.
2-Methoxy-3-sulfamoyloxy-16,17-seco-estra-l,3,5(10)-triene-16,17-imide (60)
Following method 4, a solution of 59 (70 mg, 212 jLimol) in anhydrous DMF (1.5 
mL) was treated with NaH (10 mg, 254 pmol) and the subsequent reaction with 
sulfamoyl chloride ( 6  eq.) was complete after stirring overnight. The crude product 
was purified by flash chromatography (CHCl3/acetone, 8:2) to give 60 as a white 
foam ( 6 8  mg, 79%). This compound was recrystallised from acetone/hexane (1:2) to 
give white crystals (58 mg, 67%): mp 225-230°C; IR (KBr) 3275-3160, 3065 (NH2 , 
NH), 2960-2820 (aliph CH), 1715 (C=0), 1695 (C=0), 1510 (arom C=C), 1375, 
1180 (S02) c m 1; 8 H (DMSO-c^, 400 MHz) 1.11 (3H, s, C - I 8 - H 3 ) ,  1.21-2.47 (11H, 
m), 2.71-2.75 (2H, m, C-6 -H2), 3.77 (3H, s, OCH3), 7.00 (1H, s, C-4-H or C-l-H),
7.02 (1H, s, C-l-H or C-4-H), 7.84 (2H, s, exchanged with D20 , NH2) and 10.65 
(1H, s, exchanged with D2 0 , NH); MS m/z (FAB+) 561.9 [24, (M+NBA)+], 408.9 
[100, M+]; MS m/z (FAB-) 561.2 [43, (M+NBA)'], 407.1 [100, (M-H)']; Acc MS m/z 
(FAB+) 408.1345, C 19H24NO6S requires 408.1355. HPLC (MeOH/H20 , 90:10; Xmax 
= 279.3 nm) Rt = 1.92 min, 98%. Found: C, 56.20; H, 5.99; N, 6.83. Ci9H24N0 6S 
requires: C, 55.87; H, 5.92; N, 6 .8 6 %.
5.4.4 16-Alkylidene derivatives of E l and precursors
3-Acetoxy-estra-l,3,5(10)-triene-17-one (61)
AcOH glacial (60 mL, 1.05 mmol) was added dropwise over 45 minutes to a stirred 
solution of E l (3 g, 11.1 mmol) in anhydrous pyridine (200 mL) at 0°C, under an 
atmosphere of N2 . The resulting yellow mixture was heated to reflux for 1 hour,
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allowed to cool down, poured into H2 O and ice (300 mL) and acidified with 5M HC1. 
The organics were extracted with EtOAc (300 mL), washed with H2O (200 mL), aq. 
NaHCOs (200 mL), then brine (200 mL), dried (Na2S0 4 ), filtered and concentrated 
under reduced pressure. The crystalline orange crude (3.88 g) was recrystallised from 
IPA to give 61 as light yellow needles (3.25 g, 94%): mp 106-108°C [lit. 156 (MeOH) 
120°C]; IR (KBr) 2930-2870 (aliph CH), 1765 (C=0), 1735 (C=0), 1605-1490 
(arom C=C), 1210 (C-O) c m 1; 6 H ( C D C I 3 ,  400 MHz) 0.91 (3H, s, C -I8 -H3 ), 1.45- 
2.54 (13H, m), 2.29 (3H, s, COCH3), 2.89-2.92 (2H, m, C-6 -H2), 6.81 (1H, d, J  = 2.6 
Hz, C-4-H), 6.85 (1H, dd, J  = 8.3 Hz, J  = 2.6 Hz, C-2-H) and 7.28 (1H, d, J  = 8.3 
Hz, C-l-H); MS m/z (FAB+) 466.2 [28, (M+H+NBA)*], 313.2 [100, (M+H)+], 270.2 
[8 8 , (M+H-COCH3)+], 85.1 [35]; Acc MS m/z (FAB+) 313.1808, C2 0H2 5O3 requires 
313.1804.
3-Acetoxy-16-methylene-estra-l,3,5(10)-triene-17-one (62)
Paraformaldehyde (480 mg, 15.98 mmol of HCHO unit) and dimethylamine 
hydrochloride (1.6 g, 19.6 mmol) were added to a stirred solution of 61 (1.0 g, 3.20 
mmol) in anhydrous isoamyl alcohol ( 8  mL) and the resulting mixture was heated to 
reflux for 24 hours. After cooling down, the final light yellow solution was poured 
into H2O (30 mL) and acidified with 5M HC1. The organics were extracted with 
EtOAc (2x50 mL), washed with NaHC0 3  sat. (20 mL), H2 O (20 mL), then brine (20 
mL), dried (Na2S0 4 ), filtered and concentrated under reduced pressure to give a light 
yellow oil. The residual isoamyl alcohol was distilled off using a Kugelrohr 
apparatus and the oily residue obtained crystallised overnight. This product was 
purified by flash chromatography (CHCL/EtOAc, 95:5) to give 62 as a white solid 
(527 mg, 51%). For analysis, a sample was triturated with hexane to give colourless 
crystals: mp 134-135°C; IR (KBr) 2980-2835 (aliph CH), 1765 (C=0), 1725 (C=0), 
1640-1375 (arom C=C and exocyclic C=C) cm'1; 8 h (CDCI3 , 400 MHz) 0.93 (3H, s, 
C -I8 -H3), 1.41-2.72 (11H, m), 2.29 (3H, s, COCH3), 2.90-2.95 (2H, m, C-6 -H2), 
5.41-5.43 (1H, m, C-l'-H), 6.09-6.12 (1H, m, C-L-H), 6.81 (1H, d, J=  2.5 Hz, C-4- 
H), 6 . 8 6  (1H, dd, J -  8.3 Hz, J=  2.5 Hz, C-2-H) and 7.29 (1H, d, J=  8.3 Hz, C-l-H); 
MS m/z (FAB+) 325.2 [100, (M+H)+], 282.2 [78, (M+H-COCH3)+l; Acc MS m/z 
(FAB+) 325.1822, C2 1H2 5O3 requires 325.1804. Found: C, 77.90; H, 7.50. C2 1H2 4O3 
requires: C, 77.75; H, 7.46%.
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16-Methylene-estrone (63)
A solution of KOH ( 6  mg, 110 |nmol) in H2O (2 mL) was added dropwise to a stirred 
solution of 62 (30 mg, 92 jumol) in EtOH (10 mL). The resulting mixture was stirred 
at room temperature for 30 minutes, after which the solvent was removed under 
reduced pressure, H2O added (20 mL) followed by 5M HC1 (1 mL). The organics 
were extracted with EtOAc (30 mL), washed with H2O (20 mL), then brine (20 mL), 
dried (Na2S0 4 ), filtered and concentrated under reduced pressure to give a white 
product (34 mg). The crude material was recrystallised from IPA/H2O (1:2) to give 
63 as white crystals (15 mg, 58%): mp 229-231°C; IR (KBr) 3385 (OH), 2925 (aliph 
CH), 1715 (C=0), 1635-1450 (arom C=C and exocyclic C=C) cm'1; 5H (CDCI3 , 400 
MHz) 0.93 (3H, s, C -I8 -H3), 1.39-2.72 (11H, m), 2.81-2.90 (2H, m, C-6 -H2), 4.73 
(1H, s, exchanged with D20 , OH), 5.40-5.43 (1H, m, C -lr-H), 6.09-6.11 (1H, m, C- 
L-H), 6.58 (1H, d,J =  2.8 Hz, C-4-H), 6.64 (1H, dd, J = 8.3 Hz, J = 2.8 Hz, C-2-H) 
and 7.15 (1H, d, J = 8.3 Hz, C-l-H); MS m/z (FAB+) 663.3 [65], 282.1 [72, M+],
72.9 [100]; Acc MS m/z (FAB+) 282.1620, Q 9H2 2O2 requires 282.1620.
16-Methylene-estrone (63) and 16p-ethoxymethyl-estrone (64)
A solution of KOH (41 mg, 739 jumol) in H2O (2 mL) was added dropwise to a 
stirred solution of 62 (200 mg, 616 jimol) in EtOH (20 mL) at 0°C. The resulting 
light yellow solution was stirred for 30 minutes at 0°C, after which the solvent was 
removed under reduced pressure and H2O added (40 mL). This mixture was acidified 
with 5M HC1 and the white precipitate that formed was filtered, dried (131 mg) and 
purified by flash chromatography (CHCL/EtOAc, 95:5) to give two products:
The less polar fraction gave 63 as a white solid (50 mg, 29%).
The more polar fraction gave 64 as a light yellow solid (26 mg, 13%). This 
compound was recrystallised from EtOH/H2 0  to give light yellow crystals (13 mg, 
6 %): mp 208-210°C; IR (KBr) 3370 (OH), 2970-2855 (aliph CH), 1730 (C=0), 
1610, 1505 (arom C=C), 1225 (C-O) cm'1; 5H (CDC13, 400 MHz) 0.89 (3H, s, C-18- 
H3), 1.16 (3H, t, J  = 7.0 Hz, C-2"-H3), 1.36-2.42 (12H, m), 2.81-2.85 (2H, m, C-6 - 
H2), 3.42-3.50 (2H, m, C-l"-H2), 3.61 (1H, dd, JAB = 9.4 Hz, J=  3.9 Hz, C-V-UAHB),
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3.65 (1H, dd, 7ba = 9.4 Hz, J  = 5.5 Hz, C-L-7/aHb), 4.59 (1H, s, exchanged with 
D2 0 , OH), 6.56 (1H, d, J = 2.8 Hz, C-4-H), 6.62 (1H, dd, J  = 8.5 Hz, J  = 2.8 Hz, C-
2-H) and 7.13 (1H, d, J  = 8.5 Hz, C-l-H); 6 C (CDC13, 100.4 MHz) 12.9 (q, C-2"),
15.0 (q, C-18), 25.8 (t), 25.9 (t), 26.6 (t), 29.4 (t), 32.0 (t), 37.7 (d), 44.0 (d), 48.2 (s, 
C-13), 48.9 (d), 50.2 (d), 66.4 (t, C-L or C-l"), 69.3 (t, C-L or C-l"), 112.5 (d),
115.0 (d), 126.2 (d), 131.9 (s), 137.8 (s) and 153.0 (s, C-3), C=0 not seen; MS m/z 
(FAB+) 329.1 [100, (M+H)+]; Acc MS m/z (FAB+) 329.2124, C2 1H29O3 requires 
329.2117. HPLC (MeOH/H20 , 90:10, A™* = 279.3 nm) Rt = 2.37 min, 98%. Found: 
C, 76.60; H, 8.62. C21H28O3 requires: C, 76.79; H, 8.59%.
16-Methylene-estradiol (65)
NaBFU (33 mg, 867 pmol) in H20  (2 mL) was added dropwise to a stirred solution 
of 63 (50 mg, 177 jxmol) in a mixture of MeOH/THF (3:1, 8  mL) at 0°C. The 
resulting colourless solution was stirred at 0°C for 10 minutes, after which AcOH 
glacial (4 drops) was added, followed by 10% aq. NaCl (10 mL). The white 
precipitate that formed was filtered, dried (38 mg) and recrystallised from 
acetone/hexane (1:3) to give 65 as white crystals (24 mg, 48%): mp 199-201 °C 
[lit.20 2 (acetone/hexane) 208-210°C]; IR (KBr) 3415 (OH), 3220 (br, OH), 2935- 
2865 (aliph CH), 1610-1445 (arom C=C and exocyclic C=C) cm'1; 8 h (DMSO-d6 , 
400 MHz) 0.59 (3H, s, C -I8 -H3), 1.19-2.38 (11H, m), 2.66-2.74 (2H, m, C-6 -H2), 
3.79-3.81 (1H, m, C-17-H), 4.90-4.92 (2H, m, 1H exchanged with D20 , C-L-H and 
C-17-OH), 5.02-5.04 (1H, m, C-L-H), 6.43 (1H, d, / =  2.6 Hz, C-4-H), 6.50 (1H, dd, 
J = 8.5 Hz, J = 2.6 Hz, C-2-H) and 7.04 (1H, d, J = 8.5 Hz, C-l-H), 9.00 (1H, s, 
exchanged with D20 , C-3-OH); MS m/z (FAB+) 373.2 [82], 284.1 [100, M+], 267.1 
[47, (M+H-OH)+]; Acc MS m/z (FAB+) 284.1778, Q 9H2 4O2 requires 284.1776.
16-isobutylidene-estrone (6 6 )
A solution of El (420 mg, 1.55 mmol) in anhydrous THF (5 mL) was added 
dropwise to a stirred solution of LDA (2.47 mL of a 1.8 M solution in 
heptane/THF/ethyl benzene, 4.44 mmol) in anhydrous THF (2 mL) at -78°C, under 
an atmosphere of N2. After 2 hours of stirring at -78°C, isobutyraldehyde (185 p.L,
2.03 mmol, freshly distilled from Na2 S0 4 ) was added. The resulting mixture was 
stirred overnight, during which it was allowed to warm to room temperature. The
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solvent was then removed under reduced pressure and H2O added (50 mL). The 
organics were extracted with EtOAc (70 mL), washed with H2O (20 mL) then brine 
(20 mL), dried (Na2 S0 4 ), filtered and concentrated under reduced pressure to give a 
white foam (602 mg). The crude product was purified by flash chromatography 
(CHCls/EtOAc, 9:1) to give 6 6  as a white foam (401 mg, 79%). This compound was 
recrystallised from EtOAc/hexane, yielding white crystals (325 mg, 64%): mp 188- 
190°C; IR (KBr) 3370 (OH), 2930-2890 (aliph CH), 1710 (C=0), 1645-1445 (arom 
C=C and exocyclic C=C) c m 1; 6 h (CDC13, 400 MHz) 0.92 (3H, s, C - I 8 - H 3 ) ,  1.06 
(3H, d, J  = 6 . 6  Hz, C-3'-H3), 1.04 (3H, d, /  = 6 . 6  Hz, C-4'-H3), 1.40-2.70 (12H, m), 
2.84-2.90 (2H, m, C-6 -H2), 4.67 (1H, s, exchanged with D20 , OH), 6.46 (1H, ddd, J 
= 9.8 Hz, J  = 2.7 Hz, / =  1.9 Hz, C-l'-H), 6.59 (1H, d, J=  2.7 Hz, C-4-H), 6.64 (1H, 
dd, J = 8.3 Hz, J=  2.7 Hz, C-2-H) and 7.16 (1H, d, J = 8.3 Hz, C-l-H); 5C (CDC13,
100.4 MHz) 15.0 (q, C-18), 22.3 (2xq, C-3' and C-4'), 26.4 (2xt), 27.2 (t), 29.7 (d),
29.9 (t), 32.0 (t), 38.3 (d), 44.4 (d), 48.3 (d), 48.8 (s, C-13), 113.1 (d), 115.5 (d),
126.7 (d), 132.2 (s), 134.7 (s), 138.1 (s), 144.2 (d, C-l'), 153.8 (s, C-3) and 2 1 0 . 0  (s, 
C=0); MS m/z (FAB+) 325.1 [100, (M+H)+]; Acc MS m/z (FAB+) 325.2166, 
C22H2 9O2 requires 325.2167. Found: C, 81.30; H, 8.71. C2 2H2 8O2 requires: C, 81.44; 
H, 8.70%.
16-isobutylidene-estradiol (67)
A solution of NaBFL (57 mg, 1.51 mmol) in H2O (3 mL) was added dropwise to a 
stirred solution of 6 6  (100 mg, 308 pmol) in a mixture of MeOH/THF (2:1, 9 mL) at 
0°C. The resulting solution was stirred at 0°C for 20 minutes, after which AcOH 
glacial (5 drops) was added, followed by 10% aq. NaCl (20 mL). The white 
precipitate that formed was filtered, dried ( 1 0 2  mg) and recrystallised from 
acetone/hexane to give 67 as white crystals (60 mg, 60%): mp 143-145°C; IR (KBr) 
3435-3325 (OH), 2955-2865 (aliph CH), 1695-1500 (arom C=C and exocyclic C=C) 
cm 1; 5h (CDC13, 400 MHz) 0.67 (3H, s, C -I8 -H3), 0.96 (3H, d, J=  6 . 6  Hz, C-3'-H3), 
0.99 (3H, d, J  = 6 . 6  Hz, C-4'-H3), 1.22-2.02 (13H, m), 2.81-2.87 (2H, m, C-6 -H2), 
3.91-3.98 (1H, m, C-17-H), 4.66 (1H, s, exchanged with D2 0 , OH), 5.32 (1H, ddd, J 
= 9.4 Hz, J  = 4.7 Hz, J=  2.3 Hz, C-l'-H), 6.56 (1H, d, / =  2.7 Hz, C-4-H), 6.63 (1H, 
dd, J  = 8 . 6  Hz, J  = 2.7 Hz, C-2-H) and 7.16 (1H, d, J=  8 . 6  Hz, C-l-H); MS m/z
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(FAB+) 326.2 [95, M+], 309.2 [100, (M-OH)+], 283.1 [50]; Acc MS m/z (FAB+) 
326.2252, C2 2H30O2 requires 326.2246.
16-(2f,2'-Dimethyl-propyIidene)-estrone (68) and 3-(l'-hydroxy-2',2'-dimethyl- 
propoxy)-16-(l"-hydroxy-2",2"-dimethyl-propyl)-estrone (69)
This was prepared according to the procedure used to synthesise 6 6 . E l (500 mg,
1.85 mmol) reacted with LDA (2.47 mL of a 1.8 M solution in heptane/THF/ethyl 
benzene, 4.44 mmol) and 2,2-dimethyl-propionaldehyde (261 |iL, 2.40 mmol, freshly 
distilled from Na2 SC>4) for 2 days. Purification of the crude mixture by flash 
chromatography (CHCf/EtOAc, 9:1 to 8:2, gradient) gave two products:
The less polar fraction gave 6 8  as a white crystalline solid (264 mg, 42%). This 
compound was recrystallised from EtOAc to give white crystals (113 mg, 21%): mp 
256-258°C; IR (KBr) 3350 (OH), 2960-2860 (aliph CH), 1710 (0=0), 1640-1450 
(exocyclic C=C and arom C=C), 1225 (C-O) cm 1; 6 h (CDCI3 , 400 MHz) 0.90 (3H, 
s, C -I8 -H3), 1.17 (9H, s, C(CH3)3), 1.41-2.45 (11H, m), 2.83-2.91 (2 H, m, C-6 -H2),
4.72 (1H, s, exchanged with D20 , OH), 6.59 (1H, d, J  -  2.7 Hz, C-4-H), 6.63-6.65 
(2H, m, C-2-H and C-l'-H) and 7.16 (1H, d, J  = 8.0 Hz, C-l-H); 5c (CDCI3 , 100.4 
MHz) 14.6 (q, C-18), 26.1 (t), 26.8 (t), 27.0 (t), 29.5 (t), 29.7 (3xq, C(CH3)3), 31.7 
(t), 33.7 (s, C(CH3)3), 38.0 (d), 44.1 (d), 47.0 (s, C-13), 48.0 (d), 112.5 (d), 114.9 (d),
126.0 (d), 131.8 (s), 132.8 (s), 137.5 (s), 146.5 (d, C-l'), 153.1 (s, C-3) and 209.3 (s, 
C=0); MS m/z (FAB+) 677.5 [54, (2M+H)+], 492.2 [24, (M+H+NBA)+], 339.2 [100, 
(M+H)+J; Acc MS m/z (FAB+) 339.2326, C23H310 2 requires 339.2324. HPLC 
(MeOH/H20 , 80:20; Xmm = 233.3 nm) Rt = 4.25 min, 99%. Found: C, 81.50; H, 8.96. 
C23H3 0O2 requires: C, 81.61; H, 8.93%.
The more polar fraction gave 69 as a white solid (136 mg, 17%). An analytical 
sample was recrystallised from EtOAc/Hexane (1:2): mp 126-128°C; IR (KBr) 3445 
(br, OH), 2970-2870 (aliph CH), 1700 (C=0), 1615-1505 (arom C=C) cm'1; 8 H 
(CDC13, 400 MHz) 0.80 (3H, s, C -I8 -H3), 0.93 (9H, s, C(CH3)3), 0.98-2.29 (13H, m), 
1.25 (9H, s, C(CH3)3), 2.78-2.85 (2 H, m, C-6 -H2), 3.23 ( 1 H, dd, exchanged to a 
doublet with D20 , J = 8 . 8  Hz, J = 4.9 Hz, C-l"-H), 4.68 (1H, s, exchanged with D2O, 
OH), 4.97 (1H, s, C-l'-H), 6.55 (1H, d, / =  2.7 Hz, C-4-H), 6.62 (1H, dd, J=  8.4 Hz,
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J  = 2.7 Hz, C-2-H) and 7.13 (1H, d, J  = 8.4 Hz, C-l-H), OH not seen; MS m/z 
(FAB+) 442.4 [100, (M+H)+], 341.3 [98], 323.3 [34], 283.2 [38], 159.1 [30].
16-(2 ',2 '-Dimethyl-propylidene)-estradiol (70)
A solution of NaBFL (44 mg, 1.16 mmol) in H2O (2.5 mL) was added to a stirred 
solution of 6 8  in a mixture of MeOH/THF (2:1, 15 mL) at 0°C. The colourless 
solution was stirred for 1 hour at 0°C, after which AcOH glacial (4 drops) was 
added, followed by 10% aq. NaCl solution (15 mL). The resulting white precipitate 
was filtered, dried (79 mg) and recrystallised from EtOAc/Hexane (1:8) to give 70 as 
white crystals (63 mg, 79%): mp 219-222°C; IR (KBr) 3550, 3410 (OH), 2960-2875 
(aliph CH), 1610, 1505 (aliph C=C and arom C=C) c m 1; 6 H (CDC13, 400 MHz) 0.65 
(3H, s, C-I8 -H3), 1.10 (9H, s, C(CH3)3), 1.18-2.59 (12H, m), 2.82-2.88 (2H, m, C-6 - 
H2), 3.85-3.90 (1H, app d, /  = 9.4 Hz, C-17-H), 4.60 (1H, s, exchanged with D2 0, 
OH), 5.46 (1H, dd, J  = 4.9 Hz, / =  2.5 Hz, C-l'-H), 6.55 (1H, d, J=  2.8 Hz, C-4-H),
6.61 (1H, dd, J = 8.5 Hz, J = 2.8 Hz, C-2-H) and 7.14 (1H, d, J=  8.5 Hz, C-l-H); 6 C 
(CDC13, 100.4 MHz) 11.4 (q, C-18), 26.8 (t), 27.8 (t), 29.1 (t), 30.0 (t), 30.8 (3xq, 
C(CH3)3), 33.5 (s, C(CH3)3), 36.8 (t), 38.7 (d), 42.9 (s, C-13), 44.4 (d), 47.5 (d), 85.0 
(d, C-17), 113.0 (d), 115.5 (d), 126.7 (d), 132.7 (s), 133.7 (d, C-l'), 138.3 (s), 140.2 
(s) and 153.6 (s, C-3); MS m/z (FAB+) 340.2 [49, M+], 323.2 [100, (M-OH)+], 283.2 
[92, (M-C(CH3)3)+] ; Acc MS m/z (FAB+) 340.2390, C23H3 20 2 requires 340.2402. 
HPLC (MeOH/H20 , 96:4, Xmax = 280.5 nm) Rt = 2.54 min, 99.5%. Found: C, 81.00; 
H, 9.54. C23H320 2 requires: C, 81.13; H, 9.47%.
16-(1 '-Hydroxy-propyl)-estrone (71)
Following the procedure used to synthesise 6 6 , El (500 mg, 1.85 mmol) reacted with 
LDA (2.47 mL of a 1.8 M solution in heptane/THF/ethyl benzene, 4.44 mmol) and 
propionaldehyde (160 pL, 2.40 mmol, dried on CaCL and freshly distilled from 
Na2 S0 4) overnight. Purification of the crude mixture by flash chromatography 
(CHCl3/EtOAc, 8:2) gave 71 as a white solid (363 mg, 60%). This compound was 
recrystallised from EtOAc to give white crystals (49 mg) and a further crop of the 
product (170 mg) was obtained from the residue of the mother liquor upon 
recrystallisation from EtOAc/hexane (overall yield 36%): mp 248-252°C; IR (KBr) 
3585 (OH), 3380 (br, OH), 2970-2835 (aliph CH), 1720 (C=0), 1600-1445 (arom
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C=C), 1225 (C-O) c m 1; Sh (CDCI3 , 400 MHz) 0.94 (3H, s, C -I8 -H3), 1.01 (3H, t, J 
= 7.5 Hz, C-3'-H3), 1.32-2.44 (14H, m), 2.83-2.91 (2H, m, C-6 -H2), 3.65-3.72 (1H, 
m, C-l'-H), 3.99 (1H, s, exchanged with D2O, OH), 4.69 (1H, s, exchanged with 
D20 , OH), 6.59 (1H, d ,J  = 2.7 Hz, C-4-H), 6.65 (1H, dd, J = 8.4 Hz, J  = 2.7 Hz, C-
2-H) and 7.15 (1H, d, /  = 8.4 Hz, C-l-H); MS m/z (FAB+) 329.2 [100, (M+H)+],
311.2 [30, (M-OH)+]; Acc MS m/z (FAB+) 329.2119, C21H29O3 requires 329.2117. 
Found: C, 76.60; H, 8.62. C21H28O3 requires: C, 76.79; H, 8.59%.
5.4.5 D-ring fused pyrazole derivatives of E l and precursors
3-Benzyloxy-16-hydroxymethylene-estra-l,3,5(10)-triene-17-one (72)
rBuOK (9.4 g, 84.1 mmol) was added portionwise to a stirred solution of 3 (10 g,
27.7 mmol) in anhydrous toluene (250 mL) at room temperature, under an 
atmosphere of N2. After stirring for 20 minutes, ethyl formate (14.8 mL, 194 mmol) 
was added and the resulting suspension stirred for 2.5 hours. The final mixture was 
poured into H20  (300 mL) and acidified with 5M HC1. The organics were extracted 
with EtOAc (2x200 mL), washed with H20  (3x100 mL), then brine (2x100 mL), 
dried (Na2S0 4 ), filtered and concentrated under reduced pressure. The crude product 
was triturated with boiling EtOAc to give 72 as an off-white solid (9.25 g, 8 6 %): mp 
149-151°C; IR (KBr) 3235 (OH), 2930-2855 (aliph CH), 1700, 1675-1500 (C=0, 
C=C and arom C=C) cm'1; 5h (DMSO-c^, 400 MHz) 0.81 (3H, s, C -I8 -H3), 1.31-
2.62 (11H, m), 2.79-2.85 (2H, m, C-6 -H2), 5.05 (2H, s, OCH2Ar), 6.71 (1H, d, J =
2.7 Hz, C-4-H), 6.75 (1H, dd, J = 8.4 Hz, J = 2.7 Hz, C-2-H), 7.16 (1H, d, J = 8.4 
Hz, C-l-H), 7.28-7.33 (1H, m, =CHOH), 7.35-7.43 (5H, m, C6H5) and 10.6-10.9 
(1H, br s, exchanged with D20 , =CHOJ7); 8 C (DMSO-d6, 100.4 MHz) 15.3 (q, C-18),
24.9 (t), 26.5 (t), 27.1 (t), 30.0 (t), 32.3 (t), 38.2 (d), 44.3 (d), 48.6 (s, C-13), 49.1 (d),
69.7 (t, OCH2Ar), 112.9 (d), 113.9 (s, C-16), 115.2 (d), 126.7 (d), 128.1 (2xd), 128.3 
(d), 129.0 (2xd), 132.7 (s), 138.0 (2xs), 150.8 (d, C-l'), 156.7 (s, C-3) and 209.1 (s, 
C=0); MS m/z (FAB+) 389.3 [31, (M+H)+], 91.1 [100, (CH2Ar)+]; Acc MS m/z 
(FAB+) 389.2099, C26H29O3 requires 389.2117.
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3-Benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-pyrazole (73)
Hydrazine hydrate (751 jiL, 15.44 mmol) was added to a suspension of 72 (4 g, 10.3 
mmol) in EtOH (200 mL) at room temperature, under an atmosphere of N2 . The 
resulting yellow suspension was heated to reflux for 45 minutes and allowed to cool 
down. After acidification with 5M HC1, the solvent was removed under reduced 
pressure until precipitation of the product. H2O (20 mL) was then added and the 
precipitate was filtered and dried to give 73 as an off-white powder (3.73 g, 94%): 
mp 102-105°C; IR (KBr) 3410 (NH), 2930-2860 (aliph CH), 1610-1500 (C=N and 
arom C=C), 1255 (C-O) c m 1; 5H (DMSO-d6 , 400 MHz) 0.91 (3H, s, C-I8 -H3), 1.36-
2.58 (11H, m), 2.78-2.87 (2H, m, C-6 -H2), 5.05 (2H, s, OCH2Ar), 6.72 (1H, d, J  =
2.7 Hz, C-4-H), 6.76 (1H, dd, J  = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.18 (1H, d, J  = 8 . 6  
Hz, C-l-H), 7.27 (1H, s, C-5'-H), 7.29-7.44 (5H, m, C6H5) and 12.00 (1H, s, 
exchanged with D20 , NH); MS m/z (FAB+) 385.3 [75, (M+H)+], 91.1 [100, 
(CH2Ar)+]; Acc MS m/z (FAB+) 385.2280, C2 6H29N20  requires 385.2280.
3-Benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(l'-methyl)-pyrazole (74) and 3- 
benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(2'-methyl)-pyrazole (75)
Following method 5, 73 (150 mg, 390 |imol) was treated with NaH (19 mg, 468 
pmol) in DMF ( 6  mL) and the subsequent reaction with methyl iodide (57 JiL, 780 
jimol) was complete within 50 minutes. Purification of the crude mixture by flash 
chromatography (DCM/EtOAc, 98:2 to 95:5, gradient) gave two products:
The less polar fraction gave 74 as a light yellow oil that crystallised on standing (52 
mg, 33%): mp 133-135°C; IR (KBr) 2930-2860 (aliph CH), 1606-1500 (C=N and 
arom C=C), 1245 (C-O) cm'1; SH (CDC13, 400 MHz) 1.01 (3H, s, C-I8 -H3), 1.42-
2.67 (11H, m), 2.81-2.99 (2H, m, C-6 -H2), 3.84 (3H, s, N-CH3), 5.03 (2H, s, 
OCH2Ar), 6.73 (1H, d, J = 2.5 Hz, C-4-H), 6.79 (1H, dd, J=  8.5 Hz, J=  2.5 Hz, C-2- 
H), 6.97 (1H, s, C-5'-H), 7.22 (1H, d, J = 8.5 Hz, C-l-H) and 7.29-7.45 (5H, m, 
C6H5); 5c (CDCI3 , 100.4 MHz) 18.4 (q, C-18), 24.0 (t), 26.2 (t), 27.4 (t), 29.6 (t),
34.1 (t), 37.5 (d), 38.5 (q, N-CH3), 40.8 (s, C-13), 44.4 (d), 61.1 (d), 69.8 (t, 
OCH2Ar), 111.9 (d), 114.6 (d), 121.5 (s), 124.0 (d), 125.9 (d), 127.1 (2xd), 127.5 (d),
128.2 (2xd), 132.6 (s), 136.9 (s), 137.5 (s), 156.4 (s) and 168.6 (s); MS m/z (FAB+)
399.3 [74, (M+H)+], 91.1 [100, (CH2Ar)+], 73.0 [24]; Acc MS m/z (FAB+) 399.2447,
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C2 7H3 1N2 O requires 399.2436. Found: C, 81.20; H, 7.55; N, 7.05. C2 7H3 0N2 O
requires: C, 81.37; H, 7.59; N, 7.03%.
The more polar fraction gave 75 as an off-white solid (55 mg, 35%): mp 168-171°C; 
IR (KBr) 2930-2870 (aliph CH), 1640-1495 (C=N and arom C=C), 1255 (C-O) cm' 
1; 5h (CDCI3 , 400 MHz) 1.01 (3H, s, C -I8 -H3), 1.44-2.64 (11H, m), 2.85-2.98 (2H, 
m, C-6 -H2), 3.82 (3H, s, N-CH3), 5.04 (2H, s, OCH2Ar), 6.74 (1H, d, /  = 2.8 Hz, C-
4-H), 6.80 (1H, dd, / =  8 . 6  Hz, / =  2.8 Hz, C-2-H), 7.15 (1H, s, C-5'-H), 7.20 (1H, d, 
J  = 8 . 6  Hz, C-l-H) and 7.30-7.45 (5H, m, C6H5); 6 C (CDC13, 100.4 MHz) 17.9 (q, C- 
18), 24.6 (t), 26.5 (t), 27.7 (t), 30.1 (t), 34.5 (t), 37.3 (q, N-CH3), 37.8 (d), 42.0 (s, C- 
13), 44.6 (d), 62.3 (d), 70.3 (t, OCH2Ar), 112.6 (d), 115.1 (d), 123.9 (s), 126.2 (d),
127.6 (2xd), 128.1 (d), 128.7 (2xd), 132.7 (s), 133.4 (d), 137.4 (s), 138.1 (s) and
157.0 (s), 1 singlet not seen; MS m/z (FAB+) 399.3 [55, (M+H)+], 91.1 [100, 
(CH2Ar)+]; Acc MS m/z (FAB+) 399.2434, C27H31N2O requires 399.2436. Found: C, 
81.10; H, 7.53; N, 6.87. C27H30N2O requires: C, 81.37; H, 7.59; N, 7.03%.
3-Benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(r-isobutyl)-pyrazole (76) and 3- 
benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(2'-isobutyl)-pyrazoIe (77)
Following method 5, 73 (250 mg, 650 jLimol) was treated with NaH (31 mg, 780 
pmol) in DMF (10 ml) and the subsequent reaction with l-bromo-2-methyl-propane 
(124 pL, 1.30 mmol) was complete within 2 hours. Purification of the crude mixture 
by flash chromatography (DCM/EtOAc, 95:5) gave two products:
The less polar fraction gave 76 as a pale yellow oil (121 mg, 42%): IR (KBr) 2960- 
2870 (aliph CH), 1705, 1640-1495 (C=N and arom C=C) c m '^ H  (CDC13, 400 
MHz) 0.87 (3H, d, J  = 6 . 6  Hz, C-3"-H3), 0.89 (3H, d, J = 6 . 6  Hz, C-4"-H3), 1.01 (3H, 
s, C-I8 -H3), 1.42-2.98 (14H, m), 3.81 (1H, dd, JBa = 13.8 Hz, J = 7.5 Hz, N- 
CHaHb), 3.86 ( 1 H, dd, Jab = 13.8 Hz, J  = 7.5 Hz, N-CHA//B), 5.04 (2H, s, OCH2Ar), 
6.71-6.75 (1H, m, C-4-H), 6.79 (1H, dd, J  = 8 . 6  Hz, /  = 2.7 Hz, C-2-H), 6.94-6.99 
(1H, m, C-5'-H), 7.22 (1H, d, J = 8 . 6  Hz, C-l-H) and 7.31-7.46 (5H, m, C6H5); MS 
m/z (FAB+) 441.2 [100, (M+H)+], 91.1 [93, (CH2Ar)+]; Acc MS m/z (FAB+) 
441.2894, C3 0H37N2O requires 441.2906.
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The more polar fraction gave 77 as a white crystalline solid (56 mg, 19%): mp 126- 
128°C; IR (KBr) 2960-2870 (aliph CH), 1635-1455 (C=N and arom C=C), 1255 (C- 
O) c m 1; 5h (CDC13, 400 MHz) 0.92 (3H, d, J  = 6 . 6  Hz, C-3"-H3), 0.95 (3H, d, J  =
6 . 6  Hz, C-4"-H3), 1.02 (3H, s, C-18-H3), 1.46-2.60 (12H, m), 2.89-2.94 (2H, m, C-6 - 
H2), 3.74 (1H, dd, JBa = 13.3 Hz, J  = 7.8 Hz, N-CHAUB), 3.85 (1H, dd, Jab = 13.3 
Hz, J = 7.4 Hz, N-CHAHB), 5.04 (2H, s, OCH2Ar), 6.74 (1H, d, /  = 2.6 Hz, C-4-H), 
6.79 (1H, dd, J  = 8 . 6  Hz, J = 2.6 Hz, C-2-H), 7.17-7.21 (2H, m, C-l-H and C-5'-H) ' 
and 7.31-7.45 (5H, m, C6H5); MS m/z (FAB+) 441.1 [100, (M+H)+], 91.1 [60, 
(CH2Ar)+]; Acc MS m/z (FAB+) 441.2898, C30H37N2O requires 441.2906.
3-Benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(l'-methylacetate)-pyrazole (78) 
and 3-benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(2'-methylacetate)-pyrazole (79)
Following method 5, 73 (300 mg, 78 pmol) was treated with NaH (47 mg, 1.17 
mmol) in DMF (10 mL) and the subsequent reaction with methyl chloroacetate (136 
pL, 1.56 mmol) was complete within 2.5 hours. Purification of the crude mixture by 
flash chromatography (DCM to DCM/EtOAc, 8:2, gradient, flashmaster) gave two 
products:
The less polar fraction gave 78 as a white crystalline solid (173 mg, 48%): mp 133- 
135°C; IR (KBr) 2960-2850 (aliph CH), 1750, 1740 (C=0), 1615-1500 (C=N and 
arom C=C), 1265, 1255 (C-O) cm*1; 5H (CDC13, 400 MHz) 1.03 (3H, s, C-18-H3), 
1.44-2.69 (11H, m), 2.85-2.99 (2H, m, C-6 -H2), 3.76 (3H, s, OCH3), 4.83 (1H, d, JBA 
= 17.8 Hz, N-C//aCHb), 4.88 (1H, d, Jab = 17.8 Hz, N-CHACHB), 5.04 (2H, s, 
OCH2Ar), 6.74 (1H, d, /  = 2.6 Hz, C-4-H), 6.79 (1H, dd, J  = 8 . 6  Hz, J  = 2.6 Hz, C-2- 
H), 7.07 (1H, s, C-5'-H), 7.22 (1H, d, J = 8 . 6  Hz, C-l-H) and 7.29-7.44 (5H, m, 
C6H5); 5c (CDC13, 100.4 MHz) 18.9 (q, C-18), 24.5 (t), 26.7 (t), 27.9 (t), 30.1 (t),
34.4 (t), 38.0 (d), 41.4 (s, C-13), 44.8 (d), 52.9 (d or q), 53.2 (t, N-CH2), 61.3 (d or 
q), 70.3 (t, OCH2Ar), 112.5 (d), 115.1 (d), 123.2 (s), 125.0 (d), 126.4 (d), 127.7 
(2xd), 128.1 (d), 128.7 (2xd), 133.1 (s), 137.5 (s), 138.0 (s), 156.9 (s), 169.1 (s) and
169.8 (s); MS m/z (FAB+) 457.3 [55, (M+H)+], 91.1 [100, (CH2Ar)+], 73.0 [72]; Acc 
MS m/z (FAB+) 457.2495, C29H33N20 3 requires 457.2491.
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The more polar fraction gave 79 as a pale yellow solid (70 mg, 20%): mp 78-82°C; 
IR (KBr) 2930-2850 (aliph CH), 1760, 1740 (C=0), 1635-1500 (C=N and arom 
C=C), 1260, 1210 (C-O) c m 1; SH (CDC13, 400 MHz) 1.02 (3H, s, C -I8 -H3), 1.42-
2.64 (11H, m), 2.86-2.98 (2H, m, C-6 -H2), 3.78 (3H, s, OCH3), 4.80 (1H, d, / Ba =
17.2 Hz, N-CHaCUb), 4.86 (1H, d, 7ab = 17.2 Hz, N-CHACHB), 5.03 (2H, s, 
OCH2Ar), 6.74 (1H, d, J = 2.6 Hz, C-4-H), 6.78 (1H, dd, J = 8 . 6  Hz, J = 2.6 Hz, C-2- 
H), 7.18 (1H, d, J  = 8 . 6  Hz, C-l-H), 7.25 (1H, s, C-5'-H) and 7.31-7.44 (5H, m, 
C6H5); MS m/z (FAB+) 457.3 [64, (M+H)+], 91.1 [100, (CH2Ar)+], 73.0 [27]; Acc 
MS m/z (FAB+) 457.2507, C29H33N2 0 3 requires 457.2491.
3-Benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(lf-methoxyethyI)-pyrazole (80) and 
3-benzyloxy-estra-l,3,5(10)-triene-[17,16-c]-(2'-methoxyethyl)-pyrazole (81)
Following method 5, 73 (300 mg, 780 pmol) was treated with NaH (47 mg, 1.17 
mmol) in DMF (10 mL) and the subsequent reaction with l-chloro-2-methoxy- 
ethane (142 pL, 1.56 mmol) was complete within 4 hours. Purification of the crude 
mixture by flash chromatography (DCM/EtOAc, 9:1) gave two products:
The less polar fraction gave 80 as a pale yellow solid (92 mg, 27%): mp 97-98°C; IR 
(KBr) 2930-2870 (aliph CH), 1615, 1500 (C=N and arom C=C), 1255, 1105 (C-O) 
cm'1; 6 h (CDC13, 400 MHz) 1.01 (3H, s, C -I8 -H3), 1.46-2.66 (11H, m), 2.84-2.99 
(2H, m, C-6 -H2), 3.33 (3H, s, OCH3), 3.67-3.76 (2H, m, C-l"-H 2 or C-2"-H2), 4.17-
4.28 (2H, m, C-l"-H 2 or C-2"-H2), 5.04 (2H, s, OCH2Ar), 6.74 (1H, d, J  = 2.8 Hz, C-
4-H), 6.80 (1H, dd, J  = 8.3 Hz, J = 2.8 Hz, C-2-H), 7.09 (1H, s, C-5'-H), 7.23 (1H, 
d, J = 8.3 Hz, C-l-H) and 7.31-7.45 (5H, m, C6H5); MS m/z (FAB+) 443.3 [100, 
(M+H)+], 91.1 [80, (CH2Ar)+]; Acc MS m/z (FAB+) 443.2696, C29H35N20 2 requires 
443.2698.
The more polar fraction gave 81 as a pale yellow solid (80 mg, 23%): mp 8 6 -8 8 °C; 
IR (KBr) 2930-2850 (aliph CH), 1635-1495 (C=N and arom C=C) cm'1; SH (CDC13, 
400 MHz) 1.04 (3H, s, C -I8 -H3), 1.42-2.66 (11H, m), 2.84-2.99 (2H, m, C-6 -H2), 
3.32 (3H, s, OCH3), 3.73-3.83 (2H, m, C-l"-H 2 or C-2"-H2), 4.14-4.22 (2H, m, C-l"- 
H2 or C-2"-H2), 5.04 (2H, s, OCH2Ar), 6.74 (1H, d, J  = 2.7 Hz, C-4-H), 6.79 (1H, dd,
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J  = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.19-7.21 (2H, m, C-l-H and C-5'-H) and 7.30-7.44 
(5H, m, C6H5); MS m/z (FAB+) 443.3 [100, (M+H)+], 91.1 [95, (CH2Ar)+], 73.1 
[44]; Acc MS m/z (FAB+) 443.2712, C2 9H35N2O2 requires 443.2698.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(l,-methyl)-pyrazole (82)
Following method 2, a suspension of 74 (50 mg, 125 jumol) and Pd-C (10%, 20 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give a pale yellow solid 
(31 mg). The crude-product was recrystallised from EtOH/H2 0  to yield 82 as off- 
white crystals (26 mg, 6 8 %): mp 287-289°C; IR (KBr) 3115 (OH or arom CH), 
2975-2855 (aliph CH), 1605-1500 (C=N and arom C=C) c m 1; §h (DMSO-ds, 400 
MHz) 0.89 (3H, s, C-I8 -H3), 1.32-2.57 (11H, m), 2.69-2.83 (2H, m, C-6 -H2), 3.73 
(3H, s, N-CH3), 6.45 (1H, d, J = 2.4 Hz, C-4-H), 6.52 (1H, dd, J  = 8.5 Hz, J  = 2.4 
Hz, C-2-H), 7.06 (1H, d, J  = 8.5 Hz, C-l-H), 7.24 (1H, s, C-5-H) and 9.02 (1H, s, 
OH); MS m/z (FAB+) 309.2 [100, (M+H)+], 219.2 [52]; Acc MS m/z (FAB+) 
309.1975, C20H25N2O requires 309.1967. HPLC (MeOH/H20 , 96:4, Xmm = 280.5 
nm) Rt = 1.90 min, 98%. Found: C, 77.80; H, 7.87; N, 8.90. C20H24N2O requires: C, 
77.89; H, 7.84; N, 9.08%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(2f-methyl)-pyrazole (83)
Following method 2, a suspension of 75 (50 mg, 125 jiimol) and Pd-C (10%, 20 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give a white solid (40 
mg). The crude product was recrystallised from EtOH to yield 83 as white crystals 
(20 mg, 53%): mp 321-323°C (dec.); IR (KBr) 3105-3010 (arom CH), 2935-2860 
(aliph CH), 1610-1500 (C=N and arom C=C); 6 H (DMSO-d6, 400 MHz) 0.95 (3H, s, 
C -I8 -H3), 1.32-2.52 (11H, m), 2.69-2.83 (2H, m, C-6 -H2), 3.73 (3H, s, N-CH3), 6.45 
(1H, d, J = 2.6 Hz, C-4-H), 6.52 (1H, dd, J = 8.4 Hz, J  = 2.6 Hz, C-2-H), 7.04 (1H, s, 
C-5'-H), 7.06 (1H, d, J = 8.4 Hz, C-l-H) and 9.03 (1H, s, OH); MS m/z (FAB+)
391.3 [28], 309.2 [100, (M+H)+]; Acc MS m/z (FAB+) 309.1974, C20H25N2O 
requires 309.1967. HPLC (MeOH/H2 0 , 96:4, l max = 280.5 nm) Rt = 2.41 min, 99%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(lf-isobutyl)-pyrazole (84)
Following method 2, a suspension of 76 (110 mg, 250 jimol) and Pd-C (10%, 40 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give a white solid (78
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mg). The crude product was recrystallised from MeOH to yield 84 as colourless 
crystals (42 mg, 48%): mp 122-123°C; IR (KBr) 3235 (OH), 2955-2853 (aliph CH), 
1635, 1610, 1575-1455 (C=N and arom C=C), 1230 (C-O) cm'1; ^  (CDC13, 400 
MHz) 0.87 (3H, d, J  = 6.4 Hz, C-3"-H3), 0.89 (3H, d, /  = 6.4 Hz, C-4"-H3), 1.01 (3H, 
s, C-18-H3), 1.42-2.65 (12H, m), 2.81-2.95 (2H, m, C-6 -H2), 3.81 (1H, dd, JBA = 13.7 
Hz, J  = 7.4 Hz, N-C/^Hb), 3.86 (1H, dd, Jab = 13.7 Hz, J  = 7.4 Hz, N-CHAtfB), 5.61 
(1H, s, exchanged with D20 , OH), 6.59 (1H, d, J = 2.6 Hz, C-4-H), 6.65 (1H, dd, J =
8.4 Hz, / =  2.6 Hz, C-2-H), 6.97 (1H, s, C-5'-H) and 7.16 (1H, d, J=  8.4 Hz, C-l-H); 
6 C (CDC13, 100.4 MHz) 18.5 (q, C-18), 20.0 (2xt, C-3" and C-4"), 24.1 (t), 26.4 (t),
27.5 (t), 29.6 (t), 30.0 (d), 34.2 (t), 37.6 (d), 41.0 (s, C-13), 44.5 (d), 59.6 (t, N-CH2),
61.2 (d), 112.8 (d), 115.3 (d), 121.2 (s), 123.9 (d), 126.4 (d), 132.5 (s), 138.1 (s),
153.8 (s) and 168.7 (s); MS m/z (FAB+) 351.3 [100, (M+H)+]; Acc MS m/z (FAB+) 
351.2448, C2 3H3 iN20  requires 351.2436. HPLC (MeOH/H20 , 80:20; ^ax  = 279.3 
nm) Rt = 3.27 min, 99%. Found: C, 75.20; H, 8.79; N, 7.42. C23H30N2 O.MeOH 
requires: C, 75.35; H, 8.96; N, 7.32%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(2'-isobutyl)-pyrazoIe (85)
Following method 2, a suspension of 77 (45 mg, 102 jimol) and Pd-C (10%, 20 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give a light yellow solid 
(103 mg). The crude product was recrystallised from EtOAc/hexane to yield 85 as 
off-white crystals (33 mg, 92%): mp 194-196°C (dec.); IR (KBr) 3195 (OH), 2960- 
2845 (aliph CH), 1620, 1585, 1500 (C=N and arom C=C) cm'1; 6 H (CDC13, 400 
MHz) 0.92 (3H, d, J  = 6 . 6  Hz, C-3"-H3), 0.95 (3H, d,J =  6 . 6  Hz, C-4"-H3), 1.03 (3H, 
s, C-18-H3), 1.41-2.63 (12H, m), 2.84-2.91 (2H, m, C-6 -H2), 3.77 (1H, dd, JBA = 13.4 
Hz, J = 8.2 Hz, N-C#aHb), 3.89 (1H, dd, JAB = 13.4 Hz, J  = 7.6 Hz, N-CHAtfB), 
-5.50 (-1H, br s, exchanged with D20 , OH), 6.60 (1H, d, J = 2.6 Hz, C-4-H), 6 . 6 6  
(1H, dd, J = 8.4 Hz, J  = 2.6 Hz, C-2-H), 7.14 (1H, d, J  = 8.4 Hz, C-l-H) and 7.22 
(1H, s, C-5'-H); MS m/z (FAB+) 351.3 [100, (M+H)+]; Acc MS m/z (FAB+) 
351.2444, C23H3 ]N20  requires 351.2436. HPLC (MeOH/H20 , 80:20; ^ax  = 279.3 
nm) Rt = 3.59 min, 100%.
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3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(l'-methylacetate)-pyrazole (8 6 )
Following method 2, a suspension of 78 (90 mg, 197 jimol) and Pd-C (10%, 40 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated for 6  hours to give a white solid ( 6 6  
mg). The crude product was recrystallised from MeOH to yield 8 6  as colourless 
crystals (49 mg, 6 8 %): mp 236-239°C; IR (KBr) 3210 (OH), 2955-2855 (aliph CH), 
1755 (C=0), 1610-1455 (C=N and arom C=C), 1215 (C-O) cm '1; 5H (CDC13, 400 
MHz) 1.03 (3H, s, C - I 8 - H 3 ) ,  1.41-2.69 (11H, m), 2.81-2.96 (2H, m, C-6 -H2), 3.75 
(3H, s, OCH3), 4.83 (1H, d, JBA = 17.6 Hz, N-CHAUB), 4.88 (1H, d, Jab = 17.6 Hz, 
N-CHaHb), 5.04 (1H, s, OH), 6.58 (1H, d, J  = 2.7 Hz, C-4-H), 6.64 (1H, dd, J = 8.4 
Hz, J  = 2.7 Hz, C-2-H), 7.07 (1H, s, C-5'-H), 7.16 (1H, d, /  = 8.4 Hz, C-l-H); 8 C 
(CDCI3 , 100.4 MHz) 18.8 (q, C-18), 24.5 (t), 26.7 (t), 27.9 (t), 29.9 (t), 34.3 (t), 38.0 
(d), 41.4 (s, C-13), 44.8 (d), 52.9 (d or q), 53.1 (t, N-CH2), 61.3 (d or q), 113.0 (d),
115.5 (d), 123.3 (s), 125.2 (d), 126.5 (d), 132.5 (s), 138.1 (s), 153.9 (s), 169.1 (s) and
169.8 (s); MS m/z (FAB+) 367.3 [100, (M+H)+], 73.1 [29]; Acc MS m/z (FAB+) 
367.2038, C2 2H27N20 3 requires 367.2022. Found: C, 69.60; H, 7.47; N, 7.17. 
C22H26N20 3.MeOH requires: C, 69.32; H, 7.59; N, 7.03%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(2f-methylacetate)-pyrazole (87)
Following method 2, a suspension of 79 (60 mg, 131 |imol) and Pd-C (10%, 25 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give a light brown foam 
(34 mg). The crude product was purified by flash chromatography (DCM/EtOAc, 
8  :2) to yield 87 as a light yellow foam (18 mg, 37%): mp 92-95°C; IR (KBr) 3250 
(OH), 2925-2855 (aliph CH), 1760, 1745 (C=0), 1615-1455 (C=N and arom C=C) 
cm'1; 8 h (CDCI3 , 400 MHz) 1.02 (3H, s, C -I8 -H3), 1.42-2.64 (12H, m), 2.84-2.91 
(2 H, m, C-6 -H2), 3.77 (3H, s, OCH3), 4.81 ( 1 H, d, JBA = 17.4 Hz, N-CHAHB), 4.87 
(1H, d, Jab = 17.4 Hz, N-CHAHB), 6.59 (1H, d, /  = 2.7 Hz, C-4-H), 6.64 (1H, dd, J =
8 . 6  Hz, J=  2.7 Hz, C-2-H), 7.12 (1H, d, J  = 8 . 6  Hz, C-l-H) and -7.25 (-1H, s, C-5'- 
H, under solvent peak); MS m/z (FAB+) 367.1 [37, (M+H)+], 97.0 [39], 73.0 [55],
57.0 [100]; Acc MS m/z (FAB+) 367.2029, C2 2H27N20 3 requires 367.2022.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(r-methoxyethyl)-pyrazole (8 8 )
Following method 2, a suspension of 80 (80 mg, 181 pmol) and Pd-C (10%, 35 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated for 6  hours to give a white crystalline
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solid (58 mg). The crude product was recrystallised from MeOH to yield 8 8  as white 
crystals (32 mg, 50%): mp 123-125°C; IR (KBr) 3235 (OH), 2930-2850 (aliph CH), 
1640-1505 (C=N and arom C=C) c m 1; 5H (CDC13, 400 MHz) 1.02 (3H, s, C-I8 -H3 ), 
1.43-2.66 (11H, m), 2.81-2.93 (2H, m, C-6 -H2), 3.33 (3H, s, OCH3), 3.67-3.75 (2H, 
m, C-l"-H 2 or C-2"-H2), 4.17-4.28 (2H, m, C-l"-H 2 or C-2"-H2), 5.57 (1H, bf s, 
exchanged with D20 , OH), 6.59 (1H, d, J= 2.7 Hz, C-4-H), 6.64 (1H, dd, J = 8.4 Hz, 
J = 2.7 Hz, C-2-H), 7.09 (1H, s, C-5'-H) and 7.16 (1H, d, J  = 8.4 Hz, C-l-H); MS 
m/z (FAB+) 353.3 [100, (M+H)+]; Acc MS m/z (FAB+) 353.2232, C2 2H29N20 2 
requires 353.2229. HPLC (MeOH/H20 , 80:20, A™* = 280.5 nm) Rt = 2.47 min, 98%. 
Found: C, 73.20; H, 8.07; N, 7.65. C22H28N20 2 .(MeOH)i/2 requires: C, 73.34; H, 
8.21; N, 7.60%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(2f-methoxyethyl)-pyrazole (89)
Following method 2, a suspension of 81 (70 mg, 158 pmol) and Pd-C (10%, 30 mg) 
in MeOH/THF 2:1 (30 mL) was hydrogenated overnight to give an off-white foam 
(50 mg). The crude product was purified by flash chromatography (DCM/EtOAc, 
8:2) to yield 89 as an off-white oil (25 mg, 45%): IR (KBr) 2920-2855 (aliph CH), 
1610-1500 (C=N and arom C=C), 1255 (C-O) cm'1; 5H (CDC13, 400 MHz) 1.05 (3H, 
s, C -I8 -H3), 1.42-2.61 (11H, m), 2.82-2.95 (2H, m, C-6 -H2), 3.31 (3H, s, OCH3), 
3.74-3.82 (2H, m, C-l"-H 2 or C-2"-H2), 4.12-4.23 (2H, m, C-l"-H 2 or C-2"-H2), 6.60 
(1H, d, J = 2.6 Hz, C-4-H), 6 . 6 6  (1H, dd, J = 8 . 6  Hz, J = 2.6 Hz, C-2-H), 7.14 (1H, d, 
J  = 8 . 6  Hz, C-l-H) and 7.23 (1H, s, C-5'-H), OH not seen; MS m/z (FAB+) 353.3 
[100, (M+H)+]; Acc MS m/z (FAB+) 353.2236, C2 2H29N20 2 requires 353.2229.
3-0-ter/-Butyl-dimethylsilyl-estrone (90)
Imidazole (6.3 g, 92.4 mmol) and te/t-butyl-dimethylsilyl chloride (7.8 g, 51.8 
mmol) were added to a stirred solution of El (10.0 g, 37.0 mmol) in anhydrous DMF 
(300 mL) at room temperature, under an atmosphere of N2. After stirring overnight, 
the resulting white suspension was poured into H20  (500 mL). The organics were 
extracted with EtOAc (500 mL + 300 mL), washed with H20  (2x200 mL), then brine 
(2x200 mL), dried (Na2S0 4 ), filtered and concentrated under reduced pressure. The 
crude product was recrystallised from EtOH to give 90 as white needles (14.0 g,
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98%): mp 171-173°C [lit.232 (EtOH) 170-172°C]; IR (KBr) 2960-2855 (aliph CH), 
1730 (C=0), 1605, 1495 (arom C=C) c m 1; 8H (CDC13, 400 MHz) 0.19 (6H, s, 
Si(CH3)2), 0.91 (3H, s, C-18-H3), 0.98 (9H, s, C(CH3)3), 1.37-2.55 (13H, m), 2.81- 
2.89 (2H, m, C-6-H2), 6.57 (1H, d, /  = 2.6 Hz, C-4-H), 6.62 (1H, dd, J  = 8.3 Hz, J  =
2.6 Hz, C-2-H) and 7.12 (1H, d, J = 8.3 Hz, C-l-H); MS m/z (FAB+) 384.2 [100, 
M+], 327.2 [44, (M-C(CH3)3)+], 73.0 [44]; Acc MS m/z (FAB+) 384.2477, 
C24H36C>2Si requires 384.2485.
3-0-terf-Butyl-dimethylsilyl-16-hydroxymethylene-estrone (91)
NaOMe (4.8 g, 70.2 mmol) was added portionwise to a stirred solution of 90 (9 g,
23.4 mmol) in anhydrous toluene (250 mL) at room temperature, under an 
atmosphere of N2 . After stirring for 20 minutes, ethyl formate (13.2 mL, 164 mmol) 
was added and the resulting bright yellow solution was stirred overnight. The final 
thick yellow suspension was poured into H2O (300 mL) and acidified with 5M HC1. 
The organics were extracted with EtOAc (2x500 mL), washed with H2O (3x200 
mL), then brine (2x200 mL), dried (Na2S0 4 ), filtered and concentrated under 
reduced pressure to give an off-white crude product (9.49 g, 98%). For analysis a 
sample was recrystallised from EtOH to give 91 as white crystals: mp 168-171°C; IR 
(KBr) 2930-2855 (aliph CH), 1710 (C=0), 1695-1500, 1495 (C=C and arom C=C) 
c m 1; 5 h  (DMSO-d6, 400 MHz) 0.17 (6H, s, Si(CH3)2), 0.83 (3H, s, C - I 8 - H 3 ) ,  0.96 
(9H, s, C(CH3)3), 1.32-2.63 (11H, m), 2.77-2.85 (2H, m, C-6-H2), 6.55 (1H, d, J  =
2.6 Hz, C-4-H), 6.61 (1H, dd, J  = 8.3 Hz, J = 2.6 Hz, C-2-H), 7.14 (1H, d, J = 8.3 
Hz, C-l-H), 7.40 (1H, s, =CtfOH) and 10.69 (1H, s, exchanged with D20 , =CHOH)\ 
6c (DMSO-d6,100.4 MHz) -4.3 (2xq, Si(CH3)2), 14.5 (q, C-18), 18.0 (s, C(CH3)3),
24.1 (t), 25.6 (t and 3xq, C(CH3)3), 26.2 (t), 29.0 (t), 31.5 (t), 37.3 (d), 43.6 (d), 47.7 
(s, C-13), 48.4 (d), 113.0 (s, C-16), 116.9 (d), 119.4 (d), 125.9 (d), 132.5 (s), 137.3 
(s), 149.9 (d, C -lf), 152.5 (s, C-3) and 208.2 (s, C=0); MS m/z (FAB+) 413.2 [68, 
(M+H)+], 355.1 [33, (M-C(CH3)3)+], 72.9 [100]; Acc MS m/z (FAB+) 413.2492, 




Hydrazine hydrate (440 JiL, 9.1 mmol) was added to a suspension of 91 (2.5 g, 6.1 
mmol) in EtOH (125 mL) at room temperature, under an atmosphere of N2 . The 
resulting mixture was heated to reflux for 45 minutes. After cooling down, the 
solvent was removed under reduced pressure, H2 O (200 mL) added and the mixture 
acidified with 5M HC1. The organics were extracted with EtOAc (2x10 mL), washed 
with H2O (2x50 mL), then brine (2x50 mL), dried (Na2S0 4 ), filtered and 
concentrated under reduced pressure to give a yellow foam (2.9 g). The crude 
product was recrystallised from EtOH/H2 0  to give 92 as yellow crystals (2.0 g, 
81%): mp 122-124°C; IR (KBr) 3190 (arom CH), 2930-2855 (aliph CH), 1605-1495 
(C=N and arom C=C) cm '1; 5H (DMSO-d6, 400 MHz) 0.18 (6 H, s, Si(CH3)2), 0.95 
(3H, s, C-I8 -H3), 0.96 (9H, s, C(CH3)3), 1.36-2.61 (11H, m), 2.79-2.87 (2H, m, C-6 - 
H2), 6.55 (1H, d, J  = 2.3 Hz, C-4-H), 6.62 (1H, dd, J  = 8.5 Hz, J  = 2.3 Hz, C-2-H), 
7.16 (1H, d, J  = 8.5 Hz, C-l-H), 7.28 (1H, s, C-5'-H) and 12.02 (1H, s, exchanged 
with D20 , NH); 6 C (CDC13, 100.4 MHz) -3.8 (2 xq, Si(CH3)2), 18.6 (s, C(CH3)3), 18.8 
(q, C -l8 ), 24.3 (t), 26.2 (3xq, C(CH3)3), 26.6 (t), 27.9 (t), 30.0 (t), 34.5 (t), 38.0 (d),
41.1 (s, C-13), 44.9 (d), 61.9 (d), 117.4 (d), 120.2 (d), 121.8 (s), 123.2 (s), 126.2 (d),
133.2 (s), 137.8 (s), 153.5 (s) and 168.6 (s); MS m/z (FAB+) 409.2 [100, (M+H)+],
73.0 [33]; Acc MS m/z (FAB+) 409.2662, C25H37N2OSi requires 409.2675. Found: 
C, 71.40; H, 8.93; N, 6.53. C25H36N20Si.(H20)2/3 requires: C, 71.38; H, 8.95; N, 
6 .66%.
3-0-terf-Butyl-dimethylsilyl-estra-l,3,5(lO)-triene-[17,16-c]-(lf-propionitrile)- 
pyrazole (93) and 3-O-terf-butyl-dimethylsilyl-estra-l,3,5(10)-triene-[17,16-c]- 
(2'-propionitrile)-pyrazole (94)
'BuOK (91 mg, 807 pmol) was added to a stirred solution of 92 (300 mg, 734 pmol) 
in anhydrous THF (10 mL) at 0°C, under an atmosphere of N2. After 20 minutes of 
stirring, acrylonitrile (58 pL, 881 pmol) was added and the resulting bright orange 
solution was stirred for 5 hours at room temperature. The resulting dark orange 
mixture was then concentrated under reduced pressure and H20  (50 mL) was added. 
The organics were extracted with EtOAc (2x50 mL), washed with H20  (2x30 mL), 
then brine (2x30 mL), dried (Na2 S0 4 ), filtered and concentrated under reduced
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pressure. The crude product was purified by flash chromatography (DCM/EtOAc, 
9:1) to give two products:
The less polar fraction gave 93 as a light yellow oil (29 mg, 8 %): IR (KBr) 2930- 
2860 (aliph CH), 2250 (CN), 1640-1495 (C=N and arom C=C) cm'1; 5h (CDC13, 400 
MHz) 0.20 (6 H, s, Si(CH3)2), 0.98 (9H, s, C(CH3)3), 1.02 (3H, s, C-18-H3), 1.42-2.67 
(11H, m), 2.80-3.01 (4H, m, C-6 -H2 and CH2CN), 4.28-4.40 (2H, m, N-CH2), 6.57 
(1H, d ,J  = 2.6 Hz, C-4-H), 6.63 (1H, dd, / =  8.5 Hz, J=  2.6 Hz, C-2-H), 7.10 (1H, s, 
C-5'-H) and 7.14 (1H, d, /  = 8.5 Hz, C-l-H); MS m/z (FAB+) 462.2 [100, (M+H)+],
73.0 [55]; Acc MS m/z (FAB+) 462.2914, C28H4oN3OSi requires 462.2941.
The more polar fraction gave 94 as a light brown oil that crystallised on standing (42 
mg, 12%): mp 80-82°C; IR (KBr) 2930-2855 (aliph CH), 2255 (CN), 1705-1445 
(C=N and arom C=C) c m 1; 5H (CDC13, 400 MHz) 0.20 (6 H, s, Si(CH3)2), 0.98 (9H, 
s, C(CH3)3), 1.07 (3H, s, C-18-H3), 1.41-2.68 (11H, m), 2.81-3.06 (4H, m, C-6 -H2 
and CH2CN), 4.21-4.38 (2H, m, N-CH2), 6.57 (1H, d, /  = 2.4 Hz, C-4-H), 6.63 (1H, 
dd, J=  8.7 Hz, J = 2.4 Hz, C-2-H), 7.11 (1H, d, J=  8.7 Hz, C-l-H) and 7.25 (1H, s, 
C-5'-H); MS m/z (FAB+) 462.1 [100, (M+H)+], 73.0 [79]; Acc MS m/z (FAB+) 
462.2922, C28H4oN3OSi requires 462.2941.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(l'-propionitrile)-pyrazole (95)
A 1.0 M solution of TBAF in anhydrous THF (110 pL, 110 pmol) was added to a 
stirred solution of 93 (25 mg, 50 pmol) in anhydrous THF (5 mL) at room 
temperature, under an atmosphere of N2. The mixture was stirred for 3 hours at room 
temperature, after which the solvent was removed under reduced pressure and H20  
added (50 mL). The organics were extracted with EtOAc (70 mL), washed with H20  
(20 mL), then brine (20 mL), dried (Na2S0 4 ), filtered and concentrated under 
reduced pressure. The crude yellow oil was purified by flash chromatography 
(DCM/EtOAc, 8:2) to give 95 as a light yellow oil (12 mg, 63%). This product was 
then triturated with EtOAc/hexane to give a light yellow powder ( 8  mg): mp 92- 
94°C; IR (KBr) 3230 (OH), 3095 (arom CH), 2925-2860 (aliph CH), 2265 (CN), 
1665-1500 (C=N and arom C=C), 1245 (C-O) cm'1; 5H (CDC13, 400 MHz) 0.94 (3H, 
s, C-18-H3), 1.34-2.60 (11H, m), 2.73-2.94 (4H, m, C-6 -H2 and CH2CN), 4.19-4.31
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(2H, m, N-CH2), 4.92 (1H, br s, exchanged with D20 , OH), 6.50 (1H, d, J  = 2.7 Hz, 
C-4-H), 6.55 (1H, dd, J  = 8.4 Hz, J  = 2.7 Hz, C-2-H), 7.02 (1H, s, C-5'-H) and 7.08 
(1H, d, J  = 8.4 Hz, C-l-H); MS m/z (FAB+) 348.1 [90, (M+H)+], 147.1 [64], 73.0 
[100]; Acc MS m/z (FAB+) 348.2072, C2 2H2 6N3 O requires 348.2076. HPLC 
(MeOH/H20 , 90:10, = 229.8 nm) Rt = 2.27 min, 96%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-e]-(2'-propionitrile)-pyrazole (96)
Method A: A 1.0 M solution of TBAF in anhydrous THF (150 pL, 150 jiimol) was 
added to a stirred solution of 94 (35 mg, 76 pmol) in anhydrous THF (5 mL) at room 
temperature, under an atmosphere of N2. The mixture was stirred for 3 hours at room 
temperature, after which the solvent was removed under reduced pressure and H2 0  
added (50 mL). The organics were extracted with EtOAc (70 mL), washed with H20  
(20 mL), then brine (20 mL), dried (Na2 S0 4 ), filtered and concentrated under 
reduced pressure. The crude brown oil was purified by flash chromatography 
(DCM/EtOAc, 8:2) to give 96 as a light brown oil (10 mg, 38%).
Method B: A 1.0 M solution of TBAF in anhydrous THF (916 pL, 916 pmol) was 
added to a stirred solution of 99 (220 mg, 458 pmol) in anhydrous THF (20 mL) at 
room temperature, under an atmosphere of N2. The mixture was stirred overnight at 
room temperature after which the solvent was removed under reduced pressure and 
H20  added (50 mL). The organics were extracted with EtOAc (2x50 mL), washed 
with H20  (2x30 mL), then brine (2x30 mL), dried (Na2S0 4 ), filtered and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (EtOAc/CHCf, 9:1) to give 96 as a pale pink foam (136 mg, 85%). 
This compound was then triturated with EtOAc/Hexane to give white crystals (99 
mg, 62%): mp 198-200°C; IR (KBr) 3160 (br, OH), 2925-2860 (aliph CH), 2250 
(CN), 1610-1500 (arom C=C) cm"1; 5H (CDC13, 400 MHz) 1.06 (3H, s, C -I8 -H3),
1.41-2.63 (11H, m), 2.81-3.05 (4H, m, C-6 -H2 and CH2CN), 4.22-4.34 (2H, m, N- 
CH2), 5.42 (1H, br s, exchanged with D2 0 , OH), 6.57 (1H, d, J  = 2.4 Hz, C-4-H),
6.64 (1H, dd, J = 8.3 Hz, J  = 2.4 Hz, C-2-H), 7.12 (1H, d, J  = 8.3 Hz, C-l-H) and 
7.25 (1H, s, C-5'-H); 5C (CDC13, 100.4 MHz) 18.6 (q, C-18), 19.7 (t, CH2CN), 24.5 
(t), 26.5 (t), 27.6 (t), 29.8 (t), 34.8 (t), 37.7 (d), 42.4 (s, C-13), 44.4 (d), 45.9 (t, N- 
CH2), 62.2 (d), 113.1 (d), 115.7 (d), 117.4 (s), 124.3 (s), 126.4 (d), 132.0 (s), 135.2 
(d), 138.2 (s), 154.1 (s) and 157.98 (s); MS m/z (FAB+) 348.1 [100, (M+H)+], 147.0
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[50], 85.1 [75], 73.0 [94]; Acc MS m/z (FAB+) 348.2060, C2 2H2 6N3 O requires
348.2076. Found: C, 75.90; H, 7.17; N, 12.10. C2 2 H2 5 N 3 O requires: C, 76.05; H,
7.25; N, 12.09%.
16-hydroxymethylene-estrone (97)
A 1.0 M solution of TBAF in anhydrous THF (21.3 mL, 21.3 mmol) was added to a 
stirred solution of 91 (4.4 g, 10.7 mmol) in anhydrous THF- (100 mL) at room 
temperature, under an atmosphere of N2 . The mixture was stirred overnight to give a 
brown solution. After removal of the solvent under reduced pressure, H2O (300 mL) 
was added and the organics were extracted with EtOAc (2x200 mL), washed with 
H20  (200 mL), then brine (200 mL), dried (Na2S 04), filtered and concentrated under 
reduced pressure. The light yellow crude product was triturated with boiling EtOAc 
to give 97 as a pale yellow powder (2.21 g, 69%): mp 218-220°C [lit. 229 (acetone) 
229-231°C]; IR (KBr) 3415, 3305 (br, OH), 2920-2870 (aliph CH), 1712 (C=0), 
1630-1450 (C=C and arom C=C) cm'1; 8 H (DMSO-cL, 400 MHz) 0.80 (3H, s, C-l 8 - 
H3), 1.28-2.61 (11H, m), 2.69-2.78 (2H, m, C-6 -H2), 6.44 (1H, d, / =  2.6 Hz, C-4-H), 
6.51 (1H, dd, J  = 8.5 Hz, J  = 2.6 Hz, C-2-H), 7.04 (1H, d, J  = 8.5 Hz, C-l-H), 7.38 
(1H, s, =CHOH), 9.02 (1H, s, exchanged with D20 , C-3-OH) and 10.69 (1H, br s, 
exchanged with D20 , =CHOH); MS m/z (FAB+) 299.2 [36, (M+H)+], 242.3 [100, 
(M+H-C(CH3)3)+]; A cc MS m/z (FAB+) 299.1650, Ci9H230 3  requires 299.1647.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-pyrazole (98)
Hydrazine hydrate (48 pL, 1.00 mmol) was added to a solution of 97 (200 mg, 670 
pmol) in EtOH (10 mL) at room temperature, under an atmosphere of N2. The 
resulting intense yellow solution was heated to reflux for 30 minutes. After cooling 
down, the solvent was removed under reduced pressure, H20  (50 mL) added and the 
mixture acidified with 5M HC1. The organics were extracted with EtOAc (150 mL), 
washed with H20  (2x50 mL), then brine (2x50 mL), dried (Na2S 04), filtered and 
concentrated under reduced pressure to give a pale yellow product (212 mg). The 
crude material was recrystallised from EtOH to yield 98 as pale yellow flaky crystals 
(125 mg, 64%): mp 326-328°C [lit.2l9320-328°C]; IR (KBr) 3300, 3125 (NH, OH), 
2934-2855 (aliph CH), 1615-1500 (C=N and arom C=C) cm'1; 8 H (DMSO-d6, 400 
MHz) 0.90 (3H, s, C -I8 -H3 ), 1.32-2.58 (11H, m), 2.69-2.84 (2H, m, C-6 -H2), 6.45
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(1H, d, J  = 2.6 Hz, C-4-H), 6.52 (1H, dd, J  = 8.4 Hz, J  = 2.6 Hz, C-2-H), 7.06 (1H, d, 
J=  8.4 Hz, C-l-H), 7.26 (1H, s, C-5'-H), 9.02 (1H, s, exchanged with D2O, C-3-OH) 
and 12.00 (1H, d, J  = 3.5 Hz, exchanged with D2O, NH); MS m/z (FAB+) 295.0 
[100, (M+H)+]; Acc MS m/z (FAB+) 295.1808, C19H23N2O requires 295.1810.
3-0-terf-Butyl-dimethylsiIyl-estra-l,3,5(lO)-triene-[17,16-c]-(2'-propionitrile- 
3',4 f-dihydro)-pyrazol-3 '-ol (99)
Cyanoethylhydrazine (177 |iL, 2.18 mmol) was added to a stirred solution of 91 (600 
mg, 1.45 mmol) in EtOH (50 mL) under an atmosphere of N2 . After 4 hours of 
stirring at room temperature, the resulting orange mixture was concentrated under 
reduced pressure and H2 O (100 mL) added, followed by 5M HC1. The organics were 
extracted with EtOAc (2x100 mL), washed with H2O (50 mL), then brine (50 mL), 
dried (Na2S0 4 ), filtered and concentrated under reduced pressure. The crude product 
was purified by flash chromatography (CHC^/EtOAc, 7:3) to give 99 as a pale 
yellow solid (510 mg, 73%). This compound was recrystallised from EtOH to give 
white needles (240 mg, 34%): mp 145-147°C; IR (KBr) 3380 (OH), 2950-2860 
(aliph CH), 2260 (CN), 1610, 1495 (C=N and arom C=C) c m 1; 5H (DMSO-cL, 400 
MHz) 0.15 (6 H, s, Si(CH3)2), 0 . 8 8  (3H, s, C -I8 -H3), 0.93 (9H, s, C(CH3)3), 1.19-3.16 
(11H, m), 2.70-3.16 (7H, m), 5.97 (1H, s, exchanged with D20 , OH), 6.48 (1H, d, J 
= 2.7 Hz, C-4-H), 6.56 (1H, dd, J  = 8.2 Hz, J = 2.7 Hz, C-2-H), 6.74 (1H, d, J = 1.9 
Hz, C-5'-H) and 7.10 (1H, d, / =  8.2 Hz, C-l-H); 5C (CDC13, 100.4 MHz) -4.4 (2xq, 
Si(CH3)2), 15.6 (q, C-18), 17.1 (t, CH2CN), 18.0 (s, C(CH3)3), 25.6 (3xq, C(CH3)3),
25.8 (t), 27.0 (t), 29.1 (t), 29.4 (t), 31.4 (t), 38.6 (d), 43.2 (d), 43.9 (t, N-CH2), 47.1 (s, 
C-13), 49.5 (d), 56.7 (d), 104.2 (s), 116.8 (d), 119.4 (d), 119.9 (s, CN), 126.0 (d),
132.5 (s), 137.3 (s), 144.6 (s) and 152.4 (s); MS m/z (FAB+) 480.1 [100, (M+H)+],
462.1 [63, (M+H-H20 )+], 72.9 [77]; MS m/z (FAB-) 632.3 [32, (M+NBA)']; Acc MS 
m/z (FAB+) 480.3038 C2 8H4 2N3 0 2Si requires 480.3046.
3-Benzyloxy-16-( 1 f-hydroxy-ethylidene)-estra-l,3,5(10)-triene-17-one (100)
fBuOK (438 mg, 4.14 mmol) was added to a stirred solution of 3 (500 mg, 1.38 
mmol) in anhydrous toluene ( 6  mL) and anhydrous DMSO (1.5 mL) at 0°C, under an 
atmosphere of N2. Ethyl acetate (1.27 mL, 17.94 mmol) was then added and the 
mixture was heated to reflux for 1 hour. After cooling down, the resulting brown
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solution was poured into H2O (200 mL) and acidified with 5M HC1. The organics 
were extracted with EtOAc (2x150 mL), washed with H2O (2x100 mL), then brine 
(2x100 mL), dried (Na2SC>4 ), filtered and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (DCM) to yield 100 as a light 
yellow crystalline solid (447 mg, 80%). This compound was recrystallised from 
EtOH to give yellow crystals (351 mg, 63%): mp 126-128°C; IR (KBr) 2930-2860 
(aliph CH), 1660 (C=0), 1615-1455 (C=C and arom C=C) cm'1; 8 H (CDC13, 400 
MHz) 0.83, 0.95 (3H, 2xs, C -I8 -H3), 1.38-2.49 (11H, m), 1.97, 2.37 (3H, 2xs, C-2'- 
H3), 2.87-2.92 (2H, m, C-6 -H2), 3.43 (app dd, J = 9.4 Hz, J  = 8.2 Hz, C-16-H, ketone 
tautomer), 5.02 (2H, s, OCH2Ar), 6.71 (1H, d, J  = 2.8 Hz, C-4-H), 6.77 (1H, dd, J  =
8.3 Hz, J  = 2.8 Hz, C-2-H), 7.17 (1H, d, J  = 8.3 Hz, C-l-H), 7.28-7.42 (5H, m, C6H5) 
and 12.91 (br s, exchanged with D20 , C-l'-OH, enol tautomer); MS m/z (FAB+)
403.1 [6 8 , (M+H)+], 91.0 [100, (CH2Ar)+]; Acc MS m/z (FAB+) 403.2246, C27H3 ] 0 3  
requires 403.2273. Found: C, 80.20; H, 7.56. C27H3 0O3 requires: C, 80.56; H, 7.51%.
3-0-terf-Butyl-dimethylsilyl-16-(l '-hydroxy-2 ',2 ',2 '-trifluoro-ethylidene)-estrone
(101)
*BuOK (875 mg, 7.80 mmol) was added to a stirred solution of 90 (1.0 g, 2.60 mmol) 
in anhydrous toluene (20 mL) at 0°C, under an atmosphere of N2 . After 20 minutes 
of stirring, ethyl trifluoroacetate (2.16 mL, 18.2 mmol) was added and the mixture 
heated to reflux for 2 hours. After cooling down, the resulting dark orange 
suspension was poured into H2 O (50 mL) and acidified with 5M HC1. The organics 
were extracted with EtOAc (2x50 mL), washed with H2O (2x30 mL), then brine 
(2x30 mL), dried (Na2SC>4), filtered and concentrated under reduced pressure. The 
crude orange oil that crystallised on standing was used without further purification 
(1.4 g, quant.). An analytical sample was recrystallised from EtOH to give 101 as 
light yellow crystals: mp 145-146°C; IR (KBr) 2930-2860 (aliph CH), 1690 (C=0), 
1640-1495 (C=C and arom C=C) cm 1; 5H (CDC13, 400 MHz) 0.19 (6 H, s, Si(CH3)2), 
0.98 (9H, s, C(CH3)3), 0.99 (3H, s, C -I8 -H3), 1.42-2.90 (13H, m), 6.57 ( 1 H, d, /  =
2.6 Hz, C-4-H), 6.63 (1H, dd, J=  8.4 Hz, / =  2.6 Hz, C-2-H) and 7.11 (1H, d, J=  8.4 
Hz, C-l-H), C-l'-OH not seen; 5C (CDC13, 100.4 MHz) -4.4 (2xq, Si(CH3)2), 14.8 (q, 
C-18), 18.1 (s, C(CH3)3), 25.2 (t), 25.6 (t), 25.7 (3xq, C(CH3)3), 26.7 (t), 29.3 (t),
31.0 (t), 37.5 (d), 43.9 (d), 48.5 (s, C-13), 49.5 (d), 110.9 (s, C-16), 117.4 (d), ~ 119
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(app d, J = 272 Hz, CF3), 120.0 (d), 126.0 (d), 132.0 (s), 137.4 (s), 153.6 (s, C-3), ~ 
154 (app d, /  = 38 Hz, C-l') and 216.0 (s, C=0); MS m/z (FAB+) 480.1 [47, M+],
423.0 [38, (M-F3)+], 73.0 [100]; Acc MS m/z (FAB+) 480.2296, C26H35F30 3Si 




'BuOK (875 mg, 7.80 mmol) was added to a stirred solution of 90 (1.0 g, 2.60 mmol) 
in anhydrous toluene (30 mL) at 0°C under an atmosphere of N2. After 20 minutes of 
stirring, ethyl nicotinate (2.48 mL, 18.2 mmol) was added and the mixture was 
heated to reflux for 1.5 hours. After cooling down, the resulting dark red suspension 
was poured into H20  (200 mL) and acidified with 5M HC1. The organics were 
extracted with EtOAc (2x100 mL), washed with H20  (100 mL), then brine (2x100 
mL), dried (Na2S0 4 ), filtered and concentrated under reduced pressure. The crude 
yellow solid was recrystallised from EtOH to give 102 as white flaky crystals (985 
mg, 77%): mp 169-170°C; IR (KBr) 2930-2855 (aliph CH), 1660 (C=0), 1605, 1495 
(C=C and arom C=C) c m 1; 8 h (CDC13, 400 MHz) 0.21 (6 H, s, Si(CH3)2), 0.99 (9H, 
s, C(CH3)3), 1.11 (3H, s, C-18-H3), 1.38-2.77 (11H, m), 2.81-2.95 (2H, m, C-6 -H2),
6.58 (1H, d, J  = 2.6 Hz, C-4-H), 6.63 (1H, dd, J  = 8.5 Hz, /  = 2.6 Hz, C-2-H), 7.12 
(1H, d, J = 8.5 Hz, C-l-H), 7.41 (1H, ddd, J = 8.1 Hz, J  = 4.9 Hz, J = 0.8 Hz, C-5"- 
H), 8.09 (1H, app dt, J  = 8.1 Hz, /  = 2.0 Hz, C-4"-H), 8.69 (1H, dd, J  = 4.9 Hz, J =
1.9 Hz, C-6 "-H), 8.97 (1H, app dd, J  = 2.1 Hz, /  = 0.8 Hz, C-2"-H) and 13.63 (1H, s, 
exchanged with D20 , C-l'-OH); MS m/z (FAB+) 490.1 [100, (M+H)+]; Acc MS m/z 
(FAB+) 490.2775, C30H40NO3Si requires 490.2777.
16-(1 '-hydroxy-l"-pyridin-3"-ylmethylene)-estrone (103)
A 1.0 M solution of TBAF in anhydrous THF (1.43 mL, 1.43 mmol) was added to a 
stirred solution of 102 (350 mg, 716 pmol) in anhydrous THF (10 mL) under an 
atmosphere of N2. The resulting light brown solution was stirred at room temperature 
for 3 hours, after which the solvent was removed under reduced pressure and H20  
added (100 mL), followed by AcOH glacial (5 drops). The organics were extracted 
with EtOAc (100 mL), Et20  (100 mL) and CHC13 (100 mL), washed with H20  (100
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mL), then brine (100 mL), dried (Na2SC>4 ), filtered and concentrated under reduced 
pressure. The crude product was triturated with boiling EtOH to give 103 as a pale 
yellow solid (125 mg, 50%): mp 275-278°C; IR (KBr) 2950-2855 (aliph CH), 1645 
(C=0), 1610-1500 (C=C and arom C=C) cm*1; 8 H (CDC13, 400 MHz) 1.09 (3H, s, C- 
18-H3), 1.39-2.76 (11H, m), 2.85-2.91 (2H, m, C-6 -H2), 5.48 (1H, s, exchanged with 
D 20 , C-3-OH), 6.59 (1H, d, J  = 2.7 Hz, C-4-H), 6.65 (1H, dd, J  = 8.4 Hz, J = 2.7 
Hz, C-2-H), 7.15 (1H, d, J  = 8.4 Hz, C-l-H), 7.41 (1H, ddd, J  = 8.1 Hz, /  = 4.9 Hz, J ■ 
= 0.8 Hz, C-5"-H), 8.09 (1H, dt, J  = 8.1 Hz, /  = 1.8 Hz, C-4"-H), 8.67 (1H, dd, J  =
4.9 Hz, J  = 1.8 Hz, C-6 "-H), 8.94 (1H, app d, J  = 1.8 Hz, C-2"-H) and 13.58 (1H, s, 
exchanged with D20 , C-l'-OH); MS m/z (FAB+) 376.0 [100, (M+H)+], 242.1 [54]; 
Acc MS m/z (FAB+) 376.1903, C24H26N0 3  requires 376.1913. Found: C, 74.70; H, 
6.80; N, 3.51. C24H25N0 3 .(H2 0 )i/2 requires: C, 74.98; H, 6.82; N, 3.64%.
16-(1 f-hydroxy-ethylidene)-estrone (104)
Following method 2, a suspension of 100 (200 mg, 497 jimol) and Pd-C (10%, 80 
mg) in MeOH/THF 2:1 (30 mL) was hydrogenated for 2 hours to give 104 as a white 
solid (98 mg, 63%). This product was recrystallised from acetone/hexane to give 
white crystals (72 mg, 46%): mp 211-214°C; IR (KBr) 3450 (OH), 2915-2860 (aliph 
CH), 1705 (C=0), 1655-1510 (C=0, C=C and arom C=C) cm*1; SH (CDC13, 400 
MHz) 0.83, 0.96 (3H, 2xs, C -I8 -H3), 1.39-2.40 (11H, m), 1.98, 2.37 (3H, 2xs, C-2'- 
H3), 2.83-2.89 (2H, m, C-6 -H2), 3.43 (dd, J  = 9.4 Hz, J  = 8.2 Hz, C-16-H, ketone 
tautomer), 4.70 (1H, br s, exchanged with D20 , C-3-OH), 6.55-6.57 (1H, m, C-4-H), 
6.62 (1H, dd, / =  8.0 Hz, J=  2.7 Hz, C-2-H) and 7.11 (1H, d, / =  8.0 Hz, C-l-H), C- 
l'-OH (enol tautomer) not seen; MS m/z (FAB+) 313.1 [100, (M+H)+], 73.0 [19]; 
Acc MS m/z (FAB+) 313.1799, C2oH2 50 3 requires 313.1804. Found: C, 76.60; H, 
7.82. C2oH2 4 0 3  requires: C, 76.89; H, 7.74%.
16-(1 '-hydroxy- 2  ' , 2  ',2 '-trifluoro-ethylidene)-estrone (105)
A 1.0 M solution of TBAF in anhydrous THF (4.90 mL, 4.90 mmol) was added to a 
stirred solution of 101 (1.18 g, 2.45 mmol, crude product) in anhydrous THF (50 
mL) under an atmosphere of N2. The resulting light brown solution was stirred at 
room temperature for 4 hours, after which the solvent was removed under reduced 
pressure and H20  added (100 mL). The organics were extracted with EtOAc (2x100
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mL), washed with H2O (2x80 mL), then brine (2x80 mL), dried (Na2SC>4), filtered 
and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (DCM) to give 105 as a light brown oil (535 mg, 60%). This 
compound was crystallised from cold DCM to give white crystals (249 mg, 28%): 
mp 91-93°C; IR (KBr) 3430 (OH), 2930-2860 (aliph CH), 1685 (C=0), 1610, 1500 
(C=C and arom C=C) cm'1; SH (CDC13, 400 MHz) 1.02 (3H, s, C -I8 -H3 ), 1.43-2.91 
(13H, m), 6.58 (1H, d, J  = 2.7 Hz, C-4-H), 6.64 (1H, dd, J = 8.4 Hz, J  = 2.7 Hz, C-2- 
H) and 7.14 (1H, d, J  = 8.4 Hz, C-l-H), C-3-OH and C-l'-OH not seen; MS m/z 
(FAB+) 366.1 [100, M*]; Acc MS m/z (FAB+) 366.1476, C20H21F3O3 requires 
366.1443. HPLC (MeOH/H20 , 96:4, = 280.5 nm) Rt = 1.66 min, 100%. Found:
C, 57.60; H, 5.37. C2oH2 iF30 3 .(CH2Cl2)3/4 requires: C, 57.95; H, 5.27%.
3-0-terf-Butyl-dimethylsilyl-estra-l,3,5(lO)-triene-[17,16-c]-[5'-(l"-pyridin-3"- 
yl)-3 ',4'-dihydro)]-pyrazol-3 '-ol (106)
Hydrazine hydrate (75 pL, 1.53 mmol) was added to a refluxing solution of 102 (500 
mg, 1.02 mmol) in EtOH (20 mL), under an atmosphere of N2 . The resulting pale 
yellow solution was heated to reflux for 1 hour, after which the solvent was partially 
removed under reduced pressure and H2O (100 mL) added. The resulting white 
precipitate was filtered and dried (460 mg, 89%) and an analytical sample was 
recrystallised from EtOH/H2 0  to give 106 as white crystals: mp 144-145°C; IR 
(KBr) 3480, 3330, 3190 (NH and OH), 2940-2860 (aliph CH), 1610-1495 (C=N and 
arom C=C) cm'1; 6 H (DMSO-cL, 400 MHz) 0.14 (6 H, s, Si(CH3)2), 0.92 (9H, s, 
C(CH3)3), 0.94 (3H, s, C-18-H3), 1.12-2.31 (11H, m), 2.63-2.71 (2H, m, C-6 -H2), 
3.43 (1H, app d, J  = 9.0 Hz, C-16-H), 5.97 (1H, s, exchanged with D20 , C-17-OH),
6.46 (1H, d, J  = 2.5 Hz, C-4-H), 6.55 (1H, dd, J = 8.4 Hz, J = 2.5 Hz, C-2-H), 7.10 
(1H, d, J = 8.4 Hz, C-l-H), 7.26 (1H, s, exchanged with D20 , NH), 7.35 (1H, app 
ddd, J  = 8.1 Hz, J = 4.6 Hz, J = 0.8 Hz, C-5"-H), 7.91 (1H, app dt, J = 8.1 Hz, J =
1.7 Hz, C-4"-H), 8.43 (1H, dd, J= 4.6 Hz, / =  1.7 Hz, C-6 "-H) and 8.74 (1H, app d, J 
= 1.7 Hz, C-2"-H); MS m/z (FAB+) 504.1 [100, (M+H)+], 486.1 [27, (M+H-H20 )+]; 
Acc MS m/z (FAB+) 504.3045, C3oH42N302Si requires 504.3046.
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3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(5'-methyl)-pyrazole (107)
Hydrazine hydrate (56 fiL, 1.15 mmol) was added to a refluxing solution of 104 (240 
mg, 768 jimol) in EtOH (15 mL) under an atmosphere of N2 . The resulting pale 
yellow solution was heated to reflux for 45 minutes, after which the solvent was 
removed under reduced pressure, H2O (50 mL) added and the mixture acidified with 
5M HC1. The organics were extracted with EtOAc (2x50 mL), washed with H2O (30 
mL), then brine (2x30 mL), dried (Na2S0 4 ), filtered and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (DCM/EtOAc, 
8:2) to give 107 as a pale brown solid (84 mg, 35%). This was triturated with 
acetone to give an off-white solid (32 mg, 13%): mp 234-236°C; IR (KBr) 3295 
(OH), 2930-2860 (aliph CH), 1620-1500 (C=N and arom C=C) cm'1; 6 H (DMSO-d6, 
400 MHz) 1.01 (3H, s, C -I8 -H3), 1.34-2.64 (11H, m), 2.71-2.85 (2H, m, C-6 -H2),
2.28 (3H, s, C-l"-H3), 6.45 (1H, d, J = 2.6 Hz, C-4-H), 6.52 (1H, dd, J = 8 . 6  Hz, J  =
2.6 Hz, C-2-H), 7.04 (1H, d, /  = 8 . 6  Hz, C-l-H) and 9.04 (1H, s, exchanged with 
D20 , NH or OH), NH or OH not seen; MS m/z (FAB+) 309.2 [100, (M+H)4], 95.1 
[33], 69.0 [39]; Acc MS m/z (FAB+) 309.1978, C20H25N2O requires 309.1967. 
HPLC (MeOH/H20 , 96:4, U  = 280.5 nm) Rt = 1.98 min, 99%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-(5'-trifluoro-methyl)-pyrazole (108)
Hydrazine hydrate (32 |iL, 655 pmol) was added to a refluxing solution of 105 (160 
mg, 437 pmol) in EtOH (15 mL) under an atmosphere of N2 . The resulting pale 
yellow solution was heated to reflux for 3 hours, after which p-toluene sulfonic acid 
( - 1 0  mg) was added. The mixture was then heated to reflux overnight and after 
cooling down, the solvent was removed under reduced pressure, H2O (50 mL) added, 
followed by 5M HC1. The organics were extracted with EtOAc (2x50 mL), washed 
with H2O (30 mL), then brine (2x30 mL), dried (Na2 S0 4 ), filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography 
(DCM/EtOAc, 8:2) to give 108 as a pale yellow solid (95 mg, 60%). This compound 
was precipitated from DCM/Hexane (1:5) to give an off-white solid (51 mg, 32%): 
mp 152-155°C; IR (KBr) 3220 (br, OH), 2930-2860 (aliph CH), 1610-1500 (C=N 
and arom C=C) cm'1; 6 H (CDC13, 400 MHz) 1.01 (3H, s, C-I8 -H3), 1.40-2.74 ( 1 1 H, 
m), 2.78-2.89 (2H, m, C-6 -H2), 4.63 (1H, s, exchanged with D20 , C-3-OH), 6.53
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(1H, d, /  = 2.7 Hz, C-4-H), 6.59 (1H, dd, J  = 8.2 Hz, J  = 2.7 Hz, C-2-H) and 7.08 
(1H, d, /  = 8.2 Hz, C-l-H), NH not seen; MS m/z (FAB+) 363.1 [100, (M+H)+]; Acc 
MS m/z (FAB+) 363.1689, C20H22N2F3O requires 363.1684. HPLC (MeOH/H2 0 , 
85:15, A,max = 280.5 nm) Rt = 2.43 min, 98%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-c]-[5'-(l"-pyridin-3"-yl)]-pyrazole (109)
A 1.0 M solution of TBAF in anhydrous THF (436 pL, 436 pmoi) was added to a 
stirred solution of 106 (110 mg, 218 pmol) in anhydrous THF (10 mL) at room 
temperature under an atmosphere of N2 . The resulting light brown solution was 
stirred overnight at room temperature, after which the solvent was removed under 
reduced pressure and H2O added (50 mL). The organics were extracted with EtOAc 
(2x50 mL), washed with H2O (2x30 mL), then brine (2x30 mL), dried (Na2 S0 4 ), 
filtered and concentrated under reduced pressure. The crude foam was triturated with 
boiling EtOAc/CHCl3 (1:1) to give 109 as a white powder (61 mg, 75%): mp 298- 
300°C (dec.); IR (KBr) 2980-2840 (aliph CH), 1610-1495 (C=N and arom C=C) o n  
]; 5h (DMSO-de, 400 MHz) 0.98 (3H, s, C-I8 -H3), 1.37-2.87 (13H, m), 6.45 (1H, d, 
/ =  2.6 Hz, C-4-H), 6.51 (1H, dd, / =  8.5 Hz, J=  2.6 Hz, C-2-H), 7.05 (1H, d, J=  8.5 
Hz, C-l-H), 7.37-7.48 (1H, m, C-4"-H or C-5"-H), 7.97-8.06 (1H, m, C-4"-H or C- 
5"-H), 8.42-8.49 (1H, m, C-2"-H or C-6 "-H) and 8.84-8.89 (1H, m, C-2"-H or C-6 "- 
H), 9.01 (1H, s, exchanged with D20 , OH), 12.65 and 12.72 (1H, 2xs, exchanged 
with D20 , NH); MS m/z (FAB+) 372.0 [100, (M+H)+]; Acc MS m/z (FAB+) 
372.2080, C24H26N3O requires 372.2076.
5.4.6 Other D-ring fused derivatives of E l
3-Hydroxy-17-0-aIlyl-oximino-estra-l,3,5(lO)-triene (110)
NaOAc (3 g, 10.17 mmol) followed by 0-allyl-hydroxylamine hydrochloride (4.5 g, 
41.44 mmol) were added to a solution of El (1.0 g, 3.70 mmol) in a mixture of 
MeOH/H2 0  (5:1, 180 mL). The resulting solution was stirred at room temperature 
overnight, after which the solvent was removed under reduced pressure and H2 O 
added (200 mL). The organics were extracted with EtOAc (300 mL), washed with 
H2O (2x100 mL), then brine (2x100 mL), dried (Na2S0 4 ), filtered and concentrated
266
under reduced pressure to give a white product (1.37 g). The crude material was 
recrystallised from MeOH/H20  to give 110 as white crystals (1.13 g, 94%): mp 81- 
83°C; IR (KBr) 3455 (OH), 3185 (arom CH), 2955-2845 (aliph CH), 1640-1505 
(C=N, C=C and arom C=C), 1240 c m 1; 8 h (CDC13, 400 MHz) 0.94 (3H, s, C -I8 -H3), 
1.35-2.60 (13H, m), 2.80-2.87 (2H, m, C-6 -H2), 4.50-4.60 (2H, m, C-l'-H2), 4.74 
(1H, s, exchanged with D2O, OH), 5.19 (1H, app dq, 7Cis = 10.3 Hz, J  ~ 1.5 Hz, C-3'- 
H), 5.28 (1H, app dq, Jttans = 17.2 Hz, J ~ 1.5 Hz, C-3'-H), 5.59-6.01 (1H, m, C-2'- 
H), 6.56 (1H, d, J = 2.7 Hz, C-4-H), 6.63 (1H, dd, J  = 8.2 Hz, J = 2.7 Hz, C-2-H) and
7.15 (1H, d, J  = 8.2 Hz, C-l-H); 6 C (CDCI3 , 100.4 MHz) 17.7 (q, C-18), 23.4 (t),
26.5 (t), 26.6 (t), 27.6 (t), 30.0 (t), 34.5 (t), 38.5 (d), 44.3 (d), 44.8 (s, C-13), 53.3 (d),
74.6 (t, C-l'), H3.0 (d), 115.5 (d), 117.3 (t, C-3'), 126.7 (d), 132.4 (s), 134.7 (d, C- 
2'), 138.2 (s), 153.7 (s, C-3) and 171.3 (s, C=N); MS m/z (FAB+) 326.1 [100, 
(M+H)+], 268.1 [30, OCH2CH=CH2+]; Acc MS m/z (FAB+) 326.2116, C2 ]H28N 0 2 
requires 326.2120. HPLC (MeOH/H20 , 90:10; Xmax = 279.3 nm) Rt = 3.01 min, 
99%. Found: C, 76.40; H, 8.24; N, 4.36. C2 iH27N 0 2 requires: C, 76.23; H, 8.50; N, 
4.17%.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-b]-pyridine (111)
17-O-Allyl-oxime 110 (2.45 g, 7.53 mmol) was stirred and heated to 230°C (using a 
sand bath) for 46 hours. The resulting dark brown solid was allowed to cool down 
and EtOH was added until most of the solid was dissolved. The remaining 
undissolved material was crushed to a fine powder, silica was added and the solvent 
removed under reduced pressure. This was purified by flash chromatography 
(CHC^/EtOAc, 9:1) to give 111 as a dark orange solid (200 mg, 9%). A second flash 
chromatography (CHCE/EtOAc, 95:5) yielded a light orange powder (146 mg, 6 %). 
For analysis, a sample was triturated with CHCI3 to give an off-white powder: mp 
279-284°C (dec.); IR (KBr) 3415 (OH), 3115-3025 (arom CH), 2985-2855 (aliph 
CH), 1615-1500 (C=N and arom C=C) cm'1; 6 H (DMSO-d6, 400 MHz) 0.92 (3H, s, 
C-I8 -H3), 1.36-2.83 (13H, m), 6.47 (1H, d, J  = 2.4 Hz, C-4-H), 6.54 (1H, dd, J = 8.4 
Hz, J  = 2.4 Hz, C-2-H), 7.05-7.09 (2H, m, C-l-H and C-5'-H), 7.60 (1H, d, J  = 1A  
Hz, C-4'-H), 8.25 (1H, app d, J  = 4.3 Hz, C-6 '-H) and 9.05 (1H, s, exchanged with 
D20 , OH); 5h (CDCI3 , 400 MHz) 1.01 (3H, s, C -I8 -H3), 1.43-2.96 (13H, m), 6.08 
(1H, br s, OH), 6.61 (1H, d, J=  2.6 Hz, C-4-H), 6.67 (1H, dd, J=  8.4 Hz, J=  2.6 Hz,
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C-2-H), 7.04 (1H, dd, J  = 7.4 Hz, J  = 4.8 Hz, C-5'-H), 7.18 (1H, d, J  = 8.4 Hz, C-l- 
H), 7.54 (1H, d, /  = 7.4 Hz, C-4'-H) and 8.33 (1H, d, J  = 4.8 Hz, C-6 '-H); 5C 
(DMSO-d6 , 100.4 MHz) 18.5 (q, C-18), 26.9 (t), 27.9 (t), 29.9 (t), 30.4 (t), 34.4 (t),
38.2 (d), 44.7 (d), 46.3 (s, C-13), 55.4 (d), 113.5 (d), 115.7 (d), 121.7 (d), 126.5 (d),
130.9 (s), 133.2 (d), 136.4 (s), 137.7 (s), 147.2 (d), 155.6 (s, C-3) and 173.1 (s, 
C=N); MS m/z (FAB+) 306.1 [85, (M+H)+], 207.0 [95], 114.9 [100]; Acc MS m/z 
(FAB+) 306.1864, C2 1H24NO requires 306.1858. HPLC (Me0H/H20 , 80:20; =
268.7 nm) Rt = 2.90 min, 98%. Found: C, 77.00; H, 7.16; N, 4.12. 
C2iH23NO.(CHC13)i/5 requires: C, 77.33; H, 7.10; N, 4.25%.
3-0-terf-Butyl-dimethylsilyl-16-ethoxymethylene-estrone (112) and 3-O-tert- 
butyl-dimethylsilyl-estra-l,3,5(10)-triene-[17,16-f]-(tetrazolo-[l,5-a]-pyrimidine) 
(113)
5-Aminotetrazole (187 mg, 1.82 mmol) was added to a stirred suspension of 91 (500 
mg, 1.21 mmol) in EtOH (50 mL) and the resulting mixture heated to reflux for 48 
hours. After cooling down, H2O was added (50 mL) and the organics were extracted 
with EtOAc (2x50 mL), washed with H2O (30 mL), then brine (2x30 mL), dried 
(Na2S0 4 ), filtered and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (CHCl3/EtOAc, 95:5) to give two products:
The less polar fraction gave 112 as an off-white oil that crystallised on standing (231 
mg, 43%): mp 144-146°C; IR (KBr) 2955-2855 (aliph CH), 1710 (C=0), 1635-1495 
(C=C and arom C=C) cm’1; 5H (CDC13, 400 MHz) 0.21 (6 H, s, Si(CH3)2), 0.94 (3H, 
s, C -I8 -H3), 0.99 (9H, s, C(CH3)3), 1.36 (3H, t, J=  7.0 Hz, C-3'-H3), 1.39-2.96 (13H, 
m), 4.04-4.85 (2H, m, C-2'-H2), 6.56 (1H, d, J = 2.7 Hz, C-4-H), 6.62 (1H, dd, J =
8.4 Hz, / =  2.7 Hz, C-2-H), 7.11 (1H, d, J=  8.4 Hz, C-l-H) and 7.28-7.30 (1H, m, C- 
l'-H); MS m/z (FAB+) 441.6 [100, (M+H)+], 73.1 [38]; Acc MS m/z (FAB+) 
441.2805, C27H4 i0 3Si requires 441.2825.
The more polar fraction gave 113 as a white solid (179 mg, 32%). An analytical 
sample was recrystallised from EtOH to give white crystals: mp 203-205°C; IR 
(KBr) 2930-2855 (aliph CH), 1640-1495 (C=N and arom C=C) cm’1; 5H (CDC13, 400 
MHz) 0 . 2 2  (6 H, s, Si(CH3)2), 1.00 (9H, s, C(CH3)3), 1.18 (3H, s, C -I8 -H3), 1.52-3.13
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(13H, m), 6.60 (1H, d, J = 2.7 Hz, C-4-H), 6.66 (1H, dd, / =  8.4 Hz, / =  2.7 Hz, C-2- 
H), 7.16 (1H, d, J  = 8.4 Hz, C-l-H) and 8.74-8.75 (1H, m, C-7'-H); MS m/z (FAB+)
462.5 [100, (M+H)+], 73.0 [48]; Acc MS m/z (FAB+) 462.2687, C26H36N5OSi 
requires 462.2689.
3-Hydroxy-estra-l,3,5(10)-triene-[17,16-f]-(tetrazolo-[l,5-a]-pyrimidine) (114)
A 1.0 M solution of TBAF in anhydrous THF (650 pL, 650 pmol) was added to a 
stirred solution of 113 (150 mg, 325 jumol) in anhydrous THF (15 mL) at room 
temperature, under an atmosphere of N2 . The resulting light brown solution was 
stirred overnight at room temperature, after which H2O was added (50 mL). The 
organics were extracted with EtOAc (2x50 mL), washed with H2O (2x50 mL), then 
brine (2x50 mL), dried (Na2 S0 4 ), filtered and concentrated under reduced pressure. 
The crude product was triturated with boiling EtOAc to give 114 as an orange 
powder (80 mg, 71%): mp > 340°C; IR (KBr) 3290 (OH), 2930-2860 (aliph CH), 
1642-1505 (C=N and arom C=C) cm'1; SH (DMSO-de, 400 MHz) 1.08 (3H, s, C-18- 
H3), 1.22-3.04 (13H, m), 6.46 (1H, d, J  = 2.4 Hz, C-4-H), 6.53 (1H, dd, J  = 8.5 Hz, J 
= 2.4 Hz, C-2-H), 7.08 (1H, d, J  = 8.5 Hz, C-l-H), 9.05 (1H, s, C-7'-H or OH) and
9.46 (1H, s, C-7-H or OH); MS m/z (FAB+) 391.2 [71], 348.1 [100, (M+H)+], 327.2 




3-Aminopyrazole (60 mg, 727 pmol) was added to a stirred suspension of 91 (200 
mg, 485 pmol) in EtOH (20 mL) and the resulting mixture heated to reflux for 15 
hours. After cooling down, the final white suspension was filtered, washed with 
EtOH and air dried to give 115 as a white solid (171 mg, 77%): mp 239-241 °C; IR 
(KBr) 2950-2855 (aliph CH), 1610-1405 (C=N and arom C=C) cm'1; 6 H (CDC13, 400 
MHz) 0.22 (6 H, s, Si(CH3)2), 1.00 (9H, s, C(CH3)3), 1.25 (3H, s, C-18-H3), 1.53-3.04 
(13H, m), 6.60 (1H, d, J = 2.7 Hz, C-4-H), 6.65 (1H, dd, J=  8 . 6  Hz, / =  2.7 Hz, C-2- 
H), 6.70 (1H, d, / =  2.3 Hz, C-3'-H), 7.17 (1H, d, J=  8 . 6  Hz, C-l-H), 8.13 (1H, d, J 
= 2.3 Hz, C-2'-H) and 8.43 (1H, s, C-5'-H); MS m/z (FAB+) 459.5 [100, M+], 402.4
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A 1.0 M solution of TBAF in anhydrous THF (566 pL, 566 pmol) was added to a 
stirred solution of 115 (130 mg, 283 pmol) in anhydrous THF (15 mL) at room 
temperature, under an atmosphere of N2. The resulting light brown solution was 
stirred overnight at room temperature, after which H20  was added (50 mL). The 
resulting white precipitate was filtered and air dried to give 116 as a white powder 
(98 mg, 100%). This product was recrystallised from EtOH/H20  to give a white solid 
(89 mg, 91%): mp 333-335°C; IR (KBr) 3165 (br, OH), 2940-2860 (aliph CH), 
1615-1515 (C=N and arom C=C) cm'1; 5H (DMSO-d6, 400 MHz) 1.14 (3H, s, C-18- 
H3), 1.42-2.99 (13H, m), 6.46 (1H, d, / =  2.3 Hz, C-4-H), 6.52 (1H, dd, J=  8.2 Hz, J  
= 2.3 Hz, C-2-H), 6.69 (1H, d, J  = 2.3 Hz, C-3'-H), 7.07 (1H, d, J  = 8.2 Hz, C-l-H), 
8.18 (1H, d ,J =  2.3 Hz, C-2'-H), 8.50 (1H, s, C-5'-H) and 9.04 (1H, s, exchanged 
with D20 , C-3-OH); MS m/z (FAB+) 346.1 [100, (M+H)+]; Acc MS m/z (FAB+) 
346.1898, C22H24N30  requires 346.1919.
3-0-te/tf-Butyl-dimethylsilyl-estra-l,3,5(lO),16-tetraene-[16,17-g]-(s-triazolo- 
[l,5-a]-pyrimidine) (117)
3-Amino-l,2,4-triazole (61 mg, 727 pmol) was added to a stirred suspension of 91 
(200 mg, 485 pmol) in EtOH (20 mL) and the resulting mixture heated to reflux for 
48 hours. After cooling down, H20  was added (50 mL) and the organics were 
extracted with EtOAc (2x50 mL), washed with H20  (30 mL), then brine (2x30 mL), 
dried (Na2S0 4 ), filtered and concentrated under reduced pressure. The yellow crude 
product was purified by flash chromatography (CHCl3/EtOAc, 1:1) to give 117 as a 
white solid (111 mg, 50%): mp 162-164°C; IR (KBr) 2930-2855 (aliph CH), 1695- 
1495 (C=N and arom C=C) cm'1; 5H (CDC13, 400 MHz) 0.22 (6 H, s, Si(CH3)2), 1.00 
(9H, s, C(CH3)3), 1.26 (3H, s, C-18-H3), 1.53-3.13 (13H, m), 6.60 (1H, d, / =  2.4 Hz, 
C-4-H), 6 . 6 6  (1H, dd, J  = 8.3 Hz, J  = 2.4 Hz, C-2-H), 7.16 (1H, d, J  = 8.3 Hz, C-l- 
H), 8.50 (1H, s, C-2'-H or C-5'-H) and 8.72 (1H, s, C-2'-H or C-5'-H); 5C (CDC13,
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100.4 MHz) -4.2 (2 xq, Si(CH3)2), 15.2 (q, C-18), 18.3 (s, C(CH3)3), 25.8 (3xq, 
C(CH3)3), 25.9 (t), 27.5 (t), 28.5 (t), 29.4 (t), 33.3 (t), 37.0 (d), 44.1 (d), 47.4 (s, C- 
13), 55.9 (d), 117.3 (d), 120.0 (d), 123.4 (s), 125.8 (d), 131.9 (s), 137.1 (s), 151.5 (d, 
C-2' or 0 5 0 , 153.4 (s), 155.6 (s), 156.1 (d, C-2' or C-5') and 159.0 (s); MS m/z 
(FAB+) 461.6 [100, (M+H)+], 73.0 [20]; Acc MS m/z (FAB+) 461.2739, 
C 27H37N4OSi requires 461.2737.
3-Hydroxy-estra-l,3,5(10),16-tetraene-[16,17-g]-(s-triazolo-[l,5-a]-pyrimidine)
(118)
A 1.0 M solution of TBAF in anhydrous THF (738 pL, 738 pmol) was added to a 
stirred solution of 117 (170 mg, 369 |Limol) in anhydrous THF (15 mL) at room 
temperature, under an atmosphere of N2. The resulting light brown solution was 
stirred for 5.5 hours at room temperature, after which H20  was added (50 mL). The 
resulting white precipitate was filtered and air dried to give 118 as a white powder 
(85 mg, 6 6 %): mp > 340°C; IR (KBr) 3270 (br, OH), 2955-2860 (aliph CH), 1610- 
1505 (C=N and arom C=C) c m 1; 8 H (DMSO-d6, 400 MHz) 1.15 (3H, s, C-18-H3),
1.41-3.07 (13H, m), 6.46 (1H, d, J = 2.6 Hz, C-4-H), 6.53 (1H, dd, J  = 8.2 Hz, J  =
2.6 Hz, C-2-H), 7.07 (1H, d, J = 8.2 Hz, C-l-H), 8 . 6 6  (1H, s, C-2'-H or C-5'-H), 8.81 
(1H, s, C-3'-H or C-5'-H) and 9.04 (1H, s, exchanged with D20 , C-3-OH); MS m/z 
(FAB+) 347.2 [100, (M+H)+], 242.3 [77], 219.2 [30], 73.0 [28]; Acc MS m/z (FAB+) 
347.1859, C2 iH23N40  requires 347.1872.
5.4.7 Modifications at C6, C16 and C17 on E l nucleus
3-Acetoxy-6-oxo-estra-l,3,5(10)-triene-17-one (119)
A solution of C r0 3 (673 mg, 6.73 mmol) in 10% AcOH (4 mL) was added dropwise 
over 2 hours to a stirred solution of 61 (500 mg, 1.60 mmol) in AcOH glacial, at 10- 
15°C in an ice/water bath. The resulting dark brown solution was stirred overnight at 
room temperature, after which the solvent was removed under reduced pressure and 
H20  (100 mL) added. The organics were extracted with EtOAc (100 mL), washed 
with H20  (2x30 mL), then brine (2x30 mL), dried (Na2S 04), filtered and 
concentrated under reduced pressure to give a green foam. The crude product was
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recrystallised from IPA to give 119 as grey crystals (103 mg, 20%): mp 191-194°C 
[lit.252 (acetone) 193.5-195.5°C]; IR (KBr) 2950-2850 (aliph CH), 1765 (C=0), 1740 
(C=0), 1675 (C=0), 1600, 1480 (arom C=C), 1200 (C-O) c m 1; 5H (CDC13, 400 
MHz) 0.92 (3H, s, C -I8 -H3), 1.20-2.63 (12H, m), 2.32 (3H, s, COCH3), 2.88 (1H, dd, 
7 a b =  16.8 Hz, / =  3.1 Hz, C-7-H), 7.28 (1H, dd, J=  8 . 6  Hz, J=  2.6 Hz, C-2-H), 7.46 
(1H, d, J= 8 . 6  Hz, C-l-H) and 7.77 (1H, d, /  = 2.6 Hz, C-4-H); MS m/z (FAB+)
327.2 [100, (M+H)+], 145.1 [27], 85.1 [50]; Acc MS m/z (FAB+) 327.1595, 
C20H2 3O4 requires 327.1596.
6-Oxo-estrone (120)
A solution of KOH (247 mg, 4.40 mmol) in MeOH (1.5 mL) was added dropwise to 
a stirred solution of 119 (80 mg, 245 pmol) in MeOH (1.5 mL). The resulting brown 
solution was stirred for 2  hours at room temperature, after which the solvent was 
concentrated under reduced pressure and H2O (20 mL) added, followed by 5M HC1. 
The organics were extracted with EtOAc (50 mL), washed with H2O (20 mL), then 
brine (2x30 mL), dried (Na2S0 4 ), filtered and concentrated under reduced pressure. 
The crude product (74 mg) was purified by flash chromatography (CHCL/EtOAc, 
7:3) to give 120 as a light pink powder (41 mg, 58%). An analytical sample was 
triturated with boiling acetone to give an off-white solid: mp 241-243°C [lit. 269 
(MeOH) 246-247°C]; IR (KBr) 3345 (br, OH), 2940-2880 (aliph CH), 1720 (C=0), 
1680 (C=0), 1610-1495 (arom C=C) c m 1; 8 h (CDC13, 400 MHz) 0.93 (3H, s, C-18- 
H3), 1.24-2.59 (12H, m), 2.87 (1H, dd, Jab = 17.0 Hz, J  = 3.3 Hz, C-7-H), 5.74 (1H, 
s, exchanged with D20 , OH), 7.10 (1H, dd, J=  8.5 Hz, J =  2.8 Hz, C-2-H), 7.33 (1H, 
d, J  = 8.5 Hz, C-l-H) and 7.60 (1H, d, J = 2.8 Hz, C-4-H); MS m/z (FAB+) 369.2 
[50], 285.1 [95, (M+H)+], 113.1 [6 8 ], 84.0 [94]; Acc MS m/z (FAB+) 285.1492, 
Ci8H2 i0 3 requires 285.1491. HPLC (MeOH/H20 , 90:10, XmM = 223.9 nm) Rt = 2.34 
min, 1 0 0 %.
3-Acetoxy-16-acetoxymethylene-estra-l,3,5(10)-triene-17-one (121)
Acetic anhydride (8.34 mL, 88.24 mmol) was added dropwise over 10 minutes to a 
stirred solution of 97 (230 mg, 771 pmol) in anhydrous pyridine (15 mL) at 0°C, 
under an atmosphere of N2 . The resulting yellow mixture was heated to reflux for 1 
hour, allowed to cool down, poured into H2 0 /ice (50 mL) and acidified with 5M
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HC1. The organics were extracted with EtOAc (2x50 mL), washed with H20  (30 
mL), 10% aq. Na2C 0 3 (30 mL), then brine (30 mL), dried (Na2 S0 4 ), filtered and 
concentrated under reduced pressure to give an orange foam (250 mg). The crude 
product was purified by flash chromatography (CHCl3/EtOAc, 95:5) to give 121 as a 
pale yellow oil that crystallised on standing (140 mg, 47%): mp 115-117°C; IR 
(KBr) 2930-2860 (aliph CH), 1770, 1725, 1655 (C=0), 1615, 1495 (aliph C=C and 
arom C=C), 1195 (C-O) cm'1; 5h (CDC13, 400 MHz) 0.93 (3H, s, C -I8 -H3), 1.42- 
2.84 (11H, m), 2.24 (3H, s, COCH3), 2.29 (3H, s, COCH3), 2.89-2.96 (2H, m, C-6 - 
H2), 6.81 (1H, d, J = 2.6 Hz, C-4-H), 6 . 8 6  (1H, dd, J  = 8.3 Hz, J  = 2.6 Hz, C-2-H),
7.29 (1H, d, J  = 8.3 Hz, C-l-H) and 8.15 (1H, dd, J = 2.9 Hz, J  = 1.7 Hz, C-l'-H); 
MS m/z (FAB+) 383.0 [100, (M+H)+], 341.0 [8 6 , (M+H-CH2CO)+]; Acc MS m/z 
(FAB+) 383.1852, C23H270 5 requires 383.1858.
3-Acetoxy-6-oxo-16-acetoxymethylene-estra-l,3,5(10)-triene-17-one (122)
A solution of CrC>3 (132 mg, 1.32 mmol) in 10% AcOH (750 pL) was added 
dropwise over 30 minutes to a stirred solution of 121 (120 mg, 314 pmol) in AcOH 
glacial at 10-15°C in an ice/water bath. The resulting dark brown solution was stirred 
for 2 days at room temperature. The solvent was then removed under reduced 
pressure and H20  (50 mL) and ice added. The organics were extracted with EtOAc 
(2x50 mL), washed with H20  (2x30 mL), then brine (2x30 mL), dried (Na2S0 4 ), 
filtered and concentrated under reduced pressure to give a brown product. The crude 
material was purified by flash chromatography (CHCl3/EtOAc, 8:2) to give 122 as a 
light yellow solid (13 mg, 10%): mp 96-101°C; IR (KBr) 2940-2860 (aliph CH), 
1770, 1725, 1680, 1650 (C=0), 1615, 1490 (aliph C=C and arom C=C), 1195 (C-O) 
cm'1; 5h (CDC13, 400 MHz) 0.95 (3H, s, C -I8 -H3), 1.24-2.82 (10H, m), 2.26 (3H, s, 
COCH3 ), 2.32 (3H, s, COCH3), 2.88 (1H, dd, 7ab= 16.8 Hz, / =  3.5 Hz, C-7-H), 7.29 
(1H, dd, J = 8.4 Hz, J  = 2.6 Hz, C-2-H), 7.46 (1H, d ,J=  8.4 Hz, C-l-H), 7.77 (1H, d, 
J = 2.6 Hz, C-4-H) and 8.17 (1H, dd, J  = 2.9 Hz, J = 1.7 Hz, C-L-H); MS m/z 
(FAB+) 663.5 [48], 397.2 [38, (M+H)+], 355.2 [30, (M+H-CH2C=0)+], 73.0 [100]; 
Acc MS m/z (FAB+) 397.1670, C2 3H2506 requires 397.1651.
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6-Oxo-16-ethoxymethyiene-estrone (123)
A solution of KOH (27 mg, 482 pmol) in H2O (0.8 mL) was added dropwise to a 
stirred solution of 122 (80 mg, 201 pmol) in EtOH at 0°C. The resulting bright 
yellow mixture was stirred at 0°C for 30 minutes, after which it was acidified with 
5M HC1 and the solvent removed under reduced pressure. H2O was added (50 mL) 
and the organics were extracted with EtOAc (2x50 mL), washed with H2O (2x30 
mL), then brine (2x30 mL), dried (Na2S0 4 ), filtered and concentrated under reduced 
pressure to give a pale yellow product (52 mg). The crude material was purified by 
flash chromatography (DCM/EtOAc, 75:25) to give 123 as a white solid (12 mg, 
18%): mp 314-316°C (dec.); IR (KBr) 3250 (OH), 2940-2860 (aliph CH), 1695, 
1680 (C=0), 1620-1450 (aliph C=C and arom C=C) cm ]; 8 H (CDC13, 400 MHz) 
0.94 (3H, s, C -I8 -H3), 1.10-2.72 (10H, m), 1.35 (3H, t, J  = 7.0 Hz, C-2"-H3), 2.85 
(1H, dd, 7 a b =  16.7 Hz, J=  3.1 Hz, C-7-H), 4.05-4.13 (2H, m, C-l"-H2), 5.10 (1H, s, 
C-3-OH), 7.09 (1H, dd, J  = 8.5 Hz, J = 2.7 Hz, C-2-H), 7.31-7.34 (2H, m, C-l-H and 
C-l'-H) and 7.57 (1H, d, J=  8.5 Hz, C-4-H); MS m/z (FAB+) 341.2 [100, (M+H)+]; 
Acc MS m/z (FAB+) 341.1747, C2 1H2 5O4  requires 341.1753. HPLC (MeOH/H20 , 
90:10, ^max = 253.6 nm) Rt = 2.36 min, 100%.
6-Oxo-16-hydroxymethylene-estrone (124)
A solution of K2CO3 (63 mg, 456 pmol) in H2O (1 mL) was added dropwise to a 
stirred solution of 122 (30 mg, 76 pmol) in MeOH (10 mL). The resulting pale 
yellow solution was stirred for 45 minutes, after which it was acidified with 5M HC1 
and the solvent removed under reduced pressure. H2O was added (30 mL) and the 
organics were extracted with EtOAc (2x50 mL), washed with H2O (2x30 mL), then 
brine (2x30 mL), dried (Na2S0 4 ), filtered and concentrated under reduced pressure. 
The pale yellow crude product was recrystallised from EtOAc/hexane to give 124 as 
a white powder (13 mg, 54%): mp 224-227°C; IR (KBr) 3475, 3415 (OH), 2935- 
2860 (aliph CH), 1705, 1665 (C=0), 1605, 1495 (aliph C=C and arom C=C) cm'1; 5H 
(DMSO-d6, 400 MHz) 0.80 (3H, s, C -I8 -H3), 1.41-2.65 (11H, m), 7.01 (1H, dd, J  =
8.4 Hz, J  = 2.7 Hz, C-2-H), 7.28 (1H, d, /  = 2.7 Hz, C-4-H), 7.31(1H, d, J  = 8.4 Hz, 
C-l-H), 7.41 (1H, s, =C//OH), 9.64 (1H, s, exchanged with D20 , C-3-OH) and 10.77 
(1H, br s, exchanged with D20 , =CHOtf); MS m/z (FAB+) 313.2 [6 , (M+H)+], 149.1
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[100]; MS m/z (FAB-) 311.2 [100, (M-H)']; Acc MS m/z (FAB+) 313.1450, 
C 19H21O4  requires 313.1440. HPLC (MeOH/tkO, 90:10, ^max = 221.6 nm) Rt = 2.16 
min, 1 0 0 %.
3-Hydroxy-6,17-bis-oximino-estra-l,3,5(10)-triene (125)
NaOAc (293 mg, 3.58 mmol) followed by hydroxylamine hydrochloride (274 mg, 
3.94 mmol) were added to a solution of 120 (100 mg, 352 pmol) in a mixture of 
MeOH/HaO (5:1, 18 mL). The resulting solution was stirred at room temperature 
overnight, after which the solvent was removed under reduced pressure and H2O 
added (50 mL). The organics were extracted with EtOAc (70 mL), washed with H2O 
(2x20 mL), then brine (2x20 mL), dried (Na2S0 4 ), filtered and concentrated under 
reduced pressure to give a light brown crude product (120 mg). This was purified by 
flash chromatography (CHCf/EtOAc, 7:3 to 1:1, gradient then 
CHCl3/EtOAc/acetone, 2:2:1 to 1:1:2, gradient) to give 125 as an off-white powder 
(46 mg, 41%): mp 341-344°C; IR (KBr) 3410, 3265-3050 (br, NOH, OH), 2930- 
2850 (aliph CH), 1705 (C=N), 1580-1495 (arom C=C) cm'1; 8 H (DMSO-de, 400 
MHz) 0.83 (3H, s, C-I8 -H3), 1.14-2.42 (12H, m), 3.06 (1H, app dd, / =  17.8 Hz, 7 =
3.7 Hz, C-7-H), 6.73 (1H, dd, J = 8.3 Hz, J = 2.7 Hz, C-2-H), 7.14 (1H, d, J  = 8.3 
Hz, C-l-H), 7.29 (1H, d, J  = 2.7 Hz, C-4-H), 9.28 (1H, s, exchanged with D2 0 , OH),
10.15 (1H, s, exchanged with D2 O, NOH) and 11.08 (1H, s, exchanged with D2O, 
NOH); MS m/z (FAB+) 315.1 [82, (M+H)+], 73.0 [100]; Acc MS m/z (FAB+) 
315.1715, C 18H23N2O3 requires 315.1709. HPLC (MeOH/H20 , 90:10; Xmax = 255.7 
nm) Rt = 1.77 min, 98%.
3-Hydroxy-6,17-bis-(0-methyl-oximino)-estra-l,3,5(lO)-triene (126)
NaOAc (146 mg, 1.79 mmol) followed by O-methyl-hydroxylamine hydrochloride 
(164 mg, 1.97 mmol) were added to a solution of 120 (50 mg, 176 pmol) in a 
mixture of MeOH/H20  (5:1, 9 mL). The resulting solution was stirred at room 
temperature overnight, after which the solvent was removed under reduced pressure 
and H2O added (30 mL). The organics were extracted with EtOAc (30 mL), washed 
with H2O (2x10 mL) then brine (2x10 mL), dried (Na2S0 4 ), filtered and 
concentrated under reduced pressure. The white crystalline crude product was 
recrystallised from EtOAc/hexane to give 126 as white crystals (55 mg, 92%): mp
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206-208°C; IR (KBr) 3135 (br, OH), 2995 (arom CH), 2935-2890 (aliph CH), 1670, 
1630 (CN, weak), 1570-1490 (arom C=C) cm'1; 6 H (CDC13, 400 MHz) 0.92 (3H, s, 
C -I8 -H3), 1.24-2.58 (12H, m), 3.12 (1H, dd, Jab= 18.1 Hz, J = 4.5 Hz, C-7-H), 3.84 
(3H, s, OCH3), 3.99 (3H, s, OCH3), 4.85 (1H, br s, exchanged with D20 , OH), 6.84 
(1H, dd, J  = 8 . 6  Hz, J = 2.7 Hz, C-2-H), 7.20 (1H, d, J = 8 . 6  Hz, C-l-H) and 7.29 
(1H, d, J  = 2.7 Hz, C-4-H); MS m/z (FAB+) 343.2 [100, (M+H)+]; Acc MS m/z 
(FAB+) 343.2033, C20H27N2O3 requires 343.2022. Found: C, 70.20; H, 7.57; N, 8.14. 
C20H26N2 O3 requires: C, 70.15; H, 7.65; N, 8.18%.
3-Hydroxy-17-oximino-estra-l,3,5(10)-triene (127)
NaOAc (1.5 g, 18.80 mmol) followed by hydroxylamine hydrochloride (1.4 g, 20.72 
mmol) were added to a suspension of E l (500 mg, 1.85 mmol) in a mixture of 
MeOH/H2 0  (5:1, 90 mL). The resulting suspension was stirred at room temperature 
overnight, after which the solvent was removed under reduced pressure and H2 0  
added (100 mL). The organics were extracted with EtOAc (150 mL), washed with 
H20  (50 mL), then brine (50 mL), dried (Na2S0 4 ), filtered and concentrated under 
reduced pressure to give a white crystalline crude product (627 mg). This compound 
was recrystallised from MeOH to give 127 as white crystals (426 mg, 81%): mp 251- 
253°C (dec.) [lit. 155 (MeOH) 248-250°C]; IR (KBr) 3415 (NOH), 3270 (OH), 2930 
(aliph CH), 1620 (C=N), 1585-1460 (arom C=C) cm'1; 5H (DMSO-d*, 400 MHz)
0.85 (3H, s, C -I8 -H3), 1.32-2.41 (13H, m), 2.65-2.80 (2H, m, C-6 -H2), 6.44 (1H, d, J  
= 2.6 Hz, C-4-H), 6.50 (1H, dd, J  = 8.5 Hz, J  = 2.6 Hz, C-2-H), 7.05 (1H, d, J  = 8.5 
Hz, C-l-H), 9.01 (1H, s, exchanged with D20 , OH) and 10.10 (1H, s, exchanged 
with D20 , NOH); MS m/z (FAB+) 286.1 [100, (M+H)+]; Acc MS m/z (FAB+) 
286.1809, C 18H24NO2  requires 286.1807. HPLC (MeOH/H20 , 70:30; Xmax = 280.5 
nm) Rt = 2.34 min, 98%.
3-Hydroxy-16,17-bis-oximino-estra-l,3,5(10)-triene (128)
NaOAc (556 mg, 6.79 mmol) followed by hydroxylamine hydrochloride (520 mg, 
7.48 mmol) were added to a solution of 1 (200 mg, 6 6 8  pmol) in a mixture of 
MeOH/H2 0  (5:1, 36 mL). The resulting pale yellow solution was stirred at room 
temperature overnight, after which the solvent was removed under reduced pressure 
and brine added (100 mL). The organics were extracted with EtOAc (100 mL),
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washed with brine (2x50 mL), dried (Na2SC>4), filtered and concentrated under 
reduced pressure. The crude product was recrystallised from acetone to give 128 as 
off-white crystals (109 mg, 52%): mp 245-247°C; IR (KBr) 3420-3200 (br, NOH, 
OH), 3020 (arom CH), 2935-2870 (aliph CH), 1705, 1620, 1585-1500 (C=N and 
arom C=C) cm'1; 5H  (DMSO-de, 400 MHz) 0.97 (3H, s, C - I 8 - H 3 ) ,  1.28-2.83 (13H, 
m), 6.44 (1H, d, J = 2.4 Hz, C-4-H), 6.51 (1H, dd, J  = 8.5 Hz, J  = 2.4 Hz, C-2-H),
7.04 (1H, d, J  = 8.5 Hz, C-l-H), 9.02 (1H, s, exchanged with D20 , OH), 10.81 (1H, 
s, exchanged with D20 , NOH) and 11.19 (1H, s, exchanged with D20 , NOH); 8 c 
(DMSO-de, 100.4 MHz) 14.5 (q, C-18), 26.5 (t), 27.1 (t), 27.3 (t), 29.5 (t), 35.5 (t),
37.4 (d), 43.4 (d), 46.2 (s, C-13), 49.0 (d), 113.2 (d), 115.4 (d), 126.4 (d), 130.5 (s),
137.4 (s), 155.5 (s), 155.7 (s) and 160.2 (s); MS m/z (FAB+) 315.2 [100, (M+H)+]; 
MS m/z (FAB-) 466.2 [6 6 , (M-H-NBA)'], 313.2 [100, (M-H)'], 276.1 [80]; Acc MS 
m/z (FAB+) 315.1711, Ci8H23N20 3 requires 315.1709. HPLC (MeOH/H20 , 70:30, 
Xmax = 252.1 nm) Rt = 2.71 min, 99%. Found: C, 67.30; H, 7.41; N, 7.59. 
Ci8H22N20 3 .(CH3)20  requires: C, 67.72; H, 7.58; N, 7.52%.
5.4.8 Other sulfamates of E l derivatives and precursors
3-Benzyloxy-16-ethoxymethylene-estra-l,3,5(10)-triene-17-one (129)
K2C 0 3 (595 mg, 4.31 mmol) was added portionwise to a stirred suspension of 72 
(250 mg, 643 mmol) in acetone (20 mL) at room temperature, under an atmosphere 
of N2. After 10 minutes of stirring, ethyl iodide (296 jiL, 3.70 mmol) was added and 
the resulting mixture was stirred for 36 hours at room temperature. H20  was then 
added (100 mL) and the organics were extracted with DCM (3x50 mL), washed with 
H20  (50 mL), then brine (2x50 mL), dried (Na2SC>4), filtered and concentrated under 
reduced pressure. The crude product was purified by flash chromatography 
(EtOAc/hexane, 1:3) to give 129 as a white solid (215 mg, 80%). This compound 
was recrystallised from EtOAc to give white crystals (139 mg, 52%): mp 158-160°C; 
IR (KBr) 2935-2850 (aliph CH), 1710 (C=0), 1640-1500 (aliph and arom C=C), 
1235 (C-O) cm'1; 8 H (CDC13, 400 MHz) 0.92 (3H, s, C-18-H3), 1.34 (3H, t, J  = 7.2 
Hz, C-2"-H3), 1.38-2.71 (11H, m), 2.84-2.93 (2H, m, C-6 -H2), 4.02-4.10 (2H, m, C- 
1"-H2), 5.02 (2H, s, OCH2Ar), 6.71 (1H, d, J  = 2.6 Hz, C-4-H), 6.77 (1H, dd, J = 8 . 6
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Hz, J=  2.6 Hz, C-2-H), 7.18 (1H, d, 7 =  8 . 6  Hz, C-l-H) and 7.26-7.43 (6 H, m, C-l'- 
H and C6H5); MS m/z (FAB+) 417.0 [100, (M+H)+]; Acc MS m/z (FAB+) 417.2425, 
C28H3 3O3 requires 417.2430.
16p-Ethoxymethyl-estrone (64) and 16-ethoxymethyl-estradiol (130 and 131)
Following method 2, a suspension of 129 (640 mg, 1.54 mmol) and Pd-C (10%, 200 
mg) in MeOH/THF (1:1, 60 mL) was hydrogenated for 48 hours. The crude mixture 
was purified by flash chromatography (EtOAc/hexane, 3:7) to give three products:
The less polar fraction gave 64 as a white crystalline solid (232 mg, 46%).
The following fraction gave 130 as a white crystalline solid (45 mg, 9%). An 
analytical sample was recrystallised from EtOH: mp 199-201°C; IR (KBr) 3415, 
3240 (br, OH), 2972-2865 (aliph CH), 1610-1505 (arom C=C) cm 1; 5H (CDC13, 400 
MHz) 0.83 (3H, s, C-I8 -H3), 1.12-2.51 (12H, m), 1.16 (3H, t, 7 = 7.0 Hz, C-2"-H3), 
2.79-2.82 (2H, m, C-6 -H2), 3.30 (1H, d, 7 = 4.7 Hz, exchanged with D20 , C-17-OH), 
3.45-3.61 (4H, m, C-l'-H 2 and C-l"-H2), 3.85 (1H, dd, J  = 9.9 Hz, J  = 4.7 Hz, C-17- 
H), 4.79 (1H, s, exchanged with D20 , C-3-OH), 6.54 (1H, d, J  = 2.7 Hz, C-4-H), 
6.60 (1H, dd, 7 =  8.4 Hz, 7 = 2.7 Hz, C-2-H) and 7.13 (1H, d, 7 = 8.4 Hz, C-l-H; MS 
m/z (FAB+) 331.3 [100, (M+H)+], 272.1 [25, (M+H-CH2OEt)+], 145.1 [36], 85.0 
[46]; Acc MS m/z (FAB+) 331.2291, C2 iH3 i0 3 requires 331.2273.
The more polar fraction gave 131 as a white crystalline solid (99 mg, 19%). An 
analytical sample was recrystallised from EtOH: mp 106-109°C; IR (KBr) 3315, 
3215 (br, OH), 2977-2860 (aliph CH), 1620-1495 (arom C=C) cm’1; 5H (CDCI3 , 400 
MHz) 0.84 (3H, s, C-I8 -H3), 1.21 (3H, t, J=  7.0 Hz, C-2"-H3), 1.25-2.31 (13H, m), 
2.78-2.82 (2H, m, C-6 -H2), 3.37-3.59 (5H, m, C-l'-H2, C-l"-H2, C-17-H), 4.79 (1H, 
s, exchanged with D20 , C-3-OH), 6.54 (1H, d, 7 = 2.7 Hz, C-4-H), 6.60 (1H, dd, J = 




Following method 3, reaction of 64 (100 mg, 304 pmol) with sulfamoyl chloride in 
DMA (1.5 mL) was complete within 3 hours. The crude product was purified by 
flash chromatography (CHCl3/EtOAc, 8:2) to give 132 as a colourless oil (124 mg, 
100%): IR (KBr) 3380, 3285 (br, NH2), 2970-2865 (aliph CH), 1730 (C=0), 1605- 
1495 (arom C=C), 1380, 1190 (S02) c m 1; 5H (CDC13, 400 MHz) 0.89 (3H, s, C-18- 
H3), 1.16 (3H, t, J = 7.0 Hz, C-2"-H3), 1.40-2.43 (12H, m), 2.89-2.94 (2H, m, C-6 - 
H2), 3.43-3.50 (2H, m, C-l"-H2), 3.61 (1H, dd, JAB = 9.4 Hz, / =  3.7 Hz, C-l'-HAHB), 
3.66 (1H, dd, JBA = 9.4 Hz, J  = 5.5 Hz, C-T-IT^Hb), 4.87 (2H, s, exchanged with 
D20 , S 0 2NH2), 7.04 (1H, d, J = 2.4 Hz, C-4-H), 7.07 (1H, dd, J  = 8.4 Hz, J  = 2.4 
Hz, C-2-H) and 7.29 (1H, d, /  = 8.4 Hz, C-l-H); 5C (CDC13, 100.4 MHz) 12.9 (q, C- 
2"), 15.1 (q, C-18), 25.8 (2xt), 26.4 (t), 29.4 (t), 32.0 (t), 37.4 (d), 44.3 (d), 48.2 (s, 
C-13), 49.0 (d), 50.3 (d), 6 6 . 6  (t, C -l' or C-l"), 69.3 (t, C -l' or C-l"), 119.1 (d), 
122.1 (d), 126.8 (d), 138.8 (s), 139.1 (s), 148.0 (s, C-3) and 220.8 (s, C=0); MS m/z 
(FAB+) 408.3 [39, (M+H)+], 145.1 [63], 131.1 [61], 117.1 [57], 85.1 [100], 68.0 
[50]; Acc MS m/z (FAB+) 408.1841, C2iH30NO5S requires 408.1845. HPLC 
(MeOH/H20 , 90:10, ^ax  = 267.5 nm) Rt = 2.28 min, 99%. Found: C, 59.65; H, 6.84; 
N, 3.36. C2iH29N 0 5S.(CHC13)i/6 requires: C, 59.48; H, 6 .8 8 ; N, 3.28%.
3-Sulfamoyloxy-16-oximino-estra-l,3,5(10)-triene-17-one (133)
Following method 3, reaction of 1 (200 mg, 6 6 8  pmol) with sulfamoyl chloride in 
DMA (1.5 mL) was complete within 3 hours. The crude product was purified by 
flash chromatography (CHCl3/acetone, 8:2) to give 133 as a white foam (93 mg, 
37%). This compound was triturated with hexane to give a white powder (36 mg, 
14%): mp 88-91°C; IR (KBr) 3370-3250 (NH2, NOH), 2930-2850 (aliph CH), 1740 
(C=0), 1635-1495 (C=N and arom C=C), 1380, 1185 (S02) cm'1; 8 H (DMSO-d6, 400 
MHz) 0.90 (3H, s, C-18-H3), 1.32-2.48 (11H, m), 2.78-2.94 (2H, m, C-6 -H2), 7.00 
(1H, m, C-4-H), 7.03 (1H, dd, J  = 8 . 6  Hz, J  = 2.3 Hz, C-2-H), 7.36 (1H, d, J = 8 . 6  
Hz, C-l-H), 7.92 (2H, s, exchanged with D20 , S 0 2NH2) and 12.41 (1H, s, exchanged 
with D2 0 , NOH); MS m/z (FAB+) 532.2 [32, (M+H+NBA)+], 379.1 [100, (M+H)+]; 
MS m/z (FAB-) 531.1 [40, (M+NBA)'], 377.1 [100, (M-H)']; Acc MS m/z (FAB+)
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379.1320, C i8H23N205S requires 379.1328. Found: C, 56.70; H, 6.02; N, 6.83.
C i8H22N205S requires: C, 57.13; H, 5.86; N, 7.40%.
3,l'-Bis-sulfamoyIoxy-estra-l,3,5(10)-triene-[17,16-c]-pyrazole (134) and 3- 
sulfamoyloxy-estra-l,3,5(10)-triene-[17,16-c]-pyrazole (135)
Following method 3, reaction of 98 (170 mg, 577 jimol) with sulfamoyl chloride in 
DMA (2 mL) was complete within 4 hours. The crude product was purified by flash 
chromatography (CHCl3/EtOAc, 1:1) to give two products:
The less polar fraction gave 134 as a pale yellow solid (85 mg, 32%): mp 115-120°C; 
IR (KBr) 3440, 3410 (NH2), 2930-2860 (aliph CH), 1635-1495 (C=N and arom 
C=C), 1385, 1185 (S02) c m 1; 5H (DMSO-c^, 400 MHz) 0.99 (3H, s, C -I8 -H3), 1.40- 
2.68 (11H, m), 2.85-2.90 (2H, m, C-6 -H2), 6.97 (1H, d, J=  2.3 Hz, C-4-H), 7.02 (1H, 
dd, J = 8 . 6  Hz, J  = 2.3 Hz, C-2-H), 7.35 (1H, d, /  = 8 . 6  Hz, C-l-H), 7.70 (1H, s, C- 
5-H), 7.88 (2H, s, exchanged with D2O, SO2NH2) and 8.30 (2 H, s, exchanged with 
D2 0 , SO2NH2); MS m/z (FAB+) 452.8 [100, M+], 373.9 [80, (M+H-S02NH2)+], 
171.0 [26], 116.0 [29]; Acc MS m/z (FAB+) 452.1164, Q 9H24N4 O5S2 requires 
452.1188. HPLC (MeOH/H20 , 80:20, kmax = 220.4 nm) Rt = 1.95 min, 97%.
The more polar fraction gave 135 as a white solid (123 mg, 57%): mp 219-221°C IR 
(KBr) 3370, 3305 (NH2), 2975-2860 (aliph CH), 1590, 1495 (C=N and arom C=C), 
1370, 1195 (S02) cm'1; 5H (DMSO-d6, 400 MHz) 1.17 (3H, s, C -I8 -H3), 1.38-2.59 
(11H, m), 2.85-2.90 (2H, m, C-6 -H2), 6.97 (1H, d, J  = 2.7 Hz, C-4-H), 7.02 (1H, dd, 
J = 8 . 6  Hz, J  = 2.7 Hz, C-2-H), 7.25 (1H, s, C-5'-H), 7.35 (1H, d, J  = 8 . 6  Hz, C-l-H), 
7.89 (2H, s, exchanged with D20 , S 0 2NH2) and 11.99 (1H, br s, exchanged with 
D20 , NH); MS m/z (FAB+) 747.3 [38, (2M+H)+], 527.2 [80, (M+H+NBA)+], 509.2 
[30], 443.2 [28], 374.2 [100, (M+H)+]; Acc MS m/z (FAB+) 374.1544, C^H^NsOsS 
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Appendix 1
X-ray crystallography data for 35
o
Identification code CCD Ca 211567
Em pirical formula C21 H 28 N 2 0 5  S
Form ula weight 420.51
Tem perature 150(2) K
W avelength 0.71073 A
Crystal system O rthorhom bic
Space group P 2 ,2 ,2 1
U nit cell dim ensions a = 9.7920(3)A  a  = 90°
b = 14.0950(3)A p = 90°
c =  1 4 .6 8 8 0 (5 )A y = 9 0 °
Crystal size 0.20 x  0.17 x 0.08 mm
“Cam bridge Crystallographic D ata Centre
Notes:
NH2 hydrogens located and freely refined.
Hydrogen bonds with H..A < r(A) + 2.000 Angstroms and <DHA >110 deg:
D-H d(D-H) d(H..A) <D H A  d(D..A) A
02
N 1-H1A 0.903 1.999 169.68 2.892
[ x+1/2, -y+3/2, -z+2 ] 
0 5
N 1-H2A 0.847 2.165 153.42 2.946
[ -x+5/2, -y+1, z+1/2 ]
For supplementary data, cf. enclosed CD (file name ‘suppl. 35’).
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Appendix 2
X-ray crystallography data for 62
j c 6^
Identification code h02phar2
Em pirical form ula C21 H24 0 3
Form ula weight 324.40
Tem perature 150(2) K
W avelength 0.71073 A
Crystal system O rthorhom bic
Space group P 2 ,2 j2 j
Unit cell dim ensions a = 9.29500(10)A  a  = 90°
b = 10.10900(10)A P = 90°
c =  1 7 .9 6 2 0 (2 )A y = 9 0 o
Crystal size 0.35 x 0.28 x 0.25 mm
For supplementary data, cf. enclosed CD (file name ‘suppl. 62’).
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Appendix 3
X-ray crystallography data for 64
Identification code h03bp2
Em pirical form ula C 2 1 H 2 8  O3
Form ula weight 328.43
Tem perature 150(2) K
W avelength 0.71073 A
C rystal system O rthorhom bic
Space group P 2,2 ,2 j
U nit cell dimensions a = 7.1090(1)A  a  = 90° 
b = 11.9830(2)A (3 = 90° 
c = 21.4370(4)A  y =  90°
Crystal size 0.40 x 0.13 x 0.04 mm
Notes:
H-bonded strands in lattice.
Hydrogen bonds with H..A < r(A) +  2.000 Angstroms and <DHA >110 deg:
D-H d(D-H) d(H..A) <DHA d(D..A) A
O l-H IA 0.840 1.929 170.32 2.760
0 2  
[ x, y+1, z]
N1-H2A 0.847 2.165 153.42 2.946
0 5
[ -x+5/2, -y+1, z+1/2 ]
For supplementary data, cf. enclosed CD (file name ‘suppl. 64’).
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Appendix 4
X-ray crystallography data for 84
Identification code k02farm 6
E m pirical form ula C24 H34 N2 O2
Form ula weight 382.53
Tem perature 150(2) K
W avelength 0.71073 A
Crystal system Orthorhom bic
Space group P 2 ,2 ,2 1
U nit cell dim ensions a = 8.3600(1 )A a  = 90° 
b = 13.2660(2)A p = 90° 
c =  19.1680(4) A y = 9 0 °
Crystal size 0.50 x  0.50 x 0.30 mm
Notes:
Hydrogen bonding in lattice.
Hydrogen bonds with H..A < r(A) +  2.000 Angstroms and <DHA >  110 deg:
D-H d(D-H) d(H..A) <DHA d(D..A) A
O l-H l 0.840 1.847 171.07 2.680 02
0 2 -H 2 0.840 1.911 172.59 2.746
N 2'
[ x, y+1, z]
For supplementary data, cf. enclosed CD (file name ‘suppl. 84’).
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